name <stdin>
#version: 0.2
t i
t h
a n
i n
r e
e r
e n
o n
th e</w>
e d</w>
o f</w>
r o
o n</w>
a r
a t
a l
an d</w>
o r
i n</w>
a ti
i t
s t
a l</w>
s i
i c
e s</w>
e l
a c
e c
a s
d i
e s
e r</w>
in g</w>
o r</w>
o l
t o</w>
o m
u r
u l
0 .
2 0
a s</w>
re s
ati on</w>
u n
r i
en t
e t
p ro
i l
i s</w>
p l
a n</w>
a t</w>
e m
a m
T h
u s
c h
c on
a b
e x
o s
f or</w>
e n</w>
i g
it h</w>
v e</w>
en t</w>
w ith</w>
i s
u c
ti on</w>
i d
a g
i m
e v
er e</w>
l y</w>
1 0
l o
o u
a p
f f
at ed</w>
ti on
t er
c e</w>
a d
o p
c om
e d
ati on
Th e</w>
t r
c l
) .</w>
o t
u m
g en
w as</w>
p er
w ere</w>
d e
th at</w>
it y</w>
20 0
b y</w>
s u
q u
o c
e re
l e</w>
i c</w>
p h
0 0
s e
v i
20 1
w h
c o
t s</w>
m e
s .</w>
ar e</w>
p res
s ,</w>
t ed</w>
o w
o g
v er
el l
1 9
ti n
st r
at e</w>
l e
f or
u d
m o
t e
ur e</w>
s p
i f
s h
1 1
ro m</w>
p ar
a r</w>
f rom</w>
h a
1 0.
a in
n e
n o
u t
d uc
si on</w>
ti c
i r
e t</w>
e ,</w>
p re
ent s</w>
ic al</w>
b e</w>
p o
si s</w>
g n
e p
ti v
y ,</w>
1 6
s c
in g
as e</w>
1 2
l i
e en</w>
an t</w>
ol og
p or
] .</w>
1 .
) ,</w>
re d</w>
I n
an c
p a
ere n
r a
for m
ig h
b i
as s
con t
c ell
m a
th e
e ar
o d
en ce</w>
m ent</w>
s y
1 3
re c
in e</w>
el l</w>
o b
al y
ab le</w>
th er</w>
ti c</w>
i z
t h</w>
tin g</w>
b u
0. 0
ro u
1 5
an d
en c
si gn
ti m
er s</w>
di ff
1 4
ti ve</w>
an g
re l
re g
F ig
tr an
in d
u s</w>
en d
un d
no t</w>
1 7
h y
sp ec
C h
ar i
ff ec
th is</w>
an aly
en ti
res p
et w
in c
d at
p ati
ation s</w>
f l
ic h</w>
e .</w>
f ac
s er
2 .
t er</w>
in ter
1 8
ati ve</w>
ar y</w>
f i
al ly</w>
c or
st ud
diff eren
10. 10
h i
o l</w>
u re
es ,</w>
t re
ag e</w>
v ed</w>
a y
u m</w>
y p
I n</w>
ev el
wh ich</w>
pro te
an ce</w>
tion s</w>
e al
as ed</w>
es .</w>
v al
lo w
if ic
es e</w>
al l</w>
u b
on e</w>
m in
cell s</w>
t o
an ti
ha ve</w>
oc i
ex pres
es s
ou s</w>
su b
ul ar</w>
es s</w>
b etw
a k
e -
betw een</w>
us ing</w>
i t</w>
o ur
an t
m or
2 3
re n
B i
m on
or s</w>
al l
am pl
s e</w>
v id
p os
e ffec
m an
ar g
. ,</w>
sh ow
un c
el y</w>
w e</w>
ac tiv
2 5
s o</w>
th er
o d</w>
2 4
us ed</w>
at es</w>
l in
d et
m ic
di s
g r
a v
i p
f o
t w
e l</w>
19 9
i r</w>
or y</w>
us e</w>
A l
b e
resp on
. 0
i d</w>
g rou
ac h</w>
N A</w>
v ari
res ul
c ol
ev er
y .</w>
ec t
c ell</w>
J .</w>
dat a</w>
Fig ure</w>
stud y</w>
m un
i th
1 0</w>
c i
a y</w>
ec h
r on
a f
tion al</w>
si on
un d</w>
u p
ou r</w>
ati n
i es</w>
sign ific
o v
e st
o x
al so</w>
ec ted</w>
inc re
ul d</w>
pati ents</w>
er i
a st
m at
es t</w>
n i
2 6
it s</w>
b r
y l
s ur
A n
tran s
u e</w>
m ent
ec tion</w>
t ri
cont ro
Th is</w>
om e</w>
d e</w>
2 8
lo c
c h</w>
2 7
S t
ul ation</w>
c ent
st e
p e
p ri
b een</w>
ou t</w>
3 .
se qu
in f
R e
c an</w>
on g</w>
en s
cl ud
3 0
h as</w>
c ur
or d
ab il
— C
in t
str uc
expres sion</w>
th ese</w>
m et
me th
/ j
h igh
u ro
f unc
mo d
o ther</w>
A .</w>
th an</w>
u di
fac t
M .</w>
f ol
2 9
atin g</w>
ac ter
c ri
c y
c ar
pro duc
ass oci
g l
in v
a il
os e</w>
3 8
s t</w>
me di
c ul
analy sis</w>
the ir</w>
um b
N e
a ,</w>
al s</w>
ed .</w>
w e
a in</w>
0. 00
olog y</w>
as t</w>
g h</w>
c a
y m
P ro
eal th</w>
di st
com pl
mor e</w>
w or
st udi
tre at
C om
os t</w>
il l
tw o</w>
al .</w>
s ampl
d ec
i al</w>
5 0
su p
ot h</w>
ma y</w>
ex per
i ti
t yp
ver s
ur ing</w>
d ing</w>
re por
C on
1 2</w>
re e</w>
r u
S .</w>
po si
g h
in clud
si m
de p
s uc
anc er</w>
ri bu
af ter</w>
d o
3 6
e ach</w>
ro w
igh t</w>
prote in</w>
3 7
f ic
evel op
= =
ac c
w ith
3 4
pro c
il e</w>
me as
si st
a u
2 2
T able</w>
n umb
tr ac
al .,</w>
gen er
h o
em ent</w>
R es
an g</w>
s el
s ec
re qu
bu t</w>
h um
differen t</w>
i a</w>
W e</w>
h e
4 0
t u
A c
pa th
e g
in duc
3 5
ain ed</w>
p ol
tic al</w>
4 .
ch ang
di se
( 200
b ased</w>
1 1</w>
ind ic
f in
ap pro
gen e
it e</w>
l evel
f ir
ob ser
an ts</w>
n on
per form
2 )</w>
fl u
pl ic
ation ,</w>
k n
ation al</w>
m ar
C .</w>
as es</w>
tion ,</w>
s ti
3 9
olog ical</w>
gen e</w>
on g
1 ,</w>
2 -
r ic
C A
lo w</w>
b l
m al
b oth</w>
id enti
ar d</w>
e i
ure s</w>
b o
ch em
d evelop
n o</w>
or g
G en
par tic
abil ity</w>
2 0</w>
ed ,</w>
d uring</w>
( 201
mic ro
1 5</w>
iz ed</w>
g g
dep end
grou p
r ac
ro m
pro vid
tim e</w>
N A
resul ts</w>
o ver
] ,</w>
m s</w>
com p
a re
fol low
er g
on s</w>
em ent
u al</w>
k e</w>
3 )</w>
t en
a d</w>
b le</w>
t ure</w>
f e
pa red</w>
in to</w>
4 5
re duc
l ic
c al
o f
v en
ation .</w>
vi r
numb er</w>
ro s
associ ated</w>
M e
% )</w>
s on</w>
on d
p op
prote in
m i
is h
ear ch</w>
en g
S ci
de l</w>
9 5
studi es</w>
ever ,</w>
suc h</w>
E n
form ation</w>
4 6
y n
1 -
treat ment</w>
exper im
cl in
s ol
U ni
ow ever,</w>
( S
ati c</w>
cent r
s :</w>
d es
on ly</w>
ig h</w>
reg i
10. 11
c es</w>
vi e
Fig .</w>
4 8
ain ing</w>
am in
o uld</w>
st em
1 3</w>
hum an</w>
1 )</w>
por t
p t
ac h
r ap
ri s
ter n
10.10 16
iz ation</w>
ou t
1 4</w>
m ut
cl u
im mun
R NA</w>
d ic
in hi
7 .
sy n
m ol
ec t</w>
P C
k in
ff ic
fo und</w>
contro l</w>
3 0</w>
D i
s ed</w>
gen es</w>
n or
w il
ha d</w>
t um
k ing</w>
ph y
6 0
ul ti
dist ribu
si d
if ic</w>
C D
at ure</w>
i v
( A
our n
ay s</w>
D e
8 0
b in
4 9
level s</w>
sc ri
activ ity</w>
rel ated</w>
5 .
ti s
reg ul
cl e</w>
1 6</w>
/j .
di vid
ad di
an is
ar d
2 4</w>
ep t
Uni vers
8 6
p ot
m ost</w>
E x
an n
uc le
c ancer</w>
kn ow
ther ap
d om
u es</w>
k s</w>
fi ed</w>
R .</w>
m em
s es</w>
ur al</w>
com pared</w>
ch ar
signific ant</w>
h igh</w>
mo del</w>
D NA</w>
su gg
co un
2 5</w>
a th
r an
7 0
re pres
1 7</w>
e y</w>
( C
grou p</w>
pl e</w>
A r
1 8</w>
s )</w>
spec ific</w>
g row
s en
ste m</w>
ut e</w>
it ed</w>
a -
6 .
con di
th rou
det er
ati s
C l
o us
ab l
id e</w>
D .</w>
si ve</w>
f il
ec tiv
non -
2 ,</w>
I m
enti al</w>
4 7
od y</w>
ot yp
A T
wh en</w>
show n</w>
9 .
8 .
und er</w>
P .</w>
mod el
t em
am e</w>
A d
ere d</w>
2 1</w>
ar ti
F or</w>
t ro
L .</w>
co uld</w>
3 3
9 0
effec t</w>
S ch
s k
f u
al ity</w>
M ed
H owever,</w>
1 9</w>
l arg
at er</w>
in al</w>
par t
si z
sequ enc
ot al</w>
th ree</w>
d em
a x
pl as
d ro
the y</w>
5 0</w>
U S
obser ved</w>
y ear
er ,</w>
an s</w>
des cri
repor ted</w>
t arg
inter ac
w ell</w>
4 )</w>
an y</w>
st and
signific ant
col l
t t
m ulti
do i
m it
e qu
m is
it y,</w>
o -
depend ent</w>
ac k
os ph
C T
i st
p er</w>
h ealth</w>
re ,</w>
l if
typ e</w>
pre vi
oc y
e .
effec ts</w>
b re
M o
contro l
1 .</w>
o w</w>
perform ed</w>
ati v
( Figure</w>
ain s</w>
g /
5 5
con centr
im port
g u
in divid
il d
te st
L e
at ory</w>
with in</w>
l ev
di rec
b lo
pre dic
incre ased</w>
sim il
c r
s m
’ s</w>
tion .</w>
op h
clin ical</w>
tran scri
O n
partic ip
f eren
ol .</w>
sy stem
E .</w>
char acter
0. 9
ri c</w>
tis su
enc y</w>
high er</w>
2 2</w>
10 0
g re
induc ed</w>
2 3</w>
per i
f er
r ang
C o
l y
a .</w>
ag es</w>
m ents</w>
od s</w>
5 6
m ech
m ac
tic s</w>
pri m
e ar</w>
4 4
fir st</w>
dise ase</w>
H .</w>
b ec
i ed</w>
ub l
am et
p at
sy ch
respon se</w>
throu gh</w>
show ed</w>
ris k</w>
ob t
pl ement
( B
v ing</w>
ti g
a w
S h
ing ,</w>
l im
5 )</w>
L -
b il
rec ept
lev el</w>
c ep
und er
ac t</w>
significant ly</w>
m al</w>
ind ing</w>
inv ol
Bi o
10.1016 /j.
m er
W h
( P
mol ec
id ence</w>
si ble</w>
ro le</w>
ti es</w>
ing s</w>
el i
ver y</w>
phy si
G F
c at
th ou
th ere</w>
wil l</w>
M ed</w>
func tion</w>
com bin
c re
x im
b ed</w>
H ealth</w>
u tion</w>
com par
Ne uro
5 7
- 0
9 7
= =</w>
experim ent
== ==</w>
a i
19 8
au th
s it
po st
ab ol
2 7</w>
vi v
as s</w>
g e</w>
Th ese</w>
ffic i
5 8
. 201
r ate</w>
al u
am il
sup por
T .</w>
s tim
P -
r y</w>
T o</w>
b er
res s</w>
6 7
m an</w>
al e</w>
pro t
p tion</w>
v e
2 8</w>
ap p
B .</w>
P h
en z
4 0</w>
og rap
2 6</w>
c er
path w
am ong</w>
ex p
u r</w>
tr a
fic ation</w>
s ame</w>
bi o
m ed
th ose</w>
mic e</w>
Univers ity</w>
00 0
p it
y -
ev alu
se t</w>
t otal</w>
1 ).</w>
v ol
di ag
2 9</w>
R NA
3 -
ha vi
ph osph
dec re
al ,</w>
un g</w>
1. 0
ren t</w>
M ic
gh t</w>
es tim
R -
C ent
D is
s oci
resp ectiv
I t</w>
d s</w>
h ol
sion s</w>
includ ing</w>
v is
a si
mar k
y o
tre ated</w>
P hy
for e</w>
P ar
K .</w>
es tig
I I
s ing</w>
deter min
vi ron
me an</w>
c ap
s ome</w>
st at
G A
s ing
wh ere</w>
s o
P l
pl ac
L i
S p
er o
eal th
/ /
n ucle
tt p
protein s</w>
( F
or e</w>
mech anis
a m</w>
grow th</w>
h ttp
ra di
: //
th en</w>
ad e</w>
inhi b
. 200
ur ther</w>
( M
2 .</w>
G .</w>
2. 0
H I
S C
val ues</w>
( Fig.</w>
' s</w>
ig n
ph en
or ig
ac k</w>
l ess</w>
t est</w>
ne uro
t ,</w>
Al l</w>
ra in</w>
5 9
10 0</w>
am m
3 1</w>
l y,</w>
a z
7 7
in te
d ue</w>
for m</w>
hi st
o gen
ch ild
as si
thou gh</w>
ov er</w>
im pro
in j
z ed</w>
m ot
an e</w>
ec ts</w>
or t</w>
posi tive</w>
b ri
A s</w>
ic s</w>
( 0.
t ly</w>
f amil
f requ
et s</w>
sy stem</w>
ograp h
pres ent</w>
ass ess
t e</w>
3 5</w>
3 ,</w>
P A
incre ase</w>
import ant</w>
spec ies</w>
5 -
ent ly</w>
http ://
com m
d er</w>
3 3</w>
re s</w>
t y</w>
i red</w>
ment al</w>
fact ors</w>
struc t
ex pl
C ell</w>
6 6
wor k</w>
b ody</w>
B M
on al</w>
a use</w>
t ak
e x</w>
Res earch</w>
be havi
etw or
os pit
produc tion</w>
us ,</w>
s ul
chang es</w>
inv estig
ous ly</w>
3 2</w>
U n
u k
s ch
l ine</w>
M ar
on str
w ould</w>
re vie
v er</w>
is e</w>
1 /
hy dro
u p</w>
b acter
pot ential</w>
( 3)</w>
re sist
av ail
d ru
sub j
A f
low er</w>
m us
201 2</w>
r at
ex trac
ent ed</w>
sampl es</w>
dem onstr
differen ti
simil ar</w>
201 0</w>
par amet
t .</w>
e th
pro g
ech n
a ffec
proc ess
in fl
val ue</w>
doi :</w>
om ic</w>
met abol
6 8
— H
h om
201 1</w>
201 3</w>
10.10 0
ex pos
wh ile</w>
3 7</w>
S T
po in
a di
wh o</w>
v it
C C
b inding</w>
g en</w>
ne w</w>
f ul
e )</w>
c are</w>
at a</w>
ec tive</w>
obt ained</w>
in iti
ab out</w>
A u
P L
- 1</w>
l ong
M A
gene tic</w>
as c
200 9</w>
plas m
( 2)</w>
follow ing</w>
at er
i str
b ro
al .
6 )</w>
C ar
l ab
st atis
o t</w>
differen ces</w>
li ke</w>
3 6</w>
f urther</w>
ne g
om a</w>
sc i
i f</w>
respectiv el
di d</w>
9 9
e :</w>
ord er</w>
C O
op er
anti -
descri bed</w>
tum or</w>
ro ph
e ther</w>
201 4</w>
in formation</w>
li k
se e</w>
3 4</w>
2 /
pati ent
c al</w>
t -
s ever
om et
develop ment</w>
group s</w>
identi fied</w>
k ed</w>
200 8</w>
P re
el ect
1 ,
fac e</w>
A s
pro b
cor rel
C ol
re ac
m en
7 8
fact or</w>
s um
u red</w>
sy m
( D
o ch
in flu
f r
E R
ne ur
3 8</w>
de fin
S c
y ing</w>
ear ly</w>
ourn al</w>
3 /
6 9
el d</w>
str ic
w w
n etwor
d el
res earch</w>
pop ulation</w>
s .
4 8</w>
p u
0. 8
4 5</w>
) .
ul ts</w>
pol y
d ow
j u
a ut
activ ation</w>
with out</w>
r and
pop ul
as h
id s</w>
co gn
blo od</w>
pati ent</w>
o m</w>
13 7
r al</w>
therap y</w>
is ol
i l</w>
y st
ing .</w>
in -
ro und</w>
cal cul
3 9</w>
6 0</w>
s -
) ;</w>
sen si
i g</w>
g o
an im
on d</w>
we e
4 -
im p
a ver
en viron
ox id
ic e</w>
( T
out com
it y.</w>
provid ed</w>
5 ,</w>
sequ ence</w>
2 ).</w>
( H
en e
ma j
siz e</w>
nor mal</w>
ac cor
lo g
n at
m ain
mem br
9 8
F .</w>
Z h
e ffici
part ment</w>
stim ul
7 )</w>
er ing</w>
200 7</w>
c in
C -
sampl e</w>
l l
sh ould</w>
meth od</w>
com mun
en h
T -
on ,</w>
ens ity</w>
n er</w>
at ely</w>
ac id</w>
a k</w>
pres sion</w>
4 1</w>
C a
Me th
4 ,</w>
con sist
b et
g er
p p
qu anti
d eri
know n</w>
con si
tem per
4 2</w>
hy po
m y
a e</w>
4 3</w>
a h
w om
r ati
F -
5 3</w>
R A
all y,</w>
Mic ro
si s,</w>
lo b
A t
ros s</w>
p on
e m</w>
chang e</w>
ad d
n ec
b as
sti tu
bec ause</w>
con duc
c an
re n</w>
struc ture</w>
sign al
p ur
P er
o st
prim ary</w>
mor ph
e u
201 5</w>
8 )</w>
est er
pro per
PC R</w>
sm all</w>
ag ing</w>
inhib it
pres ence</w>
200 6</w>
1 /j
er .</w>
meas ured</w>
Ch in
si s.</w>
r in
year s</w>
man y</w>
Q u
g e
expres sed</w>
4 4</w>
l it
0. 7
C I
S -
auth ors</w>
i p</w>
ab s
iti es</w>
f t</w>
ation sh
includ ed</w>
l ed
i an</w>
hy per
h ealth
J ournal</w>
S up
no v
ish ed</w>
G T
individ u
s in
feren ce</w>
re v
4 9</w>
Sci enc
larg e</w>
ag ain
A ,</w>
o s</w>
3 .</w>
c ir
meas ure
9 )</w>
et y</w>
ep ti
8 8
I L-
de red</w>
o re
ch rom
d es</w>
sing le</w>
ser v
ro n</w>
ev en</w>
ic ally</w>
N .</w>
tin g
n ing</w>
s et
compl et
yl ation</w>
De partment</w>
t en</w>
200 5</w>
o th
b rain</w>
ul t</w>
re ad
vir us</w>
tissu e</w>
4 7</w>
s l
s our
inter ven
A C
bil ity</w>
i .
Med ic
is on</w>
f em
M at
clu st
recept or</w>
iv en</w>
con tr
R es</w>
f oc
( N
C ancer</w>
t al</w>
again st</w>
fu l</w>
func tional</w>
B e
sever al</w>
es ting</w>
f ind
multi ple</w>
f ile</w>
co h
h el
g i
inf ection</w>
avail able</w>
car di
is h</w>
9 6
y s
i e
res c
sugg est
neg ative</w>
the sis</w>
° C</w>
4 6</w>
( n</w>
in form
ev idence</w>
l u
sh ow</w>
) :
yn am
em i
differen ce</w>
ar mac
cl assi
mo di
ex ampl
mat eri
inhi bi
b ar
rel ationsh
W .</w>
Im mun
( G
cor respon
re m
un i
ex amin
k ,</w>
comp on
str at
l eng
sc op
( 199
p ubl
C or
a )</w>
character is
3 ).</w>
cy t
ourn al.
/ s
( I
A M
posi tion</w>
oc cur
distribu tion</w>
Y .</w>
sequenc es</w>
re sid
7 6
invol ved</w>
gl y
previ ously</w>
A b
c as
10. 137
stand ard</w>
mon th
qu es
f our</w>
1/j ournal.
pt om
in e
know led
molec ular</w>
rev eal
F ron
p rac
pos sible</w>
targ et</w>
10.137 1/journal.
f -
rang e</w>
c op
n an
stud y,</w>
compl ex</w>
C ,</w>
o y
cont aining</w>
Bi ol</w>
qu e</w>
( R
C re
G u
st ate</w>
asc ular</w>
b er</w>
par ti
w ater</w>
reduc ed</w>
de sign
( Table</w>
( E
sc re
c ase</w>
reg ulation</w>
ch ron
am p
ap pl
lik ely</w>
ter ms</w>
cur rent</w>
oc c
d ,</w>
cy to
addi tional</w>
un g
US A
n os
an e
200 4</w>
v es</w>
or i
1 ].</w>
5 1</w>
be ing</w>
5 5</w>
S ur
ri ght</w>
d o</w>
o h
ti n</w>
7 9
r o</w>
l os
inf ec
ti s</w>
n ess</w>
previ ous</w>
m ight</w>
flu o
model s</w>
os om
accor ding</w>
cl es</w>
O r
wh ether</w>
P sych
arti cle</w>
child ren</w>
D ata</w>
N at
e y
1 10
M S
ei ther</w>
k er</w>
ri b
cont ribu
tri bu
em ents</w>
A -
Phy si
at or</w>
st s</w>
d ay</w>
c ases</w>
be fore</w>
condi tions</w>
ac t
b ur
at t
C R
tiv ity</w>
M c
/ S
d ev
res t</w>
g/ m
vi a</w>
f rac
T ran
org an
th ere
ad v
inte gr
dise as
tion s.</w>
ab et
ra y</w>
m .</w>
or al</w>
al -
s ens
a sis</w>
( L
is t</w>
con fir
p ap
plement ary</w>
[ 3
su s</w>
a ir
o id</w>
di tional</w>
d er
st ress</w>
s al
a ff
n er
r e</w>
8 9
particip ants</w>
n ot
consi dered</w>
5 2</w>
ell ular</w>
ac tive</w>
ocy t
sur face</w>
ev ol
c it
on ic</w>
am o
l ed</w>
S e
ul t
determin ed</w>
res sion</w>
l and
m in</w>
inc ub
A S
tic ally</w>
pro mot
ap plic
Ch em
1 –
obser v
0. 6
en s</w>
d oc
re stric
in dependent</w>
( 4)</w>
cogn i
tran sp
W e
gl uc
si de</w>
W ang</w>
individ ual</w>
meth ods</w>
ar ly</w>
p sych
ol e</w>
con tin
N O
s ;</w>
rel ative</w>
n it
ac y</w>
l es</w>
gr ad
ati c
sur viv
Res ults</w>
Sci ence</w>
E M
concentr ation</w>
ver se</w>
sti t
5 4</w>
5 7</w>
C lin
t ur
orig inal</w>
signal ing</w>
enz ym
ti me
regi on</w>
pa ir
us es</w>
rec ei
N ational</w>
t a</w>
ra m</w>
8 7
A P
cl e
ac ross</w>
N P
indic ated</w>
B r
d .</w>
qu ality</w>
um ,</w>
org /
N -
otyp e</w>
5 ).</w>
is m</w>
transcri p
B ar
10.10 38
5 6</w>
anc ed</w>
de f
ter m</w>
re fl
mo use</w>
we ight</w>
h em
sion ,</w>
[ 4
ation s.</w>
e. g
E l
A R
f y</w>
s co
erg y</w>
5 9</w>
ap op
comm on</w>
medi ated</w>
resist ance</w>
us cri
associ ation</w>
d ays</w>
E -
ic h
g iven</w>
man uscri
el s</w>
famil y</w>
fo re,</w>
S P
con struc
trans f
aver age</w>
olog y,</w>
al i
in tr
S ,</w>
M D
es :</w>
p epti
7 0</w>
val u
o k
I C
appro ach</w>
ear ch
r am
ri al</w>
s /
pos ed</w>
provid e</w>
wom en</w>
abl es</w>
R O
l ym
find ings</w>
ph ase</w>
200 3</w>
show s</w>
deri ved</w>
s w
mon s</w>
incre as
P D
4 .</w>
bo di
pat tern
ab le
strat eg
apop to
proc ess</w>
c anc
am mat
le ad
s mo
ma in</w>
uc h</w>
M R
8 0</w>
ol d</w>
m ag
analy zed</w>
In ter
I .</w>
maj or</w>
if ied</w>
el ial</w>
demonstr ated</w>
o ,</w>
ap h
5 8</w>
h ospit
O ur</w>
o gene
revie w</w>
ent al</w>
chem ical</w>
201 6</w>
A mer
resul t</w>
Sc i</w>
li p
rec ord
det ected</w>
analy ses</w>
Th ere</w>
er n
poin t</w>
se par
An aly
5 .</w>
mi x
S im
6 5</w>
R ec
I I</w>
F ur
al g
calcul ated</w>
G er
le ast</w>
ar ch
spec i
ammat ory</w>
20 10
F o
experiment al</w>
l a
4 ).</w>
membr ane</w>
suppor t</w>
cell s.</w>
ox y
it y
f s</w>
S u
molec ul
s ite</w>
defin ed</w>
Cre ative</w>
Amer ic
en d</w>
ativ ely</w>
Af ter</w>
R ev
Com mons</w>
s on
lif er
iz e</w>
A n</w>
00 0</w>
paramet ers</w>
N or
to x
no sis</w>
oc k
p an
interac tion</w>
st re
Med ical</w>
si g
7 5</w>
c e
rand om
6 -
car ri
d ri
ho w</w>
t on</w>
dru g</w>
[ 2
immun e</w>
7 2</w>
di sc
10.1371/journal. pon
I D
W il
at h</w>
h ar
dow n
95 %</w>
pres ented</w>
b loc
w ay</w>
exper i
Th ere
ex t</w>
indic ate</w>
v ement</w>
S tr
us t</w>
pres s
vari ous</w>
respon ses</w>
ard s</w>
su per
proc ed
are a</w>
ti l
vol um
con sid
In tern
st ar
m ,</w>
infl ammatory</w>
us e
pl ant</w>
o ff
ph ot
ne ed
spec ific
dis tin
wh ere
meth od
fluo resc
b el
V -
pro lifer
A D
end ed</w>
e tic</w>
pathw ay</w>
ol ec
S y
A p
bre ast</w>
ex t
p ul
respectivel y.</w>
J .
s ).</w>
[ 5
9 0</w>
surviv al</w>
M C
requ ired</w>
par t</w>
V .</w>
es p
A L
ment .</w>
H e
s us
O p
gen ome</w>
re pe
s en</w>
d ynam
o p</w>
de fic
ma xim
S E
regi ons</w>
val ence</w>
200 2</w>
al ized</w>
h ere</w>
m id
ment ,</w>
anc es</w>
M E
ech ni
t as
m M</w>
em s</w>
N o</w>
fact or
14 7
co -
frequ ency</w>
5 %</w>
r ates</w>
cell ular</w>
mod ul
ed uc
2- s
l at
en ,</w>
w id
man ag
h ep
st ed</w>
it or
2-s 2.0
t ub
sit es</w>
s of
ro p
com po
I N
pu t</w>
ar di
p ow
P ubl
Al though</w>
reveal ed</w>
L i</w>
es c
rati o</w>
a e
h et
f ree</w>
d -
sec ond
6 ,</w>
al ization</w>
ser um</w>
m il
M et
fi eld</w>
ac cur
I S
Fur ther
expos ure</w>
l ig
tion s,</w>
nor mal
mis sion</w>
cor rec
ag g
a c</w>
ric h
en se</w>
6 7</w>
2-s2.0 -
c ess
int ere
leng th</w>
b or
high ly</w>
200 0</w>
diag nos
6 3</w>
in s</w>
at ures</w>
al low
sym ptom
- based</w>
pl ant
er al</w>
er ro
en ing</w>
In stit
R E
val id
mor t
A g
ation s,</w>
correl ation</w>
On e</w>
c ros
concentr ations</w>
Fron t</w>
och ond
pro gr
wor k
perform ance</w>
distribu ted</w>
o S</w>
addi tion,</w>
do es</w>
h or
v al</w>
sec ond</w>
S er
vir al</w>
6 4</w>
mi R-
car b
B ody</w>
Zh ang</w>
temper ature</w>
Meth ods</w>
typ es</w>
I F
P ol
C r
in e,</w>
sel ected</w>
tim es</w>
ur ation</w>
re mo
follow ed</w>
chron ic</w>
sugg est</w>
PL oS</w>
m ine</w>
sel f-
% ,</w>
nov el</w>
( 19
6 1</w>
re le
am ine</w>
med ic
00 00
bi om
rel ev
Ne w</w>
m ed</w>
individu als</w>
ack g
9 5</w>
i k
ad min
h ear
a :</w>
ac hi
ver sion</w>
s ev
Cent ral</w>
m RNA</w>
sion .</w>
10.1038 /
on es</w>
E ffec
ig r
C H
conduc ted</w>
d am
coll ected</w>
* *
i m</w>
ad ap
lin es</w>
on -
decre ased</w>
el ine</w>
en co
ure ,</w>
o ti
compar ison</w>
gen om
Micro bi
ut ri
and ,</w>
ub lic
A B
mechanis ms</w>
op tim
sig n</w>
inj ur
o ol</w>
inf ected</w>
us e,</w>
8 -
20 0</w>
S .
St ud
m a</w>
w ell
at ten
ag e,</w>
ter min
a j
6 2</w>
duc tion</w>
2 ,
er s,</w>
R ep
F r
P E
There fore,</w>
los s</w>
cell s,</w>
physi cal</w>
G G
det ection</w>
M S</w>
it eri
k ey</w>
H y
soci al</w>
b le
10.100 7
h er
em br
11 .
imp act</w>
h al
phosph or
est abl
m ade</w>
l ight</w>
7 3</w>
N E
is ,</w>
transcri ption</w>
re plic
t echni
is su
abet es</w>
min im
cat eg
Cl in</w>
regul ated</w>
amo un
direc t</w>
clu sion</w>
th us</w>
o red</w>
0.00 0
l ay
y l</w>
combin ation</w>
4 .0
M an
in es</w>
sign al</w>
fin al</w>
manuscri pt
H u
[ 6
ab or
l l</w>
( 10
β -
RNA s</w>
Th us,</w>
u ally</w>
deter mine</w>
sc ore</w>
as p
experim ents</w>
200 1</w>
lif e</w>
ag ed</w>
on t
M A</w>
bi ological</w>
high -
reduc tion</w>
y ear</w>
( e.g
S te
H ar
mo re,</w>
v ect
develop ed</w>
i um</w>
d ed</w>
elect ro
( 5
w .
compl ex
ad ju
acc ess</w>
( O
7 1</w>
ber g</w>
( 0
( 1.
12 .
r ing</w>
ure .</w>
networ k</w>
1 ),</w>
fac il
tu red</w>
6 9</w>
( 5)</w>
contin u
b one</w>
cl os
sc ale</w>
A A
a o</w>
car cin
p r
con f
1 19
P S
post -
( b
M .
P T
at or
er s.</w>
l ung</w>
gen ic</w>
pro por
t ation</w>
C ur
l er</w>
gre ater</w>
se ,</w>
er c
tran si
d ra
dom ain</w>
f low</w>
B o
e ;</w>
appro xim
Ch en</w>
6 8</w>
W or
ass ay</w>
g s</w>
spec tr
em b
6 6</w>
v acc
ac et
pl at
h our
vie w
en e</w>
ul ated</w>
li ver</w>
olec ular</w>
le ft</w>
c u
ud e</w>
ab ly</w>
er -
en g</w>
where as</w>
1 —C
et al</w>
cr iteri
c .
ec tr
plasm a</w>
at ors</w>
ic k
v s.</w>
en ergy</w>
10.11 86
ut es</w>
A m</w>
p i
pa ren
met ast
ater al</w>
ocyt es</w>
dat ab
d en
stud y.</w>
d ensity</w>
olog y
ver sus</w>
C an
prot oc
m ass</w>
S oci
v an</w>
all el
ed ing</w>
10.11 11
S m
1 %</w>
le ar
s ’</w>
gener al</w>
fi ve</w>
P e
C y
d ay
em ic</w>
V i
p ut
ww w.
C )</w>
we igh
or ith
med ical</w>
subj ects</w>
ic ity</w>
b ene
m igr
correspon ding</w>
characteris tics</w>
inhibi tion</w>
vit ro</w>
rec ent</w>
repor t</w>
relationsh ip</w>
H ospit
− 0.
mit ochond
H um
mechanis m</w>
1 ;</w>
loc al</w>
ti vi
in sul
o ther
neur ons</w>
S D
st age</w>
N a
f ail
le y</w>
b ir
istr y</w>
ac ute</w>
P I
bacter ial</w>
[ 7
bodi es</w>
pre -
lob al</w>
Pro te
M or
revie w
statis tical</w>
tribu tion</w>
restric ted</w>
d os
pro j
t ain</w>
F in
7 7</w>
es )</w>
7 9</w>
es s,</w>
tri al</w>
B l
a i</w>
Mo re
lym ph
Instit ute</w>
ne ed</w>
Further more,</w>
repres ent
ter n</w>
7 4</w>
8 5</w>
In f
e p</w>
E p
stat us</w>
appro ach
man n</w>
exampl e,</w>
t le</w>
mus cle</w>
ter s</w>
effec tive</w>
7 8</w>
8 1</w>
Intern ational</w>
ol s</w>
H C
identi fy</w>
fi x
consist ent</w>
t ow
ast ro
ac qu
interac tions</w>
cul ture</w>
op ath
inter n
o ve</w>
pl ay</w>
partic ul
7 6</w>
gu id
pe o
T T
E uro
disc us
( see</w>
re as
test ed</w>
( 3
D -
p -
s om
repres ent</w>
bet ter</w>
) :</w>
pattern s</w>
B ,</w>
gener ation</w>
8 3</w>
initi al</w>
d u
sin ce</w>
sol ution</w>
i at
bu ff
g a
i ,</w>
T w
influ ence</w>
US A</w>
t echn
o sis</w>
ic es</w>
ackg round</w>
over all</w>
N ature</w>
anti body</w>
an k</w>
ester n</w>
all eng
X -
in de
( p</w>
sof tw
St atis
peri od</w>
C S
proper ties</w>
suppor ted</w>
dom in
pos si
M in
manuscript .</w>
ex hi
L if
v ent
200 9
of ten</w>
d ose</w>
mut ations</w>
lit er
9 7</w>
month s</w>
m el
diag nosis</w>
appl ied</w>
M ol</w>
tin al</w>
c ere
ac coun
Au th
alg orith
P A</w>
At tribution</w>
id emi
ograph ic</w>
op hy
ep ith
h owever,</w>
w ide</w>
str ain</w>
P B
Clin ical</w>
10.10 9
addi tion</w>
9 6</w>
es /
se g
re production</w>
het ero
pro fil
the m</w>
m g/
al lo
C ell
res ol
sur ger
( 2
an ,</w>
viv o</w>
complet e</w>
increas ing</w>
sensi tivity</w>
10.1016 /S
/ 0
A )</w>
gener ated</w>
em pl
0.00 1</w>
Re fs</w>
pres ent
t s.</w>
mat ri
ob j
ev er</w>
per m
p ublic
requ i
O R
in ,</w>
pre valence</w>
sec re
8 7</w>
ific ation</w>
pa in</w>
S ou
7 -
9 9</w>
gr aph
vie w</w>
4 3
P M
ch ol
pri or</w>
en n
defic i
re li
d on
s or
8 ,</w>
Li u</w>
C T</w>
8 2</w>
und s</w>
x i
fi bro
B -
decre ase</w>
con sum
ass um
medi um</w>
sc al
L ic
t om
con n
estim ated</w>
popul ations</w>
8 4</w>
ne y</w>
sour ce</w>
ec i
resul ting</w>
diff ic
10.1007 /s
over ,</w>
abs ence</w>
8 9</w>
am s</w>
cr yst
assess ed</w>
analy sis.</w>
Ad ditional</w>
micro scop
pe ting</w>
ari a</w>
1 20
C A</w>
8 8</w>
M al
mort ality</w>
per cent
A G
A t</w>
is ed</w>
8 6</w>
w ar
sel ection</w>
In te
incub ated</w>
sti ll</w>
y i
nec ess
it ation</w>
ch alleng
ab ove</w>
9 1</w>
is tic</w>
z -
A .
dis ord
re ference</w>
p H</w>
hol d</w>
T N
de sign</w>
pre gn
t s,</w>
t ative</w>
F e
d en</w>
BM C</w>
ac tivi
9 3</w>
ati n</w>
str ains</w>
vari ation</w>
lin ear</w>
P R
sub sequ
at om
al though</w>
c ess</w>
th em
T echn
det ail
sp ac
isol ated</w>
HI V</w>
I g
kin ase</w>
3 .0
Le e</w>
st ri
V al
activ ated</w>
tak e</w>
reac tion</w>
im aging</w>
( 6)</w>
anc e,</w>
stand ing</w>
( 13
9 2</w>
G r
t ol
[ 10
os ome</w>
cont rib
pat tern</w>
im ages</w>
l ong</w>
ch o
P ri
i )</w>
ful ly</w>
a ro
L ,</w>
pot enti
M ,</w>
relev ant</w>
M olecular</w>
inv a
health y</w>
di men
dec i
form ed</w>
distin c
res earch
infl amm
ca use</w>
r it
are as</w>
P ati
S ub
0.0 5</w>
ord in
(A )</w>
r .</w>
P ,</w>
More over,</w>
ot s</w>
Pl ant</w>
G e
pathw ays</w>
anc y</w>
F ig</w>
( i.
assess ment</w>
em ia</w>
mut ant</w>
direc tly</w>
en -
Analy sis</w>
F or
system s</w>
there fore</w>
B ri
carri ed</w>
tr aining</w>
volum e</w>
str ong
ak e</w>
G rou
ar ter
anim als</w>
O n</w>
amin o</w>
fr ag
ogene sis</w>
e .0
d ys
l and</w>
il d</w>
includ e</w>
um in
im plic
( 6
therap eu
ti li
9 4</w>
7 ,</w>
i di
i j
s ex
f und
( 11
2 ].</w>
t or</w>
ex ten
cul t
a u</w>
and /
t op
pl ants</w>
cont ent</w>
ad ult</w>
4 /
P o
( 15
b ers</w>
suggest ed</w>
— N
7 5
il i
appro pri
http:// www.
H ,</w>
rat s</w>
A v
vari ables</w>
9 8</w>
vers ity</w>
y :</w>
interven tion</w>
co ver
metabol ic</w>
fer red</w>
( 14
S )</w>
C L
M R</w>
m uch</w>
t og
ag e
acc um
pro bl
and/ or</w>
g li
ut ure</w>
it al</w>
S o
sm all
m m
lim ited</w>
e ting</w>
second ary</w>
y c
gluc ose</w>
sh or
sp ati
V er
sion al</w>
Ex per
( 12
press ure</w>
S I
cep t</w>
S D</w>
lo ad
10.1186 /
d r
al ong</w>
per c
control led</w>
s ),</w>
de ath</w>
N ot
ay ed</w>
immun o
a red</w>
st ,</w>
p .</w>
M a
i b
manag ement</w>
o id
Af ric
S w
cy cl
l d</w>
pro posed</w>
oph il
and s</w>
P ath
sugg esting</w>
[ 8
E d
inter pre
G re
fe atures</w>
[ 11
enc e,</w>
meth yl
c ou
fol d</w>
sub st
func tions</w>
10.1111 /j.
lic en
outcom e</w>
S al
ir e</w>
C N
s qu
Wh en</w>
J oh
Un ited</w>
el ev
ograph y</w>
ation :</w>
n .</w>
j o
M on
( 4
knowled ge</w>
or ity</w>
exp ected</w>
produc ed</w>
al tern
th res
[ 9
se en</w>
sev ere</w>
an a</w>
design ed</w>
o k</w>
p en
a b</w>
on e
cri tical</w>
z ation</w>
ac tion</w>
si l
Univers ity,</w>
J M</w>
in si
[ 12
ti ce</w>
co ur
S A
examin ed</w>
( K
S in
10.109 3/
f at
al ign
confir med</w>
d ate</w>
pl an
incre ases</w>
15 0
peo ple</w>
an i</w>
Mat eri
st res
v ey</w>
Sup plementary</w>
D ,</w>
(201 2</w>
affec ted</w>
M T
7 4
spec tive</w>
e b
fo od</w>
o z
st er
r h
c us
dat as
di g
e .,</w>
d ou
ap pe
o .</w>
M I
( c
int ro
sco res</w>
de grad
cy cle</w>
(F ig</w>
show ing</w>
anti bodies</w>
B er
le ad</w>
tak en</w>
S A</w>
w ard</w>
oc k</w>
str ain
otyp es</w>
Ph armac
effici ent</w>
me ans</w>
im age</w>
m es
S O
H -
et ed</w>
sk i</w>
1 :
distribu tion,</w>
n utri
suggest s</w>
ang i
str ong</w>
J ap
lab or
mal e</w>
ane ous</w>
L )</w>
differenti ation</w>
E C
medi um,</w>
o ste
13 0
evalu ation</w>
m m</w>
wh at</w>
D )</w>
Bio Med</w>
mut ation</w>
n s</w>
indic ates</w>
centr al</w>
p y
w a
et er
Con tro
loc ation</w>
(B )</w>
d rom
T R
2 –
meas ure</w>
10.1371/journal.pon e.0
h ost</w>
Publ ic</w>
G l
6 5
pol ym
bi t</w>
struct ural</w>
r up
re ad</w>
dow n</w>
struct ures</w>
f ig
( 7)</w>
Re g
l ack</w>
add ed</w>
it es</w>
e ff
meas ures</w>
knowled g
b ack</w>
Di ff
P S</w>
long -
sp e
perm its</w>
200 8
poin ts</w>
ast ,</w>
50 0</w>
) -
199 9</w>
org anis
trans l
y s</w>
Ac ad
enc es</w>
cap ac
predic ted</w>
reg ression</w>
pl e
app ing</w>
( 16
D evelop
di at
h ab
approxim ately</w>
H 2
6 ).</w>
r at</w>
S ec
9 -
evalu ated</w>
or ,</w>
iz ing</w>
symptom s</w>
ot ox
0. 5</w>
in ary</w>
le -
tiv ely</w>
10.100 2/
at ed.</w>
Americ an</w>
O b
mod er
cogni tive</w>
sequenc ing</w>
S N
publ ished</w>
apopto sis</w>
H E
maxim um</w>
T re
G -
fluoresc ence</w>
rec ru
A m
control s</w>
op en</w>
In t</w>
int ensity</w>
fe w</w>
func tion
H ealth
amoun t</w>
ca used</w>
Re v</w>
ogen ic</w>
st ained</w>
si x</w>
l ing</w>
th al
as e-
pre c
hear t</w>
10 -
ab und
w o
K im</w>
bas eline</w>
feren ces</w>
( %)</w>
nucle ar</w>
Com par
form s</w>
gen omic</w>
tion n
of f</w>
affec t</w>
di abetes</w>
(201 1</w>
su ffici
pre ven
f it
u res
wee ks</w>
recei ved</w>
(201 3</w>
m er</w>
w ise</w>
an o</w>
therapeu tic</w>
d eli
M P
outcom es</w>
( 18
l igh
[ 13
pos e</w>
- up</w>
int es
ur a</w>
6 .</w>
mark ers</w>
fu sion</w>
S i
in st
th ir
ass ess</w>
ad en
5 3
ell a</w>
co very</w>
B u
v ascular</w>
2 ;</w>
coun tri
chem o
process ing</w>
el ectr
to -
l et
u n</w>
app ear
indic ating</w>
ho od</w>
fi t</w>
larg er</w>
pa ir</w>
nat ural</w>
ess ential</w>
rel atively</w>
oper ative</w>
b al
ch arg
mac roph
· ·
[ 14
ro w</w>
re comm
up on</w>
anim al</w>
R ,</w>
enc ed</w>
end oth
I ,</w>
combin ed</w>
bi al</w>
regul atory</w>
Exper im
M )</w>
environ mental</w>
softw are</w>
T r
Dis cus
syn the
st ro
process es</w>
y )</w>
fem al
tissu es</w>
Dis e
im plement
inde x</w>
T L
un it</w>
Ch ar
Hum an</w>
sh ap
behavi or</w>
30 0</w>
Bi ol.</w>
com e</w>
al ph
M -
C I</w>
. org/
res our
ma il
hist ory</w>
ra ther</w>
S S</w>
appro ved</w>
ac id
cros s-
loc ated</w>
ev ents</w>
admin istr
Medic ine</w>
ser ved</w>
or s
In di
E r
Stud y</w>
d .
prolifer ation</w>
2 %</w>
C B
Ch em</w>
on omic</w>
Bi ology</w>
test s</w>
k ers</w>
compon ents</w>
E v
R o
Sci .</w>
l ast</w>
c ut
vis ual</w>
lic k</w>
t ered</w>
ne l</w>
vi sion</w>
esp eci
tu al</w>
op o
fem ale</w>
materi al</w>
M O
ex clud
i on</w>
dist ance</w>
an ch
L t
un restricted</w>
i -
dise ases</w>
ar ity</w>
M y
B ur
( 8)</w>
c .</w>
5 .0
E N
R A</w>
tri als</w>
pre v
E th
B ).</w>
B ec
lab el
u tion
w ash
dev i
re f
categ or
( 17
ren al</w>
si v
R el
especi ally</w>
r a</w>
I -
A M</w>
A N
− 0.0
no w</w>
5 4
En g
an other</w>
ing er</w>
[ 15
O .</w>
commun ity</w>
mitochond rial</w>
ex erc
peri od
a .
E GF
ren g
syn drom
id e
over n
di um</w>
rele ase</w>
ag re
ph armac
y g
is o
( P</w>
recept ors</w>
impro ve</w>
reduc e</w>
Or g
(201 0</w>
ed .
om er
st aining</w>
( 7
− 0.00
syn ap
percent age</w>
k e
il l</w>
compl ic
ov ascular</w>
C .
go od</w>
in trac
T ak
H er
investig ated</w>
- induced</w>
analy sis,</w>
R os
B ra
cur ren
empl oy
C op
Tran s
stre am</w>
ent ly,</w>
C lick</w>
ar ray</w>
n am
Discus sion</w>
ar c
col on
200 7
I T
a round</w>
numb ers</w>
st reng
injur y</w>
activi ties</w>
P O
i e</w>
0. 1</w>
( 8
(e.g .,</w>
throu gh
( p
tion ed</w>
2 ),</w>
lin ked</w>
tem por
appropri ate</w>
Sim il
ag on
cl ear</w>
P r
ro und
l ar
l a</w>
T otal</w>
[ 16
ai l</w>
ocy te</w>
ev ed</w>
2 —C
st ep
identi fication</w>
pre par
en sive</w>
mat ch
14 0
J A</w>
tre n
Euro pe
ar th
matri x</w>
e ffic
pow er</w>
ec tions</w>
gl ut
ti l</w>
s em
a er
c all
re d
pro mo
Statis tical</w>
C G
g lobal</w>
t esting</w>
u str
199 8</w>
y /
C are</w>
statis tically</w>
measure ments</w>
I f</w>
ir atory</w>
z e</w>
B lo
ar ding</w>
si a</w>
tin e</w>
A ).</w>
anc e.</w>
low -
di versity</w>
[ 18
13 .
sub str
Wh ile</w>
9 ,</w>
enh anced</w>
ent ,</w>
lin e
spati al</w>
C C</w>
le uk
ere x
lic ens
high est</w>
distinc t</w>
co ordin
il y</w>
P a
F ir
sensi tive</w>
R ob
R .
m ul
prac tic
f uture</w>
plac ed</w>
doi :
coll ection</w>
el y,</w>
g ,</w>
syn thesis</w>
pa ired</w>
[ 17
As soci
cep ti
cor related</w>
e z</w>
ne tic</w>
S ign
O R</w>
propor tion</w>
medi an</w>
per s
hour s</w>
0. 5
s af
repres ents</w>
hy bri
inc idence</w>
ec om
provid es</w>
S S
r s
aw a</w>
An ti
M i
ip s</w>
wh ole</w>
Car di
ad a</w>
l .</w>
ca re
enzym e</w>
en rich
sh if
con cer
M ac
ste p</w>
Au str
n as
im ag
criteri a</w>
poly morph
c um
expos ed</w>
ha ving</w>
( http://
( 9)</w>
E E
n ,</w>
ne w
under standing</w>
si an</w>
st able</w>
signific ance</w>
ec ting</w>
hospit al</w>
th ,</w>
dat a.</w>
Lif e</w>
pepti de</w>
compon ent</w>
col i</w>
sup pl
ap s</w>
quanti tative</w>
18 0
mem ory</w>
con st
L abor
P P
techni qu
s. org/
tw o-
( 9
b est</w>
( W
F i
a ).</w>
em o
lead ing</w>
wee k
Diff eren
u tili
ex ist
c m
environ ment</w>
l as
on .</w>
fr am
ol ic</w>
a vi
O 2</w>
k er
p t</w>
ful l</w>
po int
s es
M od
th re
α -
re tro
id es</w>
al s,</w>
(200 9</w>
rel ation</w>
oc ardi
o u</w>
de g
B L
oti de</w>
P K
fl ic
ur b
S 1</w>
patient s.</w>
ei ved</w>
te x</w>
cre ativ
pe ak</w>
clu sions</w>
cardi ac</w>
Str uc
f ish</w>
particul arly</w>
suc cess
tum ors</w>
t or
cl ass</w>
( 1)</w>
( V
s ets</w>
H a
( n
mon ary</w>
spec tro
impro ved</w>
evol ution</w>
liter ature</w>
dam age</w>
re produc
Ar ti
erro r</w>
cou pl
partic ular</w>
t i</w>
pap er</w>
D .
Grou p</w>
l -
par as
medi ate</w>
A S</w>
16 0
C al
prog ram</w>
qu al
g 00
applic ation</w>
osom al</w>
ar ,</w>
(10 )</w>
X .</w>
consid er
m ary</w>
R T
Th ey</w>
ly ing</w>
us .</w>
P D</w>
y e
en ting</w>
al s.</w>
vari able</w>
insul in</w>
L D
g ical</w>
condi tion</w>
Gen e</w>
N at</w>
As s
resist ant</w>
os yn
[ 19
u tr
stim ulation</w>
sus cepti
D NA
( a)</w>
H D
C am
Sp ec
as ,</w>
studi ed</w>
induc tion</w>
( d
publ ic</w>
s at
co v
main t
sh ort</w>
Europe an</w>
mon s.org/
mo ti
Neuro sci
respon d
vect or</w>
facil it
Y ang</w>
inhibit or</w>
ecom mons.org/
mot or</w>
creativ ecommons.org/
st -
M J</w>
14 .
comp ut
8 5
molecul es</w>
tol er
measure ment</w>
i ble</w>
bacter ia</w>
L et
6 .0
phosphor ylation</w>
19 0
ac e
phy lo
eri or</w>
f ron
R )</w>
co ding</w>
termin al</w>
membr an
- related</w>
an k
um er
Sin ce</w>
resul ted</w>
E L
3 –
W T</w>
G o
A k
a im
ic k</w>
W al
F ,</w>
epith elial</w>
sur ve
ques tionn
produc ts</w>
g in
Av ail
character ized</w>
Ac ta</w>
ren ce</w>
lear ning</w>
1 ]</w>
scre ening</w>
transp or
E G
% ),</w>
contr ast</w>
C s</w>
II I</w>
T ri
e /
contr ast,</w>
NP s</w>
< 0.0
An n
ox ide</w>
N ucle
S el
Ger man
group .</w>
hel p</w>
* *</w>
ent .</w>
- specific</w>
( 1</w>
H ol
Scienc es
f al
[ 20
at al</w>
endoth elial</w>
3 2
sup plement
coh ort</w>
inform atic
Bi om
oph ag
evalu ate</w>
po or</w>
E ach</w>
ic ation</w>
an i
A C</w>
metabol ism</w>
a qu
ob es
3 ;</w>
m en</w>
ri gh
En viron
199 7</w>
ever y</w>
l or
ann ot
fe ed
In tro
record ed</w>
5 ;</w>
trans mission</w>
z er
expres sing</w>
syndrom e</w>
In formation</w>
y r
deg ree</w>
ag e.</w>
as e,</w>
ro gen</w>
D A</w>
comp u
cul tured</w>
6 4
oxid ative</w>
di et
, 000</w>
t el
in t</w>
dat a,</w>
promot er</w>
at e,</w>
se ud
ne ural</w>
Th er
17 0
Cr yst
U sing</w>
d enti
at ,</w>
buff er</w>
fix ed</w>
st er</w>
Bi ot
Rev ie
200 0
un til</w>
Chem .</w>
lip id</w>
en ess</w>
carcin oma</w>
val ent</w>
Cell s</w>
s ent</w>
ac ts</w>
Sy stem
under st
rand om</w>
in i</w>
V A</w>
ad ults</w>
Fr anc
establ ished</w>
Z .</w>
inflamm ation</w>
dis pl
Ar ab
olog ic</w>
HI V
d uration</w>
ed u
Fin ally,</w>
ul e</w>
rem ains</w>
mit ted</w>
(11 )</w>
can di
p anc
prob ability</w>
R T-
in ser
surger y</w>
( 0.0
ad j
pro f
W estern</w>
ter i
Medic ine,</w>
ann ing</w>
dom ain
embr y
thir d</w>
on e-
( s)</w>
investig ate</w>
F er
b ul
g ra
clust er</w>
(200 8</w>
F L
ad ol
R es.</w>
met a-
adv ant
Sch ool</w>
M C</w>
10 5</w>
In stitu
v el
d y
import ance</w>
ogen ous</w>
(201 4</w>
compo unds</w>
transcrip tional</w>
o tic</w>
lim it
an th
s ection</w>
T ,</w>
am in</w>
re -
man u
ail y</w>
siz ed</w>
intes tinal</w>
15 .
pre pared</w>
ov erex
a y,</w>
I R
ol ig
cor e</w>
o v</w>
main ly</w>
peri ph
n e</w>
H O
An im
con ver
B P
he ad</w>
E S
Me an</w>
co l</w>
(b )</w>
fi el
contrib ute</w>
system atic</w>
abs or
asi c</w>
sup pres
physi ological</w>
g )</w>
es ;</w>
compar is
ang u
Chin a</w>
B ackground</w>
cont ains</w>
auth or
in ation</w>
y ro
C ).</w>
fac t</w>
spec im
O ver
Gen e
dru gs</w>
col um
induc e</w>
3 ,
subsequ ent</w>
follow -up</w>
B )</w>
b asis</w>
23 0
K -
id op
meth ylation</w>
2 16
D O
rec ur
mark er</w>
Tw o</w>
O x
ri g
adju sted</w>
mus t</w>
S M</w>
dynam ics</w>
fil e.</w>
ch ain</w>
necess ary</w>
coh ol</w>
inte rest</w>
C M</w>
ar ch</w>
l ac
I )</w>
I L
con ven
7 .</w>
k id
per cep
cat aly
intro duc
bl ast
( 2.
ol der</w>
L ond
omet ric</w>
classi fication</w>
ed -
maj ority</w>
9 /
T yp
effic acy</w>
(12 )</w>
Re ferences</w>
[ 22
f ying</w>
intere st
al iz
radi ation</w>
w ays</w>
modi fied</w>
S yn
develop ing</w>
C F
sim ul
A D</w>
er ase</w>
ma ke</w>
I P
es s.</w>
ent er
or -
ro om</w>
n m</w>
i on
sign als</w>
tic ip
om as</w>
sur vey</w>
8 4
8 .0
ne um
147 1-
reg arding</w>
doc um
In v
D M</w>
G a
re cogn
ul l</w>
carb on</w>
[ 23
i er</w>
pr inc
prog ression</w>
u sion</w>
networ ks</w>
B ased</w>
10 6</w>
c lo
s son</w>
altern ative</w>
a ir</w>
mit te
e ve</w>
b ot
en si
sk in</w>
E D
Th e
H R
enc ies</w>
al low</w>
foc us</w>
yo u</w>
oxy gen</w>
M ulti
vari ance</w>
ax is</w>
datab ase</w>
— O
lay er</w>
str um
under lying</w>
/ m
re st
Psych iat
long- term</w>
mel an
hydro x
10 %</w>
R adi
Contro l</w>
strateg ies</w>
ser ies</w>
as sign
kn ock
SC s</w>
Wor ld</w>
0. 4
ac ids</w>
ol ,</w>
c -
d a</w>
yo ung</w>
M D</w>
diagnos tic</w>
cl ero
proced ure</w>
12 0</w>
f re
thres hold</w>
ste in</w>
suffici ent</w>
ev id
inc or
10.1038/ n
tre m
w av
can not</w>
accur acy</w>
3 %</w>
E c
tempor al</w>
ol d
A A</w>
T E
. 2
T e
S a
tas k</w>
inter val
hyper ten
ern al</w>
Jap an
[ 24
well -
9 4
itor ing</w>
se ed
f ung
Intro duction</w>
(i. e.,</w>
oc amp
erg ic</w>
protoc ol</w>
capac ity</w>
exhi b
wee k</w>
me an
t )</w>
(200 7</w>
P .
ur ine</w>
enc ing</w>
1. 5</w>
ch i</w>
prog res
chem istry</w>
L a
tog ether</w>
targ ets</w>
mem bers</w>
or th
vi si
neur onal</w>
tow ards</w>
strong ly</w>
re ach
prac tice</w>
(13 )</w>
ic a</w>
F )</w>
extrac ted</w>
resid ues</w>
16 .
ther n</w>
9 .0
e ).</w>
om ics</w>
(http:// creativecommons.org/
( i
RNA -
cer tain</w>
hypo the
con served</w>
chrom osome</w>
10. 3
W ith</w>
ch ec
strateg y</w>
en ch
′ -
Al l
Sou th</w>
B oth</w>
mal aria</w>
ag e-
w ord
ca uses</w>
t et
i es,</w>
air e</w>
A R</w>
7 .0
k .</w>
patient s,</w>
( 198
h eren
migr ation</w>
O c
D ec
phen otyp
cogni tion</w>
S ol
5 –
Effec t</w>
wil d-
D el
cov ered</w>
B re
end ing</w>
algorith m</w>
at ed,</w>
cyto kin
accoun t</w>
an ical</w>
experi ence</w>
er :</w>
(C )</w>
L .
pl ate</w>
2 +</w>
det ect</w>
z ing</w>
f inding</w>
8 .</w>
wh ite</w>
a a
uni que</w>
licen see</w>
S ing
b it
[ 25
n ar
need ed</w>
C P
estim ate</w>
proper ly</w>
om en
respon sible</w>
f ic</w>
p s</w>
transp ort</w>
br al</w>
O ther</w>
10 9.
d aily</w>
ha m</w>
ol y
s le
mal ign
di tion
k el
com mon
subst anti
15 0</w>
gen c
N i
al ter
e k</w>
obt ain</w>
accum ulation</w>
anti bio
fic ial</w>
resp iratory</w>
ution ary</w>
A P</w>
ar k</w>
rec ently</w>
P at
t ors</w>
L u
lead s</w>
resol ution</w>
del e
vis u
. com
repres ented</w>
C u
2 10
phen otype</w>
ly s
Cent er</w>
intern al</w>
trans fer
T im
2. 5</w>
Fo und
guid el
I t
cal ci
Pati ents</w>
pair s</w>
i a,</w>
transf er</w>
S L
A K
predic tion</w>
to ol</w>
3 ].</w>
B rain</w>
in a</w>
v en</w>
e ph
sum mar
effec tiv
E ,</w>
produc e</w>
er t</w>
agg reg
pol ic
1. 0</w>
mix ed</w>
(14 )</w>
i si
es the
it ch
hetero gene
al k
occ ur</w>
n ur
S cal
for d</w>
se x</w>
ec onomic</w>
cl im
group s.</w>
H P
progr amm
cour se</w>
W u</w>
di ver
Develop ment</w>
ul tr
D N
O f</w>
long er</w>
ab ov
0. 0</w>
o di
0. 2</w>
t ax
M M
se arch</w>
ic ro
cardi ovascular</w>
r s</w>
D e</w>
plac ement</w>
Y or
199 6</w>
experim ent</w>
sol u
S C</w>
on set</w>
sampl ing</w>
sur gical</w>
det ect
hi pp
− 1</w>
up per</w>
clin ic
res tin
st abil
ev ent
p al
E B
ju g
am mal
μ M</w>
row n</w>
manu fact
C S</w>
gly c
tion :</w>
1 )
4 ;</w>
t a
3 ),</w>
omet ry</w>
Ep idemi
N T
at s</w>
intrac ellular</w>
sur fac
le m</w>
Arab idop
er v
r ich</w>
12 -
ill ustr
b ut
as sist
[ 26
r ab
us ually</w>
om y</w>
ul es</w>
μ g/m
Gen et</w>
ch ann
G ar
H o
repor ts</w>
um .</w>
dec l
am a</w>
Effec ts</w>
re t
Auth or
H C</w>
17 .
bri d
infec tions</w>
enti fic</w>
estim ates</w>
Com mun
approach es</w>
Op en</w>
al og
p e</w>
cor tex</w>
A ca
sit u
degrad ation</w>
U S</w>
le av
le ,</w>
s a
b eli
demonstr ate</w>
Ap pl
th ank</w>
pro file</w>
use ful</w>
er t
M L</w>
p ack
F unc
ch an
E R</w>
labor atory</w>
Sm ith</w>
( m
relationsh ips</w>
gl y,</w>
B as
chol ester
10.1371/journal.pon e.
cl ose</w>
an ol</w>
Cop y
pul monary</w>
ag ents</w>
. 00
set ting
Prote in</w>
cor tical</w>
vari ants</w>
im pl
10.1016/S 0
re combin
administr ation</w>
de ath
F ol
es/ b
ay .</w>
G ,</w>
at o</w>
exerc ise</w>
O N
di amet
ak i</w>
iti s</w>
fail ure</w>
Arti cle
R i
S E</w>
b a
– 10
En gl
n -
elev ated</w>
l ateral</w>
k a</w>
Rev .</w>
gr an
pro mis
hipp ocamp
periph eral</w>
In de
bel ow</w>
licens es/b
fin d</w>
ist s</w>
° C.</w>
licenses/b y/
I denti
contribu tions</w>
Aca d</w>
bo und</w>
H L
ad he
(15 )</w>
rap id</w>
el ements</w>
gener ally</w>
disord ers</w>
13 6
restin gly,</w>
cont act</w>
group ,</w>
dom ains</w>
deci sion</w>
sec tions</w>
Nat l</w>
transf ected</w>
R u
bi qu
24 0
Col le
so il</w>
gr ade</w>
com peting</w>
H ep
P al
h and
R N
23 .
mat ure</w>
B y</w>
com position</w>
10. 110
Microbi ol</w>
Ex pression</w>
able .</w>
til ity</w>
ell ing</w>
s pl
th i
temper at
MR I</w>
25 0
cl on
respectivel y,</w>
USA )</w>
pre g
bar ri
Pl as
2 )
potenti ally</w>
yl ated</w>
[ 27
pre h
1 :</w>
em at
multi -
18 .
optim al</w>
ri tis</w>
ere ,</w>
wild- type</w>
F rom</w>
(200 6</w>
targ eting</w>
p .
li qu
al one</w>
profil es</w>
induc es</w>
ro les</w>
a ;</w>
G i
osom es</w>
to p</w>
ti t
c ost</w>
on s,</w>
to m</w>
acc es
ro gen
conf idence</w>
in ity</w>
et .</w>
Pro c</w>
ass ays</w>
D u
2 12
er a</w>
sim ple</w>
treat ment.</w>
deli very</w>
Gen ome</w>
Hospit al</w>
exp ect
em bl
M ag
f at</w>
produc t</w>
r ad
arti cles</w>
biom ar
Org an
G L
ass emb
Blo od</w>
wil d</w>
grow n</w>
ro ot</w>
% .</w>
effici ency</w>
M ur
est ed</w>
sub -
requi re
panc re
V an</w>
inhibit ors</w>
un its</w>
S ha
J C</w>
countri es</w>
defin i
s ou
m as
ric e</w>
y a</w>
Bio ch
R P
ish ing</w>
prof es
ow n</w>
10 4</w>
USA ).</w>
an -
J L</w>
R am
ma king</w>
random ized</w>
Res earch
lo ro
v ar
ex tr
analy s
d one</w>
Lic ense</w>
intere sts</w>
Materi als</w>
m uc
er cul
2 1
Inte restingly,</w>
inj ection</w>
ati tis</w>
l )</w>
interven tions</w>
e f
t y
D is</w>
Con clusions</w>
S T</w>
g el</w>
cop y</w>
p neum
plac e</w>
2 17
C E
10 3</w>
9 .</w>
le a
di ab
physi ci
201 7</w>
k -
ad ,</w>
Chin ese</w>
Bi os
frac tion</w>
U K
A ID
f av
P F
(16 )</w>
or ts</w>
on s.</w>
S il
P res
th s</w>
targ eted</w>
continu ous</w>
ne t</w>
< 0.001</w>
In c
al b
cont ext</w>
H B
mag netic</w>
contribu ted</w>
dra w
[ 28
character ization</w>
fo und
ov a</w>
GF -
b ase</w>
diffic ult</w>
10 1</w>
j unc
0.0 1</w>
bi as</w>
n umer
ne utr
tra um
or .</w>
am y
P i
D ru
m l</w>
hab it
t un
D et
sh e
E m
F l
it er
hypo thesis</w>
si c
A pp
R T</w>
M E</w>
pro xim
br ain
st ability</w>
Copy right</w>
fat ty</w>
mer ci
und erg
% ).</w>
substr ate</w>
small er</w>
m os
paramet er</w>
ep id
H A</w>
2 23
on i
ar m</w>
enh anc
St ates</w>
li er</w>
24 .
2 15
ot rop
arti cl
spac e</w>
differenti al</w>
199 5</w>
regul ates</w>
read y</w>
p ed</w>
V ,</w>
dimen sional</w>
medi a</w>
vi ous</w>
m g</w>
3 —C
al most</w>
Ac cor
c ulation</w>
particip ant
sim pl
ex trem
my el
p ic
Immun ol</w>
S ampl
phosph ate</w>
St at
gre en</w>
st ages</w>
H .
iv er</w>
th rom
l y.</w>
tri gg
n ext</w>
aut o
comp are</w>
B a
elect ron</w>
om y
V ari
mat ernal</w>
em erg
s chem
M M</w>
respectiv ely</w>
con jug
+ /
aut om
on ucle
T A
gen otyp
bec ome</w>
A mon
cl onal</w>
id ity</w>
de pres
wash ed</w>
J an
ir a</w>
ti ous</w>
incor por
Qu anti
evel op</w>
identi fi
ce ed
tu res
N umb
V ir
mid d
an teri
ex cept</w>
(S up
hep at
os a</w>
smo king</w>
25 .
2 14
om es</w>
D R</w>
B P</w>
C ha
gener ate</w>
yi el
prob lem</w>
10 7</w>
ti al</w>
through out</w>
Fig ures</w>
time ,</w>
dynam ic</w>
defici ency</w>
H ist
[ 29
Char acter
serv ices</w>
p ig
bir th</w>
gen ce</w>
Bec ause</w>
ma p</w>
up take</w>
L o
al cohol</w>
h er</w>
10 ,</w>
mon itoring</w>
T i
child ren
Tre at
m ammal
rec tal</w>
transi tion</w>
bre ak
c am
is chem
it ud
met ry</w>
L T
isol ates</w>
d evelop</w>
li br
Experim ental</w>
10.1371/journal.pone. 00
S ome</w>
path ogen
Physi ol</w>
tre e</w>
u preg
(17 )</w>
ch ild</w>
11 0</w>
10.10 7
represent ative</w>
C X
is ting</w>
or t
or ing</w>
normal ized</w>
N F-
H igh</w>
probl ems</w>
. edu
– 1.
- dependent</w>
- 3
tic s,</w>
adol esc
G A</w>
sol ub
chan nel</w>
10.10 97
di et</w>
N an
s y</w>
2 29
Arabidop sis</w>
R S</w>
P et
requi res</w>
Soci ety</w>
label ed</w>
ag ent</w>
ro l</w>
lit tle</w>
cor on
B ro
con trac
educ ation</w>
enzym es</w>
h ,</w>
enco ding</w>
z ,</w>
ectiv ity</w>
M ol.</w>
de pression</w>
cl early</w>
S U
dis rup
cult ures</w>
ho use
de hy
appear s</w>
K ar
genc y</w>
2 20
M P</w>
provid ing</w>
ne igh
Amon g</w>
s ph
Hu ang</w>
sing le-
(200 5</w>
bi ology</w>
e w
ment s.</w>
specific ity</w>
– 5
Ad dition
pa rent</w>
M ill
inva sive</w>
sl igh
l ate</w>
sel ective</w>
ex cit
li ving</w>
re cognition</w>
ri fu
di sp
mix ture</w>
fo re
dru g
h is</w>
in put</w>
am b
l ater</w>
z z
resp ect</w>
ex tern
o vari
i es.</w>
it or</w>
bl ue</w>
loc alization</w>
organ ic</w>
s atis
[ 1].</w>
h .</w>
subj ect</w>
D uring</w>
hal f</w>
Associ ation</w>
rou s</w>
F ac
50 %</w>
or s,</w>
mon o
equ al</w>
19 .
in n
ac .
r un
Sec ond
ho u</w>
N ,</w>
D I
for ce</w>
wh e
th ic
A NO
extrac ellular</w>
consum ption</w>
[ 30
it y-
In t
6 3
fl ex
o si
decl are</w>
per son
10.1007/s 00
c m</w>
N I
le sions</w>
ic ,</w>
al le
f f</w>
mut ants</w>
f ru
repe ated</w>
in struc
pro p
Scienc es,</w>
er y</w>
techni que</w>
- 2</w>
studi es,</w>
D E
G C
associ ations</w>
GF P</w>
com pri
enz a</w>
N H
S H</w>
d op
r he
int ake</w>
allow s</w>
D C</w>
S ever
wor king</w>
k i</w>
og en</w>
const ant</w>
b p</w>
ment ation</w>
10 00
pro state</w>
S an</w>
Compar ison</w>
u biqu
vir uses</w>
com merci
he im
res ting</w>
implic ations</w>
ass es</w>
an xi
3/ p
ast ric</w>
K n
R E</w>
prot ective</w>
T a
40 0</w>
Ch ang
e f</w>
occur s</w>
S equ
5 /
agre ement</w>
cont ained</w>
vari ability</w>
ri s</w>
post erior</w>
2 11
y ).</w>
mitte e</w>
em ber</w>
se as
N ov
synap tic</w>
P )</w>
27 .
– 4
el er
26 .
compar ing</w>
equ i
ri d
impro vement</w>
t ob
atten tion</w>
Scienc es</w>
f low
ul ty</w>
ec h</w>
mg/ k
siv ely</w>
fram e
sci enc
observ ation</w>
sp inal</w>
Me di
tim icro
(18 )</w>
con flic
h and,</w>
nan op
transcri pt
regul ate</w>
2 13
p ain
W o
in strum
develop mental</w>
prepar ation</w>
nucle otide</w>
b od
sub stitu
ag en</w>
P ress</w>
Com peting</w>
H el
issu e</w>
curren tly</w>
l angu
ac tin</w>
in depend
in e-
model ing</w>
rem aining</w>
ing :</w>
diab etic</w>
fig ure</w>
allow ed</w>
w al
exampl e</w>
clust ers</w>
μ l</w>
yc in</w>
occur red</w>
classi fied</w>
K .
ast er</w>
d x
3/p nas
10.107 3/pnas
M u
b ind
k in</w>
2 28
li on</w>
Addition ally,</w>
ext ent</w>
Joh n
mic e.</w>
lin k</w>
manufact ure
vent ric
im pair
cell -
– 3
sligh tly</w>
expl ained</w>
Y es</w>
re construc
as th
calci um</w>
J P</w>
cl ear
ro b
th at,</w>
ativ es</w>
P op
gly cer
replic ation</w>
d end
c DNA</w>
add res
P ost
J i
2 18
S NPs</w>
– 6
preven tion</w>
mol /
k ine</w>
al ready</w>
fe eding</w>
pe ak
con stitu
T A</w>
A T</w>
allel e</w>
inhibit ory</w>
no de</w>
sh ip</w>
reduc ing</w>
T ur
di scri
g el
H igh
promot e</w>
( 95%</w>
system ic</w>
10 −
se .</w>
discri min
di lu
public ation</w>
O -
Mo del</w>
C ir
n ature</w>
or d</w>
em er
divid ed</w>
n ed</w>
B R
pe ti
plasm ic</w>
admin ist
pl us</w>
B acter
Di ag
D S</w>
2 24
bl ack</w>
v s</w>
prev ent</w>
occ up
100 0</w>
streng th</w>
olog ous</w>
assemb ly</w>
st ain
sk y</w>
techniqu es</w>
ang le</w>
common ly</w>
per sist
Austr al
r ine</w>
10 9</w>
Pe diat
bas al</w>
0. 3
m arg
reac tive</w>
d ance</w>
Meth od
10 2</w>
28 /
achi eved</w>
treat ments</w>
experiment s.</w>
er ic
pos ite</w>
foc al</w>
A F
kid ney</w>
ai m</w>
B el
M L
a ther
exhib ited</w>
4 %</w>
P C</w>
– 12
vari ety</w>
L ev
– 11
T )</w>
B S</w>
( t
ye ast</w>
m u
y et</w>
0 ,</w>
D R
H or
ad equ
U K</w>
in oc
p h</w>
b and</w>
Par ticip
informatic s</w>
in .</w>
e h
Pro g
A J</w>
behavi oral</w>
B .
specific ally</w>
c es
ul a</w>
not ed</w>
b )</w>
gen es,</w>
0. 3</w>
ep idemi
condi tions.</w>
10.1016/j. j
T C
D es
y ;</w>
ros ophil
B on
ver te
cent rifu
all ,</w>
model .</w>
2 19
adv anced</w>
ari es</w>
St udi
occ us</w>
Y am
foc used</w>
rec ip
B al
2 25
s plic
prim ers</w>
( 2</w>
X u</w>
it a</w>
anti gen
conven tional</w>
S 2</w>
l act
M il
5 ),</w>
k o</w>
10 8</w>
G E</w>
domin ant</w>
wid ely</w>
re al</w>
m ing</w>
gen otype</w>
call ed</w>
60 0</w>
con serv
en .</w>
as ing</w>
con sent</w>
(200 4</w>
Bra z
obes ity</w>
Ac knowledg
2 27
l in</w>
- like</w>
cyt os
spectr um</w>
vir us
ex isting</w>
M ost</w>
probl em
mal es</w>
M el
CA ,</w>
plant ation</w>
fe ature</w>
M ul
w ater
(http://creativecommons.org/ licenses/by/
S R
or s.</w>
U T
pregn ancy</w>
U .
ent s,</w>
id al</w>
abund ance</w>
detail ed</w>
Y o
Colle ge</w>
ch i
L in
3 D</w>
2 26
F u
inter view
vari ant</w>
ast er
re verse</w>
e ight</w>
K u
h u
f .</w>
E .
w all</w>
J R</w>
2 2.
my ocardi
hist o
cur ve</w>
re tin
(19 )</w>
ar ra
Hospit al,</w>
I O
att ach
thic kn
alph a</w>
ex amine</w>
sp .</w>
et ,</w>
anti gen</w>
observ ations</w>
te ,</w>
recru it
yl -
st or
com preh
remo ved</w>
read s</w>
appe ar</w>
K o
de ,</w>
g radi
( 3.
v as
up -
14 -
ch os
H R</w>
acqu isi
25 0</w>
s even</w>
ner v
28 .
st ates</w>
4 ,
D J</w>
flu id</w>
expl ain</w>
pur ified</w>
b ack
cont ain</w>
predic t</w>
t ex
inter val</w>
at e
on e,</w>
evol utionary</w>
7 ).</w>
D on
stimul ated</w>
so dium</w>
F A</w>
gi ve</w>
con cep
dis order</w>
bi op
6 /
sen se</w>
A —C
En doc
con c
gn os
re covery</w>
atten u
T ox
diagnos ed</w>
es ).</w>
ig ma
anteri or</w>
moder ate</w>
subj ect
includ es</w>
macroph ages</w>
t ures</w>
A L</w>
deri v
ec tion,</w>
D ).</w>
4 —C
A no
ul ate</w>
acqu ired</w>
hum ans</w>
D rosophil
al tered</w>
id en
S V
em is
ar a</w>
F re
bi osyn
o g</w>
ch ro
du plic
he at</w>
Nat .</w>
Fo od</w>
n a
B A</w>
e di
mo vement</w>
res on
b ackground</w>
st ly</w>
as e.</w>
B ay
6 ;</w>
A ge</w>
pepti des</w>
test .</w>
(e.g .</w>
CD 4
femal es</w>
possi bility</w>
frequ ently</w>
pos t</w>
199 4</w>
guidel ines</w>
− /
ant ly</w>
ob acter
t end
h e</w>
s '</w>
time .</w>
enti re</w>
re al-
P G
ob ic</w>
r ing
Wil li
su it
stro ke</w>
model ,</w>
Me as
descri b
b ,</w>
hom e
Lic en
8 3
ad verse</w>
1 ],</w>
Ph il
tiv ari
asp ects</w>
us al</w>
minim um</w>
id a</w>
olog ies</w>
A I
pri v
trans genic</w>
2 1.
acc ept
sol id</w>
progr am
resp ective</w>
as ym
N S
m apping</w>
Treat ment</w>
ent ation</w>
yi eld</w>
distin gu
ar ly,</w>
E )</w>
phylo genetic</w>
Labor atory</w>
invol ving</w>
contribu tion</w>
sur vi
T G
micro bial</w>
complex es</w>
recombin ant</w>
m )</w>
C ri
coron ary</w>
sc en
a ud
at tem
effectiv eness</w>
4 ),</w>
employ ed</w>
tub ercul
si s
C M
J S</w>
min .</w>
K a
el ,</w>
op en-
9 3
un it
[ 33
pl ates</w>
11 -
able ,</w>
** *</w>
requ ire</w>
( in</w>
posi tions</w>
ha pl
need s</w>
if y</w>
ash i</w>
in stitu
Found ation</w>
d ens
L in</w>
sc i</w>
extrac t</w>
l ast
12 5</w>
diet ary</w>
centrifu g
proj ect</w>
i ous</w>
– 7
ag en
Sup por
x ,</w>
j ust</w>
aut ophag
all ing</w>
M ed.</w>
mon th</w>
O S</w>
ut roph
P ub
10.11 28/
p ,</w>
R I
form ing</w>
K ,</w>
sens or</w>
maint ained</w>
l d
secre tion</w>
F lu
sour ces</w>
0. 4</w>
n ational</w>
separ ate</w>
si lic
f ar
B C</w>
har v
sever ity</w>
extern al</w>
D at
year s,</w>
Sever al</w>
um -
show n
materi als</w>
l ist</w>
proced ures</w>
N ak
is ation</w>
Neuro sci</w>
in sec
put ative</w>
el im
ro p</w>
lo ad</w>
ad op
or i</w>
at e.</w>
op e</w>
Scal e</w>
C D</w>
vit amin</w>
som e
sim ult
famil ies</w>
Typ e</w>
meta- analysis</w>
control .</w>
] ;</w>
v a</w>
reg im
m s,</w>
pro be</w>
y th
typ ical</w>
G al
tox icity</w>
v .</w>
candi date</w>
z o
confir m</w>
S J</w>
J ,</w>
H e</w>
charg e</w>
k es</w>
inform ed</w>
se p
transcrip ts</w>
molecul e</w>
s per
201 2).</w>
inhib its</w>
t on
treat ment,</w>
recomm end
D om
e ther
reac tions</w>
E ur</w>
A /
R J</w>
men tioned</w>
simil arity</w>
(201 5</w>
th .</w>
os c
vacc ine</w>
8 ).</w>
oth ers</w>
w estern</w>
in o</w>
t es
tribu ted</w>
sch ool</w>
119 .
mo de</w>
W H
I V</w>
analy sed</w>
ac u
bo und
t 00
underst and</w>
mammal ian</w>
T B</w>
3 00
I s
T .
H ear
C og
( the</w>
f ill
t able</w>
mi RNAs</w>
b ).</w>
·· ·
re pair</w>
gnos tic</w>
tro ph
SN P</w>
M T</w>
th yro
doi .org/
[ 34
ne ar</w>
ocy to
t ed.</w>
studi es.</w>
b asic</w>
li po
An der
Dise ase</w>
incub ation</w>
T ra
- 0.
valid ation</w>
mech anical</w>
B C
ma x</w>
orig in
behavi our
ed )</w>
op tical</w>
Ac cess</w>
um at
v ul
f a
min utes</w>
E S</w>
er ic</w>
end ogenous</w>
embr yo
sour c
f its</w>
extrac tion</w>
of -
H an
other wise</w>
p ass
compo und</w>
1.0 0</w>
Ch ild
os h
lin k
sex ual</w>
P an
C as
parti cles</w>
11 1</w>
P K</w>
Z ha
on to</w>
i i</w>
M ut
a ren
L oc
L C</w>
29 .
b erg
μ m</w>
C at
im a</w>
ch lor
cryst al</w>
stud ents</w>
parti al</w>
anti oxid
nec ro
diff er</w>
S H
no ise</w>
2 ]</w>
se ems</w>
co sts</w>
exclud ed</w>
fin anc
g astric</w>
rem ained</w>
atic ally</w>
RT- PCR</w>
align ment</w>
no des</w>
cho ice</w>
displ ayed</w>
Ano ther</w>
e e</w>
invol vement</w>
P s</w>
T an
en ed</w>
correl ations</w>
ab dom
port un
sul f
pl ays</w>
So c</w>
for c
de -
G .
X i
ques tions</w>
F ish
B M</w>
prot ection</w>
E duc
(Sup plementary</w>
I V
Sur g</w>
5 00
Wh it
R M</w>
cir cul
system .</w>
y el
E M</w>
ro log
N S</w>
suscepti bility</w>
A ut
o ing</w>
mo tion</w>
ad heren
ation -
J H</w>
h am
ch er</w>
T er
10 .</w>
J D</w>
7 3
n ic
hep atic</w>
interpre tation</w>
1. 2</w>
C Y
it ems</w>
201 3).</w>
review ed</w>
On c
A U
S R</w>
w ind
coun ter
feren c
refl ect</w>
differenti ally</w>
oc ar
apopto tic</w>
wh ose</w>
[ 35
2-s2.0- 00
des p
pl ot
Identi fication</w>
J J</w>
mo v
T ren
hy d
ac ter</w>
em p
ac tions</w>
ec tion.</w>
G ra
e str
integr ated</w>
hydro gen</w>
ar row
eg et
acc eler
applic ations</w>
p 53</w>
J E</w>
ad s</w>
4 –
co efficient</w>
desp ite</w>
PB S</w>
dx .
tow ard</w>
expl an
pro gen
el ess,</w>
On col</w>
high ligh
e asi
s n
le t</w>
on line</w>
dele tion</w>
ro ll
p ast</w>
activ ity,</w>
i ting</w>
M it
ap er
(200 3</w>
assign ed</w>
g am
T or
reg ard
E vol
E valu
app ed</w>
Inf ect</w>
hem at
bal ance</w>
w ard
– 13
t ail
Soci al</w>
m L</w>
Psychiat ry</w>
dx. doi.org/
A B</w>
ant agon
O l
e- based</w>
o rectal</w>
Ass ess
S P</w>
mi RNA</w>
us h
et t</w>
h ere
ind ex
N F
O s
Numb er</w>
Di abetes</w>
I R</w>
e ),</w>
olog y.</w>
In cre
Drosophil a</w>
inj ected</w>
S L</w>
L A</w>
di l
ting ,</w>
complet ely</w>
ou gh</w>
co effici
diseas e,</w>
z er</w>
microscop y</w>
stimul i</w>
T L</w>
shap e</w>
blo t</w>
4. 0</w>
Con clusion</w>
il s</w>
E C</w>
Phy s.</w>
10.1097 /
ed :</w>
( U
x -
prob ably</w>
ner ve</w>
gen es.</w>
ovari an</w>
L O
P M</w>
it ative</w>
activ ity.</w>
lea f</w>
4 ].</w>
particip ated</w>
(c )</w>
g ri
N o.</w>
the tic</w>
ver s</w>
toler ance</w>
liqu id</w>
L anc
T O
( 10</w>
feed back</w>
examin ation</w>
od e</w>
defici ent</w>
b ly</w>
h ic
compar able</w>
devi ation</w>
D ev
lik eli
i b</w>
inhibi t</w>
B en
cyt otox
implement ation</w>
Nor th</w>
administ ered</w>
tr ue</w>
ass embl
i ron</w>
f res
bet a</w>
cere bral</w>
am ide</w>
chemo therapy</w>
2 +
Y u</w>
ym al</w>
Nucle ic</w>
syn th
p seud
stimul us</w>
loc i</w>
per form</w>
vis ed</w>
M ore</w>
199 3</w>
f lo
D esp
le g
An n</w>
orig in</w>
pres cri
inva sion</w>
N on-
chang ed</w>
to ols</w>
ent s.</w>
promot es</w>
N K</w>
org an</w>
e- specific</w>
3 K
rati os</w>
pan el</w>
PA R
J o
hi a</w>
( 1
26 /
gene sis</w>
ar i</w>
typ ically</w>
C V
met ric</w>
10.1371/journal. p
ear lier</w>
tur n</w>
Bioch em</w>
questionn aire</w>
fron tal</w>
Simil arly,</w>
ar rang
se arch
a ),</w>
. ac.
Anim al</w>
op portun
pol l
HIV -1</w>
P V
saf ety</w>
condi tions,</w>
T B
li es</w>
Ser v
Z hou</w>
diseas e.</w>
C ap
Desp ite</w>
ro t
sol ute</w>
0 ,
j .
pre cur
random ly</w>
W ol
alle l</w>
d ors
rit ten</w>
G C</w>
201 1).</w>
af f</w>
2010 ).</w>
sk el
inhib ited</w>
ve hic
Ex p</w>
star t</w>
cr uc
separ ated</w>
metast atic</w>
19 7
Com put
acc ess
11 6</w>
influ enza</w>
co d
Al z
coun tr
http:// dx.doi.org/
st ored</w>
p d
ar y
scen ari
dri ven</w>
qu it
arter y</w>
Inde ed,</w>
Ac ids</w>
tion ing</w>
blo od
consid er</w>
[ 36
m ach
sle ep</w>
iz oph
d it
pan el
ment s,</w>
c ular</w>
s or</w>
cont amin
exp an
ul in</w>
loc us</w>
metast asis</w>
S ym
10. 12
main ten
w s</w>
g astro
d rin
enrich ed</w>
y er</w>
sim ulation</w>
TN F-
Accor ding</w>
phen omen
reveal s</w>
T o
m s.</w>
k it</w>
ant ,</w>
Studi es</w>
behavi our</w>
down stream</w>
K e
auth or</w>
pol ar
time -
dys function</w>
11 3</w>
– 15
c av
serv ice</w>
( J
El ect
plasm id</w>
12 1</w>
i .</w>
S F
p il
1. 1</w>
Di st
BM I</w>
ac char
– 14
B or
itud inal</w>
F urther</w>
I s</w>
cur ves</w>
vi ol
compu ted</w>
K ore
n c
us ers</w>
direc tion</w>
chos en</w>
avail ability</w>
exhi bit</w>
shif t</w>
F ar
V is
Ca 2+</w>
micro array</w>
S tre
bene fit</w>
Par k</w>
dou ble</w>
cas es,</w>
ens ure</w>
cover age</w>
h and</w>
accur ate</w>
ar t</w>
tr yp
R od
subj ected</w>
tum our</w>
mark ed</w>
com peti
spec tiv
cul tiv
fluoresc ent</w>
D em
nan o
On ly</w>
11 5</w>
bloc k</w>
no d
th es
R is
pu b</w>
( 5</w>
accor dance</w>
us ed.</w>
F ri
b on
( 3</w>
ro te</w>
manufacture r
cont ex
e j
Biot echn
vol t
trans ferred</w>
T um
I D</w>
den ot
comp an
ampl ification</w>
P H
0. 8</w>
eth yl
Afric an</w>
resul ts.</w>
genom es</w>
Alz heim
HI V-
0. 6</w>
° C,</w>
comparis ons</w>
pri mar
eng ine
ar s</w>
im paired</w>
princ i
cyto kine</w>
ther mal</w>
super nat
U l
g er</w>
of il
pres su
b ov
cholester ol</w>
- M
match ed</w>
enh ance</w>
ement .</w>
tak ing</w>
al ways</w>
re main</w>
al ;</w>
cas p
modi fic
f ar</w>
the ore
– 8
Fir st,</w>
jo int</w>
- 5
14 6
over l
I G
Gen etic</w>
pre ci
ol ar</w>
0 1</w>
g ov
ting .</w>
u st
or ation</w>
ation ;</w>
pathw ay
w an
spectr a</w>
con clud
D E</w>
L ip
Pro ceed
A G</w>
2. 0</w>
m amm
adhe sion</w>
overex pression</w>
C L</w>
radi o
Bi ophy
cytokin es</w>
di verse</w>
2 :</w>
predic tive</w>
pers onal</w>
11 2</w>
Zha o</w>
n g/m
b ox
abil ities</w>
ri tic</w>
pancre atic</w>
sub unit</w>
g ain</w>
real- time</w>
bu il
plat el
per me
estim ation</w>
appe ared</w>
bl u
Com pl
ev ent</w>
G lobal</w>
P or
integr ation</w>
W at
mag nit
prim er</w>
re p
ill us</w>
mail :</w>
pro spective</w>
gh ts</w>
h ex
de si
D H
D r.</w>
bre vi
enc e.</w>
O ut
tra ditional</w>
diamet er</w>
rap id
down -
hy th
gr ap
recruit ment</w>
[ 37
so ,</w>
P rac
phosph at
P J</w>
( −
b enz
An d
it ,</w>
refl ections</w>
Res p
r ural</w>
group s,</w>
f etal</w>
we ak
S uch</w>
un e</w>
gen der</w>
ST AT
issu es</w>
out put</w>
] ).</w>
specim ens</w>
sen sus</w>
f el
met al</w>
tren d</w>
the ory</w>
ow ever</w>
al dehy
e z-
ill ary</w>
C R</w>
L ong
f ed</w>
ation )</w>
sampl es.</w>
datas et</w>
Z n
P R</w>
descri be</w>
Fol low
plas tic</w>
9 ).</w>
10. 15
L im
z a</w>
f as
i ent</w>
(200 2</w>
IF N-
ures .</w>
v eget
u tive</w>
as tic</w>
re ly</w>
di scre
ol a</w>
bar s</w>
myocardi al</w>
colum n</w>
E D</w>
id el
discus sed</w>
sens ory</w>
read ing</w>
12 .</w>
p ac
G ri
G astro
protein s,</w>
introduc ed</w>
gre at
str a
solub le</w>
15 -
H am
n or</w>
protein -
m l
as .</w>
Endoc rin
D S
investig ation</w>
il tr
nor m
R h
psych iat
Su n</w>
im medi
commerci al</w>
ar t
n g</w>
ch loro
5 —C
H D</w>
M as
ell i</w>
y ond</w>
Cent re</w>
h ome</w>
ig n</w>
m .
U .</w>
Tren ds</w>
Particip ants</w>
urb an</w>
mo l</w>
pro -
suit able</w>
Pro t
p l</w>
on ce</w>
word s</w>
initi ation</w>
13 -
cent er</w>
G iven</w>
ste ad</w>
Dru g</w>
dos es</w>
l s</w>
tra its</w>
hydro gen
39 0
ig ene
perc eived</w>
B D</w>
chrom atin</w>
inc id
N .
m one</w>
glut am
( 4.
grow ing</w>
rang ing</w>
Ne ther
re .</w>
R F
[2 ].</w>
organ ization</w>
CO 2</w>
g al
ne utroph
min ,</w>
st ero
success ful</w>
an s,</w>
a /
b ile</w>
g iv
(D )</w>
cle av
ever th
B rown</w>
26 0
N on
correc t</w>
frame work</w>
Proceed ings</w>
M ech
T F
R he
kin e
resour ces</w>
reduc es</w>
in k</w>
109. 5</w>
4 00
siz es</w>
dep th</w>
ey e</w>
sch o
mitochond ri
aff inity</w>
C amp
clos ely</w>
h r
he ad
ques tion</w>
/ 00
E qu
cir cum
E A</w>
subsequ ently</w>
Ne w
12 ,</w>
add ress</w>
e k
for ward</w>
Nether land
5 ′-
psych ological</w>
el ic
coupl ed</w>
repor ting</w>
pl ot</w>
11 7</w>
un t
par allel</w>
sequ ently,</w>
N ic
mo bil
I M
organis ms</w>
pro gnostic</w>
T H
ti es,</w>
speci es,</w>
osc ill
embry onic</w>
Th ree</w>
likeli hood</w>
Lond on</w>
C K
F act
co ver</w>
L a</w>
R D</w>
[ 38
lim it</w>
b idity</w>
midd le</w>
design ,</w>
cer v
se l</w>
las er</w>
37 .
chann els</w>
5 ,
malign ant</w>
sel f</w>
occur rence</w>
as ked</w>
morph ology</w>
izoph ren
F ran
Com mittee</w>
commun ication</w>
o .
w er</w>
sh ar
lat ter</w>
gr ant</w>
b ron
se ed</w>
M B</w>
13 0</w>
36 .
ultr as
h ard
experi enced</w>
co m</w>
EL IS
iden tical</w>
categor ies</w>
ble -
St and
b 0
ti es.</w>
er ’s</w>
ampl it
cal i
supplement ed</w>
Q .</w>
col or</w>
and ed</w>
D o
Lanc et</w>
mat ter</w>
complet ed</w>
recei ving</w>
sp ont
s ect
Bio informatics</w>
(i. e.</w>
gly co
os clero
ne o
bro ad
fl av
achi eve</w>
J ones</w>
av oid</w>
frequ encies</w>
TL R
sk ill
D M
11 9</w>
34 .
ar com
scienc e.
hybri di
affec ts</w>
ob last
l an
Y .
H ere,</w>
ed ;</w>
bacter i
e- wide</w>
produc ing</w>
10.1186/ 1471-
in clusion</w>
on tal</w>
V ol
thou ght</w>
emo tional</w>
obj ective</w>
thickn ess</w>
vari abl
A 1</w>
R ich
ity :</w>
6 %</w>
7 %</w>
Bi ological</w>
201 4).</w>
C ali
ve al</w>
in e.</w>
I :</w>
j ect
( for</w>
Gen eral</w>
tivari ate</w>
at ter
B 1</w>
v inc
– 16
arth ritis</w>
al a</w>
fibro blast
vir ul
speci es.</w>
adj ac
6 —C
re ferred</w>
work ers</w>
or ph
mis sing</w>
trac t</w>
equi valent</w>
vari ations</w>
system ,</w>
Gen es</w>
3 )
ch am
199 2</w>
j ournal</w>
pur ch
par ts</w>
primar ily</w>
12 3</w>
Revie w</w>
A m.</w>
ak a</w>
lig and</w>
Licen se,</w>
ne on
sh o
13 3</w>
G O</w>
on c
ei j
r are</w>
omet er</w>
ac i
b .</w>
35 .
s in</w>
nucle us</w>
regul ating</w>
depend ing</w>
clust ering</w>
C d
characteris tic</w>
cit ed.
136 5-
olog ically</w>
represent ation</w>
col orectal</w>
ri st
ventric ular</w>
eth anol</w>
br anch
mainten ance</w>
S an
10 7
mag n
immun ity</w>
us er</w>
ures ,</w>
n ative</w>
4 2
r hyth
St ate</w>
financ ial</w>
direc ted</w>
polymorph is
8 %</w>
ber t</w>
10.10 2
Pol y
complic ations</w>
oxid ation</w>
[3 ].</w>
H ow</w>
sh ared</w>
hist one</w>
spe ed</w>
acquisi tion</w>
11 .</w>
sup plementary</w>
tic ity</w>
c is
og lob
ot a</w>
transcrip t</w>
un less</w>
(A d
Th om
E sch
meas uring</w>
15 7
Pro c.</w>
ext ended</w>
factor s,</w>
el der
AT P</w>
0.0 0</w>
Co h
0. 7</w>
coun t</w>
f ast</w>
in d</w>
epith eli
B ir
l uc
alter ations</w>
b ond
10 8
ep t</w>
F O
it ect
on om
ag ement</w>
reas on
ter ,</w>
S um
ch a
leav es</w>
challeng e</w>
P E</w>
larg ely</w>
t s
ric s</w>
mo tiv
[ 39
1. 3</w>
Hear t</w>
C J</w>
F em
sion s.</w>
mod ulation</w>
medic ine</w>
le f
Environ mental</w>
rab bit</w>
en sis</w>
13 1</w>
no l</w>
inf iltr
set ting</w>
detail s</w>
step s</w>
κ B</w>
Pri mary</w>
polym erase</w>
hol ds</w>
G AT
expres sion.</w>
th ers</w>
decre ases</w>
ab normal
ether ,</w>
langu age</w>
bor n</w>
c ad
manuscri pt</w>
ru n</w>
L D</w>
determin ation</w>
m e</w>
is s</w>
low est</w>
hor mone</w>
1. 00
A gr
In vit
insi c</w>
gluc os
10 6
amoun ts</w>
are s</w>
C E</w>
< 0.00
U se</w>
re ver
( Q
nit rogen</w>
en erg
10.11 26/
rou gh
ane ously</w>
col le
En vi
log ical</w>
M Y
timicro bial</w>
home ost
38 .
R C</w>
ip al</w>
100 %</w>
12 6</w>
E -0
Be havi
E pub</w>
E T
chro mat
- H
ant a</w>
R us
al ing</w>
V )</w>
there by</w>
v es
it .</w>
W .
at tri
su g
C ul
14 0</w>
erro rs</w>
AID S</w>
Lt d
C /
fung al</w>
end s</w>
Ch i
n .
st om
- old</w>
protein ,</w>
quanti fied</w>
popul ation.</w>
it ory</w>
bur den</w>
bene fits</w>
con form
oxy gen
11 4</w>
Pre dic
om on
18 0</w>
b ar</w>
L M</w>
immedi ately</w>
cruc ial</w>
RO S</w>
inf arc
abil ity,</w>
Pre vious</w>
adap tive</w>
S n
f our
health care</w>
weigh ted</w>
I .
o ids</w>
compreh ensive</w>
12 8</w>
si RNA</w>
it z</w>
John son</w>
expl ore</w>
Envi ron</w>
gen otypes</w>
[4 ].</w>
ement ,</w>
expres s</w>
(200 1</w>
extrac ts</w>
thre e-
techn ical</w>
( data</w>
N K
reg ular</w>
ench ymal</w>
– 17
0. 9</w>
I P</w>
h an</w>
research ers</w>
L ow
po ol
−/ −</w>
w ent</w>
r i</w>
N etwor
esc ence</w>
ad es</w>
N ot</w>
su ff
In hi
sign alling</w>
re tri
bet a-
atom s</w>
adequ ate</w>
present ation</w>
μ L</w>
ampl ified</w>
ve si
μ g</w>
ig u
P ot
cerv ical</w>
b al</w>
gre at</w>
F 2</w>
squ are</w>
y stem
st aff</w>
12 2</w>
Chin a
Wh ite</w>
C CA
el ement</w>
C 1</w>
Simil ar</w>
hist or
Hy per
P 1</w>
G S</w>
kin s</w>
cir cu
T M</w>
Cent er,</w>
pl os
in ated</w>
statis tics</w>
7 /
compar ative</w>
g et</w>
C H</w>
electr onic</w>
di abet
mem ber</w>
ag u
t ed,</w>
eric hia</w>
g as</w>
g overn
Immun o
recomm ended</w>
S W
J W</w>
sus p
commun ities</w>
12 7</w>
reproduc tive</w>
mic e,</w>
hypo x
10 9
A h
acc o</w>
substanti al</w>
R L</w>
an n</w>
ed ly</w>
Sign ific
/ B
12 9</w>
M G</w>
licen se,</w>
R a
T GF-
possi bly</w>
Mar tin
em ph
w ritten</w>
coll agen</w>
D en
ANO VA</w>
14 5</w>
G S
[5 ].</w>
D :</w>
M ater
interval s</w>
con clu
Tim e</w>
D av
sur round
dra f
ã o</w>
dis covery</w>
adjac ent</w>
d og
mo stly</w>
stand ardi
compl ement
w at
[ 40
m urine</w>
M H
hep atitis</w>
Eth ics</w>
Func tional</w>
ap hy
00 5
. .
verte br
ar ily</w>
construc ted</w>
S k
l ,</w>
remo val</w>
facilit ate</w>
Nat ural</w>
17 4
Ig G</w>
we b
Physi cal</w>
mil lion</w>
Col l
CD 8
interest s.</w>
ti le</w>
con sensus</w>
func tion.</w>
man ip
1 A</w>
M G
regi onal</w>
load ing</w>
A E</w>
elect ric</w>
reson ance</w>
posi tiv
at es.</w>
acet yl
Esch erichia</w>
star ting</w>
progr ams</w>
t ot
he av
Eng ine
tw ice</w>
dors al</w>
shown ).</w>
an atom
ec tin</w>
advant age</w>
g on
re veal</w>
11 8</w>
an sw
C 3
O k
[6 ].</w>
Cur rent</w>
C P</w>
frag ment</w>
13 .</w>
Hy dro
sc an</w>
D P</w>
bacter ium</w>
Ch ang</w>
n ess
Evalu ation</w>
( 4</w>
j ect</w>
u ary</w>
80 0</w>
t on,</w>
re fin
inte resting</w>
func tion,</w>
D G</w>
organ iz
S hi
experiment s,</w>
v o
adap tation</w>
Met abol
c el
[9 ].</w>
R ad
Ed itor
App l</w>
CD4 +</w>
[8 ].</w>
lo op</w>
influ enced</w>
14 .</w>
parti ally</w>
conn ected</w>
( +
depend s</w>
to ol
Ch o
z en</w>
M B
l i</w>
tubercul osis</w>
rob ust</w>
G O
level .</w>
ig en
[7 ].</w>
test ,</w>
15 .</w>
U p
13 2</w>
v in
oc or
repres enting</w>
em an</w>
[10 ].</w>
10.1126/ science.
valid ated</w>
questionn ai
sup pression</w>
mil d</w>
as es,</w>
bo x</w>
in come</w>
de .</w>
transl ation</w>
: :
sp i
P ur
ab solute</w>
inter fer
ph thal
G h
skel etal</w>
vi ability</w>
yg ous</w>
implement ed</w>
path ological</w>
eph al
e ti
long itudinal</w>
Be ha
dis play</w>
inter mediate</w>
L ou
independ ently</w>
sch izophren
ca th
col d</w>
[11 ].</w>
modi fication</w>
N utri
main tain</w>
antioxid ant</w>
17 5
[12 ].</w>
process ed</w>
1. 5
Acad em
m y</w>
path ogenesis</w>
bi ofil
embryo s</w>
10.10 80
ot t</w>
dep ic
distribu tions</w>
Zh u</w>
lym ph</w>
cell ul
re d.</w>
sub set</w>
Acknowledg ements</w>
L y
out side</w>
( k
d or
hor mon
li sted</w>
polic y</w>
assum ed</w>
15 5</w>
posi tively</w>
r an</w>
comp et
W n
ere s</w>
[13 ].</w>
arch itect
vel oc
Al ex
Re gi
cyt es</w>
20 %</w>
techn ology</w>
2009 ).</w>
mar k</w>
Suppor ting</w>
ol i
enrich ment</w>
qu in
6 –
( 5.
1. 4</w>
everth eless,</w>
ophy si
2. 1</w>
F und
impro v
13 5</w>
o il</w>
z i
frag ments</w>
for ni
is ing</w>
cy cles</w>
[14 ].</w>
12 4</w>
39 .
K A</w>
hy p
et te</w>
pl ots</w>
K O</w>
thal am
com pati
Y ,</w>
B A
Willi ams</w>
bov ine</w>
at trac
s lo
level ,</w>
Acad .</w>
ex act</w>
be yond</w>
o to</w>
differenti ated</w>
un known</w>
m g/m
r y
loc ations</w>
sion -
ir o</w>
trans formed</w>
Materi al</w>
compo und
in stead</w>
( i)</w>
a e,</w>
minim al</w>
ly sis</w>
abdom inal</w>
su m</w>
bel ong
De v</w>
lar v
inf er
mos quit
.0 )</w>
T om
C ase</w>
199 0</w>
T ai
oc .</w>
) =
(200 0</w>
micro bi
E F
L 1</w>
pur pos
rapid ly</w>
a ure
sec tional</w>
Sw it
M us
[15 ].</w>
Techn ology</w>
qual itative</w>
g e,</w>
b ell
re ach</w>
J ul
allow ing</w>
T 1</w>
heterogene ity</w>
G on
canc ers</w>
trans formation</w>
oper ation</w>
limit ations</w>
es ),</w>
ac tual</w>
ed s</w>
199 1</w>
29 3</w>
as h</w>
follow s:</w>
paren ts</w>
frequ ent</w>
anxi ety</w>
exten sive</w>
d )</w>
ti co
m ers</w>
c os
wor ld
li ve</w>
b s</w>
at tributed</w>
ynam ic</w>
L u</w>
th or
re tinal</w>
g lob
resul ts,</w>
dou ble-
T arg
ty ros
Pre ven
load ed</w>
IL- 1
- to-
magnit ude</w>
23 1</w>
nanop articles</w>
( 0.9
G M</w>
at us</w>
i. e.,</w>
f ur
u t</w>
bin d</w>
to o</w>
M arti
20 ,</w>
Not e</w>
Co unc
od es</w>
16 .</w>
f ro
m im
[16 ].</w>
D P
st ag
cali br
Tran scri
bio chemical</w>
D L</w>
dev ice</w>
WH O</w>
b ond</w>
3 18
M any</w>
moti f</w>
20 .</w>
al is</w>
N o
achi ev
b en
ill ance</w>
ro d
el ing</w>
Sy stem</w>
16 0</w>
45 .
( x
Mill er</w>
con cept</w>
13 7</w>
J F</w>
cat en
Inte gr
suppor ting</w>
P 2
Bio chem
5 ].</w>
amplit ude</w>
[17 ].</w>
bel ow
easi ly</w>
Sur ger
s s
L ow</w>
Gene tics</w>
sk a</w>
cas e,</w>
dend ritic</w>
N 1</w>
G ol
0.0 2</w>
diff usion</w>
F il
Cam brid
C p
gradi ent</w>
man if
Follow ing</w>
open- access</w>
dem ographic</w>
- derived</w>
ing ly</w>
s lic
consist s</w>
T C</w>
p ing</w>
op ic</w>
con version</w>
ert ain
fi ber</w>
P- 1</w>
R S
co hol
aim ed</w>
s ting</w>
a h</w>
N ag
R 2</w>
an alog
level s.</w>
Cur r</w>
( doi:
identi ty</w>
Po si
00 1</w>
cor d</w>
Ther ap
d ark</w>
infec tion.</w>
su peri
ant .</w>
tr ain
er 's</w>
k D
comp ens
inf ants</w>
B ru
reach ed</w>
success fully</w>
e a</w>
H S</w>
11 7
year s.</w>
h t
Ac cess
H F
he ight</w>
sim ulated</w>
E vid
conflic t</w>
transfer ase</w>
g est
hyperten sion</w>
clim ate</w>
fal se</w>
Avail able</w>
D er
[18 ].</w>
ed ic
ar -
g .</w>
N evertheless,</w>
N L
def ects</w>
Appl .</w>
16 6
vari ed</w>
sid es</w>
Inc .,</w>
ell ed</w>
in ner</w>
identi fying</w>
H )</w>
sc aff
av en
dilu ted</w>
si s:</w>
dro me
Inv estig
impair ment</w>
R s</w>
ap parent</w>
10.1038 /s
sc h</w>
membran es</w>
t /
0.0 5).</w>
1 %)</w>
pol ar</w>
g o</w>
n ine</w>
i bility</w>
L ind
12 8
con sequences</w>
Pati ent</w>
ph yl
- S
adju st
con nec
not e</w>
particul ar,</w>
Rec ent</w>
R P</w>
inter -
c n
Min istry</w>
Di rec
– 18
gu t</w>
B —C
percep tion</w>
f ish
Ab brevi
ad der</w>
M is
9 %</w>
Cali forni
sw itch
E V
T U
45 0</w>
9 00
dist al</w>
conjug ated</w>
o ked</w>
hor iz
h ot
r ant</w>
fi bri
ult ural</w>
11 ,</w>
14 1</w>
(Ad ditional</w>
– 19
perc ent</w>
an a
col on</w>
si c</w>
p s
10 5
fe at
39 /
d ry</w>
( N</w>
l or</w>
t z</w>
expan sion</w>
ili bri
clin ically</w>
ant ly,</w>
Swit zer
conf ig
M er
Or th
CI :</w>
Clin .</w>
st .</w>
- 00
arter ial</w>
Im p
3. 0</w>
ocar cin
allel es</w>
absor ption</w>
M H</w>
D L
[19 ].</w>
infec tious</w>
tu be</w>
it one
10.11 36
ain e</w>
i. e.</w>
ech nol</w>
Afric a</w>
pre domin
Braz il
( or</w>
tic ul
recogn ized</w>
loc alized</w>
particip ant</w>
proc ess.</w>
em a</w>
@ g
In t.</w>
ti ll
isol ation</w>
g es</w>
m aps</w>
M ax
un treated</w>
s u</w>
N P</w>
C ),</w>
27 0
solu tions</w>
B ot
c c
R R</w>
Health ,</w>
Invit rogen
11 8
am ,</w>
nat al</w>
y le</w>
er arch
mon it
h eal
serv ic
0.0 5
B S
f er</w>
reas on</w>
n a</w>
nerv ous</w>
N D</w>
con sul
multi pl
construc t</w>
polymorph ism</w>
man ner</w>
b c.
0.000 1</w>
Sci entific</w>
L ar
con strain
ma x
2 A</w>
consist ed</w>
protein s.</w>
mes enchymal</w>
le u
occur ring</w>
expres sion,</w>
fibro sis</w>
affec ting</w>
scop y</w>
H um</w>
prec ip
17 .</w>
h abil
ing -
str ati
W est</w>
14 7</w>
A ),</w>
13 9</w>
a or
min or</w>
T RA
quanti fication</w>
consid ering</w>
es .
v ess
[20 ].</w>
K um
purch ased</w>
particip ate</w>
on ia</w>
7 —C
phot o
var ying</w>
d ur
wa ve</w>
ac ting</w>
( X
wav el
19 6
Lt d.
hydro ph
Gre en</w>
ma kes</w>
hydrox y
st atic</w>
v an
Academ y</w>
ol e-
e fl
P ap
b -
ar y,</w>
an esthe
H S
T ay
L ab
id -
opath y</w>
bro ad</w>
com posed</w>
Tox ic
P I</w>
therap y.</w>
invol ves</w>
Agr ic
cre ated</w>
e an</w>
or rh
pos s
18 .</w>
u ,</w>
ass ay
reli able</w>
M I</w>
shor t-
Sup pl</w>
ro g
a x</w>
por t</w>
parti cle</w>
10 )</w>
yo ung
commun ic
fund ed</w>
le sion</w>
vari ate</w>
paren tal</w>
prog nosis</w>
L uc
es tion</w>
k ne
medic ation</w>
on co
14 3</w>
sc ap
co ated</w>
repe at</w>
tu ally</w>
Neurosci .</w>
16 8
on in</w>
k ill
ent ry</w>
” ,</w>
biomar kers</w>
ol -
comput ational</w>
micro gli
gre en
/ v
man n
d i</w>
insi ghts</w>
phen otypes</w>
1. 6</w>
unc ertain
oxid ase</w>
categ ory</w>
cl asses</w>
M g
– 20
control ,</w>
3 2-
on i</w>
A K</w>
sci entific</w>
suc cess</w>
over la
end oc
gen d
Ph ot
asth ma</w>
hippocamp al</w>
emis sion</w>
R ole</w>
peak s</w>
12 9
D H</w>
ak er</w>
B r</w>
co ,</w>
synthe tic</w>
inter face</w>
larg est</w>
2. 2</w>
ex clu
H T
Assess ment</w>
respon si
O ral</w>
coun ts</w>
W i
H al
ab normal</w>
knock down</w>
def ine</w>
Sp r
be gin
ac compan
Th ir
h our</w>
[2 1].</w>
W ith
Franc is
D avi
12 7
R em
simul ations</w>
wh y</w>
Marti n</w>
conn ectivity</w>
70 0</w>
tox ic
8 —C
EG F</w>
morph ological</w>
paras ite</w>
ga p</w>
significant .</w>
ant s,</w>
regul ator</w>
ON E</w>
t ting</w>
day s.</w>
en roll
Pro gr
S ar
pl asi
tro p
15 3</w>
sal ine</w>
( -
u ter
I ll
ex cep
N MR</w>
B ul
Organ ization</w>
av oid
activ ate</w>
w ri
p- value</w>
46 .
Ac tiv
M ad
el ong
19 .</w>
1 —
diag no
mo un
12 5
thyro id</w>
Austr ali
M ath
D 1</w>
15 7</w>
on e.</w>
3 3.
depend ence</w>
z in
0 )</w>
i ons</w>
ob ese</w>
sol v
al )</w>
6 ),</w>
elder ly</w>
biosyn thesis</w>
I sl
r ho
± 0.
Can ad
de ple
we ak</w>
de pl
K le
I S</w>
p ip
S he
antibio tic</w>
co de</w>
M F</w>
descri ption</w>
H i
sion s,</w>
otrop ic</w>
sp read</w>
G )</w>
ad ult
mil k</w>
l ess
od ds</w>
o ro
control ling</w>
coll abor
l ung
I EE
initi ally</w>
sol ved</w>
our s</w>
equ ation</w>
aster n</w>
.201 0.0
C 2
fil ter</w>
eth n
emb ed
en berg</w>
A CT
1. 8</w>
ed ical</w>
syn drome
T el
2 1.</w>
at om</w>
ol ip
wo od</w>
13 6</w>
re combination</w>
analy ze</w>
10.1073/pnas .
l ing
ph ag
m ir
vect ors</w>
at e-
theore tical</w>
m T
13 4</w>
[22 ].</w>
R 1</w>
X- ray</w>
challeng es</w>
O NE
ne arly</w>
amy lo
( 6.
sp ring</w>
m ess
allo graph
N ut
– 9
analys es.</w>
b and
2008 ).</w>
ay er</w>
roph ore
ep it
K M</w>
ell it
numer ous</w>
K r
struct ure
ex on</w>
at es,</w>
ad o</w>
48 .
reli ability</w>
het er
child hood</w>
dis per
1. 7</w>
del ay</w>
loc k</w>
j ud
24 -
pot ent</w>
ex ec
networ k
Ad v
P ear
diat ric</w>
log istic</w>
.201 1.0
ag ain</w>
hybri d</w>
pro long
cy clo
il ep
zer o</w>
correl ates</w>
wid th</w>
15 ,</w>
sh ock</w>
z i</w>
canc er.</w>
S K</w>
epid er
t an
uc id
15 1</w>
K at
P seud
barri er</w>
res ,</w>
ed a</w>
J B</w>
t ory</w>
] )</w>
is e,</w>
H u</w>
control s.</w>
f ,</w>
e i</w>
It al
Ar ch</w>
H is
interac t</w>
mac ro
adolesc ents</w>
G F</w>
ell er</w>
e ous</w>
Multi ple</w>
it em</w>
overex pres
Auth or</w>
ment ed</w>
fac ial</w>
i ther</w>
sit u</w>
I C</w>
or ies</w>
L ang
ran k</w>
Ris k</w>
H om
circul ating</w>
F 1</w>
fol low</w>
Res pon
coeffici ents</w>
u an</w>
medi ates</w>
cre dit
per f
es -
tion ally</w>
discus sion</w>
dec line</w>
exten sion</w>
16 3</w>
V it
.200 9.0
SE M</w>
er yth
14 9</w>
W ,</w>
syn chron
under went</w>
ac illus</w>
t ext</w>
K i
k y</w>
s emi
adheren ce</w>
profes sion
qu ad
tox ic</w>
n ull</w>
Fron ti
ow ski</w>
re vers
r p
equ ip
Th omas</w>
Gen om
as y</w>
Prog ram</w>
Gen er
str and</w>
contrib utes</w>
t ail</w>
cap ture</w>
efl y,</w>
28 0
de ep</w>
[23 ].</w>
promis ing</w>
igene tic</w>
enco ded</w>
valid ity</w>
( mean</w>
recru ited</w>
pregn anc
16 5</w>
nat ure
bene ficial</w>
C ru
resid ue</w>
T em
F amil
enti l
th o
acc ep
15 8
find ing
e uk
Cl ,</w>
G P
de gener
201 4
L PS</w>
polymorphis ms</w>
phen yl
R om
wor k,</w>
mat ch</w>
M ol
metabol ites</w>
resour ce</w>
resid ual</w>
bo hyd
H ay
iz es</w>
rele ased</w>
N ur
Th or
0.0 4
ect omy</w>
neutr al</w>
C i
G ly
b ear
0.0 5,</w>
ed ge</w>
assess ing</w>
13 8</w>
promo ting</w>
i tin
z one</w>
al cohol
tr ained</w>
M os
c ,</w>
st ere
v il
ha z
am i</w>
sign s</w>
G E
0.0 5)</w>
15 9</w>
datas ets</w>
neg atively</w>
7 55
repor ter</w>
In iti
R ap
Phy s</w>
overn ight</w>
L P
abil ity.</w>
H ence,</w>
v ary</w>
M ale</w>
phenotyp ic</w>
p ron
U N
Gastro enter
2 D</w>
ri se</w>
intern ational</w>
impro ving</w>
ori entation</w>
sal t</w>
cleav age</w>
R ab
ann ual</w>
al ize</w>
Car l
cyto plasmic</w>
de pos
Bri efly,</w>
9 —C
iti es.</w>
l um
Ch ild</w>
k now</w>
[ 44
R en
6 00
defini tion</w>
C G</w>
synthe sized</w>
rang ed</w>
struc tures
pl es</w>
path ogenic</w>
correc ted</w>
(S igma
K ing
Cy to
vacc ination</w>
por tion</w>
Let t</w>
p ell
2-s2.0- 8
per fusion</w>
t al
at tit
us e.</w>
popul ation
gen us</w>
there fore,</w>
- Al
bre eding</w>
seg ment</w>
- 3</w>
b is
u g
inst ance,</w>
method .</w>
ather osclero
anti bod
emp ir
17 5</w>
stor age</w>
establ ish
in tra
metabol is
spont aneous</w>
t :</w>
con str
wor ld</w>
15 5
D T
@g mail
W ar
ex change</w>
recei ve</w>
a e)</w>
% ;</w>
behavi ors</w>
path ogen</w>
ex ac
. n
interest .</w>
N /
ca using</w>
work .</w>
z y
bloc k
proj ect
[24 ].</w>
it ch</w>
sat ur
are ,</w>
m o</w>
( Figures</w>
melan oma</w>
S oc.</w>
3. 5</w>
G il
opo ie
D F
ent er</w>
P ac
16 7</w>
wo und</w>
amo to</w>
m ic</w>
mar ine</w>
necro sis</w>
level s,</w>
determin ing</w>
complex ity</w>
b p
r in</w>
c ross</w>
microscop e</w>
de hydrogen
Sh ar
14 4</w>
canc er,</w>
appro val</w>
NF- κB</w>
l ap
Quanti tative</w>
16 1</w>
A F</w>
practic es</w>
D ue</w>
link age</w>
gen e,</w>
Struc t
pur pose</w>
25 .</w>
car r
.200 8.0
17 0</w>
Ar ch
O ne
all y.</w>
int en
be g
ful l-
ca ro
and er</w>
L am
Ar th
a ,
M a</w>
te ach
reg ard</w>
pi x
cataly tic</w>
(n =
eb ra
mg/ d
siz e,</w>
all s</w>
Al so,</w>
N one</w>
cap able</w>
Dist ribu
ur inary</w>
particip ation</w>
. )</w>
ec ological</w>
restric tion</w>
( s
adju v
2. 3</w>
junc tion</w>
12 6
Struc ture</w>
0.0 3</w>
Li br
( 1.0
en ough</w>
st rom
ot or</w>
immuno histo
C ro
mul tivariate</w>
tic s.</w>
f ri
o ffic
10.11 6
e h</w>
scal es</w>
el d
M 1</w>
49 .
in side</w>
Diag nos
ant s.</w>
respon s
ser ve</w>
14 ,</w>
gen ital</w>
1 —N
omon as</w>
D B</w>
suppl ement</w>
E mer
m /
28 0</w>
80 %</w>
smo k
implic ated</w>
ischem ic</w>
mar row</w>
Bios ci
experiment s:</w>
cl ones</w>
transi ent</w>
IEE E</w>
conserv ation</w>
m ill
N R
z ero
7 2
hum an
speci al
ig ible</w>
ep is
od er
pl ast
Spec ific
23 .</w>
psychiat ric</w>
am bi
S ens
Wh at</w>
el ucid
pregn ant</w>
sup press
profil ing</w>
Americ a</w>
er i</w>
S ection</w>
ar yn
an timicrobial</w>
ti d
dis h</w>
G row
z ym
period .</w>
H en
b our
74 /j
at -
prob es</w>
24 .</w>
74/j bc.
el eg
proxim al</w>
fo rest</w>
10.10 74/jbc.
0 –
D F</w>
16 9</w>
( v
de gre
autophag y</w>
respond ents</w>
.201 2.0
in s
[25 ].</w>
Fronti ers</w>
S Y
shor ter</w>
overla p</w>
fact ,</w>
b ic
Par as
ra f
visi t</w>
superi or</w>
H ER
sus pen
amm a</w>
G old
Joh n</w>
Let t.</w>
E arly</w>
neigh bor
ar yo
to ok</w>
sampl es,</w>
20 -
veloc ity</w>
r y.</w>
[ 45
k ey
22 .</w>
Univers it
N M
sp or
min ut
tog ether,</w>
17 1</w>
ou ter</w>
Pharmac ol</w>
M ah
R and
year s)</w>
over -
fiel ds</w>
m s
frequ enc
) )</w>
( 7.
au er</w>
Im port
Cog ni
fibroblast s</w>
O '
tre es</w>
infec tion,</w>
f all</w>
- 000
Fac ulty</w>
Ch ron
tin c
m -
peri ods</w>
P f
rou tine</w>
p um
Com m
fail ed</w>
Ji ang</w>
C l</w>
abund ant</w>
R et
scre en</w>
3. 1</w>
tas ks</w>
Par kin
go al</w>
Institu te,</w>
access ed</w>
1 *
correc tion</w>
201 5
scop ic</w>
(i i)</w>
aldehy de</w>
3 ′</w>
Microbi ol.</w>
ic als</w>
Le w
enh ances</w>
x .</w>
Acad emic</w>
2007 ).</w>
P MC
bl adder</w>
CA T
37 °C</w>
tra it</w>
S em
intr insic</w>
e z
F .
mort al
mono clonal</w>
Physi ol.</w>
stric t</w>
bio tic</w>
rel ax
ten tion</w>
consi sting</w>
survi val
Ne g
don or</w>
fo od
plat form</w>
ob struc
G 1</w>
ha em
R ed
ne ph
2 O
tis h</w>
ELIS A</w>
fund ing</w>
Ander son</w>
neuro n</w>
14 6</w>
Pub Med</w>
separ ation</w>
Cor respond
n one</w>
sh are</w>
) /
et ti</w>
prote ase</w>
or ly</w>
, ”</w>
oste o
ver tical</w>
calcul ate</w>
aer obic</w>
ic s,</w>
T S</w>
e sian</w>
correspon ds</w>
M id
post operative</w>
29 0
chec k
monit ored</w>
therap y,</w>
E stim
ro r</w>
B ern
B R</w>
di c</w>
( r
] –
el ement
n al</w>
et t
_ 0
up stream</w>
10 —C
W ash
influ ences</w>
20 5</w>
sup port
17 3</w>
w rote</w>
ul ative</w>
con sec
regi str
al ter</w>
ou th</w>
kine tics</w>
D D
( as</w>
X ,</w>
ul f
pul se</w>
aly sis</w>
oc occus</w>
rou ght</w>
new ly</w>
vi sible</w>
sampl ed</w>
(d )</w>
15 2</w>
attem p
14 2</w>
fru it</w>
h ed
ga ve</w>
R H</w>
Dat ab
F our
treat ment
ill ness</w>
k ept</w>
if erase</w>
v ag
i o</w>
ch ick
Yor k</w>
1. 4
AR T</w>
C F</w>
R F</w>
inn ate</w>
establ ish</w>
al d</w>
O phthal
tyros ine</w>
sens ing</w>
- 7
H z</w>
[26 ].</w>
prop ag
coupl ing</w>
6 ,
h r</w>
per spectiv
T E</w>
vid e
th is,</w>
bloc ks</w>
docum ented</w>
suscepti ble</w>
libr ary</w>
dat es</w>
2009 ;</w>
3 %)</w>
Ltd. This</w>
tob acco</w>
cut aneous</w>
Re present
aud itory</w>
s clero
T- cell</w>
develop ment.</w>
s er</w>
ol e
20 1</w>
G CT
uc tu
fal ci
A V
trans plantation</w>
17 7</w>
AT P
nec k</w>
le th
n ers</w>
trans duc
C CT
10.3 38
iti es,</w>
au gh
fluo ro
en o
abl y,</w>
res us
2010 ;</w>
res .</w>
H ere</w>
2. 4</w>
Su per
fil am
eter min
leuk emia</w>
Evid ence</w>
/ 000
rap h
K ir
canc er
surround ing</w>
11 —C
m t
16 7
end er</w>
bind s</w>
CI )</w>
34 0
reas ons</w>
co ag
h owever</w>
mo bile</w>
Pop ulation</w>
Yo ung</w>
( Z
recur rent</w>
path ology</w>
N O</w>
ex ic
HC V</w>
or b
t ac
Over all,</w>
enc ephal
q PCR</w>
activ ating</w>
- -
falci par
qu ite</w>
10.1038/ nature
L /
T P
al es</w>
16 8</w>
flu x</w>
90 %</w>
respon sive</w>
standardi zed</w>
dem enti
F (
S am
maxim al</w>
as e
hetero z
biom ass</w>
15 6</w>
30 %</w>
b ands</w>
S of
IL- 6</w>
cur v
(199 9</w>
U r
R educ
1 a</w>
ven ess</w>
i i)</w>
s low</w>
1/ 2</w>
H J</w>
A 2</w>
ann ed</w>
13 ,</w>
Al tern
se -
18 5</w>
di an</w>
O ,</w>
eryth ro
Co un
mg/k g</w>
plas ticity</w>
Mar k
ab er
CD8 +</w>
fact ory</w>
bec omes</w>
hi erarch
cre di
[ 46
17 9</w>
K an
20 )</w>
3 ]</w>
spectr al</w>
E- mail:</w>
R B
5 8.
tren ds</w>
chang ing</w>
( 1:
A ff
10.338 9/
di s</w>
er ts</w>
20 3
ri es</w>
ces sive</w>
MA ,</w>
Con flic
w ards</w>
L ear
Chem ical</w>
p el
smo oth</w>
wavel eng
10. 0
20 5
ex ist</w>
effec tively</w>
Rec ently,</w>
virul ence</w>
/ J
record s</w>
L S</w>
rel ap
Y -
b ol
Nut r</w>
00 2</w>
wor th</w>
adi g
201 5).</w>
10.1111/j. 1365-
grap h</w>
aure us</w>
electro de</w>
EGF R</w>
Tay lor</w>
deple tion</w>
publ ish
underst o
M ann
p tions</w>
ver ,</w>
30 ,</w>
9 ;</w>
[27 ].</w>
tis m</w>
substr ates</w>
s i</w>
Det ection</w>
Sw ed
ilibri um</w>
H un
explan ation</w>
N C</w>
is .</w>
Nat l.</w>
20 3</w>
ec k
ang l
exist ence</w>
ac ad
CS F</w>
ra w</w>
S chem
knowledg e,</w>
annot ation</w>
intr a-
15 4</w>
( f
26 .</w>
int ensi
differen c
10 4
eb o</w>
et h</w>
cre ate</w>
vent ral</w>
induc ing</w>
c i</w>
surve illance</w>
T J</w>
( II
22 0</w>
2008 ;</w>
G yn
vehic le</w>
14 8</w>
r ain
am ura</w>
accep ted</w>
36 0
rom y
cl ar
st on</w>
predic tor</w>
sub strat
T R</w>
P ow
ir ing</w>
cross- sectional</w>
t agg
T ok
Im pro
K 1</w>
rat e,</w>
/ g
35 0</w>
struc tured</w>
Wil son</w>
And re
o und</w>
d s
J ac
18 1</w>
te am</w>
9 9.
pool ed</w>
D un
gran ul
D a
y e</w>
Ser um</w>
og ram
15 6
( 25
ant um</w>
10.3389/ f
ch ,</w>
201 1;</w>
T ol
Qu ality</w>
satis fac
eff orts</w>
.200 7.0
Counc il</w>
H an</w>
recur rence</w>
stat us,</w>
Ap plic
Second ,</w>
is es</w>
ud es</w>
p rin
16 ,</w>
sh e</w>
20 8
neon atal</w>
Ch eng</w>
bl ind
18 3</w>
fi bers</w>
http://dx.doi.org/ 10.
et r
Character ization</w>
ac e</w>
upreg ulated</w>
I A</w>
pl ane</w>
ch ond
r RNA</w>
aryo tic</w>
Th en,</w>
- 6
al ities</w>
equ ally</w>
▶ );</w>
y a
per son</w>
tre at</w>
gl ass</w>
uc k
frac tions</w>
W all
198 9</w>
El ectr
fl uctu
fi br
m om
pack age</w>
m apped</w>
Can ada</w>
tr av
Incre ased</w>
ep ing</w>
19 5</w>
G P</w>
E P
v entil
er b
C 2</w>
nucle i</w>
16 4</w>
Meas ure
recommend ations</w>
di a</w>
est er</w>
B erg
O 2
24 0</w>
elect rophore
M ay</w>
et a</w>
pathogen s</w>
16 6</w>
( Invitrogen
form ul
. gov
u ed</w>
synth ase</w>
E 2</w>
es h
27 7</w>
0.0 4</w>
Represent ative</w>
Pro ject</w>
Jap an</w>
18 7</w>
f ab
th ym
tic ular</w>
G lu
P eri
hom olog
liter at
Publ ishing</w>
pl an</w>
sequenc ed</w>
suppor ts</w>
predic tors</w>
u ate</w>
dis placement</w>
eren ce</w>
v ic
15 9
m ad
27 5</w>
house hold</w>
combin ations</w>
larv ae</w>
In flu
P ere
P ul
se di
algorith ms</w>
Indi an</w>
v acu
setting s</w>
S B</w>
16 2</w>
al izing</w>
tra ject
R y
M en
cere visi
19 1</w>
se e
3 :</w>
condi tion
10.1186 /s
re in
rou gh</w>
T M
assist ed</w>
8 –
consider able</w>
Pa ul
16 -
00 3</w>
and -
15 8</w>
precur sor</w>
[28 ].</w>
Stud ent
spec ial</w>
align ed</w>
J G</w>
l ost</w>
model s.</w>
2007 ;</w>
1. 9</w>
Fem ale</w>
H ong</w>
27 .</w>
10.1016/S 00
ograp hy
emer gency</w>
phosphor yl
P u
20 6
T s
2 10</w>
com es</w>
lay ers</w>
17 2</w>
harv ested</w>
oti des</w>
7 –
death s</w>
Sampl es</w>
car til
28 .</w>
us ual</w>
49 0
B one</w>
Hep at
j i
fit ness</w>
( 6</w>
olog i
K aw
22 5</w>
lin ed</w>
F C</w>
fill ed</w>
[ 47
electr ical</w>
correspon d</w>
modific ations</w>
iti n</w>
30 .</w>
se em</w>
50 ,</w>
fres h</w>
18 9</w>
mitochondri a</w>
fr ame</w>
5 %)</w>
27 9</w>
int ensive</w>
diff rac
com posite</w>
19 9</w>
19 3</w>
extrem ely</w>
S 1
16 9
St ro
me t</w>
ing ly,</w>
aim s</w>
leu kin
lac king</w>
utili zed</w>
ho use</w>
are .</w>
ed er
I sol
Educ ation</w>
lim itation</w>
. 100
del ayed</w>
k en</w>
ther m
P L</w>
re d,</w>
th -
develop ment,</w>
11 5
n d</w>
( a</w>
kin etic</w>
ay ing</w>
N D
targ et
Ex p.</w>
8 ;</w>
factor s.</w>
B B
Austral ian</w>
and a</w>
fe wer</w>
carr ying</w>
reconstruc tion</w>
kne e</w>
pap er.</w>
s b
plas m</w>
Reg ulation</w>
0.0 3
oly tic</w>
righ t-
transf ection</w>
valu able</w>
sor ption</w>
protoc ols</w>
ca us
itone al</w>
g ir
ec k</w>
Indi a</w>
D ou
b ow
decre asing</w>
en able</w>
comput er</w>
M un
w i
.edu .
ch ing</w>
S M
obj ect</w>
transl ational</w>
et er</w>
experi ences</w>
z ebra
li v
relev ance</w>
m p
ste ad
neg ativ
CD 4</w>
α ,</w>
pres er
end os
profes sional</w>
iz ation,</w>
struct ure,</w>
embed ded</w>
d ram
20 7</w>
clos ed</w>
continu ed</w>
mor bidity</w>
22 1</w>
agg res
t am
e- scale</w>
hybridi zation</w>
g ent</w>
mo thers</w>
in direct</w>
O h
A sian</w>
tion -
tim ing</w>
phosphor ylated</w>
ci a</w>
ocy tic</w>
anti bodi
ell ite</w>
10.102 1/
Wash ing
Val ues</w>
glyc os
U. S.</w>
4.0 /
F F
moti fs</w>
ation s:</w>
sc anning</w>
sil encing</w>
/ b
begin ning</w>
esc ent</w>
obser ve</w>
Elect ro
25 ,</w>
22 3</w>
Im aging</w>
su ic
S and
b .
K it</w>
b0 13
a que</w>
Chron ic</w>
n ess,</w>
C U
it ol</w>
nutri ent</w>
Th er</w>
lo t</w>
E ).</w>
nutri tion</w>
M V
aden ocarcin
adi pose</w>
th in</w>
g ang
ex cell
Gon z
V EGF
A ver
fol lic
n M</w>
bot tom</w>
aphy loc
ot roph
et e</w>
norm ally</w>
m ellit
prac tical</w>
k g</w>
therap ies</w>
it ary</w>
ris ks</w>
perform ing</w>
G GA
ur ally</w>
19 0</w>
c )</w>
[ 1,
colle ag
og ram</w>
N R</w>
repe ti
24 ,</w>
P 2</w>
arra ys</w>
.200 6.0
immun os
O H</w>
countr y</w>
popul ation,</w>
B J</w>
28 1</w>
Author s’</w>
horiz ontal</w>
( Fig
medi al</w>
c id
bre ak</w>
Bay esian</w>
igh t
remo ve</w>
ain ,</w>
appear ance</w>
el y.</w>
splic ing</w>
per tur
17 6
expl o
p es
[29 ].</w>
del iv
0. 25</w>
ter .</w>
pl anning</w>
hist ological</w>
3 ′
K ey</w>
enhanc ement</w>
5 2
are tt
( and</w>
M ay
K en
par adig
Plas modi
( h
N- terminal</w>
w ay
temper atures</w>
17 4</w>
d ental</w>
200 6).</w>
K al
( 8.
emerg ing</w>
seg ments</w>
sion :</w>
strong er</w>
tet ra
C ellular</w>
volt age</w>
tin ,</w>
s a</w>
proc ess,</w>
Yor k,</w>
og ly
ab str
star ted</w>
b013 e
adap ted</w>
chrom osomes</w>
ad ding</w>
.0 b013e
25 6</w>
cere bell
per spective</w>
.201 3.0
paras it
- up
macroph age</w>
ran ial</w>
intro duction</w>
re fer
them sel
casp ase-
mi R
c a</w>
Austral ia</w>
K er
7 ,
pre lim
draw n</w>
− 17
n ever</w>
heav y</w>
evid ent</w>
ev a</w>
whe at</w>
b at
S B
annot ated</w>
H ir
am id
ep igenetic</w>
ep ilep
through put</w>
um ab</w>
valu es.</w>
4. 5</w>
M W</w>
ens en</w>
J am
Neuro l</w>
ot e</w>
prolong ed</w>
ir radi
E B</w>
M ont
N 2</w>
12 —C
int act</w>
d rich
Psych ol</w>
air way</w>
T y
pres ents</w>
is tics</w>
effec ts.</w>
op recip
S 3</w>
23 5</w>
at eri
( 100
os al</w>
pers ons</w>
ra ft</w>
3. 3</w>
genom e-wide</w>
lo op
G CA
sci ence</w>
T issue</w>
19 7</w>
D C
h a</w>
de position</w>
aw aren
fil m</w>
expl ored</w>
Libr ary</w>
t ase</w>
Re ference</w>
28 5</w>
Ph osph
ectiv ely</w>
lymph ocytes</w>
consec utive</w>
in k
ic al,</w>
Fir st</w>
ene sis</w>
un te
1 A
00 4</w>
S ac
201 2;</w>
at omic</w>
O ’
ble .</w>
[ 48
2 %)</w>
show n.</w>
Ox ford</w>
predic tions</w>
y cl
ari ties</w>
dist ances</w>
Imp act</w>
wor d</w>
enti ally</w>
R K
lo g</w>
enco ur
TN F
Sci enti
Phy lo
ly -
educ ational</w>
ic in</w>
indic ator</w>
gu ide</w>
B ut
ch e</w>
Grow th</w>
27 3</w>
Eng l</w>
carcin om
inser tion</w>
Gen omics</w>
princ ipal</w>
se q</w>
adjuv ant</w>
di sci
HC C</w>
hypothe sized</w>
U -
Ev en</w>
line age</w>
S en
car bohyd
abnormal ities</w>
inf ra
ograph ical</w>
le .</w>
exp on
summar ized</w>
20 9</w>
e Lif
colleag ues</w>
li st
abov e,</w>
Com pared</w>
m osph
in ess</w>
transpor ter</w>
sur pri
3. 2</w>
young er</w>
Sampl e</w>
cop y
en abl
7. 5</w>
ho c</w>
D MS
D W</w>
tri plic
enzym atic</w>
e- dependent</w>
17 6</w>
ec os
29 .</w>
p ub
/ )</w>
z h
2. 6</w>
hom ogene
fund am
[30 ].</w>
c asc
g round</w>
200 6;</w>
hom ologous</w>
enc e:</w>
Inf ec
20 4
o es</w>
ur y</w>
supernat ant</w>
anti- inflammatory</w>
ex cess</w>
traum a</w>
19 2</w>
18 2</w>
W ell
25 1</w>
F P</w>
28 9</w>
respon d</w>
H A
Path ol</w>
Neuro log
g old</w>
B /
p tom</w>
physici ans</w>
2 15</w>
” .</w>
L E
Sch o
a ult</w>
TNF- α</w>
int ell
L C
dev ices</w>
aro se</w>
elim in
G ro
cros s
indic ators</w>
classi cal</w>
17 9
deli ver
Gu o</w>
transcript ome</w>
S l
In divid
as -
K in
progres sive</w>
bl ast</w>
re placement</w>
B ank</w>
ten sion</w>
uni vers
16 5
s h</w>
Vi rol</w>
17 8</w>
Spr inger</w>
ch es</w>
interac ting</w>
Switzer land
.200 5.0
chrom e</w>
li e</w>
23 0</w>
no .</w>
Bri tish</w>
pow er
underg oing</w>
25 -
or a</w>
28 3</w>
h eli
trans form
cu t</w>
Q -
mat uration</w>
empir ical</w>
Mech anis
C- terminal</w>
vul ner
fir st-
am ous</w>
( a
ang e</w>
ocyto sis</w>
ang ,</w>
7 ;</w>
angi ogenesis</w>
18 ,</w>
Appl ied</w>
g -
yel low</w>
compl i
2 11</w>
lim b</w>
F s</w>
30 1</w>
y ),</w>
(199 8</w>
cy ste
wind ow</w>
N SC
bi a</w>
J -
throm b
al. ;</w>
lig ands</w>
mov ements</w>
Tum or</w>
E N</w>
U V
ol ds</w>
ing )</w>
demonstr ates</w>
S ak
Plasmodi um</w>
retro spective</w>
bec ame</w>
de z</w>
c o</w>
ati cal</w>
G 2</w>
B ),</w>
Re fin
os in</w>
0.00 0</w>
B ou
P G</w>
s ac
dis soci
activ ates</w>
m yo
ol l
I M</w>
an al
situ ation</w>
secre ted</w>
up- regulated</w>
D ep
20 4</w>
Re p</w>
R B</w>
s ors</w>
com part
Con ference</w>
ig arett
cl one</w>
g amma</w>
v .
18 4</w>
37 0
ath i
f ati
St .</w>
O rig
G GT
8 /
pres enting</w>
resid u
detect able</w>
trans duction</w>
1 —O
predomin antly</w>
O )</w>
ne gl
bloc king</w>
sof t</w>
ag es,</w>
J K</w>
I U
jud g
neuro logical</w>
platel et</w>
Ge org
B L</w>
v on</w>
persist ent</w>
bloc ked</w>
er s:</w>
Z o
12 4
c ).</w>
Epidemi ol</w>
2. 8</w>
G R</w>
198 8</w>
Francis co,</w>
pu ts</w>
g yr
20 7
p tive</w>
prog ress</w>
falcipar um</w>
J os
chrom osomal</w>
2 ],</w>
k et
E ur
au g
s on,</w>
ubiqu itin
2. 7</w>
10.11 77
3 1
22 9</w>
H z
E J</w>
ag o</w>
hi p</w>
id er</w>
function ing</w>
disci pl
de generation</w>
re tur
to ,</w>
22 7</w>
μ m.</w>
rhe umat
lif est
plot ted</w>
18 6
L E</w>
aw ay</w>
( CD
ox yl
H 3K
effec tor</w>
materi al
h app
tion )</w>
deliv ered</w>
28 7</w>
20 6</w>
gene tics</w>
habil itation</w>
u gin
u k</w>
po ol</w>
Sequ ence</w>
ir ation</w>
inhibi ting</w>
27 8</w>
oc ellular</w>
ass ay.</w>
H T</w>
ash ed</w>
op posite</w>
ex plic
S. A.</w>
Scienc e,</w>
vas cul
11 .0
temperat ure.</w>
27 1</w>
Evol ution</w>
evalu ating</w>
oc ular</w>
ak e
period ,</w>
am p</w>
T S
' -
uk i</w>
gener ating</w>
P en
cham ber</w>
gl omer
ap ical</w>
2 13</w>
tox in</w>
00 5</w>
ble ,</w>
Chang es</w>
23 3</w>
wh il
r y,</w>
ca re,</w>
enc e
regi on.</w>
impro ves</w>
exampl es</w>
0.0 6
l ater
demonstr ating</w>
homeost asis</w>
at ely,</w>
[3 1].</w>
ac ic</w>
( 100</w>
protein .</w>
fil tered</w>
dist urb
18 7
[ 49
27 0</w>
re al
B O
95 .
M K</w>
Statis tics</w>
s ed
ect or</w>
DNA -
K S</w>
( with</w>
N J</w>
Se q</w>
27 6</w>
Ak t</w>
ser ious</w>
) 00
utili zation</w>
(E )</w>
S ong</w>
mem ber
re tention</w>
90 0</w>
ul l
pil ot</w>
simult aneously</w>
ti d</w>
hospit als</w>
38 0
30 3</w>
ide a</w>
op en
cor tex
Mic ha
w ing</w>
interpre ted</w>
ang les</w>
mul tic
op i
tr unc
as es.</w>
ip p
method ,</w>
un able</w>
clin ic</w>
ell o</w>
prelim inary</w>
bear ing</w>
13 —C
analy tical</w>
canc er:</w>
w an</w>
18 6</w>
traum atic</w>
som atic</w>
cardi omy
L og
arg in
O A</w>
cl ass
aor tic</w>
environ ments</w>
R ed</w>
Com bin
Ch rom
ace ae</w>
vacc in
am mon
J T</w>
articl e,</w>
hom oz
dec om
os ,</w>
Un der
meth yl</w>
et on</w>
18 8
11 4
predic ting</w>
W el
M V</w>
res tim
70 %</w>
Q TL</w>
Con sist
2 1,</w>
sp ar
20 2</w>
T /
22 2</w>
ro se</w>
System s</w>
– 26
H em
Struct ural</w>
) ).</w>
H P</w>
gastro intestinal</w>
lif e
semi -
vit ro
por e</w>
– 24
d ot
vol unte
ag es.</w>
be an</w>
fil es</w>
’ ,</w>
model s,</w>
un know
Int ere
a ur
cut -
ur ity</w>
sal iv
36 8
dis solved</w>
( Y
consist ently</w>
barri ers</w>
MM P-
ab i
V EGF</w>
Posi tive</w>
Compar ative</w>
highligh ted</w>
fac es</w>
Japan ese</w>
overl apping</w>
syn erg
ang ha
On t
aver aged</w>
abil ity
10.1111/j. 14
k ind
Pre valence</w>
Inhi bi
B is
ti tion
37 5</w>
b t
an o
W M</w>
acces sion</w>
K L</w>
method s.</w>
200 5;</w>
inter ference</w>
My co
C K</w>
H M</w>
Commun ity</w>
23 7</w>
lim its</w>
D etermin
25 %</w>
skill s</w>
12 )</w>
it self</w>
pat h</w>
D ow
23 9</w>
P eter
me g
dig ital</w>
Bre ast</w>
sensi tiv
18 8</w>
( 9.
G ao</w>
Dom ain</w>
ep tive</w>
t os
A 1
eri a</w>
acad emic</w>
F ox
N ex
c d
Con sid
z e
luc iferase</w>
5. 0</w>
2 17</w>
di ar
29 5</w>
day s,</w>
clon ed</w>
s ?</w>
Di vision</w>
prec ise</w>
b b
L J</w>
B eij
2 1-
ol i</w>
pro min
T G</w>
eu tical</w>
Differen t</w>
mm H
plac ebo</w>
insi ght</w>
A H</w>
cell s/
K ey
86 .
at .</w>
as k</w>
an ne
res ection</w>
acet ate</w>
si ties</w>
classi fi
rolog y</w>
sampl e.</w>
er )</w>
B h
am ph
a q
al /
S om
tem plate</w>
zin c</w>
In tr
10.1093/ nar
2- 0
HL A-
M 2</w>
appl ies</w>
ec al</w>
C ere
end omet
Parkin son
fix ation</w>
sens ors</w>
en di
[3 2].</w>
H all</w>
17 ,</w>
ak ing</w>
R :</w>
G J</w>
i ans</w>
or y,</w>
T est</w>
d n
man ual</w>
illustr ated</w>
I sh
− 3</w>
famil i
sensi ti
K h
con sequence</w>
y our</w>
architect ure</w>
al li
absor b
s low
erro r
E st
sch ed
se a</w>
supplement ation</w>
25 5</w>
Neurosci ence</w>
C er
h aps</w>
G D</w>
hom ogen
dom es
refl ects</w>
wh om</w>
al ve
Sur vey</w>
19 5
invol ve</w>
alk al
B cl
( http://www.
** *
autom ated</w>
induc ible</w>
Co st
p ure</w>
I /
arcom a</w>
30 5</w>
ex clusion</w>
I N</w>
aqu eous</w>
b ud
kel etal</w>
Further ,</w>
it o</w>
50 -
S I</w>
Cl assi
M aj
determin ants</w>
caten in</w>
con found
T F</w>
great ly</w>
28 6</w>
separ ately</w>
X .
throm bo
g .
le p
S af
dep end</w>
be am</w>
10.1073/pnas .0
antigen s</w>
T ang</w>
mus cl
h is
di vision</w>
ul tim
hol d
id ine</w>
30 7</w>
ro l
= 1
In fl
dil ution</w>
h ence</w>
b ra
tic ,</w>
36 5</w>
C 57
op ter
Ec ology</w>
L e</w>
S to
Ger many</w>
oph age
p as
es tive</w>
plasi a</w>
qu arti
sub mitted</w>
– 9</w>
E ast</w>
aer ugin
ax ial</w>
biop sy</w>
cy s
pres um
modul ate</w>
or dered</w>
knock out</w>
ten d</w>
M es
A ST
Ch rist
30 -
heal ing</w>
L ung</w>
10 8.
ó n</w>
ne ither</w>
T op
Qu es
an .</w>
lin ks</w>
tak es</w>
gen e.</w>
M exic
0. 1%</w>
o economic</w>
L V
H 2</w>
accompan ied</w>
S G</w>
H ),</w>
trans location</w>
progen itor</w>
sc oring</w>
t ag
96 -
Thom p
intr aven
li a</w>
B an
l en
A :</w>
spec ified</w>
Z -
cal culation</w>
abs ent</w>
ophage al</w>
initi ated</w>
ab e</w>
1- 0
ro ots</w>
fav or
pneum oni
x y
regard less</w>
author (s)</w>
28 2</w>
dri ed</w>
an ine</w>
glutam ate</w>
Sel f-
200 5).</w>
Rep ort</w>
20 8</w>
S 1).</w>
N T</w>
Ob st
S /
oper ating</w>
198 7</w>
8 ,
19 4</w>
respon se.</w>
IC U</w>
i pati
ves sel</w>
excell ent</w>
H L</w>
2 19</w>
cod on</w>
0.0 6</w>
29 7</w>
schizophren ia</w>
analy z
ph ases</w>
correl ate</w>
K J</w>
centrifug ed</w>
abov e.</w>
( r</w>
reg res
N )</w>
Famil y</w>
polym er
pro pose</w>
pre ference</w>
Datab ase</w>
suppress or</w>
EE G</w>
Anti -
It aly
observ ed.</w>
nov o</w>
od ,</w>
ad mission</w>
Fish er</w>
cyt ometry</w>
surfac es</w>
tom ography</w>
.201 3.
25 3</w>
ord ers</w>
Networ k</w>
mo bility</w>
maint aining</w>
iz ation.</w>
lin e,</w>
et ric</w>
M ass
jo in
po orly</w>
b us
match ing</w>
r ul
manufacturer ’s</w>
bre ast
M n
priv ate</w>
il lin
lin es.</w>
GA PD
12 .0
30 9</w>
lic ense</w>
CA )</w>
M F
v ill
19 8</w>
cult ural</w>
Psych ol.</w>
substanti ally</w>
pe diatric</w>
adi an</w>
Sing h</w>
rec ord</w>
biomar ker</w>
Des cri
S F</w>
antibio tics</w>
00 6</w>
c oc
( w
refl ected</w>
B ol
drin king</w>
ch im
c ited</w>
B us
appl ying</w>
su stained</w>
25 9</w>
F uture</w>
23 8
3 1.</w>
respectivel y).</w>
Bacter i
GF P-
9 –
construc ts</w>
29 1</w>
200 4;</w>
22 6</w>
Ph ase</w>
2. 9</w>
regi on,</w>
4 %)</w>
Beha v</w>
bas el
25 7</w>
wal king</w>
6 8.
Ev ol</w>
inf ant</w>
op a
24 5</w>
C B</w>
eth an
vess els</w>
idi c</w>
frac ture</w>
26 5</w>
co st
10.1074/jbc. M
distingu ish</w>
3 A</w>
res erv
Dav is</w>
γ -
CR C</w>
27 4</w>
P ublic
29 0</w>
phenomen on</w>
t es</w>
advant ages</w>
29 9</w>
Sal mon
os ens
Thomp son</w>
22 -
hem orrh
hel ped</w>
b ab
a @
cas es.</w>
S we
30 2</w>
view s</w>
review s</w>
.201 2.
k b</w>
l amin
R oy
L and
org ans</w>
ob acter</w>
Research ,</w>
T rac
det ecting</w>
E con
I r
Res our
p unc
Ac ute</w>
credi t</w>
conclu sion,</w>
gener al,</w>
V acc
a udi
re mark
sper m</w>
24 1</w>
10 /
kin d</w>
D ar
id ation</w>
visu alized</w>
repe at
M U
[33 ].</w>
path y</w>
26 7</w>
zebra fish</w>
ac tually</w>
cad her
cor ne
gene tically</w>
( including</w>
K ol
Jan uary</w>
( Å
19 6</w>
Z e
carb on
Bi ology
def ense</w>
ca regi
concer ning</w>
es pre
depres sive</w>
I B
ot es</w>
G W
hel p
x yl
pro pos
factor -
2 14</w>
resol ved</w>
auto immune</w>
assum ption</w>
dehydrogen ase</w>
24 9</w>
o res</w>
34 0</w>
Cryst .</w>
C 5
sum mary</w>
disrup tion</w>
E P</w>
Epidemi ology</w>
High -
AM P</w>
resour c
ac r
D ay</w>
aggreg ation</w>
met allo
um in</w>
S ept
S W</w>
L R
Environ .</w>
h o</w>
follow -up
tion ;</w>
re vised</w>
az ole</w>
36 0</w>
at mosph
care .</w>
wom en
plan ted</w>
diver gence</w>
random ised</w>
Rel ative</w>
34 .</w>
Experim ent</w>
Sh im
m b
substitu tion</w>
( 10.
cri tically</w>
cytotox ic</w>
id ,</w>
us -
3 50
el e</w>
land scap
L R</w>
immun oprecip
fro zen</w>
_ 00
7 %)</w>
Inhibi tion</w>
ob vious</w>
tagg ed</w>
4 4.
26 9</w>
biofil m</w>
ph al
d ex
N 2
m mol/
F ren
all -
HP V</w>
m ation</w>
CI D:</w>
prote as
ro c
anc h</w>
tin -
o virus</w>
Zh eng</w>
G ib
Mic e</w>
alph a-
29 8</w>
< 0.05</w>
24 7</w>
Sum mary</w>
end -
popul ations.</w>
T 2
Cho i</w>
w in
simpl y</w>
4 7.
ov as
Man agement</w>
0.00 1)</w>
28 8</w>
st op
Import antly,</w>
11 8.
26 0</w>
J une</w>
research .</w>
Y e
. com</w>
est rogen</w>
s ”</w>
O D
24 3</w>
do m</w>
require ments</w>
pharmac ological</w>
28 4</w>
H F</w>
26 1</w>
S z
manif est
epidemi ological</w>
22 4</w>
26 3</w>
facil ities</w>
I GF
oglob in</w>
T ow
24 7
um a</w>
re generation</w>
n ame</w>
assist ance</w>
th y</w>
preven ting</w>
h ind</w>
K ur
prolifer ative</w>
di min
lim iting</w>
heterogene ous</w>
anc estr
E col</w>
B O</w>
depos ited</w>
S ul
Im age</w>
e 0
ipati ng</w>
PM CID:</w>
integr ity</w>
arti ficial</w>
Abbrevi ations</w>
en a</w>
h on
suppres sed</w>
P PAR
com it
ca usal</w>
(199 7</w>
10.10 46
sat ellite</w>
paras ites</w>
4/ eLif
sel ect</w>
re placed</w>
stres s,</w>
x en
it em
Pr inc
rad ical</w>
instrum ent</w>
23 7
H b
.200 4.0
conc eived</w>
bor ne</w>
fol ding</w>
retro viral</w>
Signific ant</w>
sex ,</w>
M O</w>
755 4/eLif
co st-
fil ter
K D</w>
com or
Fron t.</w>
resul t,</w>
F T
complement ary</w>
Differen tial</w>
1. 6
contribu ting</w>
W J</w>
F our</w>
9 ,
character ize</w>
0.0 5.</w>
14 5
Cryst al</w>
40 ,</w>
μg/m l</w>
stand ards</w>
con stit
[ 50
us )</w>
satur ated</w>
ca dian</w>
cre atin
qu i
The ir</w>
Ch an</w>
ich ,</w>
eth ical</w>
ric k</w>
P P</w>
ar rest</w>
27 2</w>
40 %</w>
re covered</w>
se iz
ag ric
attach ed</w>
DO I:</w>
J e
An t
b ackg
colon ies</w>
mon itor</w>
engine ering</w>
U V</w>
E F</w>
56 /
( <
kD a</w>
beli eve</w>
acid ,</w>
10.1128/ J
Aver age</w>
mod elling</w>
Differen ces</w>
h ard</w>
a id</w>
2 12</w>
S K
tum orig
diff ered</w>
M em
M SCs</w>
22 8</w>
25 4</w>
colon y</w>
I ran
label ing</w>
N ig
p et
Di et
coh or
( red
upreg ulation</w>
giv es</w>
40 5</w>
c igarett
201 3
pro per</w>
off er</w>
R as
her it
wh ole-
dog s</w>
ses sion</w>
) *</w>
11 )</w>
tre ating</w>
Biochem .</w>
phosphat ase</w>
Publ ish
V en
0.00 1).</w>
dat a:</w>
10 –
R W</w>
AS T</w>
Coh en</w>
A N</w>
h i</w>
Biophy s</w>
diseas e:</w>
ation ).</w>
/v )</w>
propor tional</w>
eleg ans</w>
T 2</w>
y ama</w>
In :</w>
Lond on,</w>
P ain</w>
.201 4.0
regul ators</w>
199 0
ay a</w>
f aster</w>
conclud ed</w>
Inv est</w>
diffic ulti
hippocamp us</w>
30 8</w>
M ental</w>
V ic
satisfac tion</w>
sco red</w>
ym ous</w>
We in
C 14
23 6
R och
Gr ant</w>
Distribu tion</w>
cy an
Infec tious</w>
habit at</w>
fundam ental</w>
St aphyloc
grow th,</w>
46 0
bo ok</w>
nutri tional</w>
C 4
19 ,</w>
Met ab</w>
R G</w>
construc tion</w>
co vari
sequenc es.</w>
[34 ].</w>
sh ip
Tak en</w>
con sci
seg reg
W ong</w>
schem e</w>
2.0 ),</w>
Kum ar</w>
– 8</w>
perform ed.</w>
adi p
hem is
Br ad
1 B</w>
fab ric
Pol ic
Br un
18 5
record ing</w>
saf e</w>
Dise ases</w>
23 2</w>
Chem istry</w>
C ros
b y:</w>
Access ed</w>
Gen omic</w>
analys es,</w>
P ic
34 1</w>
th ali
ow s</w>
stat ement
az ol
interview s</w>
optim ization</w>
( >
E X
rang es</w>
50 )</w>
on ical</w>
(0 )</w>
imp acts</w>
Sch war
L op
umin a</w>
od .</w>
( 00
r ag
investig ations</w>
2010 )</w>
c ot
36 3</w>
10.1046 /j.
opoie tic</w>
os ine</w>
Character istics</w>
regi st
20 9
Specific ally,</w>
ultras ound</w>
dop amine</w>
weigh ts</w>
F B
a p</w>
es ophageal</w>
P os
6 ].</w>
German y)</w>
cap tured</w>
sc atter
22 ,</w>
adjust ment</w>
L aw
We i</w>
ast e</w>
T rop</w>
coordin ation</w>
re ferenc
chann el
S igma
.200 9.
Cogni tive</w>
/ d
Gyn ec
2 0.
cerevisi ae</w>
dis charge</w>
p yl
infer red</w>
Pro c
ve in</w>
We b
diseas es,</w>
E L</w>
W om
yiel ded</w>
la red</w>
00 7</w>
C lo
quanti fy</w>
R eal
48 8</w>
suppl y</w>
T I
Biot echnol</w>
troph ic</w>
strom al</w>
coun ted</w>
(D O
b asi
Ne ph
Engl ish</w>
method ology</w>
SD S-
F is
L L
ri x</w>
necess arily</w>
46 /
p in
tic s
D 2</w>
35 3</w>
th an
ubl ic</w>
ag ent
Con sequently,</w>
iso forms</w>
17 7
bil ateral</w>
tas k
nit ric</w>
Hy po
- 1.
replic ates</w>
respon ding</w>
it z
phot osyn
ors '</w>
espre ad</w>
F GF
el u
buil ding</w>
g p
def ect</w>
trans mit
sym ptom</w>
adi ly</w>
Ch ap
lys ates</w>
stand ard
D ic
kin ases</w>
sp in
D Cs</w>
micro tub
addres sed</w>
Can adian</w>
gly col
istr y,</w>
stre t
volum es</w>
vis its</w>
con focal</w>
Pediat r</w>
3 37
transp os
awaren ess</w>
− 1.
ro ot
plasm ids</w>
30 4</w>
sit es.</w>
compl ement</w>
y me
/B F
29 6</w>
concer ns</w>
lin king</w>
sy st
Un der</w>
H PL
Co x</w>
T et
201 3;</w>
spectro metry</w>
sub units</w>
o therapy</w>
M ari
34 5</w>
23 8</w>
O ffic
33 3</w>
- mediated</w>
some times</w>
25 8</w>
S r
23 4</w>
T H</w>
prac tition
D AP
ish man
μ M)</w>
e tion</w>
S NP
inde ed</w>
ac ted</w>
re frac
anatom ical</w>
(S D)</w>
modul e</w>
struct ure.</w>
’ t</w>
dec lared</w>
g ro
CN S</w>
d ar
B ow
int ak
arth ro
r ule</w>
ch e
practic e.</w>
V eter
tra ffic
35 5</w>
ag ar</w>
dimen sions</w>
assum e</w>
C 2—C
underg o</w>
all y-
D ),</w>
e.g .,</w>
c ally</w>
G G</w>
ma them
d a
um e</w>
J ack
col .</w>
10.116 1/
hypox ia</w>
chond ro
u tility</w>
O N</w>
gra f
shap ed</w>
cartil age</w>
embry o</w>
A pri
or n
H ow
preci sion</w>
par a
PC R.</w>
Stand ard</w>
Preven tion</w>
10.1038/n r
K am
0.0 8</w>
8 00
55 /
L B</w>
34 2</w>
on t</w>
bound ary</w>
40 -
c eived</w>
35 7</w>
2 16</w>
N av
MA PK</w>
r .
II ,</w>
mut ated</w>
ti tle</w>
45 -
el son</w>
F ).</w>
dec id
Mi y
Co ch
Rep ublic</w>
4. 7</w>
μ g/
2 a</w>
36 7</w>
re si
5 49</w>
pre ferred</w>
35 .</w>
fit ted</w>
3. 4</w>
( from</w>
im mer
emph a
t- test</w>
L V</w>
dev ic
en vel
N E</w>
discrimin ation</w>
d ual</w>
16 4
struc tion</w>
( 11.
experiment .</w>
extrem e</w>
mamm ary</w>
gend er,</w>
er ing,</w>
1 α</w>
Cp G</w>
Au g
m ap
M ),</w>
atic s</w>
D U
36 1</w>
iz ed,</w>
compri sed</w>
K id
bur g</w>
á n
23 6</w>
cum ulative</w>
wri ting</w>
30 6</w>
CY P
e asy</w>
physi ology</w>
anis h</w>
us ed,</w>
cer t
P U
34 3</w>
With in</w>
p ent
mo ther
Pe o
det ail</w>
stat ement</w>
Pseud omonas</w>
[35 ].</w>
mus cles</w>
is ot
run ning</w>
18 4
t ant</w>
fo ot</w>
e bo
p es</w>
fibri ll
regi ons.</w>
com promis
35 9</w>
it t
recept or-
Sh i</w>
thes es</w>
pathw ay.</w>
conver ted</w>
u -
B E
ong oing</w>
25 2</w>
ger min
( 50</w>
improv ements</w>
19 4
ori es,</w>
e.g .</w>
200 4).</w>
38 0</w>
A z
P RO
q .</w>
Ste m</w>
AC S</w>
polym er</w>
A CA
33 7</w>
5 9.
ph on
33 .</w>
us ep
b an
W a
Ex trac
en ic</w>
as :</w>
regi on
hemis ph
Medi an</w>
fl ag
.201 4.
trac king</w>
op in
te en</w>
Pre -
+ ,</w>
f if
charg ed</w>
5 6.
d in
cover ing</w>
assembl ed</w>
in activation</w>
Cri t</w>
tic a</w>
cont ents</w>
35 1</w>
tr ic
2 18</w>
ul ture</w>
isol ate</w>
tr u
ER K
29 2</w>
ch ains</w>
Pro b
d u</w>
23 ,</w>
Ph en
ma ,</w>
re a</w>
ph il
Bu t</w>
S ex</w>
W ill
ver ified</w>
A sh
Rhe umat
3 2.</w>
n ell</w>
over view</w>
seed ed</w>
er o</w>
ere ly</w>
Fri ed
smo kers</w>
198 6</w>
30 )</w>
48 0
eff ort</w>
33 9</w>
P H</w>
0.0 7</w>
in son</w>
K ra
opo ul
M K
rib osomal</w>
os in
A I</w>
d ).</w>
defic its</w>
CO PD</w>
F requ
paramet ric</w>
ous ly,</w>
C anc
h und
enroll ed</w>
correspon d
8 %)</w>
p <0.0
Ch e
T P</w>
solv ent</w>
- 67
3 r
ar is</w>
method s,</w>
24 8</w>
K el
RNA ,</w>
h eld</w>
10.1016 /0
ge ographic</w>
pl atin</w>
qu antum</w>
f ever</w>
fe asi
olog ia</w>
86 /
W C</w>
Bi o-
temperat ure,</w>
Sh angha
partic ipating</w>
40 1</w>
rh iz
36 9</w>
pp .</w>
34 7</w>
2-s2.0-8 48
Euro pe</w>
activ ator</w>
ref er</w>
em pt
dis ability</w>
eng ue</w>
Revie w
33 5</w>
em ed</w>
omer ic</w>
R ever
37 3</w>
Neg ative</w>
seed s</w>
phylo gen
pl atin
inoc ulated</w>
Refin ement</w>
CC R
mark edly</w>
(http://creativecommons.org/licenses/by/ 2.0),</w>
co ol
38 9</w>
simil arly</w>
/j c
amylo id</w>
34 9</w>
C V</w>
excep tion</w>
sw itch</w>
indic es</w>
u l</w>
u d</w>
lip id
phy to
trop ical</w>
ill a</w>
H 1</w>
Instit utes</w>
olog ies,</w>
( 12.
ir radiation</w>
di mer
th ink</w>
v ox
e ”</w>
metast ases</w>
23 9
equ ilibrium</w>
datab ases</w>
N MD
N it
g ue</w>
( CA
V I
exist .</w>
22 )</w>
retri ev
ti p</w>
an om
Er ror</w>
Sh en</w>
F M</w>
re ticul
38 5</w>
200 3;</w>
rel ations</w>
Nor mal</w>
T T</w>
fil ms</w>
sub types</w>
Q i
pre feren
prot ect</w>
3. 6</w>
exp anded</w>
(O R</w>
instruc tions.</w>
bi ased</w>
8 ].</w>
chlor ide</w>
clear ance</w>
RNA i</w>
a w</w>
bin ary</w>
endoc rine</w>
3 +</w>
ang er</w>
uncertain ty</w>
Inter ven
sit e.</w>
opportun ity</w>
201 6
pot assi
Ne ural</w>
lin ear
Sm all</w>
ra ised</w>
Bio chemistry</w>
Bi ology,</w>
(201 6</w>
20 –
38 1</w>
ad mis
diseas es.</w>
4. 1</w>
D D</w>
ic -
Gen et.</w>
at i</w>
Conflic t</w>
weigh t,</w>
( PC
off spring</w>
29 4</w>
Cor relation</w>
f lies</w>
effec ts,</w>
opath ological</w>
Avail ability</w>
48 0</w>
33 1</w>
Th us</w>
bond s</w>
epti de</w>
1 *</w>
mal ari
olig onucle
Dec ember</w>
Scienti fic
Nex t,</w>
cy te</w>
+ +</w>
Cardi ovascular</w>
complic ated</w>
40 3</w>
a ac
g ray</w>
F a
o resc
e ating</w>
t ly,</w>
mo ving</w>
im mediate</w>
R I</w>
L L</w>
f ing
W A</w>
26 8</w>
t .
S our
4 )
Sof tw
G s</w>
A b</w>
36 .</w>
programm e</w>
oc ca
belong ing</w>
S ah
En h
attenu ated</w>
( 20</w>
ya ho
red und
Bl ack</w>
expect ed,</w>
excit ation</w>
month s.</w>
D s</w>
other .</w>
45 4</w>
coordin ates</w>
L an
V .
16 S</w>
38 3</w>
scre en
a 0
34 4</w>
D ur
fer tili
o king</w>
37 1</w>
ol ys
ni a</w>
60 %</w>
Davi d</w>
18 9
berg er</w>
Author (s)</w>
D al
CA 1</w>
Cor por
dementi a</w>
5 5.
relationsh ip
ed itor
17 8
G raph
Engine ering</w>
squ amous</w>
S anta</w>
3 2.
D i</w>
deriv atives</w>
A ra
[36 ].</w>
year -old</w>
n es</w>
experiment ,</w>
os .</w>
, 3
au x
la g</w>
radio therapy</w>
6 6.
inter leukin
gr u
sign ature</w>
K on
C 3</w>
Fu j
lin e.</w>
d y</w>
ni h
Microbi ology</w>
Fact ors</w>
a id
Oc tob
fit ting</w>
00 8</w>
L F
0.9 300</w>
Jul y</w>
Sil va</w>
for d,</w>
k h
materi al.</w>
R ic
val id</w>
consist ency</w>
spectro scopy</w>
ect .</w>
F low</w>
9 8.
o bi
re modeling</w>
Bios ystem
-Al drich
sep sis</w>
N 1—C
et ting</w>
mar ks</w>
S por
Can di
soci o-
ke eping</w>
nic o
elev ation</w>
Sch mid
constr ained</w>
a e.</w>
acr yl
l ane</w>
S mo
D ed
modul ated</w>
epider mal</w>
BL /
F ab
ter -
t y-
I T</w>
lip s</w>
prev ents</w>
can onical</w>
in ver
hepat ocellular</w>
re arrang
ar ization</w>
asp ect</w>
M s</w>
ses sions</w>
el igible</w>
PA GE</w>
rheumat oid</w>
labor ator
pepti d
38 7</w>
f rom
ter m
immun ob
T ris
.201 1.
e- induced</w>
ori ent
lab elled</w>
Staphyloc occus</w>
produc es</w>
8 ),</w>
( ±
el le</w>
. org
di ast
epitheli um</w>
D B
ethn ic</w>
er son</w>
obt ain
graph s</w>
roph y</w>
os s</w>
H z,</w>
respon se,</w>
exist s</w>
acchar ide</w>
23 5
ev oked</w>
condi tion.</w>
T ex
enz yme
W ater</w>
sub group</w>
10.10 56/
10 ,
26 6</w>
24 2</w>
lymph oma</w>
o unc
diffic ulty</w>
Pro f
interac ts</w>
prot ected</w>
W he
G H</w>
com ing</w>
fi b
L ym
P /
Techn ology,</w>
typ e,</w>
German y
ast -
ER K</w>
ge al</w>
G R
re j
11 6
uni form</w>
ff er</w>
37 7</w>
K ri
fir ing</w>
guid ed</w>
ill in</w>
En ter
0. 15</w>
S N</w>
concer n</w>
37 0</w>
pap er,</w>
blood -
C 15
f MRI</w>
4. 2</w>
40 2</w>
T ub
Equ ation</w>
En do
subst ance</w>
Ger man</w>
degener ative</w>
p ed
pertur b
C 1
om b
P y
individu al
Mar ch</w>
insec t</w>
il ity</w>
variabl es.</w>
cryst all
ven ous</w>
x on</w>
hom ology</w>
A O
26 4</w>
H 3</w>
10.1111 /
Rel ationsh
( pH</w>
deci sions</w>
9 6.
summar y,</w>
P in
por al</w>
sy non
p up
: e
Ch er
adop ted</w>
Americ a
ok a</w>
en coun
enco des</w>
0 /
ocyt es,</w>
inform ation.</w>
wid espread</w>
F ed
ic z</w>
precip it
s ent
C 6
H emat
37 9</w>
slo pe</w>
environ ment.</w>
Salmon ella</w>
r ub
gl u
alve olar</w>
M AT
ey es</w>
B et
me et</w>
reach ing</w>
O li
or im
Gre en
un likely</w>
trigg er</w>
S MA
vi able</w>
Sub j
bow el</w>
el se
6 %)</w>
ol og</w>
pri or
00 9</w>
10.1007 /BF
ro tation</w>
accum ul
Ch ic
ro bu
Y an</w>
mag ne
gl and</w>
36 6</w>
if ying</w>
for ces</w>
.200 8.
24 4</w>
Com pu
4 ]</w>
physici an</w>
lear n
Lim it
P T</w>
ad ing</w>
at o
ul atory</w>
T rop
sp ent</w>
R ub
form er</w>
expres sions</w>
- resistant</w>
posi tion,</w>
part ner
Ann ual</w>
V s</w>
nam ely</w>
aerugin osa</w>
D ig
L S
over weight</w>
1. 7
Go od
atin gs</w>
15 )</w>
shar ing</w>
A V</w>
D ani
Whit ney</w>
optim ized</w>
increas ingly</w>
v ast
st ated</w>
5 7.
0 9
m erg
Endocrin ol</w>
set .</w>
d h
R og
accur ac
Par t</w>
system s.</w>
effec t.</w>
Anim als</w>
suspen sion</w>
month s,</w>
st ock</w>
Th at</w>
gen ,</w>
S ig
hydroph obic</w>
pl oid</w>
E ll
de m</w>
9 7.
H SP
NE J
Th en</w>
scre ened</w>
3. 8</w>
appl y</w>
soci oeconomic</w>
trans membrane</w>
c ine</w>
am ycin</w>
Lew is</w>
if e</w>
T su
bu s</w>
calibr ation</w>
nur sing</w>
ran e</w>
fil tr
sp ots</w>
A E
fig ures</w>
inter view</w>
is s
In form
an s.</w>
L arg
oph armac
er s
ap o
accur ately</w>
, 7
Nutri tion</w>
C 16
Ac tivity</w>
clos ure</w>
Consist ent</w>
d yst
a uc
well .</w>
Su z
obj ectiv
buil t</w>
spe ech</w>
ad ren
e –
co ded</w>
[37 ].</w>
Bas eline</w>
H as
24 6</w>
E t
over come</w>
j i</w>
predic ts</w>
contin ue</w>
10.1016 /00
mon ol
L H</w>
per haps</w>
(I )</w>
17 -
athi one</w>
examin ing</w>
C 3—C
Engl and</w>
Cl ar
approach ,</w>
combin ing</w>
M N
10.1056/ NEJ
system s,</w>
ous ,</w>
methyl ated</w>
incorpor ated</w>
ul us</w>
tissu es.</w>
discus s</w>
M ü
pl ex
exac erb
at ed
W S</w>
O 1</w>
amb igu
rec i
ac knowledge</w>
38 .</w>
L iver</w>
phosph olip
39 1</w>
mus cular</w>
Ca 2+
sem an
35 8</w>
gh ,</w>
chromat ography</w>
w in</w>
cir cadian</w>
De part
Ga us
H sp
trigg ered</w>
ster ile</w>
– 2.
electro des</w>
blo tting</w>
24 8
surve ys</w>
ma ize</w>
E g
ap ol
G L</w>
35 2</w>
39 3</w>
24 )</w>
26 2</w>
themsel ves</w>
C 4—C
Rec om
H and
9 ].</w>
On co
ad ul
sou thern</w>
enc y,</w>
pathw ay,</w>
Biom edical</w>
K im
n m.</w>
conclud e</w>
ph age</w>
28 ,</w>
(199 6</w>
β 1</w>
U g
profession als</w>
promo ters</w>
od ynamic</w>
198 5</w>
oc cal</w>
r ite</w>
23 )</w>
pen etr
14 )</w>
myel oid</w>
favor able</w>
ure -
Fund ing</w>
pron ounc
mid -
Ul tr
bl ack
g em
leng ths</w>
cytotox icity</w>
are a.</w>
37 .</w>
cal c
cyto chrome</w>
short- term</w>
emer gence</w>
Op in</w>
loc al
10.10 37
L X
CI ,</w>
ay ers</w>
promin ent</w>
meth an
60 -
39 7</w>
Diagnos tic</w>
sequenc e,</w>
dri ve</w>
1 _
.0b013e 318
B oy
numer ical</w>
lo be</w>
A si
D ut
0.0 9</w>
ha ir</w>
end o
P <0.0
microbi ota</w>
compati ble</w>
cl i
P lo
FO X
olog ists</w>
experiment ally</w>
go at</w>
provid ers</w>
f ine</w>
( 95
em ble</w>
et y,</w>
CX CR
h l
Uni ver
sug ar</w>
36 8</w>
0 7
par i
eg g</w>
G all
us age</w>
requ iring</w>
part ner</w>
mon om
y .
ei er</w>
C ra
USA ),</w>
as ting</w>
27 ,</w>
W in
F lo
140 -67
F el
13 )</w>
ar an</w>
140-67 36
L iv
classi fic
Long -
34 6</w>
pres sive</w>
40 7</w>
ost er
sit es,</w>
ost er</w>
3. 7</w>
connec tions</w>
minim ize</w>
sp ot</w>
10.11 46/
On ce</w>
. 12
39 5</w>
ann ure
Th i
repe ats</w>
10.1146/ annure
help ful</w>
consider ation</w>
F uk
L ac
hal f-
R ou
0. 10</w>
kid ne
Second ary</w>
pur ification</w>
down- regulated</w>
at rial</w>
un n
behaviour al</w>
Mo ore</w>
path ophysi
br anch</w>
ack age
them .</w>
t oc
38 4</w>
op tion</w>
bio informatic
1 b</w>
L ong</w>
nur ses</w>
40 .</w>
Inter net</w>
see king</w>
0 8
36 4</w>
simult aneous</w>
39 0</w>
criteri on</w>
dri ving</w>
0. 95
5. 5</w>
v oc
op tic</w>
ANO V
estim ating</w>
@ yaho
inform ation,</w>
Con t
usep ackage
\ usepackage
land s</w>
nor thern</w>
N M</w>
competi tion</w>
mod es</w>
Netherland s</w>
valu es,</w>
re agent</w>
carri er</w>
giv ing</w>
an ticip
euk aryotic</w>
regi ons,</w>
enhanc ing</w>
sp p.</w>
F al
differenti ate</w>
au x</w>
romy ces</w>
ti s,</w>
op tions</w>
38 2</w>
se y</w>
sp ir
H ub
34 8</w>
B I
beli eved</w>
B os
H2 O2</w>
ocy an
credit ed.
tri glycer
obj ects</w>
Cur r.</w>
me i
degre es</w>
part ly</w>
moder n</w>
16 00
ch ed</w>
IF N
7 ),</w>
we b</w>
aggres sive</w>
conn ection</w>
leng th
D T</w>
Cir culation</w>
200 2;</w>
cut- off</w>
Wil ey</w>
us :</w>
z o</w>
st ay</w>
36 2</w>
En tom
require ment</w>
subj ective</w>
ing ;</w>
D A
are a,</w>
39 9</w>
yiel ds</w>
130 39/
vesi cles</w>
SP SS</w>
wa iver</w>
Kn ow
cellul ose</w>
.ac. uk
33 6</w>
T am
f inger</w>
) ]</w>
2 A
g rain</w>
men ing
- 4
ch est</w>
wor ks</w>
nam ed</w>
el -
S eg
gr ate
sor ti
st op</w>
ox idi
de :</w>
H op
Ltd .201
infarc tion</w>
C O</w>
a rom
h n
000 0</w>
C ast
plos plos
Labor ator
if i
0.00 2</w>
pig s</w>
fl an
lin es,</w>
analy zing</w>
H os
dis covered</w>
at yp
An d</w>
s ://
b ach</w>
r ated</w>
ic illin
den at
attem pt</w>
/ 10
100 ,</w>
fas ting</w>
33 8</w>
dra ft</w>
centr e</w>
participant s.</w>
ation /
no tic
v ic</w>
fe ar</w>
ab in
ide al</w>
muc osal</w>
35 6</w>
Sur ve
F ile</w>
st ac
\usepackage {
chrom osom
S pe
function ally</w>
d b
35 4</w>
anc es,</w>
pre valent</w>
M HC</w>
intensi ties</w>
Mor ph
mach in
http s://
/ A
ag a</w>
m RNAs</w>
S ensi
o x</w>
attach ment</w>
pol yp
Con tribu
bir ds</w>
b ell</w>
An g
0.0 1,</w>
cycl ic</w>
gen ous</w>
IO N</w>
ind ustr
37 2</w>
hy dr
inser ted</w>
ge ometry</w>
dis sem
super vised</w>
PE T</w>
end emic</w>
manufacturer 's</w>
[ 55
pro phyl
effici ently</w>
vi al</w>
C :</w>
[38 ].</w>
tax a</w>
land ,</w>
@gmail .com
p us</w>
investig ating</w>
Str at
vertebr ate</w>
H I</w>
identifi es</w>
exten sively</w>
M W
ov ic</w>
pol i
ex ogenous</w>
9 %)</w>
G T</w>
reason able</w>
ar ri
cap sul
prolifer ation,</w>
sl ight</w>
ar y.</w>
institu tional</w>
Roy al</w>
CT T
β ,</w>
E T</w>
un clear</w>
obacter ia</w>
techn ologies</w>
n on</w>
opath ic</w>
it s,</w>
1. 3
princi ples</w>
O X
strati fied</w>
I K
2 nd</w>
B asic</w>
Per form
modul ates</w>
perme ability</w>
Surger y</w>
in nov
38 6</w>
n ich
H 5
ology :</w>
inf erior</w>
− 1
CC L
syst olic</w>
op er</w>
ha ir
population -based</w>
ity )</w>
specim en</w>
bur g,</w>
ect ed.</w>
T GF
intraven ous</w>
lifest yle</w>
re adily</w>
fres h
trans mis
p ass</w>
m id</w>
ang ular</w>
Sy st</w>
con sequ
10.1038/s j.
cr yp
Activ ation</w>
waveleng th</w>
(i ii)</w>
diag ram</w>
difficulti es</w>
R aj
T D</w>
/ 1.0
oci al</w>
cha romyces</w>
Ques tionn
it ors</w>
l am
Apri l</w>
domain /
mon d</w>
C N</w>
10.11 58
break s</w>
fic i
ativ ely,</w>
potassi um</w>
exp ect</w>
draf ted</w>
self- reported</w>
pair wise</w>
incid ent</w>
re habilitation</w>
S cre
(0 2)
softw are.</w>
larg e-scale</w>
sub type</w>
el a</w>
ast s</w>
depic ted</w>
Sept ember</w>
R K</w>
En d
per mission</w>
Respon se</w>
qu es</w>
P t</w>
aw are</w>
6 9.
0. 11
ju ven
int ens
lar val</w>
a g</w>
gli al</w>
/ -</w>
cont acts</w>
Quanti fication</w>
Gl uc
xen og
dat e,</w>
S ant
hour s.</w>
tel om
ver bal</w>
I l
har a</w>
in verse</w>
candi dates</w>
dy e</w>
up d
im mobil
− 1)</w>
set ,</w>
( Δ
os ing</w>
im um</w>
T u
Ad ju
exclu sively</w>
ar bit
Ill umina</w>
Pro cess
He La</w>
en i
Ded ication</w>
ag o,</w>
transcri bed</w>
c up
2 B</w>
consi de
B at
cav ity</w>
P an</w>
docum ent
dist ant</w>
programm ing</w>
4. 3</w>
Mater .</w>
O V
conduc t</w>
individu ally</w>
V et</w>
Par amet
Key words</w>
nit ro
sc ans</w>
En ergy</w>
v ate</w>
public domain/
S us
zero /1.0
publicdomain/ zero/1.0
200 3).</w>
small -
Inde x</w>
surger y,</w>
Di eg
au l</w>
cyto plasm</w>
V an
malign anc
Bacter ial</w>
Cru z</w>
publicdomain/zero/1.0 /)</w>
C W</w>
group ed</w>
propor tions</w>
as k
c s</w>
pre frontal</w>
< 0.0001</w>
ret ained</w>
0 6
od on
GT T
Ther mo</w>
Eur .</w>
injur ies</w>
end it
high light</w>
M ak
(http://creativecommons.org/licenses/by/ 4.0/
stro k
mellit us</w>
33 4</w>
ric es</w>
K it
j ourn
L P</w>
50 1</w>
desi red</w>
ud a</w>
re activity</w>
12 /
37 8</w>
pl ur
h s
C o-
rat e.</w>
Plas ma</w>
mon ocytes</w>
stat ed.
37 6</w>
bul k</w>
Comput ational</w>
co des</w>
metabol ite</w>
le uc
im oto</w>
cat tle</w>
men opa
Pl at
observ ational</w>
l ings</w>
sym b
es h</w>
do x</w>
II I
pi ec
Har ris</w>
Sou thern</w>
n et
T og
10.1093/nar /g
devi ations</w>
pro ved</w>
he igh
centrifug ation</w>
research ,</w>
M N</w>
proper ty</w>
(http://creativecommons.org/ publicdomain/zero/1.0/)</w>
b rown</w>
on a</w>
De sign</w>
40 9</w>
O ste
electrophore sis</w>
sampl e,</w>
24 6
N CB
Chang e</w>
stud ying</w>
facil ity</w>
Mit ochond
respectivel y)</w>
trans mitted</w>
condi tion,</w>
plant s.</w>
j a</w>
ip ot
lip ids</w>
An atom
C 1—C
- of-
empl o
Medic ine
C57 BL/
vari es</w>
- 6</w>
Rep ort
hierarch ical</w>
– 0.
outcom es.</w>
39 8</w>
S 4</w>
d rought</w>
con gru
flex ible</w>
16 )</w>
33 2</w>
R R
d le</w>
tissu e.</w>
reduc tase</w>
at um</w>
0.0 7
adolesc ent</w>
IFN- γ</w>
Immun e</w>
j us
13 5
re ward</w>
qu er
backg round
buff ered</w>
f ly</w>
resus p
ap or
0.9 3</w>
op es</w>
amin o
mit otic</w>
man ,</w>
T est
adenocarcin oma</w>
D im
UT R</w>
Wom en</w>
commun ity-
cor tico
ri gu
N B
G ab
stimul ate</w>
ac tic</w>
p 5
pro- inflammatory</w>
hapl otype</w>
- 8
adap t
AN D</w>
J in</w>
able :</w>
s we
3 1.
shif ts</w>
vers ely,</w>
sci enti
in equ
be ads</w>
T an</w>
ol ym
immuno deficiency</w>
b ular</w>
H aw
de ep
con clusions</w>
gr ants</w>
4 2/
Biosci enc
stres s-
lo x
A GA
ind er</w>
K H</w>
Ag ing</w>
y stem</w>
n om
hear ing</w>
suppres s</w>
epidemi ology</w>
rou tin
attit udes</w>
Dev .</w>
con comit
st age,</w>
gre y</w>
P it
26 ,</w>
NO S</w>
inf usion</w>
Op tim
anim als.</w>
lab el</w>
1 Table</w>
gener alized</w>
avail able.</w>
H H</w>
9 ),</w>
P N
39 .</w>
surger y.</w>
forc ed</w>
oly sis</w>
N E-
29 ,</w>
23 4
mo tility</w>
10.1016/S0 140-6736
sourc e,</w>
13 8
[39 ].</w>
sequenc es,</w>
wh it
Y osh
German y).</w>
full- length</w>
Jac ob
siz e.</w>
Ev ans</w>
Intere st
40 4</w>
transl ated</w>
ac ous
o ks</w>
accoun ted</w>
vide o</w>
tic ancer</w>
bo ot
C 18
micro -
absorb ance</w>
(199 5</w>
[ 56
ac tin
regist ered</w>
Alzheim er’s</w>
compli ance</w>
en ables</w>
si bility</w>
e. s.
G ender</w>
sl ides</w>
pronounc ed</w>
subject s.</w>
c ues</w>
fo ot
E s
n t</w>
ot arg
fer ron
( green
i i
An gel
sclero sis</w>
cys tic</w>
re turn</w>
Octob er</w>
seas on</w>
one- way</w>
5 47
ogram s</w>
EM BO</w>
Onc ology</w>
L act
part ners</w>
Z ,</w>
C are
de priv
ch aper
normal ization</w>
3. 9</w>
Sing le</w>
Li ang</w>
id ae</w>
40 8</w>
2 σ
S o</w>
ent -
alb umin</w>
govern ment</w>
calcul ations</w>
plac ebo
copy right-
17 /
Child ren
interpre t
Auth ors'</w>
40 )</w>
M az
statement ©</w>
e- copyright-
e-copyright- statement©</w>
genotyp ing</w>
nih .gov
PC s</w>
oz o
power ful</w>
B 2</w>
, 5
A qu
c ent</w>
4 °C</w>
fel t</w>
w ise,</w>
cle an
f os
Mal ay
un de
Gr ad
12 3
all ergic</w>
impl ies</w>
S ab
attri b
Not ably,</w>
W ag
ac etic</w>
ent ary</w>
f ut
B acillus</w>
U RO
, 4
n =
in sufficient</w>
I P-
( 1–
sh am</w>
Jo int</w>
46 0</w>
il ,</w>
tur no
microgli a</w>
H 1
v ed.</w>
c ass
b ing</w>
ap tic</w>
Orig inal</w>
sub sets</w>
K E</w>
sequ ential</w>
(A p
25 8
Develop mental</w>
Wn t</w>
car ry</w>
M ir
Ad ol
bre ath
All ergy</w>
gen e-
m on</w>
CR P</w>
ble eding</w>
CX CL
K ang</w>
14 8
pro s
K l
lo ok</w>
tion s:</w>
S le
28 )</w>
C an</w>
ver si
g els</w>
al is
mo ther</w>
en s,</w>
av a</w>
e ur
38 8</w>
HB V</w>
A x
dec ay</w>
37 4</w>
com for
rel l</w>
protoc ol.</w>
en or
flav on
24 9
te -
D oc
er man</w>
HI F-
sti ff
I ts</w>
ref ers</w>
O d
equ ations</w>
15 %</w>
cyste ine</w>
n oc
graph ene</w>
C 4</w>
t z
min ute</w>
50 3</w>
rec all</w>
Ste in
ma -
E 1</w>
cl ade</w>
1. 8
50 5</w>
ach e</w>
Mo use</w>
clust ered</w>
ar sen
Myco bacterium</w>
Fi ve</w>
vit al</w>
ol factory</w>
4 :</w>
B :</w>
(13 .
0 5
ethyl ene</w>
4. 6</w>
stimul ating</w>
b ac
poss ess</w>
int ended</w>
] ,
sur ge
polar ization</w>
L ),</w>
stres s.</w>
com pos
y i</w>
umin escence</w>
iv es</w>
] ),</w>
Child ren</w>
C 5—C
bi di
Cl ark</w>
Pro duc
t ended</w>
ti ally</w>
marg in</w>
mit t
cop ic</w>
O 3</w>
CD K
ric k,</w>
45 1</w>
exhib its</w>
endi x</w>
rever sible</w>
40 6</w>
constrain ts</w>
regard ed</w>
con s
qu ick
39 2</w>
ser ial</w>
ex ual</w>
con formation</w>
Der mat
au d</w>
ST -
libr aries</w>
water .</w>
T 3</w>
ok ine</w>
IL- 10</w>
14 9
re mot
10. 4
Contribu tions</w>
t ).</w>
sur ance</w>
P le
pres s</w>
scho ol
bri ef
( Ch
scatter ing</w>
Fren ch</w>
27 )</w>
neutroph ils</w>
infiltr ation</w>
c p
G B</w>
Bl ack
scenari o</w>
resusp ended</w>
log -
thali ana</w>
.201 0.
P t
quanti ty</w>
. 10
stat e,</w>
for tun
Braz il</w>
met er</w>
19 -
un clear
g i</w>
carri ers</w>
posi tion.</w>
tend ency</w>
Mat su
( “
IF )</w>
B ull</w>
par asi
line ages</w>
wat er,</w>
Sp ain
conform ational</w>
Pear son</w>
deci sion-
T s</w>
don ors</w>
hypo thalam
Rod rigu
P as
viv o.</w>
tum ours</w>
26 )</w>
d ingly,</w>
ex in</w>
Flu oresc
on ing</w>
contamin ation</w>
if er
dec ad
potenti als</w>
ati le</w>
mi RNA
IL-1 β</w>
c ann
q RT-PCR</w>
ff ic</w>
attri but
an ia</w>
m m,</w>
6 7.
om ing</w>
organis m</w>
control s,</w>
three- dimensional</w>
lat ent</w>
ex tinc
ba um</w>
recept or
200 1;</w>
3 13
air y</w>
Resp ir</w>
V as
avi an</w>
cop ies</w>
Consid ering</w>
c all</w>
EC s</w>
describ es</w>
exten d</w>
fe ed</w>
wa y,</w>
z es</w>
7 6.
24 4
I L</w>
(P D
– 7</w>
ta g</w>
L N
it ri
( 8</w>
as er</w>
A AT
eren t</w>
Meth od</w>
rec t
T al
nas al</w>
scop e</w>
ex cessive</w>
Ob es
A ri
cir cl
int ron</w>
grad ually</w>
g00 1
Measure ment</w>
ischem ia</w>
cas e-
r ,</w>
0. 12</w>
patient s’</w>
spi ke</w>
d ox
3 a</w>
r -
e fs</w>
W est
6 5.
con tig
vacc ines</w>
ish i</w>
0 2</w>
y es</w>
J AM
homoz ygous</w>
Ca ro
ed ).</w>
seas onal</w>
con genital</w>
paramet ers.</w>
0.9 5</w>
Prote ins</w>
bal anced</w>
b row
L ys
Cambrid ge</w>
O t
Neuro n</w>
sp ik
H ill</w>
Spec ific</w>
( blu
39 6</w>
C 6—C
45 3</w>
rough ly</w>
A β</w>
hemat opoietic</w>
quanti t
eth ics</w>
Arth ritis</w>
7 /S
U /m
D op
odi c</w>
E ar
[40 ].</w>
si s-
Real -
47 3</w>
H od
b j
st ain</w>
ph ase,</w>
ak is</w>
world wide</w>
G H
c t
8 8.
and .</w>
accept able</w>
Fr ance</w>
organ ized</w>
7 8.
18 )</w>
k g
Over all</w>
great est</w>
mo ve</w>
princi ple</w>
G I
3 28
in s,</w>
es cent
G overn
ag arose</w>
re dox</w>
os ocial</w>
cent ers</w>
PA ,</w>
( g
mean ing</w>
Eth i
opo ro
Spor ts</w>
45 5</w>
3 15</w>
consider ably</w>
K ing</w>
so und</w>
et s.</w>
yg d
lipo protein</w>
4. 4</w>
F eng</w>
[ 57
K R</w>
Lu o</w>
Schem atic</w>
assess ments</w>
ex ci
children .</w>
e in</w>
Jack son</w>
Physi ology</w>
ris k
Org anis
mi x</w>
O C</w>
In c.</w>
F rac
four th</w>
am ygd
( 20
pas sive</w>
u z
T ER
ar o</w>
(14 .
coun ting</w>
. ”</w>
V el
3 20</w>
at :</w>
st o
10.1097/ 0000
K w
av eng
Sur viv
5 ′</w>
direc tional</w>
adv ances</w>
flag ell
enc y.</w>
Comm un</w>
In strum
tin ib</w>
evol ved</w>
d ay,</w>
MD A-
P ak
: 1</w>
concentr ated</w>
ic s.</w>
th us,</w>
arch ae
39 4</w>
as aki</w>
10.3 390
10.110 1/
M MP
opportun ities</w>
calcul ating</w>
exp endit
V ill
go ing</w>
otroph ic</w>
up date</w>
chec ked</w>
β- catenin</w>
some what</w>
ll er</w>
compri sing</w>
46 1</w>
▶ ).</w>
System atic</w>
to s</w>
N r
st och
ro ute</w>
l nc
p ec
Subj ects</w>
O v
fati gue</w>
0000 -000
astro cytes</w>
sit e,</w>
sou ght</w>
8 9.
lymph ocyte</w>
concep ts</w>
00 7
univers al</w>
J ourn
tum or-
activ ation,</w>
elong ation</w>
f )</w>
integr in</w>
(0 3)
29 3
post natal</w>
2000 ;</w>
sp ine</w>
parti cl
popul ations,</w>
cert ain
Wal ker</w>
ten sive</w>
Institu tional</w>
(F )</w>
Wor k
b an</w>
Gu idel
om orph
198 4</w>
in- like</w>
suppres ses</w>
ser ine</w>
h )</w>
es ’</w>
heli x</w>
ant enn
al s
Nov el</w>
B ab
pro ven</w>
I SP
. 17
Sign al</w>
16 005
asp ir
Be fore</w>
mm )</w>
* P</w>
25 )</w>
Sch ul
Micha el</w>
percent ages</w>
per itoneal</w>
diff use</w>
il lo
Re pro
L F</w>
neph ro
cryst allograph
R /
wom en,</w>
χ 2</w>
lin s</w>
n emat
Sub sequently,</w>
dis pers
ubiqu itin</w>
T able
bl ing</w>
ra z
valid ate</w>
pati al</w>
metast asi
G ram
eg gs</w>
Bon ferron
eff lu
fem oral</w>
famil y,</w>
Ad min
it s.</w>
Sch ne
ben ign</w>
guid ance</w>
k ar</w>
modul es</w>
0. 10
K ob
pre term</w>
vin ce</w>
neigh bour
Gonz al
par aff
F IT
form ula</w>
per man
( 1,
resid ents</w>
w est</w>
dro p</w>
ow ,</w>
i or</w>
P B</w>
200 2).</w>
complex ,</w>
Influ ence</w>
ch ose</w>
Al g
quarti le</w>
yo ,</w>
R ol
pyl ori</w>
susp ected</w>
in spec
on omy</w>
modi fi
RN A.</w>
1 —H
4. 8</w>
di vers
od a</w>
0.9 9</w>
sp ind
visu alization</w>
V ar
t man</w>
process es.</w>
d ashed</w>
Gu ang
DNA ,</w>
e- related</w>
ic ally,</w>
respons es.</w>
or cid
denot es</w>
approach .</w>
orcid .org/
49 0</w>
45 7</w>
ME M</w>
mech an
pd f</w>
orcid.org/ 0000-000
Lou is,</w>
l ign
anti viral</w>
35 ,</w>
a ved</w>
Ital y</w>
repres sion</w>
networ k.</w>
dem and</w>
ell ul
e o
cadher in</w>
j o</w>
s un
hyperten sive</w>
O g
process es,</w>
poss ess
neur on
19 80
pap ers</w>
4 A</w>
r ical</w>
rat s.</w>
G en</w>
b or</w>
incorpor ation</w>
flu or
d engue</w>
er ;</w>
plur ipot
18 -
termin us</w>
cam era</w>
cit ed.</w>
Inf ection</w>
mathem atical</w>
tr y</w>
pain ,</w>
Aug ust</w>
ra rely</w>
fung i</w>
et -
effic ac
micro RNA</w>
tim es.</w>
K enn
sp ot
correc tly</w>
health ,</w>
ser a</w>
ac knowledg
ail s</w>
Th rom
m c
c rop</w>
us ting</w>
M ach
Stro ke</w>
46 7</w>
inter f
clon ing</w>
Biotechn ology</w>
Cambrid ge,</w>
(+ )</w>
ill umin
kin son</w>
NE- D-
so y
.com /
0 ·
bioinformatic s/
s ell</w>
An th
C ou
al i</w>
49 9</w>
29 )</w>
sub trac
ti zed</w>
Na Cl,</w>
S ho
ed ges</w>
switch ing</w>
W H</w>
poll en</w>
L I
F L</w>
l as</w>
00 6
discre te</w>
. 16
44 5</w>
C 7
coordin ated</w>
A min
questionnai res</w>
off ers</w>
w all
ï ve</w>
F ree</w>
au tism</w>
R ot
th ick</w>
conduc t
epid emic</w>
M B-
arth ri
compl etion</w>
Immun ol.</w>
17 )</w>
elim ination</w>
Syn thesis</w>
60 ,</w>
34 ,</w>
describ ing</w>
Coch rane</w>
mus cul
in hal
44 1</w>
ari o</w>
3r d</w>
oc h</w>
a z</w>
pneum onia</w>
K or
leth al</w>
ser ot
iso form</w>
Mod er
ge ographical</w>
MD ,</w>
g round
O ce
MC F-
201 2
High er</w>
chem icals</w>
[4 1].</w>
µ M</w>
heteroz ygous</w>
- activated</w>
mosquit o</w>
f et
P el
X ie</w>
2. 5
symptom atic</w>
pl ated</w>
cir rho
S ev
PO NE-D-
com mittee</w>
b a</w>
8 7.
Serv ice</w>
46 3</w>
í a</w>
man di
fo ods</w>
y an</w>
Δ ρ
Sac charomyces</w>
48 5</w>
influ encing</w>
al log
MS /
i od
G I</w>
sulf ate</w>
F A
if t</w>
par ation</w>
di alysis</w>
B ell
discipl inary</w>
Sc ott</w>
Pri or</w>
− 0.000
7 7.
d p
10.1093/ bioinformatics/
Al cohol</w>
exclud e</w>
Ann u</w>
lo com
bri ef</w>
asym ptom
( such</w>
immunos up
pl aque</w>
Californi a</w>
cryst als</w>
i re
A g</w>
di ed</w>
in puts</w>
ation ally</w>
k m</w>
46 5</w>
R ho
( e
config uration</w>
t ap
un t</w>
ens in</w>
trans -
RA S</w>
ori ented</w>
T ru
B E</w>
Col um
li sts</w>
b es</w>
olog ist</w>
7 9.
week s.</w>
gest ational</w>
Pro vinc
frac tion
[ 58
es cap
Rel ated</w>
de b
B row
te l</w>
T ables</w>
percep tions</w>
n ess.</w>
fiel d
replic ate</w>
49 1</w>
1 +
Ex ampl
D an
Cryst allograph
u ous</w>
N ar
up ta</w>
den sities</w>
Perform ance</w>
st one</w>
diagno sis,</w>
19 32-
3 13</w>
Ap pro
melan og
ativ e,</w>
0. 11</w>
pathway s.</w>
lat ency</w>
y en</w>
a virus</w>
6 203
D 3</w>
acces sible</w>
Pac ific</w>
em ann</w>
anc e
Ne ur
al This</w>
menopa usal</w>
Classi fication</w>
Isol ation</w>
phosph o
foc using</w>
ro om
K )</w>
down regulated</w>
meth anol</w>
exclud ing</w>
50 9</w>
ur ia</w>
198 3</w>
Accor dingly,</w>
patient ’s</w>
he par
50 6</w>
id e,</w>
Tw ent
’ .</w>
with draw
ap preci
n es
fin ally</w>
k i
° ,</w>
tissu es,</w>
emerg ed</w>
sti g
( which</w>
Phylo genetic</w>
im plantation</w>
ed ema</w>
44 0</w>
J on
empt y</w>
vi br
X )</w>
ad mitted</w>
mean ing
Con versely,</w>
om at
finding s,</w>
N ik
approxim ate</w>
50 7</w>
diast olic</w>
genom ics</w>
plosplos one
plosplosone PLoS</w>
ONE 1932-
ONE1932- 6203
ONE1932-6203 Public</w>
One PLoS</w>
ONE plosplosonePLoS</w>
M ail
thres holds</w>
Gaus sian</w>
su stain
N C
nat urally</w>
lin d</w>
Rob erts</w>
f un
Metabol ic</w>
So il</w>
ri son</w>
10.1186/ 17
v or
tub es</w>
dimen sion</w>
genom e.</w>
W is
http:// orcid.org/0000-000
no is
addi tive</w>
pp ed</w>
36 ,</w>
condi tioning</w>
Post -
49 7</w>
antagon ist</w>
gra ft</w>
tail ed</w>
Direc t</w>
ap paren
squ ares</w>
eri at
in complete</w>
p ock
44 9</w>
immun ost
H ard
are as.</w>
gl auc
relax ation</w>
com b
( ~
yl ase</w>
anal ge
F ern
neutroph il</w>
design ated</w>
angi ogenic</w>
Cl u
pneumoni ae</w>
fibro blast</w>
3 11</w>
a 2</w>
Polic y</w>
B Y
25 6
cir culation</w>
V e
- associated</w>
ot echn
00 000
d ense</w>
hol der</w>
GAPD H</w>
cr ude</w>
[2 ,
test s.</w>
stero id</w>
point s.</w>
b y-
Mater nal</w>
row s</w>
0.00 1,</w>
condi tioned</w>
6. 0</w>
44 7</w>
A CC
Å −3</w>
45 9</w>
ens on</w>
stat us.</w>
3 25</w>
ophil ic</w>
Admin istr
.200 7.
agon ist</w>
89 /
cap illary</w>
glut athione</w>
19 )</w>
Analy zed</w>
l amy
( Re
G M
rang e,</w>
- L
high- risk</w>
li pop
Nucle ar</w>
vir tual</w>
suc rose</w>
° C)</w>
ful ness</w>
St an
Pot ential</w>
guidel in
oblast oma</w>
sel ectively</w>
Pol ym
V ie
mach ine</w>
De fin
u tion.</w>
wom en.</w>
Kid ney</w>
, 0
arti cle
J. M.</w>
Me an
10.1038/s rep
ing ham</w>
K C</w>
ri sti
ad ic
10.1016/j. neuro
Cur ren
grow th.</w>
de press
D r
iter ran
expon ential</w>
Ph ar
min eral</w>
T ax
36 )</w>
J r</w>
oph osph
di stric
prev ented</w>
(16 .
50 2</w>
F J</w>
int ense</w>
H 3
Stre pt
ation s
sper mat
44 3</w>
refl ecting</w>
B G</w>
Per formed</w>
p tion,</w>
le ak
sc aveng
R N</w>
ver ify</w>
week ly</w>
CO ;
48 7</w>
ad dic
activ ation.</w>
ah l</w>
pic ture</w>
B ost
h all
( 7</w>
st en
Fact or</w>
ho t</w>
D ri
ca ud
F P
diar rhe
low ,</w>
J un
N/ A</w>
wash ing</w>
HIV /
tissu e,</w>
solu tion.</w>
duplic ation</w>
lact ate</w>
Univer sid
10.110 7/S
ic s
g00 2
condi tional</w>
bu ild</w>
F lor
in heren
T rit
l ets</w>
ach ing</w>
Alzheim er's</w>
P- value</w>
valu e.</w>
1 200
S G
BM J</w>
Gri ff
* p</w>
49 5</w>
33 ,</w>
unknow n.</w>
Suz uki</w>
trans plant</w>
polic ies</w>
Immuno histo
stat e.</w>
ah ashi</w>
Mic h
spl it</w>
0.7 5</w>
categor ized</w>
H )
In duc
Gen Bank</w>
0. 20</w>
hypo xi
cul tures
µ g/m
S V</w>
46 8</w>
3 19</w>
detect or</w>
neur ons.</w>
.n l
min er
bron ch
w a</w>
S ),</w>
Cy t
am ong
Evol utionary</w>
ay ashi</w>
min )</w>
S 2).</w>
C 17
3 17</w>
B RA
ocor tico
enc e-based</w>
effec t,</w>
wil d
off ered</w>
Sign aling</w>
Z eal
in clu
onucle ar</w>
diabet es,</w>
( 0.00
zym e</w>
Strat eg
(15 .
opoul os</w>
ot ub
dig ested</w>
paramet ers,</w>
c rop
am .</w>
materi al,</w>
v e,</w>
ari th
.201 5.0
con clusion</w>
( at</w>
w al</w>
y- based</w>
mT OR</w>
exper t</w>
cytos olic</w>
gli oma</w>
48 9</w>
colon ization</w>
F V
0.9 8</w>
Con ceived</w>
Neurolog y</w>
produc tion,</w>
1, 000</w>
ne ,</w>
follow s</w>
peo pl
56 2</w>
hydro lysis</w>
sy no
45 .</w>
symptom s,</w>
( F</w>
ect om
arbit r
reserv o
3 21</w>
c z
Nov ember</w>
down regulation</w>
am -
Nor thern</w>
D y
10.1016/j. c
sm an</w>
seman tic</w>
, 6
N Y</w>
- free</w>
dig estion</w>
omet ry.</w>
[4 2].</w>
46 9</w>
trac he
E E</w>
Ass ay</w>
pari etal</w>
displ ays</w>
form ation.</w>
47 5</w>
0. 5%</w>
promot ed</w>
trans plant
H off
form al</w>
ch ance</w>
Medi a</w>
Tai wan
Ex pl
streng th
dist ress</w>
F c
H il
T ar
201 4;</w>
( not</w>
omer ase</w>
3 10</w>
Interest s:</w>
stra p</w>
i a.</w>
p and
50 4</w>
ter ti
registr ation</w>
children ,</w>
tri als.</w>
U RE</w>
Le uk
Mar t
acous tic</w>
ma k
environ ment,</w>
ultim ately</w>
com partment</w>
Mc G
Jam es</w>
H M
wor se</w>
ity ;</w>
B DN
tan dem</w>
D o</w>
di al</w>
ATP ase</w>
Au stri
e au</w>
simil arities</w>
Q o
0. 67
ou ,</w>
perform ance.</w>
H 8
b ed
45 ,</w>
Tran sl
imp ed
e po
from :</w>
3 23</w>
, 13
fund ers</w>
0 4
25 7
O P
fe el</w>
S on
medi ators</w>
lap aro
[ 59
D P-
f used</w>
Bo x</w>
ex cre
m i</w>
biop si
Y uan</w>
st ation
p 38</w>
Correspond ence:</w>
str anded</w>
E lev
high- throughput</w>
app a</w>
en ko</w>
Schmid t</w>
All en</w>
L at
ann er</w>
m ind
config ur
def ault</w>
M .,</w>
establish ment</w>
et s,</w>
0. 13</w>
countri es,</w>
( Pro
com ments</w>
circu it</w>
Comput er</w>
10.1080 /0
loc aliz
proc e
In j
ger m
re y</w>
Ca o</w>
fe a
chick en</w>
de oxy
Avail able:</w>
n m
per oxid
my co
age- related</w>
point ,</w>
Rap id</w>
Immun ology</w>
inf erence</w>
- 1
4 1.</w>
H ig
Camp bell</w>
48 3</w>
[ 1,</w>
pl ex</w>
p in</w>
Serv ices</w>
35 )</w>
sym met
ar .</w>
h id
. 23
allel ic</w>
cycl in</w>
en larg
46 4</w>
olog ist
c ation</w>
pre p
P il
. 11
, 15
ar ro
K as
JAM A</w>
47 7</w>
U L
curren ts</w>
ag enesis</w>
Intern al</w>
3 27</w>
c ru
re vis
D or
B AL
inter sti
chec k</w>
view ed</w>
+ )</w>
origin ally</w>
S :</w>
g all
pre dat
SD )</w>
1 B
Ar g
moun ted</w>
repor ted.</w>
D ong</w>
ynam ics</w>
0. CO;
, 14
glycol y
d. 's</w>
anom al
paradig m</w>
r ules</w>
f eld</w>
vers ely</w>
0 3
u .</w>
individu als.</w>
T od
49 3</w>
38 ,</w>
s av
autom atic</w>
U ,</w>
in put
occup ational</w>
Tan aka</w>
b und
ic al
AS D</w>
Rep .</w>
om eg
j p
S or
Al -
ocyt es.</w>
el es</w>
feasi bility</w>
e.s. d.'s</w>
47 0</w>
recogn ize</w>
b on</w>
stead y</w>
In sul
conduc ting</w>
orth olog
a ve</w>
depl eted</w>
dro pl
e ase</w>
a emia</w>
Con tin
l .
emi a,</w>
k o
G /
suffici ently</w>
thres hol
28 7
S av
48 1</w>
insec tic
pro vinc
challeng ing</w>
Washing ton,</w>
traffic king</w>
ç ão</w>
perc enti
betw e
ex ceed
pre dominant</w>
m atic</w>
glycer ol</w>
Electr onic</w>
pan els</w>
plan k
tax onomic</w>
4 2.
nucle otides</w>
ag ic</w>
F S</w>
ex ons</w>
S tim
it ting</w>
trac e</w>
HC l</w>
coag ul
S EM
medic ations</w>
et c.</w>
instruc tions</w>
( all</w>
be hind</w>
en to</w>
prec ed
LD L</w>
ce phal
8 5.
el astic</w>
promo tion</w>
pl anned</w>
G am
47 1</w>
1 st</w>
thre at
umb ar</w>
DN A.</w>
denot e</w>
us k
plant s,</w>
prob abilities</w>
V and
di mer</w>
inst ability</w>
shor t
day .</w>
inflamm ation,</w>
L eg
Le ft</w>
S ter
AL S</w>
ph one</w>
6. 5</w>
Ch o</w>
Labor at
appl i
ass ay,</w>
J Y</w>
NE URO
s ar
os mo
0. 57
cor ro
Re sist
B W</w>
MA P</w>
equip ped</w>
( q
ke ep</w>
assum ing</w>
typ es,</w>
typ es.</w>
i- square</w>
ren c
0.00 3</w>
th in
y o</w>
per ic
Individ ual</w>
Bo ard</w>
lif e-
loc ally</w>
g row</w>
pl ied</w>
publish ,</w>
er y
form ,</w>
Ca uc
point .</w>
x ed</w>
microscop ic</w>
obt aining</w>
ect ed,</w>
M ass</w>
V o
0. 55
3 29</w>
competi tive</w>
S Y</w>
up- regulation</w>
ev i
0 .</w>
C 8—C
variabl es,</w>
O L</w>
poly clonal</w>
obstruc tive</w>
( 99
hapl otypes</w>
Onco gene</w>
00 8
il a</w>
man ually</w>
C 8
seg mentation</w>
mann er.</w>
ic ular</w>
S i</w>
0.9 6</w>
Neuro bi
n u
T 1
2 1)</w>
carbohyd rate</w>
mar ri
per mitted</w>
48 6</w>
Eth ical</w>
factor ,</w>
Ad ap
as e;</w>
T rial</w>
Sur gical</w>
F u</w>
kin es</w>
le g</w>
F an</w>
D am
3 30</w>
V I</w>
li pos
el sen</w>
concomit ant</w>
M embr
cop per</w>
Mo di
10.1007/s 10
alb ic
sequenc e.</w>
In nov
smo oth
44 4</w>
she ep</w>
Mor ris</w>
10.100 2
F /
d '
Veter inary</w>
desi r
3 A
Bi ol
metallo protein
P 3</w>
O ver</w>
45 2</w>
, 12
chem okine</w>
5 A</w>
mem or
im id
wor l
[4 3].</w>
ambi ent</w>
K ong</w>
educ ation,</w>
00 4
- 7</w>
jo b</w>
45 8</w>
cut off</w>
pharmac o
ther mo
om a,</w>
0. 86
, 16
produc tion.</w>
Rob inson</w>
ear li
ar ise</w>
in form</w>
bur n</w>
W rote</w>
aryn geal</w>
L it
Cardi ol</w>
prot ects</w>
0 =
Mechanis ms</w>
la b</w>
N elson</w>
Bel gi
supernat ants</w>
plic ations</w>
Tai wan</w>
adj usting</w>
S ER
Z .
( 12</w>
val ve</w>
F D
C GA
clinic ians</w>
C 9—C
ont ology</w>
bi polar</w>
EM S</w>
7 5.
L em
H owever</w>
ker atin
Cardi ovas
CD -
por ted</w>
Revie ws</w>
0. 14</w>
n t
PI 3
47 4</w>
sho ul
thor acic</w>
to sis</w>
s ed.</w>
metabolis m,</w>
50 .</w>
1 A).</w>
poll ution</w>
py ro
N am
S HE
10.15 23
la w</w>
b ),</w>
alter ation</w>
led ge</w>
un a</w>
S 1.</w>
w t</w>
ic e,</w>
0 0</w>
IC 50</w>
per ox
Is ra
A sia</w>
Cy cl
34 )</w>
50 8</w>
B il
li p</w>
ab use</w>
expl or
Publish ers</w>
DMS O</w>
D r</w>
e ach
X 2</w>
re new
sub groups</w>
strain s.</w>
pap er:</w>
Per cent
well s</w>
10 97
immunob lo
ep i
Regi onal</w>
haz ard</w>
dop amin
mo od</w>
ad ed</w>
coh orts</w>
4. 9</w>
re plac
pl au
neur ons,</w>
se pt
prescri bed</w>
(Q i
W ild
surfac e.</w>
asym metric</w>
ph ase.</w>
Toxic ol</w>
h n</w>
D ub
Fi eld</w>
cycl ing</w>
k el</w>
N Y,</w>
Cri tical</w>
corne al</w>
4 2.</w>
201 4.</w>
perspectiv es</w>
lif e.</w>
F IG
answ er</w>
sp in</w>
scal ing</w>
pl ast</w>
p ig</w>
Rep or
fol ded</w>
W R</w>
emb ol
applic able</w>
ent ered</w>
endoth eli
Qu e
gri d</w>
pre operative</w>
45 6</w>
g ing</w>
Prot oc
Inte rest</w>
ograph s</w>
medi ating</w>
STAT 3</w>
I k
R D
out break</w>
Wil co
SDS- PAGE</w>
0. 80
pressu re,</w>
manip ulation</w>
ec ology</w>
o side</w>
sat uration</w>
ul um</w>
il ed</w>
0. 56
Ch ung</w>
Se e</w>
S lo
Mar ine</w>
in active</w>
diffrac tion</w>
0.9 7</w>
pre mature</w>
precip itation</w>
na ïve</w>
, 17
ga it</w>
– 6</w>
Li m</w>
(R O
n m,</w>
identifi ed.</w>
t au</w>
47 9</w>
( e)</w>
them ,</w>
l ens</w>
emo tion</w>
μ m
Fe br
record ings</w>
Me yer</w>
C 7—C
ing s,</w>
1 B).</w>
s ay</w>
Prac tice</w>
3 ],</w>
mad e.</w>
landscap e</w>
Spec ies</w>
- 4</w>
opath ology</w>
eng agement</w>
s am
eth yl</w>
Pa ren
produc tive</w>
h ind
m ating</w>
spl een</w>
ant i</w>
correspond ence</w>
indic ation</w>
0. 70
pathway s,</w>
confound ing</w>
l aw
0. 16</w>
H ill
transpor ters</w>
HPL C</w>
form .</w>
(199 4</w>
15 3
py ru
life time</w>
sh ell</w>
con e</w>
issu e-copyright-statement©</w>
F I
sy l
u i
C s
di sh
v -
0. 90
activ ely</w>
At lan
2. 7
T ro
bi ting</w>
Guidel ines</w>
b if
K re
re agent
ger m</w>
cell .</w>
ph y</w>
AK T</w>
Rand om
0. 66
Tan z
confir ming</w>
ent a</w>
M ).</w>
Tok yo,</w>
a a</w>
elic ited</w>
re per
N gu
sign atures</w>
among st</w>
] :</w>
B ren
stabil ization</w>
continu ously</w>
oc occal</w>
/0 1.
l up
arrow s</w>
ma d</w>
anti retroviral</w>
atherosclero sis</w>
Microbi al</w>
S .,</w>
inter fac
C 9
0. 77
py rid
Swe dish</w>
loc k
defin ing</w>
H end
immun oglob
word s,</w>
Ar n
, 18
0. 58
Relationsh ip</w>
ac idic</w>
pum p</w>
L evel
susp ended</w>
ator s,</w>
R ac
vag inal</w>
- G
g ate</w>
form ation,</w>
Radi ation</w>
event ually</w>
ag en,</w>
dram atically</w>
retri eved</w>
38 )</w>
10.11 55/
ap on
[14 ]</w>
F ram
b lind</w>
propag ation</w>
A W</w>
St ev
slic es</w>
otyp ic</w>
S u</w>
G y</w>
[12 ]</w>
phosph ati
44 2</w>
0 3</w>
J N</w>
environ ment
[ 1]</w>
2 B).</w>
7 5%</w>
responsi veness</w>
ag netic</w>
m ass
sol ve</w>
Vir us</w>
anim als,</w>
suic ide</w>
Psych ology</w>
cr y
II .</w>
[13 ]</w>
unde restim
24 5
end or
patient .</w>
f ate</w>
Sh e</w>
m es</w>
quick ly</w>
u chi</w>
Neuro psych
k an
stimul ates</w>
0. 12
ap pa
cor tis
ec onom
ad d</w>
T echni
Cell .</w>
m mol
u a</w>
46 2</w>
200 1).</w>
t b
agre ed</w>
casc ade</w>
H E</w>
k ary
s kin
stres s
countri es.</w>
Offic e</w>
non linear</w>
facilit ates</w>
[15 ]</w>
y ed</w>
ap i
P aul</w>
10.1080 /
persist ence</w>
g ated</w>
cir cular</w>
l enti
Co A</w>
Cardiovas c</w>
t l
[16 ]</w>
poly s
super oxide</w>
ow ing</w>
interac tions.</w>
Californi a,</w>
Loc al</w>
L T</w>
bo ard</w>
(Ap plied</w>
10.10 17
characteris tics,</w>
Im ages</w>
Proc ed
oscill ations</w>
fri end
present ,</w>
Kore a</w>
dos age</w>
di vi
il ent</w>
out patient</w>
Therap eu
op ening</w>
H all
sen escence</w>
L ).</w>
ul i
3 1,</w>
C ore</w>
lys ine</w>
com pa
g ar
te .</w>
n av
are as,</w>
clos er</w>
ol ar
MDA- MB-
Ros en
10.1016/j. cell
caro tid</w>
house holds</w>
structure :</w>
arom atic</w>
con dens
Na Cl</w>
(17 .
edi ting</w>
epis odes</w>
44 8</w>
phosph o-
O F</w>
bel ong</w>
remot e</w>
(0. 8
ad i</w>
C z
C 10—C
tri al
turno ver</w>
A pop
° )</w>
P F</w>
top ic</w>
Mur ray</w>
need le</w>
30 –
L A
Progr amm
direc tions</w>
overexpres sing</w>
60 1</w>
0.8 6</w>
transi tions</w>
2 A).</w>
sec tion.</w>
[17 ]</w>
E u
di e</w>
0.00 5</w>
manip ul
it t</w>
m ig
ampl ic
, 19
Med iterran
ag ree</w>
method ological</w>
0.0 8
em enting</w>
e 100
et c.
en su
Cauc asi
fron t</w>
ic illin</w>
def ective</w>
recip i
abl ation</w>
C av
Behavi oral</w>
tri al.</w>
ess entially</w>
ah n</w>
(18 .
Con tributed</w>
reci proc
n an</w>
Mor t
Ret ro
model ed</w>
s —
AU C</w>
unt ary</w>
60 9</w>
ul tra
L yn
198 2</w>
domes tic</w>
A y
’ -
consum ed</w>
on :</w>
49 8</w>
te m</w>
44 6</w>
war t</w>
ventil ation</w>
she et</w>
off -
C 11—C
N is
u tion,</w>
modul ating</w>
0.0 1)</w>
H ind
me eting</w>
35 -
W right</w>
m r
μg/m L</w>
death .</w>
58 -
di strict</w>
elucid ate</w>
health .</w>
preven tive</w>
46 6</w>
' t</w>
oper ated</w>
m it</w>
homogene ous</w>
R CT
reduc tions</w>
w el
ax onal</w>
, 2
G ran
b rom
Con serv
my c
NCB I</w>
A .,</w>
illustr ate</w>
constit ute</w>
0. 78
[18 ]</w>
leng th,</w>
1 ±
[44 ].</w>
ha us
dist or
10 ].</w>
Al ber
A po
protoc ol
methyl -
ent r
96- well</w>
vi ri
ri fic
o )</w>
ar ms</w>
imag es.</w>
K os
AL L</w>
0. 68
tra ffic</w>
immun ization</w>
mt DNA</w>
Surger y,</w>
frac tures</w>
pap ill
participant s,</w>
7 ].</w>
Com p
accum ulated</w>
2 b</w>
H o</w>
0. 18</w>
B aker</w>
44 .</w>
Under standing</w>
form at</w>
M é
proxim ity</w>
J a
N Y
n ight</w>
[11 ]</w>
C ity,</w>
g00 3
acet ylation</w>
ic .</w>
gir ls</w>
4 1.
201 3.</w>
Agric ultural</w>
Repro d</w>
ma z
adv ice</w>
http://dx.doi.org/10. 13039/
v ig
gyr us</w>
Ram an</w>
dis c</w>
categ ori
10.1146/annure v.
pro inflammatory</w>
J u
(T IF)</w>
cell s:</w>
ligh t-
ur i
P eng</w>
90 -
tic k</w>
tin a</w>
structures ,</w>
H B</w>
ech ocardi
Resp iratory</w>
om i
B s</w>
licens ed</w>
10.1186/ 147
Cl ust
ap par
10 7.
Al so</w>
indic ative</w>
ari an</w>
W L</w>
ogene sis,</w>
let ters</w>
25 9
dissoci ation</w>
volunte ers</w>
Applic ation</w>
understo od</w>
mosquit oes</w>
situ ations</w>
16 3.
ad sorption</w>
ge ometric</w>
[19 ]</w>
asymptom atic</w>
os oma</w>
compu ting</w>
− 1,</w>
to oth</w>
mol ar</w>
re r</w>
form aldehyde</w>
[10 ]</w>
micro RNAs</w>
cho ose</w>
plement al</w>
ubiqu it
un related</w>
con fin
0.8 5</w>
up unc
Ch risti
lin ,</w>
D K</w>
5 '-
Math em
[ 60
49 -
domain ,</w>
col our</w>
Tr yp
fer mentation</w>
Co oper</w>
om al</w>
dis till
St ress</w>
year ,</w>
mark et</w>
0.0 5;</w>
antibodi es.</w>
Beha v.</w>
else where</w>
k r
R V
pr one</w>
SC C</w>
Ophthal mol</w>
co variance</w>
agric ultural</w>
ass ayed</w>
” )</w>
Frequ ency</w>
measure ments.</w>
sh all</w>
H ab
—H ⋯
lep tin</w>
cere bro
cis -
, 20
reproduc e</w>
ag er</w>
amin ation</w>
ro bo
00 9
CV D</w>
re gener
attemp ts</w>
E 2
mamm als</w>
le x</w>
medi um.</w>
accoun ts</w>
H2 O</w>
Pat el</w>
p ine</w>
Cl im
47 6</w>
[20 ]</w>
e- associated</w>
. 18
D I</w>
St age</w>
G or
10.102 1/j
Sc ot
fluctu ations</w>
percep tual</w>
ect ual</w>
minut es.</w>
anc ing</w>
sil ver</w>
37 ,</w>
lung s</w>
diff ers</w>
tim es,</w>
il e
x ia</w>
25 5
seed lings</w>
Th ose</w>
scho ols</w>
envel ope</w>
sec tion,</w>
id s,</w>
. 19
Sequ encing</w>
[8 ]</w>
st rom</w>
si a,</w>
Hum .</w>
um s</w>
2. 8
(0 1)
stoch astic</w>
synon ymous</w>
48 4</w>
49 4</w>
distribu tion.</w>
Trop ical</w>
G ir
b ases</w>
ti gh
CD 11
5. 1</w>
ill ing</w>
irradi ated</w>
0. 22</w>
sle ep
Adv anced</w>
berg ,</w>
osh i</w>
preser ved</w>
om ial</w>
ere r</w>
0 5</w>
regim en</w>
v ed,</w>
trac k</w>
a f</w>
RO C</w>
Com put</w>
10 3
highligh ts</w>
49 2</w>
A S-
illustr ates</w>
ö r
sp an</w>
align ments</w>
an te
tub ulin</w>
engine ered</w>
ho sts</w>
50 –
utili zing</w>
U /
O 3
0. 17</w>
remo ving</w>
relap se</w>
ant -
ur i</w>
A gency</w>
O P</w>
47 2</w>
gener a</w>
retur ned</w>
Path ology</w>
nih.gov /
H ou
B ak
istr y
contex t,</w>
on y</w>
n s
al anine</w>
sched ul
49 6</w>
Vis ual</w>
exerc is
per oxidase</w>
R G
c lock</w>
1. 9
adol escent
P W</w>
ect able</w>
proj ection</w>
cre ating</w>
speci alized</w>
Cost a</w>
e osin
Sp ring
te eth</w>
ten s</w>
compati bility</w>
R PM
GT P
ter med</w>
Vir al</w>
radi al</w>
stre ptom
ob last</w>
A β
ann a</w>
structures .</w>
10.100 6/
creatin ine</w>
t RNA</w>
uni variate</w>
V og
pl y</w>
ent rop
11 ].</w>
ec tion
hyper troph
aggreg ates</w>
ing u
aqu es</w>
nar row</w>
r ation
n i</w>
R MS
radi us</w>
ch el
develop ment
W ind
R V</w>
C 10
4 3.</w>
fea sible</w>
pres erv
ecos ystem
10.10 86/
K oh
no -
Reg arding</w>
tom ato</w>
( red</w>
3 12</w>
nar row
2 _
an on
H amil
inj ured</w>
Four ier</w>
refer ral</w>
f ast
ak es</w>
ateri als</w>
ell ip
enco de</w>
Sp ect
4 3.
e c</w>
robu st
circum st
Engine ering,</w>
t us</w>
28 -
b /
motiv ation</w>
hypo theses</w>
M ik
splic e</w>
G om
p c
Mur phy</w>
22 ].</w>
. 15
sev erely</w>
) +
[9 ]</w>
2. 6
Commun .</w>
M end
ng/m l</w>
Determin ation</w>
ancestr al</w>
[2 1]</w>
198 0</w>
Gl ut
r as
I Q
f alls</w>
T ab
48 2</w>
teach ing</w>
L G</w>
Tak ahashi</w>
dele tions</w>
Shar ma</w>
( range</w>
L Y
J un</w>
el lo
m iti
Long- term</w>
immun ol
res embl
ach er</w>
Hu gh
immuno fluorescence</w>
10.1523 /J
NEURO SC
sh ear</w>
ec l
ES T</w>
c ast
60 3</w>
39 ,</w>
cer al</w>
ard i</w>
··· A</w>
ro po
Com po
10.1017 /S
excit atory</w>
func tions.</w>
s me
King dom
Tran s.</w>
3 24</w>
GF P
event s.</w>
al location</w>
10.1523/J NEUROSC
H ut
proteas ome</w>
cigarett e</w>
filter ing</w>
Wo od</w>
46 .</w>
posi tioned</w>
care fully</w>
M itch
immunohisto chemical</w>
pre disp
stud ent</w>
(red )</w>
sub cutaneous</w>
p )</w>
al ed</w>
[45 ].</w>
M SC
ec tin
Hel sin
cerebell ar</w>
Ad ult</w>
Pi er
Dieg o,</w>
Low er</w>
sh RNA</w>
Chin a,</w>
In sec
ing /
t ;</w>
I ran</w>
Th ail
um )</w>
D aw
scenari os</w>
ind ust
prote omic</w>
H G</w>
retriev al</w>
control l
Surviv al</w>
saliv ary</w>
En g</w>
intersti tial</w>
phot on</w>
Not ch</w>
Ex pos
indust rial</w>
rat es,</w>
part y</w>
HE K
3 16</w>
23 ].</w>
Xi ao</w>
tri als,</w>
u til
Gram -
0.0 )</w>
Inter n</w>
determin es</w>
fi ber
r ating</w>
hydro ly
aff ili
w ant</w>
match es</w>
ac in</w>
Ne u
acc id
v is</w>
scaff old</w>
2000 ).</w>
J. -
26 6
sect or</w>
brain ,</w>
de ad</w>
Acknowledg ments</w>
under taken</w>
v ation</w>
CA ).</w>
an tin
id ae)</w>
brid ge</w>
Gar cia</w>
C 6</w>
fas hi
re vision</w>
wid er</w>
J en
W B</w>
intr am
upd ated</w>
otox in</w>
0. 50</w>
0 4</w>
bil ity,</w>
ver .</w>
o ic</w>
pre ferences</w>
An timicro
aber rant</w>
avail able,</w>
[22 ]</w>
per mit
2010 ,</w>
t00 1Table</w>
person ality</w>
sub til
0. 15
mix ing</w>
c k</w>
sel ectivity</w>
material s/
Onc otarg
reagent s/
denot ed</w>
K +</w>
chol ine</w>
pres sed</w>
Uni on</w>
t oph
201 5.</w>
de partment</w>
defic it</w>
om ycin</w>
CA M
uc ci</w>
48 ,</w>
marg inal</w>
0. 59
An gi
Biophy s.</w>
TGF- β</w>
K B</w>
7. 0</w>
Col labor
Inter action</w>
en comp
ili ary</w>
ig er</w>
expos ures</w>
37 )</w>
NA DP
Therap y</w>
repeti tive</w>
otox icity</w>
Atlan tic</w>
Cent re,</w>
re cover
Analy ses</w>
categor ical</w>
an y
inj ections</w>
Mitochond rial</w>
el .</w>
C ;</w>
go od
interfer on</w>
hi m</w>
3 B</w>
k g/m
) ,
intere sted</w>
typ e.</w>
pre y</w>
ro s</w>
ch ain
glyco protein</w>
C ab
200 6
17 3
cytos kel
sorti um</w>
b yp
go als</w>
h at
hund red</w>
sol ely</w>
finding s.</w>
G B
cle aved</w>
c ity</w>
Le ishman
10.1136 /b
retin a</w>
A Q
Student ’s</w>
stud ent
gri d.
ni k</w>
de z-
- 0000
b id
ri a</w>
(0. 7
Sim on</w>
fac ts</w>
mat rices</w>
t od
en sion</w>
: 10
py ram
plast y</w>
crystallograph ic</w>
tum our
vil le,</w>
tas k.</w>
Obes ity</w>
branch es</w>
review ,</w>
ran ked</w>
er ve</w>
S anch
muc osa</w>
t ab
contrac tion</w>
down- regulation</w>
interven tion.</w>
co oper
Vit amin</w>
fre e
De pression</w>
ur on
psych osocial</w>
47 8</w>
materials/ analysis</w>
2 Table</w>
char t</w>
( 98
Bru ker</w>
[3 ,
investig ators</w>
pro vision</w>
f are</w>
out .</w>
ator ,</w>
(201 2)</w>
BL AST</w>
trigg ers</w>
k er,</w>
manag ed</w>
enabl ed</w>
ard o</w>
el ess</w>
39 )</w>
Pre paration</w>
27 6
spectro phot
SHE LX
il ic</w>
p- values</w>
nucle ic</w>
60 )</w>
Pak ist
st atin</w>
Ob j
o ocytes</w>
F ul
e IF
201 6).</w>
coordin ate</w>
Gastroenter ology</w>
w ere
[23 ]</w>
preferen tially</w>
.200 6.
man s</w>
198 1</w>
stated. Background</w>
HD AC
Y H</w>
3 '</w>
V /
Franc e
pa thetic</w>
reagents/ materials/analysis</w>
lif e,</w>
(O H)
Rob ert</w>
App endix</w>
lin e)</w>
R at
T AT
extr a</w>
fre e-
E is
an aerobic</w>
per g
S yst
argin ine</w>
determin ed.</w>
Pediat ric</w>
He idel
Con n
sol ar</w>
s an
Cul ture</w>
ed u</w>
ic on
D ing</w>
differenti ation,</w>
jo int
60 5</w>
H av
> 3.
cell s
) 000
con cor
Saf ety</w>
. 20
grad uate</w>
44 ,</w>
b y
m g
F ang</w>
magn ification</w>
uc k</w>
MS C</w>
attribut able</w>
C 5</w>
Ti O2</w>
70 1</w>
ator .</w>
sac rific
B- cell</w>
0. 25
ere d.</w>
Tem per
cess ation</w>
assay s.</w>
N 2—C
r ings</w>
There fore</w>
al one.</w>
ex c
, 000
disp ens
C 12—C
pre treatment</w>
Re sid
prep are</w>
gener ic</w>
13 9
( t)</w>
grate ful</w>
re pair
i sion</w>
Chin a.</w>
de part
anti- CD
). 23
Wo od
Mag netic</w>
Lip id</w>
datab ase.</w>
13 4
a vid
pre val
th ous
10 ).</w>
moder ately</w>
ad h
deriv ative</w>
Qu al
cited. Background</w>
indic ated.</w>
K au
rac e</w>
199 9;</w>
Wor king</w>
[6 ]</w>
apparen tly</w>
P enn
0.00 4</w>
perf ect</w>
individu als,</w>
(201 3)</w>
pl ayed</w>
1- 2</w>
M arg
IN G</w>
coll ect</w>
st aff
con struct
Mal aria</w>
re perfusion</w>
infra red</w>
elimin ate</w>
0.8 2</w>
accoun ting</w>
P W
(http://creativecommons.org/licenses/by/4.0/ ),</w>
d d
M. A.</w>
B ac
O per
K K</w>
neuro degenerative</w>
flex ibility</w>
CO X-
Su g
adi c</w>
histor ical</w>
L oss</w>
ali qu
second -
filtr ation</w>
(R och
ff e
F as
10.1155/ 201
45 )</w>
agu chi</w>
cit ation</w>
Febr uary</w>
or ub
t abl
K han</w>
ane ur
b in</w>
C 11
R iver</w>
.201 5.
( 23
P O</w>
C 19
( 24
Tre g</w>
g ed</w>
no tion</w>
A Z
F ore
serv es</w>
G ot
( un
test s,</w>
colum ns</w>
ex ce
F ind
affec tive</w>
- 8</w>
] -
70 ,</w>
pes tic
bi d</w>
Dis .</w>
caro ten
cis platin</w>
7554/eLif e.
ri e</w>
am eli
biom edical</w>
broad er</w>
(199 3</w>
al ised</w>
ogene sis.</w>
S qu
gal act
ting s</w>
( 9</w>
µ l</w>
5 :</w>
3 14</w>
J ensen</w>
br ains</w>
hormon es</w>
26 8
sep tic</w>
ch r
ar ticular</w>
valu e,</w>
posi tioning</w>
ong ,</w>
bec oming</w>
im plant</w>
sy ring
assum ptions</w>
proced ure.</w>
St ar
/ r
Candi da</w>
ing ton</w>
O z
3 22</w>
Un fortun
G U
[7 ]</w>
3 B).</w>
47 .</w>
prote ome</w>
in tim
B B</w>
juven ile</w>
I ).</w>
ch ip</w>
He ad</w>
15 -0
fiel d,</w>
autom atically</w>
15 4
Chic ago,</w>
low ering</w>
wav es</w>
psych o
O ri
s ure</w>
G upta</w>
consul t
eg er</w>
neuro path
S patial</w>
aw i</w>
- treated</w>
Ad v</w>
Cl 2</w>
other ,</w>
Lear ning</w>
C 20
CA M</w>
c ro
5 ]</w>
adul tho
RNA- seq</w>
and ing</w>
expos ure.</w>
b its</w>
ram er</w>
dam aged</w>
am eth
V M</w>
K un
R L
ay ama</w>
slic e</w>
(Sigma -Aldrich
k awa</w>
cal e</w>
0 1
ser i
e astern</w>
precur sors</w>
B T
An y</w>
injur y.</w>
week s,</w>
perman ent</w>
per s</w>
[46 ].</w>
cap ability</w>
Biom ed</w>
G ord
con current</w>
alkal ine</w>
Wag ner</w>
ul cer
Ac cur
[24 ]</w>
Pl ac
Ex p
ammon ium</w>
k ov</w>
u ch
ph er
Sensi tivity</w>
year .</w>
possi ble.</w>
al .201
B enn
Ig G
Ngu yen</w>
ti tr
silic a</w>
3 26</w>
synap ses</w>
an ticancer</w>
E- Mail
por cine</w>
behaviour s</w>
PI 3K
analyz ed.</w>
Hb A1
cent ered</w>
55 5</w>
ore r</w>
Rec ept
D EN
u x</w>
angi ot
. 24
plac ental</w>
S pain</w>
depriv ation</w>
Ed wards</w>
O 1—C
pre natal</w>
soy bean</w>
l- like</w>
oblast s</w>
ing s.</w>
below .</w>
a rest</w>
C ut
overexpres sed</w>
veget ation</w>
with in-
public ations</w>
us ;</w>
201 3)</w>
the ast</w>
ra is
om ers</w>
0.0 1).</w>
Dut ch</w>
inter rup
B K</w>
Kore an</w>
repor t
att end
det eri
r atings</w>
Dis ord
tom y</w>
heteroz yg
K 3
5. 2</w>
for ward
sh i
instrum ents</w>
80 1</w>
resid ent</w>
subst ances</w>
disord ers,</w>
7 00
- 0.0
nam es</w>
Pan el</w>
h -
Shangha i</w>
3 28</w>
Mediterran ean</w>
pit u
SE M.</w>
ro l.</w>
pe er</w>
W ard</w>
C le
F R</w>
ax el</w>
pro pi
48 .</w>
O 1
25 ].</w>
nan dez</w>
est .</w>
od ing</w>
Val idation</w>
PC A</w>
Fig ).</w>
S uc
intr aper
Ex erc
rel ating</w>
N utr
ric k
ure :</w>
L C-
0000 0000
ax on</w>
form ulation</w>
@gmail .com</w>
do or</w>
strain s,</w>
beg an</w>
Techn ologies,</w>
Cros s-
(C O
coag ulation</w>
p tion.</w>
R an
is otropic</w>
ex ert</w>
od en
at rophy</w>
B I</w>
β- actin</w>
os p
2. 1.</w>
G ill
thes e,</w>
0. 19</w>
us h</w>
o ul
UK )</w>
ard ,</w>
vulner able</w>
Ap proxim
Bonferron i</w>
(I Q
li z
201 1
b ic</w>
en s.</w>
Gastroenter ol</w>
n /
D /
pl er</w>
let ter</w>
7. 4</w>
K ap
Ac qu
Fo rest</w>
Aut om
G ard
3 A).</w>
201 2)</w>
micro organisms</w>
uter ine</w>
l umbar</w>
duc t</w>
EM T</w>
canc er-
col ored</w>
obj ect
an a,</w>
marg in
remark able</w>
S ti
) 2</w>
foc i</w>
ast al</w>
ro mat
Strept ococcus</w>
0. 21</w>
con flu
ure a</w>
P b
pro spec
apopto sis,</w>
pix el</w>
c ame</w>
four -
enti rely</w>
arg um
ha emat
chang e.</w>
ad el
op re
intell ectual</w>
di tion</w>
c en
B etw
oste oporo
it ly</w>
D ol
osteo cl
boot strap</w>
behavi or.</w>
sa id</w>
og l
70 5</w>
G W</w>
D u</w>
resc ue</w>
presum ably</w>
bound aries</w>
substitu tions</w>
De ath</w>
Endocrin ology</w>
gener ates</w>
scal e.</w>
[ 1],</w>
enc ap
Y ao</w>
( Al
U V-
60 7</w>
os us</w>
M o</w>
TE M</w>
un k</w>
Sp i
H ).</w>
as es
sp ut
disper sion</w>
dos e-
E col.</w>
epit ope</w>
chol in
patient ,</w>
Ar e</w>
win ter</w>
P V</w>
hypox ic</w>
resist ance,</w>
event s,</w>
li ver,</w>
defini tions</w>
g aps</w>
he ating</w>
E V</w>
sid ase</w>
re strain
ro ad</w>
F IS
so il
26 7
li ved</w>
ul c
sub unit
Questionn aire</w>
jus ti
E astern</w>
Schne ider</w>
introduc e</w>
del et
Tran s</w>
p =
coll ap
E H</w>
Fed eral</w>
Initi al</w>
T ob
Ste ph
E s</w>
( 2-
z ol
PB S,</w>
system atically</w>
tool s:</w>
Nic hol
in i
10 ,000</w>
T uk
B T</w>
i asis</w>
famil ial</w>
cu stom
ar ising</w>
S ão</w>
Ni elsen</w>
F EB
decid ed</w>
Cl ass</w>
3 18</w>
complex .</w>
tum ors.</w>
U C</w>
A sp
ste ad,</w>
creativecommons.org/ licenses/by/
Si x</w>
EC M</w>
Pub Med
fol d
V L</w>
Experim ents</w>
W er
Beij ing</w>
( black</w>
C 12
P ut
symptom s.</w>
rec ently,</w>
m and
k b)</w>
P ris
roph yl
phylogen y</w>
routin ely</w>
0. 69
E G</w>
ad sor
Infl amm
refin ed</w>
J. A.</w>
S 5</w>
Car cin
statis tic</w>
. :</w>
L ab</w>
Ren al</w>
Ver sion</w>
attrac tive</w>
leg al</w>
AC C</w>
Den mark
silic on</w>
im mature</w>
s o-
op ia</w>
[25 ]</w>
Brazil ian</w>
Rever se</w>
tiv es</w>
G od
s lower</w>
3 2,</w>
Gynec ol</w>
ch lo
L 2</w>
hem oglobin</w>
h p
f 2</w>
com /
cell ,</w>
( lef
5 4.
represent ations</w>
E q.</w>
trans verse</w>
p g/m
0.CO; 2-
station ary</w>
Hel ic
0 9</w>
NI H</w>
S NA
t p
G ul
9 3.
al ters</w>
R ati
re agents</w>
10.1128/ A
x y</w>
or g</w>
il le</w>
Dem ographic</w>
Genom e-wide</w>
test ).</w>
oph en
contr al
In duction</w>
ar rhyth
The ore
tel eph
H ur
h im
viol ence</w>
Co .,</w>
57 0</w>
E :</w>
fu r</w>
colum n
F oc
Ro ad,</w>
H W</w>
trunc ated</w>
p ts</w>
block ade</w>
80 3</w>
hour s,</w>
Neuro physi
0 6</w>
carcin omas</w>
os ity</w>
H et
month ly</w>
v e-
call s</w>
revers ed</w>
coll ection,</w>
HIV- infected</w>
G C-
cycl e.</w>
N ish
os keletal</w>
casp ase</w>
Y e</w>
Techn ologi
sl id
glucos e,</w>
whil st</w>
Per spec
in surance</w>
F F</w>
uni versity</w>
collabor ation</w>
I GF-
Altern atively,</w>
W E</w>
v r
+ CD
e able</w>
R ud
0.8 8</w>
produc tivity</w>
par allel
4 25</w>
bil ities</w>
tum or
19 86
unclear .</w>
J ung</w>
sub cellular</w>
0. 35</w>
, 8
silic o</w>
activi ties.</w>
tic es</w>
J r
Ox id
0. 14
[5 ]</w>
C GT
3 -0
proj ections</w>
S id
carb oxyl
cultiv ated</w>
reticul um</w>
dis section</w>
bir th
conduc tivity</w>
lat tice</w>
ag it
E ch
subject s,</w>
triplic ate</w>
descri ptive</w>
contro versi
(S D</w>
Up on</w>
qu ery</w>
met agen
gluc ocortico
tri al,</w>
prot on</w>
diagnos es</w>
Ad ams</w>
0.8 4</w>
pow der</w>
challeng ed</w>
S ato</w>
lear ned</w>
investig ated.</w>
st al
Por tu
Ab str
com pression</w>
Psych ological</w>
t y,</w>
Don ald</w>
key s</w>
tot al,</w>
support .</w>
diver si
contamin ated</w>
includ ed.</w>
alcohol ic</w>
dispers al</w>
abi otic</w>
3 36
e @
[4 ]</w>
10.1038/nature 0
C 13—C
here .</w>
P BM
rel li</w>
form in</w>
2. 2.</w>
gre n</w>
trans form</w>
per in
anti sense</w>
cop e</w>
resist ance.</w>
Lym ph
6. 1</w>
observ ed,</w>
4 1
Pre v</w>
Avail ability
Mut ations</w>
industr y</w>
melanog aster</w>
N B</w>
4 15</w>
refrac tory</w>
0. 16
inoc ulation</w>
ess or</w>
diff u
hom olog</w>
W it
A 549</w>
d ent
lo oking</w>
func tions,</w>
las ting</w>
re z</w>
4 31</w>
phen ol</w>
surviv ors</w>
70 3</w>
C um
acchar ides</w>
p end
c AMP</w>
SI RT
10.1107/S 16005
Do es</w>
di ets</w>
wan ted</w>
under -
ne ar-
Correspond ence</w>
[10 ],</w>
ation ),</w>
analy si
V P
qu ar
gen s</w>
sco re,</w>
scaff olds</w>
F e</w>
stiff ness</w>
hed ral</w>
S 2
B inding</w>
char acter</w>
AID -
st ake
Ch ol
l ay</w>
dos e-dependent</w>
uni form
10.11 59
( to</w>
ant e</w>
b red</w>
l o</w>
201 2,</w>
W -
dehy dr
explic it</w>
10. 40
ax ons</w>
( 30</w>
g ing
[47 ].</w>
m m.</w>
ax is
employ ment</w>
Environ ment</w>
AD HD</w>
tr ad
CR ISP
µ m</w>
48 )</w>
exec utive</w>
0. 45</w>
al ity,</w>
L ag
e es</w>
chang es.</w>
am orph
sp ong
5. 3</w>
Hugh es</w>
y n</w>
poin ted</w>
O w
g ent
E ST
suff ering</w>
hum ans,</w>
Mod els</w>
>3. 0.CO;2-
Un it</w>
_ _
ox in</w>
consider ations</w>
respons es,</w>
6 2
dimin ished</w>
sel ecting</w>
Bio chemical</w>
smo ke</w>
An .</w>
ri k
I w
H ag
medic inal</w>
di str
[8 ],</w>
- -</w>
We b</w>
3 /j
str a</w>
dem ograph
A J
expl oration</w>
g00 4
http:// creativecommons.org/licenses/by/
N u
terti ary</w>
0 %</w>
An oph
inhibit or,</w>
recept ors,</w>
Maj or</w>
c k
G SE
pharmac eutical</w>
ly sed</w>
acceler ated</w>
R ock
tri pl
practic e,</w>
( years)</w>
GA B
si l</w>
FEB S</w>
L is
atyp ical</w>
Col lins</w>
HD L</w>
ri um</w>
In du
clar ify</w>
med .
og e
domin ated</w>
mechanis tic</w>
m :</w>
vir us,</w>
prescri ption</w>
aster is
Y S</w>
, 24
initi ate</w>
flow ering</w>
o il
ho st
h in
ra v
f air
H K</w>
oid es</w>
[26 ]</w>
MA PK
56 0</w>
34 -
N s</w>
13 C</w>
survival .</w>
h op
60 2</w>
design .</w>
AB C</w>
loc ation:</w>
enter ic</w>
str y</w>
Tr aining</w>
ed y</w>
S ox
* ,</w>
met als</w>
distill ed</w>
Lev el</w>
Compl ete</w>
ag i</w>
M IC
c yl
B SA</w>
201 2.</w>
constitu tive</w>
ell es</w>
midd le-
eri ous</w>
intes tine</w>
Ch am
0.9 0</w>
, 26
M yc
on en</w>
Un like</w>
ser ver</w>
fill ing</w>
de al</w>
distingu ish
0. 24</w>
Pet er</w>
X 1</w>
0. 23</w>
R ight</w>
The ory</w>
trav el</w>
10.11 8
(19 .
V ascular</w>
Zn O</w>
49 .</w>
Ob serv
E ),</w>
) 90
San tos</w>
Pow er</w>
D N</w>
TN F</w>
Paras itol</w>
De f
re l</w>
Har t
T W</w>
Spec ial</w>
j ee</w>
sid ed</w>
Grad uate</w>
0. 13
F ish</w>
0.8 9</w>
[12 ],</w>
reconstruc ted</w>
hel ic
achiev ing</w>
onco genic</w>
diagno sis.</w>
S at
O 4</w>
R ah
offic ial</w>
acid s,</w>
G arc
form al
e- to-
H /
proper ties.</w>
Han sen</w>
[9 ],</w>
covari ates</w>
Val ue</w>
anne aling</w>
a –
Scre ening</w>
Con tr
ed er</w>
Fran k
b ou
arro whe
I z
S 6</w>
NSC LC</w>
Y u
ul i</w>
He in
op ho
H us
C our
E ss
brain .</w>
C Y</w>
R ig
Diag nosis</w>
cont ain
0. 30</w>
wor m</w>
[11 ],</w>
contig s</w>
meaning ful</w>
(201 1)</w>
af ter
A di
G el
secre tory</w>
Diet ary</w>
BDN F</w>
an z
y lo
E ffic
B ad
inheren t</w>
zz i</w>
4 11</w>
Sp ear
neighbor ing</w>
1/j am
y s,</w>
10.100 1/jam
it os
test oster
15 –
Li ke
coun sel
fil l</w>
27 ].</w>
Commun ic
nav ig
Schwar tz</w>
NH S</w>
[6 ],</w>
Govern ment</w>
pro to
log ic</w>
.0 0</w>
end ro
ge omet
Met a-
w is
run s</w>
ul in
doc tors</w>
k ov
J .,</w>
los ses</w>
ecos ystem</w>
search ed</w>
E ye</w>
antibod y.</w>
it sel
w ast
n r
ic e.</w>
m un</w>
fr uc
lymph oid</w>
nur se</w>
endo plasmic</w>
201 1,</w>
S ep
inv est
49 ,</w>
ran i
We is
60 4</w>
identi fic
per for
ab sc
ag e:</w>
56 1</w>
ator s.</w>
Nak amura</w>
h ere,</w>
5. 6</w>
prec eding</w>
rin k
A ni
M an</w>
B rand
electro ly
r é
F oster</w>
T K</w>
11 /
it ted</w>
Sle ep</w>
bu ild
angl ad
PC R-
g ian</w>
Thir d,</w>
MT T</w>
Fis cher</w>
leuk ocyte</w>
23 -
H ere
k :</w>
non- coding</w>
( 23.
Yam amoto</w>
( 97
[13 ],</w>
cont ent.</w>
Percent age</w>
NF- k
f um
resp iration</w>
G ros
pass ed</w>
— H</w>
ox if
scal e,</w>
Ar c
Bacteri ol</w>
E l</w>
3 38
L eng
10.109 3/j
concentr ation,</w>
d f</w>
C u</w>
A GT
80 ,</w>
ific ation,</w>
Vacc ine</w>
Emer gency</w>
b ev
( Thermo</w>
s es,</w>
D MEM</w>
stain ing.</w>
albic ans</w>
st age.</w>
10.1016/j. b
proper ties,</w>
endomet rial</w>
nit rogen
sti r
FIG URE</w>
facilit ated</w>
B ail
5 3.
[7 ],</w>
l ack
Rep orts</w>
pl o
euk ary
pal li
cell s)</w>
s and
lig and
insec ts</w>
Wat an
ro id</w>
10.1136 /
patient 's</w>
M ob
Softw are</w>
Phil lips</w>
e ties</w>
immun ological</w>
Y in</w>
57 9</w>
25 4
min d</w>
S it
tas k,</w>
ari um</w>
N L</w>
diver gent</w>
suppl ied</w>
g a</w>
O TU
). 24
outcom e.</w>
Cl 2,</w>
Q TL
e v</w>
e- free</w>
Ag ents</w>
t ude</w>
U e
IN T
[27 ]</w>
o sis,</w>
whil e,</w>
Obst et</w>
mim ic</w>
ab e
l av
T echnol</w>
q W
fiel d.</w>
L ig
60 6</w>
Max imum</w>
GA BA
rod ent</w>
W )</w>
ro unds</w>
Tur ner</w>
− 2.
cre d
T K
kind s</w>
MS/ MS</w>
Ros s</w>
R ib
[14 ],</w>
concep tual</w>
N umer
rat es.</w>
extinc tion</w>
Cd c
G ray</w>
rel ess</w>
o .com
escap e</w>
Fer r
F ro
domain .</w>
W D</w>
clin ics</w>
Organ ic</w>
[3 ]</w>
obtain ed.</w>
B H</w>
ot ti</w>
od al</w>
hyperten sion,</w>
g f
Out comes</w>
46 )</w>
In tensive</w>
P ed
bat ch</w>
ve ira</w>
divid ing</w>
pat ch</w>
ac compl
H at
tran sc
0.8 3</w>
Hyper tension</w>
transcri ptom
ti g</w>
m/ z</w>
[2 ]</w>
fer tility</w>
ana esthe
O T
injur y,</w>
Ca i</w>
Rich ard
(A ),</w>
90 1</w>
shif ted</w>
def ect
junc tions</w>
Adju sted</w>
Exper t</w>
Davi es</w>
1 H</w>
k ow
(H )</w>
10.1371/journal.p gen
As so
li th
M /
R ay
8. 0</w>
commerci ally</w>
beli efs</w>
were :</w>
25 –
0. 18
orig ins</w>
expos ure,</w>
[5 ],</w>
g 0
c ue</w>
cath eter</w>
AP O
am ent</w>
sym metric</w>
11 7.
P N</w>
0 -
( 11</w>
proj ects</w>
G D
g ol
C t</w>
Sur face</w>
5 2.
Ste wart</w>
58 0</w>
intell ig
lear n</w>
networ k,</w>
Pharmac ol.</w>
d ol
R av
5 1
modi fy</w>
Tw o-
ren d
y ou
DAP I</w>
attemp ted</w>
ED T
Kle in</w>
or ange</w>
56 3</w>
death ,</w>
in er</w>
Clu ster</w>
abol ic</w>
F us
201 3,</w>
er ty</w>
57 5</w>
cortis ol</w>
analy sis:</w>
Swed en</w>
p ep
del ine
Expos ure</w>
g ap
(0. 6
bi ologically</w>
doc king</w>
SD ,</w>
59 5</w>
chang es,</w>
Ac c
imp ul
nutri ents</w>
M ot
biopsi es</w>
eng er</w>
al :</w>
e ?</w>
10.110 9/
compri ses</w>
anti- mouse</w>
x )</w>
bacter ia,</w>
0. 17
in directly</w>
determin ant</w>
nc bi
consequ ently</w>
G mb
prim ing</w>
T reg
In trac
ex er
conserv ative</w>
plan ar</w>
Q ,</w>
l ati
70 2</w>
Unfortun ately,</w>
complic ation</w>
el in</w>
il li
incor rec
aden osine</w>
n ai
mix tures</w>
4 20</w>
10.1016/j. ij
ect opic</w>
B anglad
m ia</w>
HER 2</w>
well ,</w>
synerg istic</w>
om yc
s ativ
ard ed</w>
PubMed :</w>
0.9 2</w>
[48 ].</w>
new born</w>
micro environment</w>
N H</w>
inform ative</w>
70 )</w>
ren e</w>
H is</w>
58 1</w>
X en
70 4</w>
mon onuclear</w>
c ock
vis ceral</w>
T n
M ain
bi os
Ital ian</w>
hospit alization</w>
con sol
shor ten
[15 ],</w>
flan king</w>
tr ich
4 10</w>
anti depress
(L ife</w>
v eter
intes tin
pan ic</w>
case- control</w>
point s,</w>
d airy</w>
micro satellite</w>
discre p
28 ].</w>
5 ′
. 199
Ka plan
enh ancer</w>
S ud
chem ot
[4 ],</w>
4 35</w>
wom an</w>
0 7</w>
tum ors,</w>
B j
d ’
Suppor t</w>
matri x.</w>
Tran si
S core</w>
l '
surpri sing</w>
do g</w>
50 110
MCF- 7</w>
Ta q
L .,</w>
199 8;</w>
rel ate</w>
PT EN</w>
calcul ated.</w>
cont ent,</w>
( version</w>
B F</w>
n ose</w>
( accessed</w>
Vari able</w>
sym metry</w>
part um</w>
Trit on</w>
. ht
S ir
Am pl
46 ,</w>
wh ich,</w>
NO V
S D.</w>
end ,</w>
osi tion</w>
sul ph
sh op</w>
small ,</w>
4 21</w>
ne arest</w>
immunohisto chemistry</w>
at t</w>
O .
10.1046/j. 1365-
literat ure,</w>
idi opathic</w>
F :</w>
(II )</w>
58 5</w>
0.9 1</w>
att ending</w>
concentr ations.</w>
py ri
decision- making</w>
tiv e,</w>
Cardi ac</w>
a 1</w>
3 1-
56 7</w>
mon itor
Gar ci
Dru gs</w>
rati o,</w>
anti tumor</w>
23 37
ti a</w>
G reg
som at
os h</w>
treat ments.</w>
trans forming</w>
G ).</w>
Asso c</w>
0.9 600</w>
pell et</w>
glut amine</w>
pseud o
0. 33</w>
ma .</w>
v i</w>
concentr ation.</w>
(100 )</w>
67 -
0.9 4</w>
BM I,</w>
su d
Student 's</w>
H ed
70 9</w>
assign ment</w>
g ained</w>
i onic</w>
significant ,</w>
es ophag
op us</w>
m 2</w>
E- cadherin</w>
Se a</w>
b order</w>
ell ar</w>
M. J.</w>
nit rate</w>
cl er
vacc inated</w>
MO ,</w>
ind o
4 -0
purpos es</w>
literat ure.</w>
HL A</w>
95 %
sw im
tivi ties</w>
port al</w>
NA D
59 0</w>
se emed</w>
Oc cup
v ast</w>
ext ending</w>
y met
. de
12 6.
vitro .</w>
sco re
C asp
ut h</w>
all ic</w>
2 *</w>
poll ut
G un
( righ
efflu x</w>
Un it,</w>
L ep
pass age</w>
electro chemical</w>
C ot
.nl m.
Fer re
hand ling</w>
chang e,</w>
prob abil
60 8</w>
vi ously</w>
al one,</w>
survival ,</w>
conduct ance</w>
V S</w>
part ,</w>
Int ell
L ight</w>
id .</w>
Ac tive</w>
out lined</w>
hepat ocytes</w>
B og
8. 5</w>
prec is
Physi ci
not .</w>
ro -
J ur
57 7</w>
lo ci
j ej
55 7</w>
an tim
respon ded</w>
is son</w>
impl ement</w>
10.3390 /
Prac t</w>
am ic</w>
[28 ]</w>
an us</w>
Sel ection</w>
PD -
Parkinson ’s</w>
s ected</w>
L ake</w>
Con centr
all erg
cam pa
stre pt
ri p
ob acillus</w>
Mid dle</w>
Clo stri
discus sions</w>
C x
9 4.
fat al</w>
Anoph eles</w>
cycl e,</w>
L es
Sm ad
St ock
Compl ex</w>
disord ers.</w>
coh erence</w>
leav ing</w>
70 7</w>
Sc and</w>
C it
[16 ],</w>
occ ip
conside red.</w>
ti ght</w>
0.8 0</w>
eng age</w>
F 3</w>
(199 2</w>
sp r
P 4</w>
mut agenesis</w>
Func tion</w>
59 3</w>
Ultr as
im posed</w>
HD L-
Con cep
com mit
49 )</w>
stero ids</w>
Reduc ed</w>
47 )</w>
An a
5. 4</w>
[4 ,
201 1)</w>
sor ted</w>
star ch</w>
compromis ed</w>
ic us</w>
mom ent</w>
Ov erex
j e</w>
ncbi .nlm.
step ,</w>
2 —
Out come</w>
MS ,</w>
lo s</w>
ep tion</w>
network s.</w>
ep s</w>
is tic
ac upunc
4 23</w>
F ER
55 1</w>
4 17</w>
signal ing,</w>
ti s.</w>
patient s:</w>
0. 35
epit opes</w>
olog ical,</w>
compet ent</w>
behavi or,</w>
ur g
ol er
dis charg
ti er</w>
cor al</w>
H of
immunoprecip it
58 9</w>
bene fit
or ial</w>
spind le</w>
Bl ue</w>
ter s,</w>
raf ts</w>
C HI
sor ting</w>
4 13</w>
0. 26</w>
sph eres</w>
anc est
ameli or
anesthe sia</w>
Le h
Laborator y,</w>
immunoprecip itation</w>
dec ades</w>
27 7
Mo h
read er</w>
Gu id
Lin ear</w>
58 3</w>
US A.</w>
56 5</w>
in- induced</w>
LP S-
habit ats</w>
P ast
o vi
mon ic</w>
traject ories</w>
[3 ],</w>
Bas el,</w>
ris k.</w>
op posed</w>
yl ate</w>
un usual</w>
ever y
activi ties,</w>
yel low
nich e</w>
ens or</w>
Gol gi</w>
Effic acy</w>
bon ding</w>
ine a</w>
4 33</w>
strong est</w>
anc es.</w>
S tri
0.8 7</w>
acryl amide</w>
ific ation.</w>
enabl ing</w>
Mitch ell</w>
D eng</w>
H2 O
Ste p</w>
Kel ly</w>
well- known</w>
ax :</w>
29 ].</w>
0.00 1),</w>
epilep sy</w>
Ma p</w>
4 37</w>
10.1097 /01.
pl oid
e al</w>
Health care</w>
W HO
ere d,</w>
om a.</w>
group )</w>
Wh ere</w>
Le u
A l</w>
Inf ect.</w>
b ig
M and
leuk in</w>
P =
C 22
. 000
m ang
lup us</w>
( 1-
vi e</w>
59 4</w>
rp m</w>
AB A</w>
y outh</w>
des c
tion ).</w>
.200 5.
xim ab</w>
We ight</w>
R id
telom ere</w>
H w
Ch IP-
10.1136/b m
58 7</w>
f ec
sing ly,</w>
verte bral</w>
Rhe um</w>
com mod
In dic
u i</w>
Comm on</w>
k ova</w>
56 9</w>
wor thy</w>
B ank
blo t
PC R,</w>
55 9</w>
os ensi
frag mentation</w>
57 1</w>
10.1007/s 11
Watan abe</w>
pel vic</w>
sum mer</w>
outcom es,</w>
inc en
health -related</w>
re main
Sh ort</w>
equip ment</w>
I ),</w>
famili ar</w>
0. 32</w>
57 3</w>
impl y</w>
K P</w>
[17 ],</w>
att ack</w>
Mic ros
Mart í
30 8
M iz
5 )
Reg ul
dopamin ergic</w>
Integr ated</w>
os itol</w>
E 3</w>
hypothe tical</w>
drug s,</w>
sed entary</w>
un like</w>
b ;</w>
bo ys</w>
agon ists</w>
sb ad,</w>
T yr
( 2010)</w>
el er</w>
[ 66
all evi
26 5
I rel
Ma dis
imp rin
3 39
(S ch
0. x</w>
aff ord
26 9
0 8</w>
0. 28</w>
inver ted</w>
59 1</w>
ver sions</w>
K y
po rous</w>
E /
Ha em
exac tly</w>
H ous
wav e
esp an</w>
C e
K W</w>
O L
55 3</w>
crystall ine</w>
B D
amygd ala</w>
tub ular</w>
Sour ce</w>
ti zation</w>
cl aims</w>
). Fig.</w>
redund ant</w>
S co
is land</w>
e us</w>
4 B).</w>
speci es
an ian</w>
4 50
Nutr .</w>
per oxide</w>
ill ness
refin ement</w>
annot ations</w>
traject ory</w>
ath let
prote omics</w>
apopto sis.</w>
Tr ust</w>
H az
D ynamic</w>
H on
day )</w>
evid ence-based</w>
studi ed.</w>
er s’</w>
depres sion,</w>
medi ator</w>
( ER
eti ology</w>
plau sible</w>
top ology</w>
Th r
stag land
me ,</w>
G n
NMD A</w>
ann on</w>
fur ther
Know ledge</w>
mat ur
Al ph
ro ll</w>
mechanis ms.</w>
cryst alli
M ack
eri al</w>
comparis on,</w>
MI C</w>
require d.</w>
ac yl
re ally</w>
Br d
refl ection</w>
oph thal
ml /
C57BL/ 6</w>
(Fig s</w>
D '
0. 27
P es
G u</w>
di methyl
manifest ations</w>
E R-
C14 —C
ord er
0. 28
( μ
exper ti
< 0.000
interac tions,</w>
exhi biting</w>
S t</w>
ogly c
si cal</w>
Sp ectr
80 )</w>
genom e,</w>
har m
10.1093/nar/g k
pre clinical</w>
Pre gn
G CC
Har v
A Ch
program .</w>
programm ed</w>
lin ing</w>
al isation</w>
ch -
GO :
[29 ]</w>
an es</w>
P rice</w>
gu an
contral ateral</w>
s mar
0. 37
ent e</w>
gr ass</w>
10.1016/S 000
molecul es,</w>
concep tion</w>
siv e,</w>
( 22
( both</w>
An xi
fl at</w>
Bcl -2</w>
[2 ],</w>
Pro duction</w>
n ation
membran e.</w>
machin ery</w>
second s</w>
bot t
vesi cle</w>
mun ic
phen olic</w>
stres ses</w>
eth eless,</w>
os e,</w>
enti n</w>
differen tly</w>
A P-
mic ron
attenu ation</w>
p iv
Swed en
z ones</w>
aut onom
Regi on</w>
index ,</w>
d on</w>
os hi
L ane</w>
Betw een</w>
[49 ].</w>
Prot ection</w>
am i
5 2/
ed /
26 -
fol i
rang e.</w>
need ed.</w>
( 30
T 4</w>
feat ures,</w>
S 100
less er</w>
so ils</w>
eu tic
E du
Di abet
dic h
th ick
L N</w>
establ ishing</w>
Gener ation</w>
0. 27</w>
B rac
expl oring</w>
ch t</w>
blind ed</w>
depl oy
Like wise,</w>
arbitr ary</w>
3 15
sugg es
vol untary</w>
f is
Alex a</w>
oc r
O lig
R ao</w>
trans loc
ME T
) °</w>
ab ine</w>
Dec re
4 19</w>
atin g,</w>
4 29</w>
anti bacterial</w>
0. 29
O D</w>
pre -</w>
amph i
Wilco xon</w>
prepar ations</w>
c row
4 27</w>
N ano</w>
olec ules</w>
W F</w>
h un
rich ness</w>
at onin</w>
arter ies</w>
1 R</w>
Cal ci
4 18</w>
fing er
obser ver</w>
d ots</w>
dimen sion
ear s</w>
sh op
My c</w>
– 5</w>
segreg ation</w>
Physi ological</w>
pri ority</w>
S 1-
polymorph ic</w>
R ),</w>
avoid ance</w>
[18 ],</w>
Be sides</w>
decom position</w>
anth rop
con stric
(2 2.
te a</w>
n ex
met rics</w>
confir ms</w>
Sp anish</w>
ov e
CD 8</w>
59 7</w>
59 9</w>
201 2),</w>
Fluoresc ence</w>
Sup pl
peri odic</w>
L ist</w>
200 5
guid eline</w>
so on</w>
ud i</w>
G lo
bl ed</w>
S 3).</w>
or n</w>
V inc
GF R</w>
6 A</w>
ap p</w>
2009 ,</w>
Am ster
Wh ere
kill ing</w>
19 79</w>
do ing</w>
b o</w>
pol e</w>
12. 5</w>
10.1523/JNEUROSC I.
m is</w>
Struc t</w>
ag awa</w>
C all
P arti
Japan )</w>
practition ers</w>
s f
sh ed</w>
6. 2</w>
prob able</w>
Neuro image</w>
4 A).</w>
P ad</w>
otox ic</w>
47 ,</w>
H Y</w>
oxidi zed</w>
w et</w>
exclud ed.</w>
Pri mer</w>
surfac e,</w>
4 12</w>
30 ].</w>
me al</w>
O S
5. 8</w>
ew ski</w>
c us</w>
Method s
in adequate</w>
M apping</w>
We ber</w>
Level s</w>
oc at
(Å ,</w>
cat al
squ ared</w>
m outh</w>
rou p</w>
im plant
9 2-
70 8</w>
atten tional</w>
ampl itud
two- dimensional</w>
gon ad
ic s:</w>
Applic ations</w>
Sec ond</w>
M erc
Transcri ption</w>
ma ster</w>
cat ar
iz ed.</w>
10.1002 /j
meth ion
0. 38
0. 34
N G</w>
tri ple</w>
conc ept
Sh ir
fir e</w>
Ts ai</w>
a us
G N</w>
characteris tics.</w>
ic hi
B ud
e igen
co ating</w>
R ow
f lower</w>
Alg orith
Univers ity
emplo ying</w>
J er
broad ly</w>
Da vid
Real- time</w>
RN ase</w>
II I,</w>
14 —C
out ,</w>
in activated</w>
F und</w>
dram atic</w>
g c
k al
ecl amp
M ov
do t</w>
Nic ol
p <0.00
i a-
bi ol
@yaho o.com
H H
b ench
Dis ord</w>
addres sing</w>
substitu ted</w>
be e</w>
amin o-
G eriat
( Bio-
distingu ished</w>
2010 ),</w>
∑ i
ver at
2 :
[19 ],</w>
exper ts</w>
us ers.</w>
integr al</w>
As perg
F if
bo w</w>
ad renal</w>
on ly.</w>
6. 3</w>
ro d</w>
patient -
uc l
Gen ev
( rang
tet rac
per t
ple ’s</w>
po ver
ation -induced</w>
2 B
( 27
0.6 7</w>
SA S</w>
Neurosci ence
(green )</w>
adi pon
Paras it
d edic
0. 36
p 2</w>
bio informatics</w>
iv )</w>
Mac mill
BL AST
betwe en-
J ar
inter medi
<0.0 1</w>
00 ,</w>
bin s</w>
s arcom
desir able</w>
pro ve</w>
gi ene</w>
ou red</w>
chem ically</w>
anc e:</w>
10.10 23
assi st</w>
bot tom
). Table</w>
N F</w>
ker t</w>
neutr alizing</w>
Gene tics
integr ating</w>
PI ,</w>
mortal ity.</w>
solu tion,</w>
im ura</w>
evid enced</w>
F at
L ai</w>
[30 ]</w>
pre treated</w>
C el
c bi
panel )</w>
t one</w>
100 ,000</w>
ax is.</w>
Peter son</w>
glomer ular</w>
0. 23
Larg e</w>
3. 1.</w>
10.10 89/
os es</w>
criteri a.</w>
w ai
ograp h</w>
ous ly.</w>
dis ulf
Canad a
plic ation</w>
Im age
are :</w>
. 7
oxid ant</w>
Dec lar
paren ch
mg/m l</w>
fil ters</w>
PF C</w>
EM )</w>
F R
mo ved</w>
ar k
cas e.</w>
me at</w>
su ch,</w>
mT OR
quanti ties</w>
Th re
EG G</w>
Y C</w>
rel ig
pyru vate</w>
N V
withdraw al</w>
0.6 5</w>
k le</w>
recip ient</w>
reper to
[ 67
C .,</w>
sph er
L ist
wo und
Enh anced</w>
Garci a-
or y
( 1,</w>
exp ensive</w>
de form
in sp
70 6</w>
hid den</w>
biosyn thetic</w>
C 12</w>
un il
as on</w>
0.7 8</w>
hol e</w>
classifi er</w>
d c
breast feeding</w>
follow-up .</w>
Sup plemental</w>
7. 2</w>
m ar</w>
Alex ander</w>
d in</w>
@ u
mov ement
cer ti
b atter
in di
in -1</w>
An n.</w>
G an
dra w</w>
ref .</w>
Macmill an</w>
review .</w>
recomm end</w>
I L,</w>
1 −
Com preh
F E</w>
sion )</w>
co ch
l en</w>
Wh ole</w>
P ell
Vi enn
Interven tion</w>
5. 7</w>
O 4
C 13
an emia</w>
epti des</w>
em ul
y s.</w>
loop s</w>
N i</w>
56 8</w>
rog ate</w>
U )</w>
ip ter
0.8 1</w>
6. 7</w>
T ian</w>
fl ight</w>
F T</w>
10.1111/j. 15
pix els</w>
lig ase</w>
il ing</w>
glycos ylation</w>
Prote omics</w>
3 30
Inhi bit
blo ts</w>
ear ly-
1 );</w>
si um</w>
D V
sp o
Mon itoring</w>
viv o,</w>
H su</w>
servic es.</w>
comp ute</w>
discrimin ate</w>
physi cally</w>
l an</w>
Hod g
robust ness</w>
ing e</w>
MA )</w>
bi g</w>
N y
str ö
Me h
T N</w>
interf ere</w>
Resist ance</w>
thre at</w>
Administr ation</w>
microgli al</w>
non- specific</w>
applic ations.</w>
bec k</w>
human s.</w>
Ophthal m
F AS
C ard
pop ular</w>
1 100
adi po
fe el
BR CA
R oth
Ste f
ber ry</w>
0. 24
5 50</w>
prior iti
T radi
docum ent</w>
0.9 500</w>
dr ain
metabol it
Gord on</w>
S po
P ol</w>
LD L-
blast oma</w>
Mort ality</w>
photosyn thetic</w>
7. 1</w>
k en
emph asis</w>
10. 13
gam bi
1, 0
me e
Im mun</w>
Tri als</w>
th ing</w>
- 0</w>
search es</w>
67 5</w>
in et
alg ae</w>
R ice</w>
addi tionally</w>
Metabol ism</w>
buff er,</w>
4 30</w>
ret t</w>
2. 9
w ,</w>
organiz ations</w>
uc e</w>
CK D</w>
ne sted</w>
random ized,</w>
ac t.</w>
famil y.</w>
A H
m us</w>
dis sected</w>
es ?</w>
P av
children ’s</w>
circu its</w>
( 26.
diff ering</w>
all ed</w>
BP 1</w>
0. 29</w>
im aged</w>
4 39</w>
inhibit or
M t
polar ized</w>
present .</w>
expendit ure</w>
contrib ut
[20 ],</w>
view ,</w>
M uk
Washing ton</w>
Up per</w>
cop ing</w>
dist rib
Sch w
Vi et
@ 163.
pyram idal</w>
stri atal</w>
g amet
nico tine</w>
cult ure,</w>
K ell
- Whitney</w>
merg ed</w>
hypothe sis,</w>
del iver</w>
Curren tly,</w>
CX )</w>
compl ain
quin ol
Com p</w>
can ine</w>
In vol
mo ist
pa id</w>
spati ally</w>
3/ 0
prog ester
a ção</w>
10. 230
D re
1– 2</w>
( #
Sp eci
understo od.</w>
mod est</w>
conf id
ev en
GG AT
bi osens
[ 68
J NK</w>
hab di
accum ulate</w>
E K</w>
2 ±
un saturated</w>
Tex as</w>
tri gu
201 4)</w>
O T</w>
Mul tivariate</w>
fibr in
P anc
control )</w>
hel ical</w>
X ia</w>
d s,</w>
ut aneous</w>
sedi ment</w>
Li ke</w>
is er</w>
ed g
199 7;</w>
(0 –
review ers</w>
exci sion</w>
Euro p
group s:</w>
jej un
lys ate</w>
Rodrigu ez</w>
A ;</w>
yn aptic</w>
k man</w>
slow ly</w>
m app
Man ual</w>
Leishman ia</w>
4 B</w>
Ur ban</w>
ho ff</w>
initi ating</w>
where by</w>
ro ,</w>
C os
Non etheless,</w>
c s
hard t</w>
recept or,</w>
tumorig enesis</w>
T g
c at</w>
web site</w>
—N 1—C
f ecal</w>
Mat the
0. 40</w>
Ox y
stabil ized</w>
Kob ayashi</w>
perox is
glu tin
m L/
fram es</w>
Coll ection</w>
hel ps</w>
Institu t</w>
F ),</w>
n m)</w>
yro id</w>
e. 201
mod al</w>
gli oblastoma</w>
0. 39
( 26
Re in
\usepackage{ am
Mul ler</w>
K T</w>
psych otic</w>
[50 ].</w>
hot mail
Ch est</w>
un affected</w>
d t</w>
B our
E ffici
ograph y,</w>
H 4</w>
(A T
Access This</w>
Overex pression</w>
TLR 4</w>
HIV/ AIDS</w>
regul arly</w>
found .</w>
Bu ch
consi st</w>
ut t
P ax
Biotechn ol.</w>
Em br
0. 26
Sh ap
Th 17</w>
q q
provid er</w>
Vari ables</w>
uni qu
dem ands</w>
A –
Predic tion</w>
ar row</w>
0. 45
os arcoma</w>
f li
0. 30
L AT
CC D</w>
(t )
Sh in</w>
Ann u.</w>
high- resolution</w>
5 12</w>
differenti ation.</w>
Hep G2</w>
compart ments</w>
immunoglob ulin</w>
Recom bin
G Ps</w>
log arith
facilit ating</w>
disrup ted</w>
datas et.</w>
4 °C.</w>
(p <0.0
rel la</w>
mark ers,</w>
attrib utes</w>
atin ib</w>
tin i</w>
elu ted</w>
abstr act</w>
immun ore
0. 40
rat s,</w>
et es</w>
A ffec
:: AID-
10.230 7/
K az
cont ent
factor .</w>
Cor responding</w>
A. M.</w>
an al</w>
27 8
drug -
T en</w>
trans gene</w>
tion /
aver age,</w>
V is</w>
panel ).</w>
mmH g</w>
Cu i</w>
G li
B ell</w>
Sing ap
Path ogen
[ 2,</w>
um :</w>
inv asi
interac tive</w>
CC ,</w>
am y</w>
l umin
J ak
ie w
Dis covery</w>
on ate</w>
objectiv es</w>
0. 31</w>
in variant</w>
[8 ,
tes ting.</w>
pro bed</w>
Zeal and</w>
( 29
S AM
10.10 98
St at</w>
rein forc
viol et</w>
hs a-
10.1371/journal.p cbi
le af
PT SD</w>
gh t
Ph arm</w>
201 1.</w>
11 3
c b
ur ic</w>
di hydro
well- being</w>
duplic ate</w>
r n
2 =
function ality</w>
(PD F)</w>
( 28
Ch lamy
A gu
M organ</w>
ch ir
fru its</w>
identifi ed,</w>
f all
10 -0
cortex ,</w>
Ad v.</w>
real istic</w>
po orer</w>
** P</w>
Gu er
fre ed
( figure</w>
ation .
66 0</w>
Ann als</w>
Sha h</w>
Georg e</w>
0.00 6</w>
Rep e
effec t
sequenc ing.</w>
em poral</w>
m ild
We iss</w>
Per cep
reli es</w>
Lt d.</w>
W W</w>
95 0</w>
compl y</w>
i z</w>
(B ).</w>
Techn ical</w>
[3 1]</w>
i an
programm es</w>
Pharmac eutical</w>
explic itly</w>
(B D</w>
un expected</w>
si de-
as part
70 -
f s
responsi bility</w>
gu n</w>
5. 9</w>
bidi ties</w>
en e,</w>
sens or
K EGG</w>
sign ed</w>
1. x</w>
se :</w>
RS V</w>
). 25
T ask</w>
D EG
Mod eling</w>
mos a
az ine</w>
CO N
t ext
R en</w>
67 3</w>
un stable</w>
ar m
AT CC</w>
S tra
spe ak
rec es
c ub
K il
inter mitt
det ach
eth ing</w>
80 5</w>
epis ode</w>
Whe ther</w>
L angu
co astal</w>
search ing</w>
f ail</w>
iz er</w>
associ ate</w>
ar re
Hep atitis</w>
li van</w>
el ve</w>
Co ok</w>
discrep ancy</w>
pos ing</w>
os por
phenotyp e.</w>
serot onin</w>
D ’
.200 4.
/ p
37 °C.</w>
GA BA</w>
cho ices</w>
day s)</w>
Lo ren
Mar ch
201 3),</w>
C a</w>
deri ve</w>
( 0</w>
( no</w>
respectivel y;</w>
at ely.</w>
67 1</w>
0.7 9</w>
ail ed</w>
Res ult
se ek</w>
A ge
l n
ab .</w>
Contro ll
otyp ing</w>
6. 8</w>
ti ter</w>
sol ving</w>
3 ′-
st ly,</w>
Phosph or
9 2.
A 3</w>
(f )</w>
M ar</w>
as e)</w>
r us</w>
us s</w>
ic ul
67 7</w>
Qu in
W id
pa st
incorpor ating</w>
AT P-
D ent</w>
7 50</w>
6. 4</w>
( 27.
Rus sell</w>
Cog n.</w>
se e:</w>
Pediat rics</w>
el i</w>
Qo L</w>
** p</w>
approxim ation</w>
t ou
al umin
in com
2010 .</w>
Hy g</w>
in er
weak ly</w>
lan es</w>
C r</w>
gl ands</w>
18 –
K α</w>
90 ,</w>
placebo -
equi val
co il</w>
Orth op</w>
cholester ol
infec tions,</w>
perform ance,</w>
N 1
M aster</w>
0 1.
10.1186/ 14
min ing</w>
az z
om er</w>
[2 1],</w>
other s.</w>
(S I
des :</w>
g001 Fig</w>
fav or</w>
Vol ume</w>
th elial</w>
coll ecting</w>
he at-
Tran sp
H CT
(Invitrogen ,</w>
9. 5</w>
CA T</w>
ID :</w>
Emer g</w>
S F-
0.7 6</w>
igh t.</w>
Ed ited</w>
tw o
co operation</w>
0.7 0</w>
elic it</w>
ed ited</w>
cot ton</w>
Sev ere</w>
setting s.</w>
h its</w>
lo oked</w>
Smo king</w>
S un
yiel ding</w>
pp ing</w>
I HC</w>
group ).</w>
A gg
S cri
Dis orders</w>
o y</w>
ad ver
0.7 7</w>
water -
(DO CX)</w>
gen -
attenu ates</w>
g ame</w>
tox ins</w>
29 -
strain ,</w>
oligonucle otide</w>
SC -
Im plications</w>
Cat eg
v ap
W ater
( g)</w>
l ag
Japan ).</w>
[ 3,</w>
( 1)
reproduc ibility</w>
S 6
H A-
her ited</w>
t b0
Econ omic</w>
Behavi or</w>
wor ms</w>
las tic</w>
re ferences</w>
m ing
membran e-
tid ine</w>
Approxim ately</w>
examin ed.</w>
spec ulate</w>
regul ation,</w>
on es.</w>
Tris -
On line
Descri ption</w>
Sh er
sid es,</w>
st ably</w>
P ro</w>
N N
lin e;</w>
regim ens</w>
Sm ith
U p</w>
H ass
3. 2.</w>
(199 1</w>
D Y
lipop olys
k il
E sp
dis ordered</w>
osmo tic</w>
v im
( 24.
g ),</w>
1. 000</w>
par ag
I to</w>
lif espan</w>
ch in
Carl sbad,</w>
x 1</w>
(B as
perme abil
G ST
A rea</w>
1/ 2,</w>
set s.</w>
Com mitte
progen itors</w>
al e
Vari ous</w>
Clar ke</w>
or ic</w>
C ity</w>
10.100 1/
enc e-
P ER
Vis u
modi fying</w>
habdi tis</w>
col onic</w>
( RA
nan ow
et y.</w>
Fo x</w>
Vi rology</w>
det ri
v are
Cr yp
MA -
Oli veira</w>
caregi vers</w>
SD S</w>
acces sibility</w>
L ap
sho ot</w>
D ob
cit rate</w>
paren t
pock et</w>
E b
un changed</w>
/ w
degrad ed</w>
as s,</w>
ED TA</w>
Individ u
0. 38</w>
yn e</w>
(3 3.
K om
( y
tra p</w>
Australi a
One -
[5 ,
Sens ors</w>
tun ing</w>
0. 34</w>
en ia</w>
ir respective</w>
W s</w>
intr av
s tic
PI3 K</w>
in suffici
I F</w>
ator ial</w>
spac e.</w>
Th rough</w>
group ;</w>
a is</w>
58 2</w>
199 9).</w>
Immun ity</w>
synthe sis,</w>
all er
55 2</w>
k ar
pluripot ent</w>
Cell s
H U
p to
rest rial</w>
Martin ez</w>
mortal ity,</w>
Z eng</w>
ac ks</w>
platel ets</w>
mi um</w>
201 1),</w>
B am
– 3.
con junction</w>
tryp sin</w>
Aut o
tem plat
Y as
cir cles</w>
× 10−
.0 %</w>
hypertroph y</w>
w alls</w>
per -
nucle oti
fre ely</w>
hi t</w>
56 4</w>
PS )</w>
58 8</w>
Ri o</w>
kn ess</w>
28 8
Ig E</w>
( Le
T es
10.1016/S0 16
them es</w>
st and</w>
( 28.
compon ents,</w>
Gonzal ez</w>
and rogen</w>
Biotechn ology,</w>
ut ation</w>
s al</w>
S ;</w>
smok ing,</w>
68 5</w>
S Q
her bi
ic o</w>
Wor k</w>
G V
in organic</w>
J I</w>
Gr ade</w>
man age</w>
od endro
13 3
0.7 1</w>
consci ous</w>
( 25.
ol o</w>
Compar ing</w>
0. 36</w>
hospit aliz
0.7 2</w>
T esting</w>
Eth n
( 50
[22 ],</w>
tivari able</w>
[3 2]</w>
Sh ig
stres sed</w>
35 6
80 9</w>
Bur k
El sev
0.7 4</w>
assay s,</w>
Co ul
Abbrevi ations:</w>
(201 4)</w>
be et
N g</w>
Mü ller</w>
men ,</w>
fin ite</w>
bio genesis</w>
58 4</w>
j apon
ain en</w>
0.6 3</w>
syno vial</w>
ho used</w>
chlo rophyl
Ch and
Combin ed</w>
+/ +</w>
q a
tiv eness</w>
corro bor
293 T</w>
cult ure.</w>
10.10 39/
n l
on es,</w>
Ar m
as al</w>
10.1001/ arch
b c
Pl us</w>
pattern s.</w>
aggreg ate</w>
byp ass</w>
o b</w>
66 1</w>
t00 2Table</w>
is m,</w>
comput ation</w>
Stat ement</w>
67 0</w>
( 25</w>
aber r
evalu ations</w>
Carl o</w>
r as</w>
icon duc
olog ie</w>
congru ent</w>
a ther</w>
é s</w>
In c.
[5 1].</w>
K G</w>
Re yn
om od
0.7 3</w>
an j
e- mail:</w>
59 2</w>
t rou
cin ,</w>
IL- 6,</w>
S et
12 %</w>
ni er</w>
F ax:</w>
ameth as
5 10</w>
reciproc al</w>
lea ve</w>
basel ine,</w>
test ed.</w>
z el</w>
Z n</w>
strain .</w>
es ”</w>
signal ing.</w>
(C C</w>
Com mission</w>
200 8,</w>
m Ab</w>
appar atus</w>
u .
ery them
acid -
CT ,</w>
mas sive</w>
eth nic
lin e:</w>
problem s,</w>
57 6</w>
( %
lum inal</w>
consul tation</w>
57 8</w>
Targ et</w>
ex ,</w>
55 6</w>
Scienc e
K ub
sc ar
adult s.</w>
R un
impl ementing</w>
201 4,</w>
dox orub
w ind</w>
obacter ium</w>
(n )</w>
mechanis ms,</w>
st en</w>
Amin o</w>
Induc ed</w>
I 2</w>
me l</w>
Mexic o</w>
medic ines</w>
vertebr ates</w>
v in</w>
f ra
10.1007/BF 0
L und
ob st
AM L</w>
entrop y</w>
Th ough</w>
mis match</w>
on )</w>
0. 48
L. )</w>
p a</w>
' ,</w>
5 1.
F ra
Be h
3 —H
membran e,</w>
igh t,</w>
hum idity</w>
29 8
behavi or
A u</w>
lig ation</w>
Pul monary</w>
ne a</w>
Pat tern
(200 9)</w>
G K</w>
w ish</w>
tal k</w>
ous .</w>
Asperg illus</w>
AM PK</w>
coll ection.</w>
de formation</w>
P ag
80 7</w>
Cr iteri
b ach
6 3.
ap art</w>
Em erg
sal inity</w>
he ated</w>
se c</w>
id s.</w>
B ag
dec lined</w>
58 6</w>
An esthe
cytoskel eton</w>
C ow
k )</w>
enor habditis</w>
[ 69
ach us
P ae
ati s</w>
the sis,</w>
B N</w>
F H</w>
is -
IL- 8</w>
99 9</w>
5 1.</w>
40 –
germin ation</w>
(s )
Physi ology
é r
Programm e</w>
A tt
consum ing</w>
F E
k 1</w>
O tt
0. 46
contr adic
68 0</w>
otub es</w>
AD AM
k a
ant en
Tra uma</w>
K 2</w>
subtil is</w>
progres sion.</w>
uni -
ti ters</w>
CE S</w>
Adv ances</w>
CA D</w>
ag e)</w>
P rin
Targ eting</w>
y ’s</w>
oper ations</w>
1. 25</w>
di i</w>
0.6 6</w>
bor ing</w>
( arrow
integr ate</w>
g00 5
T it
sti ll
bri o</w>
c ing
C15 —C
Par ker</w>
conduc tion</w>
constitu ted</w>
Hydro gen</w>
arter i
teleph one</w>
P ),</w>
Crystallograph y</w>
rele asing</w>
sym pathetic</w>
bu b
O u
200 9)</w>
st aging</w>
H MG
my osin</w>
immun ized</w>
import antly,</w>
mit ogen
S v
pol arity</w>
ric ally</w>
Chem istry,</w>
19 78</w>
optim um</w>
los s,</w>
rest ored</w>
analy se</w>
cros sing</w>
y- state</w>
in /
join ing</w>
ca u
Sou th
Richard son</w>
Coh ort</w>
bir d</w>
Parkinson 's</w>
de acetyl
ac commod
neo plastic</w>
el as
back bone</w>
i dis
suff er</w>
" ,</w>
transduc ed</w>
amin e,</w>
56 6</w>
oc clusion</w>
du al-
possi ble,</w>
ho st-
cum in</w>
V il
Prof essor</w>
N V</w>
ex port</w>
pathophysi ology</w>
explor atory</w>
( M</w>
E Q
sensitiv ity,</w>
S ).</w>
Multi -
ster ic</w>
Insul in</w>
rest oration</w>
86 3</w>
V ent
posi tional</w>
eng aged</w>
1.0 1</w>
(2 1.
50 6
P on
Mus cle</w>
Ro y</w>
Mon o
0.6 8</w>
00 3
articl e.</w>
cred ited</w>
adip ocytes</w>
Col l</w>
[9 ,
f e</w>
feat ures.</w>
GA L
Ch u</w>
10.1136/bm j.
un infected</w>
[ 1–
66 7</w>
Benn ett</w>
fo x
t ),</w>
si x
m l)</w>
Dani el</w>
57 4</w>
del eted</w>
0. 42</w>
- 2.
hormon al</w>
id e-
world wid
56 .</w>
pp m</w>
sym bol
80 2</w>
ch itos
in ability</w>
Wall is</w>
L et</w>
fav our
long ev
0.6 4</w>
4 15
Compreh ensive</w>
expl aining</w>
RE T</w>
displ aying</w>
4 14</w>
osens ory</w>
Na +</w>
aqu atic</w>
95 °C</w>
ster il
fl ur
Transcri p
00 )</w>
arrang ement</w>
Ver y</w>
Per son
Nan o
34 9
Vi sion</w>
plas tic
b rought</w>
grad ed</w>
Oxid ative</w>
57 2</w>
measure d.</w>
8 3.
[23 ],</w>
Ken ya</w>
86 0</w>
el ig
Y J</w>
16 -0
protein- protein</w>
or ption</w>
Gra ham</w>
aux in</w>
0.0 9
fif th</w>
am bul
g ad
d re
fi ve-
mis sed</w>
g al</w>
pul ses</w>
1.0 2</w>
Sp ring</w>
so- called</w>
prophyl axis</w>
pol lin
en sur
as e:</w>
eg g
0. 47
rec ycl
tur n,</w>
j e
d educ
6. 6</w>
adj ust</w>
shoul der</w>
30 7
K ro
testoster one</w>
An al</w>
infec tions.</w>
rel im
i odi
D V</w>
st y
20 45-
w aste</w>
Altern ative</w>
clos est</w>
2. 3.</w>
Y ou</w>
ul monary</w>
train ing,</w>
E co
W G</w>
N ep
Sha w</w>
parasi tic</w>
const ants</w>
D ental</w>
Twent y-
og lo
- 5</w>
not able</w>
N il
up ,</w>
adi pos
cultiv ation</w>
PA R</w>
l es
process ing.</w>
A X
en o</w>
10.1056/NEJ Mo
ri er</w>
al c
du oden
ur ance</w>
os e-
sh el
n ick
conver gence</w>
N et
Caro lin
69 5</w>
0.6 2</w>
[ 4,</w>
est rogen
66 3</w>
8 4.
ic e-
bur st</w>
ocy te
T c
J ord
58 )</w>
V 1</w>
quad r
anatom y</w>
Ca enorhabditis</w>
t ometer</w>
mo re
ot omy</w>
Defin i
incorpor ate</w>
mer cur
sion ;</w>
Joh an
der mal</w>
Z i
b all</w>
il ia</w>
ran king</w>
igh t-
Univers ity.</w>
C 7</w>
Het ero
the -
Nor we
femal es,</w>
mes h</w>
P is
im pairs</w>
me 3</w>
orb ital</w>
draf ting</w>
Di versity</w>
drug s.</w>
0.6 9</w>
o is</w>
cri tic
Madis on,</w>
expect ations</w>
Caucasi an</w>
mess ages</w>
P é
TNF α</w>
on itri
OR F
e ‐
trans planted</w>
Health y</w>
revers al</w>
[33 ]</w>
lu te
P IN
2 C</w>
strö m</w>
cent res</w>
record ed.</w>
B J
a W
detect ed.</w>
55 4</w>
19 77</w>
H UV
Rec og
emis sions</w>
im planted</w>
tigh tly</w>
Y i</w>
small est</w>
@ hotmail
7 3.
encoun tered</w>
inf eren
cir cle</w>
Cent ers</w>
dop ed</w>
60 8
qu e
um ann</w>
) ),</w>
10.1177 /0
special ist</w>
Inc idence</w>
mim ic
Gl c
Insec t</w>
Licen se.</w>
osph ere</w>
bacteri a.</w>
ob lastic</w>
PC R)</w>
(G )</w>
character s</w>
syndrome ,</w>
box es</w>
An dr
proced ure,</w>
t onic</w>
COX- 2</w>
H Y
18 3
mel ting</w>
(B ),</w>
compon ents.</w>
fore ign</w>
interven tion,</w>
é t
Mass achus
Sul livan</w>
In stead,</w>
dens ity,</w>
po ols</w>
epid em
B loc
M et</w>
t y.</w>
pos it
flu x
sp anning</w>
( 15</w>
nico tin
Ab out</w>
opin ion</w>
aryn g
1 %,</w>
utili ze</w>
Ac et
g ram</w>
circum ference</w>
n y</w>
. 10.1016/j.
siv ity</w>
AP P</w>
as cor
0. 37</w>
th al</w>
inf er</w>
D eci
2. x</w>
16 40</w>
E W</w>
w .</w>
correspon ded</w>
compos ites</w>
67 9</w>
On line</w>
10 9/
( NA
p sy
Hist ory</w>
Mark ov</w>
4 32</w>
clim atic</w>
br ing</w>
Conserv ation</w>
ed o</w>
4 24</w>
b ank</w>
evol ution
IL- 2</w>
F res
branch ing</w>
1.0 3</w>
5 11</w>
o h</w>
4 38</w>
Chin a).</w>
tend on</w>
33 ].</w>
ul ating</w>
le y,</w>
56 )</w>
Neuro l.</w>
u h
aut osomal</w>
mu sic</w>
Bec ker</w>
m d
regul ation.</w>
oc ks</w>
gl and
Beij ing,</w>
Rob ert
nan os
ai ,</w>
- 2
L av
au tis
L os</w>
[5 2].</w>
spor adic</w>
rel atives</w>
Con sortium</w>
si st</w>
Y ok
gu ar
or um</w>
hyper glyc
Apop tosis</w>
10.11 52/
mandi bular</w>
c rac
ar ach
o sis.</w>
19 70
34 7
(v /v)</w>
R ag
l ),</w>
e- like</w>
im migr
el s,</w>
est er,</w>
delet erious</w>
Th 2</w>
Al i</w>
ncbi.nlm. nih.gov/
phen yl</w>
vulner ability</w>
A GG
10.1161/ 01.
( 96
(A NOV
.00 1</w>
80 6</w>
re vi
T at
dot ted</w>
adel ph
s es.</w>
lat er,</w>
g as
it al
59 6</w>
[24 ],</w>
ol es</w>
- down</w>
O H
Second ly,</w>
7554/eLif e.0
w ay.</w>
par ac
T b
Peo ple</w>
F itz
sco res.</w>
Scientific ,</w>
mg/k g)</w>
10.1007/s00 4
to :</w>
ker nel</w>
S ain
67 )</w>
um ;</w>
0. 55</w>
ech ,</w>
m ou
in e)</w>
id in</w>
X ue</w>
ic )</w>
ik awa</w>
55 )</w>
L U
33 -
N N</w>
period ontal</w>
Li ao</w>
confin ed</w>
in versely</w>
5 p</w>
C re</w>
prin t</w>
algorith m.</w>
Find ings</w>
0.6 1</w>
− 1.</w>
Phy to
weak er</w>
ple ural</w>
4 16</w>
opi oid</w>
ad eh</w>
55 8</w>
ple as
fabric ated</w>
pl ayers</w>
W T
8 -0
( 35
Pet ers</w>
Incre asing</w>
H 7
typ ing</w>
D ul
ne ar
H yp
Nor mal
g ins</w>
15 /
q i
90 5</w>
Mean while,</w>
sur g
5- year</w>
Q in</w>
manuscript ,</w>
ng/m L</w>
Mann -Whitney</w>
.200 3.
F BS</w>
microtub ule</w>
ti z
dis continu
Li po
estr adi
immobil ized</w>
6. 9</w>
hemorrh age</w>
perform s</w>
dri ver</w>
Ab sorption</w>
defin es</w>
exclu sive</w>
neuro genesis</w>
Wn t
Ander sen</w>
W ri
rhyth m</w>
0.00 7</w>
sec urity</w>
0. 19
GW AS</w>
neuro transmit
be it</w>
N uc
cm 2</w>
adap t</w>
antagon ists</w>
SE S</w>
resi li
not e,</w>
J eff
King dom</w>
opo si
Op in.</w>
Ser ies</w>
B ron
100 )</w>
EGF P</w>
vast atin</w>
95 5</w>
a eg
dic hot
bio diversity</w>
[7 ,
obes ity,</w>
MC F
0. 43</w>
doc tor
ma kers</w>
bil i
belong s</w>
comb ine</w>
Mc K
cap t
rej ection</w>
( median</w>
± 1.
4 th</w>
f ect
conflic ts</w>
acqu ire</w>
b ,
breath ing</w>
C ron
investig ation.</w>
HI F
HE PE
experi enc
decre as
pl ann
u ang</w>
anc ient</w>
V L
CC )</w>
az ep
ar box
6 4.
Th 1</w>
bio active</w>
institu tions</w>
ir ub
80 8</w>
(P h
0. 44</w>
Bar t
Process ing</w>
plac es</w>
90 3</w>
um i</w>
pressu res</w>
Rec on
9 1.
(S hel
c y</w>
C 8</w>
6 4,</w>
compens ation</w>
mut ations,</w>
Pro vince</w>
chloro plast</w>
j ab
r c
fut ure.</w>
J im
cool ing</w>
F EV
amplitud es</w>
4 36</w>
malign ancy</w>
Measure ments</w>
Table ).</w>
BAL B/
fol ate</w>
Helic obacter</w>
depres sed</w>
0. 39</w>
69 3</w>
trac es</w>
d yl
[ 1-
5 20</w>
T CA
10.118 2/
J. L.</w>
sk ew
I A
Con f
80 4</w>
interfer ing</w>
ph im
conf er</w>
pur ity</w>
an )</w>
L K</w>
Comput .</w>
(199 0</w>
0. 48</w>
D .,</w>
ag glutin
( *
Bioch im
eri an</w>
V a
4 22</w>
out put
95 3</w>
u el</w>
[34 ]</w>
att ended</w>
NADP H</w>
op y</w>
4 a</w>
rib onucle
i res</w>
69 9</w>
iti s,</w>
& D</w>
5- HT
Institu to</w>
4 ],</w>
kill er</w>
par alog
g over
pa y
pac lit
compu ter
Biom ar
As th
signific ance.</w>
tw ent
P ra
Op tical</w>
nanop articl
del ays</w>
hospit alized</w>
measure ments,</w>
Depart ment,</w>
cell s;</w>
M aria</w>
a sive</w>
68 1</w>
s d
participant s’</w>
pain .</w>
0. 20
e -</w>
visu alize</w>
MS )</w>
– 23
domin ance</w>
7 4.
rib osome</w>
Associ ated</w>
yl- CoA</w>
( one</w>
K ul
66 5</w>
g az
et z</w>
if er</w>
di am
Ag ilent</w>
66 9</w>
stop ped</w>
servic es,</w>
un paired</w>
cass ette</w>
sin us</w>
optim ize</w>
ex osomes</w>
qu ist</w>
compound s,</w>
H 9
som ething</w>
H ell
7. 8</w>
): e
CM V</w>
col oc
C ath
loc ation,</w>
F ast</w>
check point</w>
n ig
T rich
1.0 5</w>
An al.</w>
concentr ations,</w>
disturb ance</w>
Public ation</w>
5 15</w>
bil ity.</w>
m ast</w>
0. 41</w>
germ line</w>
nan om
ERK 1/2</w>
transi ently</w>
arsen ic</w>
Neph rol</w>
gen der
Al ign
acceler ation</w>
C –
A us
mod ality</w>
Investig ation</w>
compet ence</w>
(00 )
suc cessive</w>
An timicrobial</w>
ar y-
U. S.A.</w>
setting .</w>
out breaks</w>
[ 5,</w>
Switzer land</w>
Differen ti
bi o-
dedic ated</w>
glauc oma</w>
90 )</w>
in consistent</w>
2 —H
PA )</w>
S 2.</w>
59 8</w>
ne u
K ot
95 9</w>
in us</w>
atherosclero tic</w>
m Cher
ov ary</w>
oder m</w>
de struction</w>
16 3
+/ −</w>
si RNAs</w>
obacter i
S ut
68 3</w>
ach i</w>
− 2</w>
asi s,</w>
Impro ved</w>
an ium</w>
Sel ective</w>
br uc
H og
termin ation</w>
survi ve</w>
Report s
5 25</w>
Sym metry</w>
two- way</w>
95 7</w>
9. 1</w>
K F</w>
14 -0
inst ance</w>
0. 50
phenomen a</w>
cat ech
A —H
Tor on
bi ases</w>
Clostri dium</w>
arg ued</w>
SY BR</w>
tri me
L ak
M ater</w>
ser um-
15 —C
out li
N CT
po d
oxyl in</w>
( left</w>
stimul ation.</w>
5 -0
10. 37
.0 %)</w>
19 75</w>
MDA-MB- 231</w>
g ).</w>
ser ving</w>
P d
1 C</w>
4 28</w>
FIS H</w>
ous ness</w>
az o
W omen
1.0 4</w>
a fore
g002 Fig</w>
I b
6 2.
56 -
limit ations.</w>
ili ated</w>
Fi bro
Exerc ise</w>
e ’</w>
reach es</w>
fin e-
4 26</w>
1 +</w>
11 -0
ement :</w>
qu asi
ist ,</w>
- containing</w>
low ship</w>
3. x</w>
34 ].</w>
(b ot
14 /
V S
29 9
Therapeu tic</w>
Ben j
occup ied</w>
ed ),</w>
inten tion</w>
57 )</w>
St or
Edu c</w>
mmol/ L</w>
P ad
MR SA</w>
pro pan
f t
( α
pa e
ocat aly
(200 8)</w>
ens es</w>
86 7</w>
arg ue</w>
rom agnetic</w>
rati o
gang lion</w>
DI SC
wor ked</w>
er ies</w>
administr ative</w>
(Shel d
recipi ents</w>
re mission</w>
86 1</w>
– 20</w>
Y ear</w>
f ).</w>
J )</w>
gradi ents</w>
am at
m L
scal ed</w>
4 34</w>
olig odendro
8. 1</w>
H ipp
gr ass
organiz ational</w>
ad vis
reac tion.</w>
B ran
PI3K /
app end
um atic</w>
ag ents,</w>
67 6</w>
7. 3</w>
toler ant</w>
Scho ol,</w>
90 7</w>
K ine
fer ment
dec ade</w>
CT CA
(F o
Co ordin
criteri a,</w>
0.00 8</w>
Re f
ll a</w>
FER EN
D ys
ech anical</w>
ine /
fibr e</w>
shar p</w>
differenc es.</w>
5 17</w>
(Sheld rick,</w>
s r
adult s,</w>
per t</w>
C- reactive</w>
AC T</w>
HbA1 c</w>
g ain
TF s</w>
x i</w>
idi um</w>
prog no
67 4</w>
gener ations</w>
Me dium</w>
H V
Corpor ation</w>
l und</w>
acupunc ture</w>
J. C.</w>
meas ures.</w>
reservo ir</w>
sl er</w>
- R
AC E</w>
mac rom
19 3
pip eline</w>
H si
dri ves</w>
Dop pler</w>
follic ular</w>
sco re.</w>
cent rom
plement ation</w>
viv ax</w>
5 2.</w>
Ad d
j um
f en
L IN
P ost</w>
hem e</w>
pic tures</w>
Temper ature</w>
1 C).</w>
xenog raft</w>
origin ating</w>
216 4-
filam ents</w>
F ACS</w>
st atin
streng ths</w>
’ )</w>
prote ases</w>
carcin ogenesis</w>
atmosph ere</w>
( m,</w>
har boring</w>
bri ght</w>
adv oc
immunost aining</w>
cul tur
eg u
t ong
- T
or ang
sp reading</w>
Hepat ology</w>
Eng .</w>
con g
Vi rol.</w>
ubiquitin ation</w>
reveal ing</w>
g ating</w>
Elect ron</w>
[1, 2].</w>
ma y
filam ent</w>
accept ance</w>
emo tions</w>
I RE
Mag n
ca ffe
S imp
defini tive</w>
L G
pur su
palli ative</w>
angiot ensin</w>
Rich ard</w>
RNA s,</w>
patient s'</w>
H 4
Im ag
30 6
po is
[25 ],</w>
CI )
adequ ately</w>
fa ec
1 (
5 @
classi c</w>
C ys
0 10
support ,</w>
M ang
D Q
endos copic</w>
Nor th
P ack
K ru
in herited</w>
0. 60
Ex amination</w>
o rous</w>
ens emble</w>
cl ad
activ ity
fil es.</w>
yl ic</w>
stre am
dissem ination</w>
shap es</w>
Y an
D ai</w>
69 1</w>
und et
0. 60</w>
68 7</w>
fo rest
chim eric</w>
dam age,</w>
In ou
Gluc ose</w>
inter play</w>
Review ed</w>
86 9</w>
immunore activity</w>
( US
numb er,</w>
thre on
w alk
h an
[5 3].</w>
h k
O m
compound ,</w>
if f</w>
Phil adelph
Wol f</w>
R U
y an
problem s.</w>
m V</w>
) 2
, j
0. 56</w>
u ted</w>
Xi a
M g</w>
si mon
tic us</w>
attit ude</w>
0. 46</w>
osteo arthritis</w>
SV M</w>
sur fact
S tren
sol e</w>
al ge
95 1</w>
4 2,</w>
0. 52</w>
id es,</w>
fi bron
Afric a,</w>
anten atal</w>
n er,</w>
microscop y.</w>
experi encing</w>
om eth
Hw ang</w>
process ing,</w>
princi pl
100 -
di hedral</w>
Wh y</w>
10.1371/journal.pone.0 14
socio- economic</w>
app rais
vi ously,</w>
0. 58</w>
instruc ted</w>
Lop ez</w>
G ur
g lo
perc ei
cytokin es,</w>
Ani m</w>
(A b
contin ues</w>
O 2—C
[ 6,</w>
om in
ah an</w>
3 000</w>
g/ L</w>
disper sed</w>
transpor ted</w>
ex haus
Ug anda</w>
ophag y</w>
metabolis m.</w>
we an
respond ers</w>
sul fur</w>
tag s</w>
(P <0.0
Mar k</w>
7. 6</w>
Ma x</w>
x in</w>
syn ucle
simil ar
mat ern
dam age.</w>
Where as</w>
tr ab
alter ing</w>
ting :</w>
HIF- 1α</w>
atmosph eric</w>
S ad
ic um</w>
M use
Hy bri
Grou p,</w>
indo or</w>
S und
2/ 3</w>
bio tics</w>
86 5</w>
inst ances</w>
g/ d
in patient</w>
Tog ether,</w>
Rog ers</w>
t oral</w>
simpl ified</w>
is lands</w>
it -
an ni
beg in</w>
P :</w>
omen cl
ex tra
res in</w>
ham ,</w>
ag ents.</w>
caspase- 3</w>
an ter
0. 49
A ch
0 x
(Invitrogen )</w>
0. 47</w>
90 9</w>
qu ench
penetr ation</w>
min ority</w>
histor y,</w>
pen icillin
Pharmac ology</w>
rolog ical</w>
diffrac tometer</w>
asym metry</w>
ogen icity</w>
Dep end
s ple
fung us</w>
design s</w>
al located</w>
CT TT
easi er</w>
u e,</w>
Norwe gian</w>
idi fied</w>
nai ve</w>
prop ensity</w>
si x-
2-s2.0- 77
86 74
25 (OH)
down loaded</w>
x +
40 6
10.1098 /r
( ≥
ho p</w>
constr ued</w>
EM G</w>
Aff ymet
contex tual</w>
19 76</w>
homolog s</w>
gene tic
le an</w>
Zh ong</w>
sel en
confir mation</w>
0.9 800</w>
expl ains</w>
polym ers</w>
it ter</w>
plank ton</w>
s acc
9. 0</w>
150 0</w>
pitu itary</w>
C 23
vacu um</w>
78 0</w>
tur ned</w>
Ac tion</w>
E gg
laparo scopic</w>
rin sed</w>
spar se</w>
Ex cell
poli tical</w>
migr ation,</w>
- F
S ize</w>
[ 70
ol in</w>
Mod el
5 40</w>
hypothe size</w>
am an</w>
re di
66 2</w>
H ob
mal es,</w>
Wat son</w>
M ap
progester one</w>
fir st,</w>
h us
S b
can al</w>
sist er</w>
inflamm ation.</w>
in )</w>
ac clim
adheren t</w>
Go od</w>
Ber g</w>
n ick</w>
9. 2</w>
F D</w>
3 D
molecul es.</w>
K op
Cr y
J r.</w>
design ing</w>
Signific ance</w>
P RE
in sect
umb il
55 .</w>
69 7</w>
microbi ome</w>
weigh t.</w>
W RK
ography .</w>
Mar shall</w>
ir rig
69 0</w>
perin atal</w>
0. 49</w>
stal k</w>
stom ach</w>
: 6
or adi
col itis</w>
Ev ol.</w>
pand emic</w>
papill om
mei otic</w>
Netherland s
ub er</w>
(C -
pi i
Y L</w>
al ity.</w>
frequenc y,</w>
5 19</w>
á n</w>
elim inated</w>
* Correspondence:</w>
cu st
leak age</w>
produc ts.</w>
Char les</w>
50 8
Anxi ety</w>
ext ends</w>
allog r</w>
D anish</w>
000 ,</w>
ester ase</w>
Universit é</w>
F DR</w>
BR CA1</w>
Tem poral</w>
Sy d
( ±</w>
Pri mers</w>
[35 ]</w>
classi fy</w>
H .,</w>
k at
ercul osis</w>
Sch u
M eg
DNA s</w>
S aw
C16 —C
cataly zed</w>
(A ,</w>
person nel</w>
V 2</w>
67 ,</w>
ul ations</w>
Law rence</w>
9 10
Transcrip tional</w>
si bl
[26 ],</w>
anti- rabbit</w>
cre te</w>
g etting</w>
spl en
set up</w>
Ox ford,</w>
T D
Si x
10.1177 /
ment :</w>
8. 3</w>
pattern s,</w>
10.110 4/
Laborat ories,</w>
EC G</w>
Spect ro
Ne on
fe eling</w>
199 6;</w>
10.1023 /A
Cryst allogr</w>
rati o.</w>
hi d</w>
55 ,</w>
t ar
bir ths</w>
1 G
st ad</w>
(M il
afore mentioned</w>
produc ts,</w>
C g
m M)</w>
T X
B S)</w>
pl ans</w>
Massachus et
occup ancy</w>
C ult
5 3.</w>
10.1104/ pp
nan o-
Path ology,</w>
flu ids</w>
RE FEREN
H G
0. 53</w>
200 7,</w>
replic ated</w>
compri se</w>
occip ital</w>
p our</w>
interpre t</w>
Numb ers</w>
R on
prote olytic</w>
introduc ing</w>
47 -
stead y-state</w>
t au
200 4
wal d</w>
an um</w>
other s,</w>
Ch i</w>
pancre as</w>
Mat sum
Bec k</w>
ces sion</w>
b i</w>
PC -
ophysi cal</w>
ji ang</w>
diarrhe a</w>
ed es</w>
rap amycin</w>
A X</w>
MC s</w>
86 )</w>
repres sor</w>
Lact obacillus</w>
c ite</w>
f /
F ung
c amp
ra ise</w>
of t</w>
8. 2</w>
imped ance</w>
35 ].</w>
intrac ranial</w>
0.9 700</w>
C 9</w>
qual ity,</w>
ov en</w>
s g
Pris m</w>
68 9</w>
RNA- Seq</w>
descri ptions</w>
- type</w>
si a.</w>
V ide
enzym es,</w>
Pro cess</w>
or ch
est ,</w>
Dat as
for aging</w>
af en
cirrho sis</w>
bio tin
ir i</w>
evol ving</w>
F ull</w>
5 '</w>
. 25
si d</w>
M uc
90 4</w>
( blue</w>
Assess ing</w>
dend rit
SL E</w>
( 29.
bi as.</w>
(M D
Grou ps</w>
Fran k</w>
punc t
cost- effectiveness</w>
( St
er .
network s,</w>
P aper
p rice</w>
adv ance</w>
10.1056/NEJ M
aut ologous</w>
5 35</w>
Un known</w>
– 25
ris k,</w>
3 Table</w>
ma th
tion s
E U
poly acrylamide</w>
J i</w>
S AR
60 .</w>
201 5;</w>
ox y-
lys osomal</w>
it er</w>
month s)</w>
ove restim
factor s:</w>
A ,
hem odynamic</w>
met formin</w>
M igr
br ack
g ross</w>
concer ned</w>
Clim ate</w>
non- small</w>
201 7
Fir stly,</w>
B ed
C ant
3 b</w>
dam ,</w>
ar in</w>
mac ular</w>
i k</w>
chemo kines</w>
( 2,
F G</w>
super family</w>
met allic</w>
0. 54</w>
mil li
G SH</w>
N U
70 7
35 8
ish ment</w>
pot ency</w>
aneur ys
ac t,</w>
T V</w>
wo od
lymph atic</w>
cle an</w>
3 p</w>
L ang</w>
L M
Mon te</w>
capsul e</w>
c el</w>
97 3</w>
TC R</w>
aer os
2) ]</w>
arrang ed</w>
Inter actions</w>
sc att
stri king</w>
Cor rec
). 19
at ter</w>
hy dra
T on
sel ection.</w>
p p</w>
electr on
cultiv ars</w>
An ton
ti de</w>
o i</w>
Chap man</w>
diag ram
Exampl es</w>
mon ocyte</w>
t sch
di aly
/000 8-
cre ation</w>
bronch ial</w>
do s</w>
her bal</w>
lab els</w>
but y
malignanc ies</w>
underg one</w>
anth ocyan
tub ul
isot ope</w>
Phy t
precis ely</w>
al beit</w>
Lev y</w>
J V</w>
5 13</w>
constitu tively</w>
Chem other</w>
domain s,</w>
top ological</w>
at e)</w>
5 21</w>
90 2</w>
intermitt ent</w>
ili br
descri pt
care ful</w>
est s</w>
5 B).</w>
monol ayer</w>
tryp toph
Path way</w>
cav e
0. 57</w>
µ L</w>
PS S</w>
interac tion.</w>
K oz
(A g
1 200</w>
0. 51</w>
biom ed
UK ).</w>
coch le
rel ates</w>
66 4</w>
diabet es.</w>
ampl ify</w>
k k
CT ION</w>
wal k</w>
endomet ri
Declar ation</w>
- B
t ose</w>
del ta</w>
Chin a)</w>
yl )
suppres sing</w>
le is
cam er
Ig M</w>
immuno therapy</w>
Sing le-
pro pri
á le
Me y
N 3</w>
[10 ,
7 2/
Col d</w>
Sym ptom
project .</w>
W P</w>
sel ection,</w>
cur ric
Z im
199 8).</w>
mut ations.</w>
har m</w>
ing ”</w>
95 8</w>
orth og
C ac
ver b
ond o</w>
antibodi es,</w>
Stren g
He ad
pre fer
od or</w>
crop s</w>
59 )</w>
excre tion</w>
cont ext
in version</w>
56 ,</w>
el and</w>
mark ers.</w>
Sa udi</w>
ig an</w>
spher ical</w>
H b</w>
az aki</w>
86 4</w>
di oxide</w>
m Ab
60 6
posi tivity</w>
D eli
Pro vid
proj ected</w>
ra ,</w>
inter quartile</w>
( 37
ific ations</w>
ó pe
t- test.</w>
S j
( 40
discre panc
fore sts</w>
endoc rin
sc anned</w>
detri mental</w>
Anatom y
thromb in</w>
( except</w>
C 25
hydro l
Ry an</w>
' —C
mon keys</w>
D in
star ts</w>
es ch
(N I
Well come</w>
IF N</w>
S O</w>
typ e-
REFEREN CES</w>
10 A</w>
ot ri
Met ast
up tak
ol d,</w>
suc cin
mess age</w>
Sh eld
str o</w>
tr ust</w>
in herit
form s,</w>
Bar cel
L ud
D ynamics</w>
[7 ,</w>
inser t</w>
μ mol/
B F
grad u
10.1107/S16005 368
aggreg ated</w>
vi r</w>
A ther
examin ations</w>
volum e,</w>
50110 000
Bcl -
spectro met
Psychiat ric</w>
Ar gen
schem atic</w>
69 -
S per
ric s,</w>
Oncotarg et
P- 2</w>
super ficial</w>
high ,</w>
es cal
( 4-
se aled</w>
(N o.</w>
treat ments,</w>
Dow n
H ash
R ange</w>
health -
an ion</w>
o ke</w>
posi um</w>
minut es,</w>
conven i
view ing</w>
distinc tion</w>
II )</w>
Tol l-like</w>
67 2</w>
Stand ards</w>
anesthe tized</w>
micro arrays</w>
Yosh ida</w>
0.00 1;</w>
(0. 5
PC R
sl ide</w>
PD ,</w>
2009 ),</w>
µ g</w>
connec ting</w>
67 8</w>
c up</w>
st ation</w>
H och
Ont ology</w>
men str
D el</w>
u ff
d augh
on a,</w>
10.1182/ blood-
Mut ation</w>
proced ures.</w>
U U
strateg ies.</w>
stimul i.</w>
I 1</w>
68 2</w>
s arcoma</w>
E-Mail :</w>
foc uses</w>
200 8)</w>
F eld
appa B</w>
5 23</w>
mechanis m.</w>
C GG
H 12
é e</w>
o ocyte</w>
meth ane</w>
electr ons</w>
epti d
C 24
k owski</w>
i P
68 )</w>
547 2.
95 2</w>
Ab d
x 2</w>
USA ;</w>
mar row
29 7
Orth op
har t</w>
ch i-square</w>
[27 ],</w>
TR PV
coll ective</w>
Y. -
ves ti
ip sil
oc occ
l es,</w>
lum en</w>
My ers</w>
Antimicro b</w>
(w /v)</w>
tail ored</w>
di mers</w>
lin ker</w>
66 6</w>
5 A).</w>
ob stac
hor n</w>
R eli
notic ed</w>
int ui
46 -
g ains</w>
harm ful</w>
e b</w>
bet a
ps ori
N G
biofil ms</w>
if era</w>
for ums</w>
[5 4].</w>
soci ety</w>
sud den</w>
. 8
lar yn
S 1,</w>
G ross</w>
oc e
1: 1</w>
domain s.</w>
R ut
hemisph ere</w>
Ji ang
[36 ]</w>
Bost on,</w>
48 -
sex ually</w>
aver aging</w>
leng th.</w>
Sh or
M ain</w>
Sh in
g au
h rs</w>
Sah aran</w>
problem .</w>
re fu
caud al</w>
ri ver</w>
collabor ative</w>
larg e,</w>
in ium</w>
neighbour ing</w>
36 ].</w>
as e/
Obst et
Yam ada</w>
if ies</w>
techniqu es,</w>
er s)</w>
+/ -</w>
a 0</w>
glyc ine</w>
J an</w>
z )</w>
guar ante
ad ox
pregnanc y,</w>
° .</w>
ing redi
ne ut
on ly,</w>
5 —H
W ei
Dermat ol</w>
mel atonin</w>
10.1371/journal.pone.0 12
10.1158 /0008-
27 -
influ enz
t able
R ech
Nor way</w>
C d</w>
tit ude</w>
Qual itative</w>
positiv e,</w>
statis tic
analy tic</w>
struct urally</w>
p H
B oh
amm er</w>
Kaplan -M
Q i</w>
10. 2337
0.0 5),</w>
conf ers</w>
man aging</w>
vitro ,</w>
Har rison</w>
bro th</w>
mmol )</w>
articl e:</w>
pro mp
as hi
In vent
En zym
cl ades</w>
S ph
in ski</w>
fail ure,</w>
78 1</w>
L W</w>
ol l</w>
http://creativecommons.org/licenses/by/ 4.0/
strati fication</w>
% 20
col or
ar b
000 )</w>
79 5</w>
5 39</w>
Micro array</w>
p5 3-
antibod y,</w>
( reviewed</w>
Res on
I so
mut ational</w>
( 1),</w>
omy el
10.1158/0008- 5472.
stri atum</w>
N ob
T op</w>
fi bre
gi ant</w>
II -
77 -
0. 2%</w>
coun s
sh ell
el abor
volt age-
hab its</w>
anticip ated</w>
5 29</w>
scri pt</w>
86 8</w>
ter restrial</w>
un published</w>
16 —C
sem iconduc
hy pot
ab a
cerebell um</w>
thin king</w>
9. 3</w>
cour se,</w>
adipon ectin</w>
on ly
B ure
Sequ ences</w>
1- 1</w>
roph ic</w>
anim al
78 )</w>
10.1186/s 12
Vari ation</w>
ensur ing</w>
( ),</w>
5 27</w>
ca .</w>
specific ation</w>
progen y</w>
adop t</w>
rod ents</w>
(Å 2)</w>
20 /
PB S.</w>
( iv)</w>
Fried man</w>
hist ology</w>
5 30</w>
4 10
dilu tions</w>
de emed</w>
38 9
sw elling</w>
Car ter</w>
( non-
ne st
78 5</w>
depend ency</w>
ethn icity</w>
ec tions.</w>
f arm</w>
In dependent</w>
3 24
ist er</w>
201 4),</w>
. 1000
ir regular</w>
d am</w>
sp on
m ari
Hamil ton</w>
). 17
oc ene</w>
( 1).</w>
C ases</w>
(S h
ac to
Yor k:</w>
Com pon
3 19
ration ale</w>
synap se</w>
atin g
Sp ine</w>
migr atory</w>
re ward
cour ses</w>
vi sion,</w>
virus -
201 5,</w>
40 7
percenti le</w>
W en</w>
M ai
A 2
B —H
pl aques</w>
90 6</w>
noc ic
[ 8,</w>
Bri st
Elsev ier</w>
G BM</w>
Ant oni
5 31</w>
CT )</w>
RA ,</w>
er @
impl ying</w>
Intern et
G old</w>
Nis hi
(G E</w>
c g
r DNA</w>
— Fe
sic k</w>
s ed,</w>
st yle</w>
N ad
preserv ation</w>
genotyp ed</w>
D as</w>
2– 3</w>
agit tal</w>
F ail
Car bon</w>
tend s</w>
0. 59</w>
Syst .</w>
leuk ocytes</w>
sign al.</w>
m ;</w>
N og
( s,</w>
det ox
Org an</w>
N ord
correc tion:</w>
PPAR γ</w>
Ac id</w>
) ].</w>
hist opathological</w>
+ -
inspec tion</w>
200 6,</w>
path ologic</w>
calibr ated</w>
evalu ated.</w>
pro stagland
disulf ide</w>
4 —H
po s</w>
pres ynaptic</w>
Col om
gli a</w>
fresh water</w>
E SC
CS C</w>
ed ”</w>
ari al</w>
Colle ge,</w>
M :</w>
inj ection.</w>
dig es
solub il
interven tions.</w>
materi als.</w>
ax is,</w>
ter s.</w>
two- tailed</w>
86 6</w>
manag ement.</w>
N ow
origin ated</w>
A maz
Schem e</w>
Pro per
( 36
transcript ase</w>
co operative</w>
K O
hy al
lac ks</w>
the ories</w>
dos ing</w>
J N
gran ule</w>
V ector</w>
cy clin
sugg estive</w>
seiz ures</w>
under stand
pa y</w>
Fig s</w>
orth ologous</w>
95 4</w>
inter leukin</w>
66 8</w>
97 5</w>
oper ational</w>
ace ous</w>
asi s.</w>
Agric ulture</w>
92- 8674
86 2</w>
unil ateral</w>
dis cover
10.1093/bioinformatics/ bt
l ).</w>
aci ón</w>
( 95</w>
9 -0
ow ner
le )</w>
stra ight</w>
et ta</w>
simul ate</w>
ic i
stric tly</w>
1.0 6</w>
sph ere</w>
al e,</w>
Se q
sten osis</w>
Kaplan-M eier</w>
sp ite</w>
el man</w>
(200 7)</w>
community- based</w>
eu than
equ ilibr
a rent</w>
ing ).</w>
Rati o</w>
v ent</w>
5 B</w>
2 C).</w>
Cor n
Sur pri
adren ergic</w>
myel oma</w>
wor ker</w>
fu el</w>
6 :</w>
TGF- β1</w>
hsa- miR-
(S 1</w>
diet ,</w>
l ’
fertili zation</w>
57 .</w>
Ac tin
(blu e)</w>
Arch .</w>
γ ,</w>
R .,</w>
alb umin
resid ence</w>
O h</w>
T ),</w>
n ch
Dise ases
avoid ing</w>
7. 7</w>
oxygen ase</w>
es in</w>
thalam ic</w>
n )</w>
ap point
Con g
U s
encap sul
le tin</w>
ep iso
C 18</w>
U TR
3 2)</w>
recru it</w>
est ock</w>
68 6</w>
P s
r í
QTL s</w>
2 D
pre d
5 45</w>
meas ures,</w>
es on</w>
10.1371/journal.pone.0 10
F EMS</w>
nod ules</w>
2008 ),</w>
95 6</w>
Cor on
denat uration</w>
develop ments</w>
inv ited</w>
Intell ig
vis ually</w>
gambi ae</w>
verat rol</w>
Ig A</w>
sc ram
C ob
fl ora</w>
suppor tive</w>
quantit atively</w>
mut ual</w>
non- invasive</w>
34 /
hel per</w>
el ed</w>
R oh
F C
Ah med</w>
path s</w>
aci onal</w>
Resour ces</w>
ri go
Transcri pt
R [
G os
Y i
Per s
encour age</w>
coh erent</w>
buff er.</w>
bo ok
- D
conjug ate</w>
obstruc tion</w>
AP C</w>
ste in-
stat es.</w>
8 99
sch e</w>
synth et
contex ts</w>
– 30</w>
bar ley</w>
onco gene</w>
2.0 )</w>
ser otype</w>
[28 ],</w>
(A r
Techn ol.</w>
R ate</w>
Le on
es us</w>
ch em</w>
il er</w>
en er</w>
experti se</w>
met aph
let on</w>
load s</w>
ine ph
w as
pro found</w>
form s.</w>
therapeu tics</w>
pl aying</w>
Pattern s</w>
K .,</w>
12 -0
perturb ation</w>
78 3</w>
97 7</w>
Hand book</w>
Eg yp
S CA
69 2</w>
10.10 99
tempor ary</w>
multipl ex</w>
Ltd .,</w>
4 3,</w>
well ing</w>
col li
SI ON</w>
Ex peri
G rap
astro cyt
Gonz ále
w R
A re
tr a</w>
sacrific ed</w>
ill i</w>
Meas uring</w>
ü r
pig ment</w>
Physi cs</w>
4 1,</w>
Ne o
58 .</w>
u stri
Nur s</w>
5 4.</w>
regim e</w>
PS C</w>
M en</w>
reg ards</w>
cy st
P Y
onc ology</w>
A 4</w>
self- report</w>
sco res,</w>
Pro spective</w>
4.0 ),</w>
66 )</w>
sin ,</w>
alph a
PP I</w>
le ishman
0.0 1;</w>
l ect
are an</w>
plat forms</w>
analog ous</w>
5 a</w>
Calci um</w>
impair ments</w>
per pend
e ’s</w>
pat ches</w>
76 1</w>
po res</w>
Contin uous</w>
Membr ane</w>
micro vascular</w>
10.1158/0008-5472. CA
saliv a</w>
L as
ur s</w>
Willi am
ank le</w>
ur ium</w>
30 9
spont aneously</w>
M yo
M b</w>
Pres ent</w>
v ac
Å 3</w>
caus ative</w>
Recom m
3. 8
dit ary</w>
deep er</w>
W y
ot ed</w>
A O</w>
omeg al
gra v
ph ase-
[2 1,
V ect
o is
R ural</w>
ho using</w>
u ximab</w>
g yn
K ato</w>
69 6</w>
6 1.
Microbi ology
ur ac
77 1</w>
ph an
loc ks</w>
Tryp an
Ha emat
cent ric</w>
Nig eria</w>
sch ist
Fram e
Cy cle</w>
eff or
heav ily</w>
Sol id</w>
Elev ated</w>
TB I</w>
MMP- 9</w>
Harv ard</w>
Ad dic
J ia</w>
k y
E O
77 7</w>
(0. 5</w>
6 50</w>
2 −
virus es,</w>
[37 ]</w>
S e</w>
gene ic</w>
hol m</w>
stain ing,</w>
79 1</w>
aut onomic</w>
stag es.</w>
interfer on-
M ess
than ks</w>
con ve
Lit tle</w>
HP V
d :</w>
carb oxy
magn et
10.1371/journal.pone.0 13
syndrome :</w>
yl )-
Hop kins</w>
Trans plant</w>
97 1</w>
cit ed,</w>
techniqu es.</w>
35 %</w>
Stev ens</w>
pseud o-
p 21</w>
mas k</w>
cod ons</w>
mo i
F ru
Reduc tion</w>
. 9
vis cos
10. 0</w>
pl ay
fair ly</w>
50 7
S ite</w>
Long itudinal</w>
GABA ergic</w>
public ly</w>
PS A</w>
fi st
— figure</w>
ophil us</w>
scaveng ing</w>
11 ).</w>
g003 Fig</w>
hol ding</w>
SO D</w>
é n
cyl ind
Bar r</w>
dr ich</w>
4. x</w>
int /
vi an</w>
Associ ations</w>
Educ ation,</w>
B AC</w>
( 37.
ash ima</w>
hold ers</w>
B AC
compens atory</w>
Transl ational</w>
199 5;</w>
[55 ].</w>
[9 ,</w>
el s.</w>
Con nor</w>
Ye ast</w>
( mg/d
5 41</w>
Q )</w>
La ure
Kr usk
Fox p
( A</w>
cap ital</w>
ling u
Mc C
rad icals</w>
post synaptic</w>
em i</w>
28 9
reli ably</w>
V O
commun ity.</w>
0.00 9</w>
0.00 1.</w>
-3 ′
er on</w>
ther mod
97 9</w>
8. 4</w>
star vation</w>
- binding</w>
Toron to,</w>
F K
matri x
Moder ate</w>
polymer ization</w>
f a</w>
maxim ize</w>
77 3</w>
12 –
dy lin
Pear son
97 0</w>
moti f
L ópe
Affymet rix</w>
ambigu ous</w>
11 ,
tes ting,</w>
69 4</w>
d é
ch s</w>
7 2.
ri o</w>
stra ight
h l</w>
indic ations</w>
recur renc
oc t
( 33
10.1371/journal.pone.0 16
Sr c</w>
Ch in</w>
ab brevi
admis sions</w>
A er
analy zer</w>
mar ital</w>
interac tion,</w>
exp and</w>
w ar</w>
manag ement,</w>
seg ment
69 )</w>
pell ets</w>
76 3</w>
train ing.</w>
re x
68 8</w>
Pro gnostic</w>
ste at
neighbor hood</w>
M in</w>
tam oxif
(lef t)</w>
be es</w>
90 8
ocardi al</w>
ar tem
ot opic</w>
37 ].</w>
@yaho o.
wh o.
dichot om
piv otal</w>
ore d.</w>
76 5</w>
DNA- binding</w>
stig ma</w>
PBM Cs</w>
b ever
201 5)</w>
imag es,</w>
S. M.</w>
prim ate</w>
fibrill ation</w>
re t</w>
Tel .:</w>
US A,</w>
sph ing
PC ,</w>
doc tor</w>
78 9</w>
mic row
st an
Bi o</w>
wor sen
Gib son</w>
resul t
para formaldehyde</w>
mon key</w>
99 %</w>
5 37</w>
resul tant</w>
Mac roph
5 th</w>
re programming</w>
R 3</w>
cal f</w>
join ts</w>
trans fusion</w>
col our
adhe sive</w>
Ch IP</w>
as g
t 1</w>
Cyto kine</w>
/ F
D ra
ho od
rig id</w>
97 8</w>
Sch mit
1 N
Langu age</w>
atic ,</w>
Sch i
re cogni
chaper one</w>
seiz ure</w>
– 27
pt .</w>
w ealth</w>
( −0.
cl amp</w>
35 7
3 34
B ae
phosphat e-
E ag
loc ation.</w>
cor por
68 4</w>
sm a</w>
ga ard</w>
dri vers</w>
multic enter</w>
trab ec
Sw iss</w>
Bioch im</w>
CXCR 4</w>
car ni
diffic ul
S MA</w>
opharmac ology</w>
b old</w>
perm it</w>
zy k</w>
76 7</w>
O ut</w>
3 10
idel ity</w>
GT TT
tic -
Leng th</w>
G e</w>
tt i</w>
re tain</w>
Neurobi ol</w>
ou n</w>
). 18
m eri
10.1159 /000
we ar</w>
BALB/ c</w>
44 -
i x</w>
60 –
U iso
vis t</w>
o @
de bri
(200 8).</w>
electro static</w>
p un
I B</w>
anti genic</w>
mid w
swim ming</w>
end ocytosis</w>
new bor
. Fig.</w>
( right</w>
per mis
Dis tinc
um ar</w>
incub ation,</w>
d ers</w>
chlorophyl l</w>
permit ted,</w>
mm −1</w>
mo de
Dise ases,</w>
RA D
L az
Availability All</w>
X L</w>
the or
post menopausal</w>
IL- 4</w>
Ed in
L en
C ad
5 33</w>
69 8</w>
As sum
mann er,</w>
% –
E k
posi tion
spac e,</w>
EB V</w>
repor ted,</w>
ur is
grad ual</w>
d s.</w>
repres sed</w>
pot ato</w>
ar dis
77 9</w>
a res
Robert son</w>
Br y
5 43</w>
Ac t</w>
ex empl
I G</w>
59 ,</w>
resol ve</w>
R v
pos es</w>
Y M</w>
H ost</w>
ak ed</w>
end point</w>
muscul oskeletal</w>
characteris ed</w>
j a
bili ary</w>
86 -
y +
kin ase-
pressu re
influ x</w>
vari able.</w>
Ear th</w>
dex amethas
break down</w>
im plants</w>
cor pus</w>
dat a;</w>
J AK
Radi at</w>
1600 -0
post- hoc</w>
olog ic
co vers
S earch</w>
ME T</w>
Infl ammatory</w>
( 1/
t ure.</w>
T ong</w>
14 4
B CL
( also</w>
( d,</w>
78 7</w>
Compu ting</w>
not ably</w>
B od
sensiti zation</w>
9. 4</w>
ill er</w>
Di ab
Princ i
[29 ],</w>
P ep
conver ting</w>
post eri
Gu ide</w>
CY P2
7 A</w>
in es,</w>
scienti sts</w>
P 450</w>
Compar is
compound s.</w>
1.0 7</w>
intere st,</w>
0. 5,</w>
58 ,</w>
wai ting</w>
zz y</w>
sub tle</w>
Impro ving</w>
Er b
9 2
G ö
b im
I J
Δρ min</w>
macroph ages,</w>
reces sive</w>
B uck
cholester ol,</w>
10.1101/ gr
49 /j
ster one</w>
Canc er
off set</w>
sh ad
as i</w>
inv ent
ag i
MD A</w>
pattern ing</w>
m ur
em por
77 0</w>
ti s:</w>
Stre et,</w>
fati gu
d ans</w>
H. -
90 8</w>
iz umab</w>
( 35.
( a),</w>
w et
p .,</w>
80 °C</w>
editor s.</w>
Cor tex</w>
af t</w>
8. 6</w>
12 ).</w>
(I C
glyco gen</w>
sur rogate</w>
eg el</w>
49/j immunol
fluor ide</w>
ei ,</w>
ine ;</w>
j an
microscop e.</w>
X Y</w>
( 36.
3 '
o und
p id
in ate</w>
. Frontiers</w>
79 9</w>
et ers</w>
( by</w>
2 1–
first- line</w>
f ar,</w>
P ren
Perspec t</w>
Estim ation</w>
210 5-
OR F</w>
G ),</w>
not e
mor al</w>
10.1111/j. 17
disord er,</w>
77 5</w>
Ste in</w>
Con sent</w>
mi RNA-
constrain t</w>
datab ase,</w>
SU LT
mod alities</w>
Sim ulation</w>
IL- 17
Br it
40 8
vol atile</w>
79 3</w>
Pat tern</w>
bre ed
com b</w>
R as</w>
6 20</w>
ah l
all a</w>
amin es</w>
ST ,</w>
T ext</w>
( 34.
syndrom es</w>
Mat rix</w>
Low -
ent ering</w>
term s.
inoc ul
es —
L- 1</w>
77 )</w>
nucle osome</w>
ah ara</w>
ortholog s</w>
Cat al
licens or</w>
pro m
t =
th ings</w>
6 3/
d a,</w>
3 27
poin ting</w>
8. 8</w>
li ver
hypoxi a-
Corpor ation,</w>
10.1001/jam a.
ach es</w>
V D
electro physiological</w>
E mo
fac ing</w>
13 /
trigg ering</w>
10.40 49/jimmunol
rat e-
femal es.</w>
ub ation</w>
2009 .</w>
w it
h ur
nanop article</w>
tr ain</w>
cul ating</w>
ech o</w>
200 7)</w>
Rand om</w>
increas ed,</w>
concor dance</w>
B lu
devi ation.</w>
f 1</w>
Mc Car
n am</w>
Ch ur
B ar</w>
BY ).</w>
phen ol
Ber lin</w>
un -
m er,</w>
constit utes</w>
m ati
L ;</w>
3 3)</w>
H K
Over view</w>
wind ows</w>
dis mut
bind ing,</w>
Gre ec
Journ als</w>
invol v
flo or</w>
7. 9</w>
[38 ]</w>
( New</w>
sub family</w>
contr ary,</w>
th en,</w>
as simil
R CT</w>
suff ered</w>
accompan ying</w>
76 9</w>
5 32</w>
In don
W ritten</w>
−/ −
N W</w>
feed back
extr apol
8 5%</w>
cros sed</w>
let t</w>
DS M-
) 6
t ables</w>
For mation</w>
pr int
(Pro meg
L ack</w>
por tions</w>
10.1037 /00
pro xy</w>
). 16
μ m,</w>
pe di
Mech anical</w>
rup ture</w>
protein- coding</w>
Ltd .200
NF- κ
tri ed</w>
TU NE
repor t,</w>
integr ative</w>
ec tion:</w>
B ig
Universid ad</w>
present ed.</w>
ref lex</w>
8 2.
emi a.</w>
u o</w>
[10 ,</w>
He at</w>
Δρ max</w>
zh ou,</w>
10.1371/journal.pgen .100
ob lig
in ic</w>
Ch im
D K
174 2-
Ethi opia</w>
C17 —C
pathogen icity</w>
arrowhe ad
n ude</w>
Stat es,</w>
author ized</w>
negl igible</w>
necro tic</w>
F c</w>
10.1016/j.neuro imag
wa ist</w>
tran s</w>
ipsil ateral</w>
3 _
sustain able</w>
Mo ham
P .,</w>
thrombo sis</w>
ST )</w>
di ploid</w>
pattern .</w>
c ),</w>
imag e.</w>
ogl u</w>
mut ants.</w>
ric ular</w>
Panc re
cyto plasm
ev apor
Sub sequ
ro utes</w>
Syn drom
neigh b
Re productive</w>
met a
air s</w>
O M</w>
3 ±
Children ’s</w>
kin em
Onc ology,</w>
3 35
ep h</w>
enn e</w>
D HA</w>
tr ap
10.1371/journal.pone.00 8
homogen ized</w>
D um
duc tal</w>
B est</w>
answ ers</w>
3 C).</w>
suppres sive</w>
CA -
ucle otide</w>
Reg ression</w>
insul in-
immunosup pressive</w>
L ei
Wis con
in nerv
stabil ize</w>
placebo- controlled</w>
cri min
o z</w>
10.3389/f n
Hun ter</w>
progres sively</w>
fer ri
dro pped</w>
iz u</w>
gam ma-
rh od
lat e-
col lo
problem ,</w>
7 -0
C yp
bp )</w>
ev es</w>
ultras on
occa sion
ag ue</w>
ul y</w>
rid ge</w>
renew al</w>
36 -
2009 .0
bi -
im possible</w>
F B</w>
RPM I</w>
Po isson</w>
38 ].</w>
(0.0 )</w>
benz ene</w>
Individu als</w>
Fr ag
war ming</w>
sub- Saharan</w>
(C ).</w>
ot ax
gener aliz
ol ateral</w>
att i</w>
Recept or</w>
target s.</w>
23 22
En dos
perform ed,</w>
am ed</w>
ocy ste
Xen opus</w>
10.1016 /000
it an</w>
morph ogenesis</w>
time -dependent</w>
p ra
v et
up .</w>
free zing</w>
li ves</w>
ativ e.</w>
moist ure</w>
gn ess</w>
(C H
Bri en</w>
Let ters</w>
His panic</w>
highligh ting</w>
97 6</w>
Method s).</w>
acet onitri
L um
ent )</w>
igh ts</w>
centr al.
( 3-
el ast
Peri ph
F AC
For ce</w>
anti fungal</w>
59 .</w>
– 12</w>
AL T</w>
recept ors.</w>
3. 7
lin early</w>
Ag ain,</w>
Od ds</w>
ed em
T- cells</w>
ret ard
—H 8
methyl transferase</w>
statis tics,</w>
constitu ents</w>
E Z
s ing,</w>
effec tors</w>
a ul
si de
GA GA
mor ning</w>
set s,</w>
Serv ic
2- 69
satis factory</w>
op res
201 6.</w>
Not es</w>
B eth
acces sions</w>
re cover</w>
setting ,</w>
ill o</w>
cohor t.</w>
t ure,</w>
De ut
n s,</w>
comfor t</w>
3. 6
organis ms.</w>
anc o</w>
NP C</w>
10.1371/journal.p pat
Limit ations</w>
(C ar
threat ening</w>
vic tim
cr yo
7 1.
os -
fish ,</w>
z ation,</w>
certain ly</w>
Phy s
pro line</w>
k s,</w>
nor mo
37 8
aeg yp
NA C</w>
ation s)</w>
Di et</w>
Influ enza</w>
im balance</w>
10.1186/1471- 2164-
(198 9</w>
al d
Sou za</w>
fl at
Occup ational</w>
57 ,</w>
ap ex</w>
enlarg ed</w>
G ag
+ 1</w>
Ep ith
lef t-
E PA</w>
97 4</w>
Cir c</w>
J CI
cardi o
i a:</w>
Mod ulation</w>
cli ents</w>
bar ,</w>
ass e</w>
approach es.</w>
accept or</w>
34 6
[56 ].</w>
T ric
hydrox yl</w>
CI R
77 4</w>
stabil izing</w>
U. S.
laborator ies</w>
vir us.</w>
omat ous</w>
D ick
w are</w>
Pro state</w>
step wise</w>
W ak
methion ine</w>
streptom ycin</w>
tid al</w>
stud y
marri ed</w>
INT RO
min us</w>
wee k,</w>
cholin ergic</w>
L ut
sp ra
sph ero
μg/m l)</w>
respon se
0= vr
ob viously</w>
System s,</w>
Man n</w>
l em
sic ular</w>
Rh od
AK I</w>
spectro meter</w>
10 ),</w>
qu et</w>
Resour ce</w>
st a
7. x</w>
5 %,</w>
l /
att ack
ci ties</w>
im pair</w>
aspart ate</w>
ti tis</w>
intraper itoneal</w>
cho osing</w>
1 A,</w>
, 9
os yl
flu idic</w>
1.0 8</w>
p ure
T CT
( 38
[30 ],</w>
1– 3</w>
50 9
follow-up ,</w>
Gu t</w>
ste el</w>
CA CA
rearrang ements</w>
differenti ating</w>
E A
S 4).</w>
" .</w>
Hist ological</w>
Alzheim er</w>
co ar
A. J.</w>
29 6
medi ation</w>
ung ,</w>
D eg
V R</w>
EDT A,</w>
gang li
rest ore</w>
/ f
trache al</w>
Edin bur
Re f.</w>
satis fied</w>
c ranial</w>
s );</w>
struc tive</w>
program (s)</w>
U rol</w>
here :</w>
less ons</w>
F inal</w>
asym met
Ph D</w>
John ston</w>
Det ails</w>
Gene tics,</w>
Stat us</w>
SC ,</w>
2σ (I)</w>
Nan j
Kenn edy</w>
qual ity.</w>
qu ine</w>
qu ez</w>
10.1128/A EM
( %</w>
cohor t,</w>
10.1371/journal.pone.0 15
Extrac tion</w>
tryp an
G as
cent ury</w>
fabric ation</w>
10.11 72/
random ization</w>
F un
O ff
ation al,</w>
16 /
ob ut
Vi brio</w>
p all
datas et,</w>
wat ers</w>
scatt ered</w>
10.1172/ JCI
AM P-
200 5,</w>
– 4</w>
10.1371/journal.pone.0 11
gang lia</w>
oligonucle otides</w>
sc anner</w>
phenotyp e,</w>
Det ailed</w>
Hi ro
locom otor</w>
8. 7</w>
tes tis</w>
g ot</w>
in :</w>
AS ,</w>
gest ation</w>
domes tic
Wri ting</w>
Inou e</w>
USA 2</w>
Contro ls</w>
DU CTION</w>
B y
.. ..
si le</w>
ocor tical</w>
-3 ′</w>
brief ,</w>
graph ical</w>
( 34
y- related</w>
umbil ical</w>
Al vare
reperto ire</w>
sou th</w>
Tradi tional</w>
air -
pol y-
( 38.
righ ts</w>
G M-
3. 3.</w>
interval s.</w>
genom es.</w>
er c</w>
Me eting</w>
ocy cl
in appropriate</w>
Radi ology</w>
reac tor</w>
intak e,</w>
ch ez</w>
(F 2)</w>
post partum</w>
l amb
Tanz ania</w>
Per spectiv
sh aw</w>
sal mon</w>
ventric le</w>
counsel ing</w>
cing ulate</w>
fl oral</w>
abol ished</w>
s and</w>
Sec tions</w>
G RA
10.1186/147 5-
at e;</w>
locom o
(http://creativecommons.org/licenses/by/ 4.0),</w>
od em
1, 2,
commit ment</w>
pac king</w>
ind ustri
ven om</w>
sc atter</w>
signal s.</w>
og r</w>
Universid ade</w>
L ate</w>
blind ,</w>
m L)</w>
m ate</w>
PL OS</w>
fibro tic</w>
– 10</w>
intr ons</w>
C ,
str ing
n g/
5 000</w>
Wal sh</w>
Genom ics
) a</w>
F S
Ec ological</w>
sol vent
id ae
W I</w>
J. P.</w>
il ly</w>
38 8
μ M,</w>
Modi fied</w>
view .</w>
pressu re.</w>
… ,
( rs
disrup t</w>
beli ef</w>
Martí ne
BM D</w>
Princ ipal</w>
u al
Q U
G ou
(Fig s.</w>
po protein</w>
ai ab
hy pop
replic ates.</w>
demonstr ation</w>
NM _00
An not
d ust</w>
( In
age ing</w>
ar aj
di sequ
( that</w>
kill ed</w>
cover s</w>
cor tic
+ ++</w>
energ ies</w>
VEGF -
100 .</w>
stimul ation,</w>
co des:</w>
78 6</w>
inter faces</w>
72 °C</w>
Re ad
cyt ometry.</w>
c m,</w>
(03) 00
dur ation,</w>
6 47</w>
lead er
5 14</w>
chem il
El -
In st</w>
Ber lin,</w>
assess ment.</w>
stat es,</w>
[11 ,</w>
week -old</w>
S ob
ben th
Tak ing</w>
thous ands</w>
v ely</w>
prescri bing</w>
Wein berg</w>
S anger</w>
Ad en
wi reless</w>
or ally</w>
bur y</w>
( 200</w>
cap abilities</w>
acid .</w>
Ch r
N I</w>
credit ed.</w>
S exual</w>
99 1</w>
mg/ L</w>
cultures .</w>
explan ations</w>
Ta ip
12 ].</w>
structure -
protoc ol,</w>
( .
contex t.</w>
erythem at
necess ary.</w>
flex i
Nur sing</w>
5 47</w>
L B
electro por
he im</w>
r um
don ’t</w>
Pl ants</w>
CAM -1</w>
BRA F</w>
ast om
Par k,</w>
L ast
d ail
a j</w>
PE G</w>
9 80
n est</w>
K lo
s sen</w>
RT- PCR.</w>
C 10</w>
Te am</w>
A ir</w>
0 ).</w>
hist ogram</w>
3 1)</w>
0.0 1.</w>
b el</w>
” ).</w>
H g</w>
( ‘
p f
ni tion</w>
below ).</w>
radi ographic</w>
4 14
ing ),</w>
me tic</w>
66 ,</w>
polyp eptide</w>
SP ,</w>
comm s
diversi fication</w>
co- expression</w>
N SA
A i
mean ±
Paramet ers</w>
- 1,</w>
[39 ]</w>
1 D</w>
sh ed
program ,</w>
R. A.</w>
48 8
m g,</w>
od ec
98 0</w>
V E</w>
qual it
comp any</w>
Q OL</w>
N 3
o :</w>
Ag ro
found ,</w>
R M
Be sides,</w>
De sign
P ay
70 8
micro bes</w>
(200 6)</w>
R C
ti er
n ett</w>
cm )</w>
95 ,</w>
79 7</w>
cataly st</w>
O ther
high- density</w>
Str ain</w>
linear ity</w>
k ing,</w>
AD ,</w>
clust er
pl ing</w>
9. 6</w>
S. J.</w>
oth i
matri x,</w>
L K
tw e
K RAS</w>
ar is
ab aq
How ard</w>
OTU s</w>
Respon ses</w>
97 2</w>
5 ’-
un igen
pri ori</w>
5 18</w>
hel min
rain fall</w>
yl es</w>
research er</w>
Anti bodies</w>
en /
distric ts</w>
oper ator</w>
(S anta</w>
T MS</w>
CO L
direc tion.</w>
P eder
ax es</w>
ull ary</w>
t aste</w>
recommend ation</w>
R CC</w>
ecosystem s</w>
pro of</w>
sti s</w>
Techn ologies</w>
colle ge</w>
bio chem
e uro
st a</w>
Al li
dig estive</w>
(p =
aw a,</w>
cor n</w>
Comparis ons</w>
I E</w>
Y oshi
RO I</w>
An ge
Accur acy</w>
is cha
Pur ification</w>
ting -
sput um</w>
With out</w>
J O</w>
Emerg ing</w>
prolifer ation.</w>
propor tion
bl es</w>
virul ent</w>
INTRO DUCTION</w>
exp anding</w>
s ley</w>
compens ate</w>
19 78
w ick</w>
dri ft</w>
( Bio
N acional</w>
uc ker</w>
8. 9</w>
cust om</w>
Bul letin</w>
age- specific</w>
ent h</w>
Z immer
M am
nemat ode</w>
m asses</w>
ill s</w>
adop tion</w>
99 8</w>
ent ries</w>
non- linear</w>
MA LD
P ort
reas on,</w>
Roch e</w>
ucle ar</w>
Periph eral</w>
uniform ly</w>
C lear
S pl
resid ential</w>
sh ot</w>
V C</w>
.0 5</w>
R ose</w>
Mis sing</w>
drain age</w>
Bioscienc es,</w>
ere c
ak i
ic idal</w>
dist ur
ti e</w>
DEG s</w>
neuro imaging</w>
possess es</w>
Simp son</w>
Sa ito</w>
perf ect
(S D
(O x
H A.
27 9
Reyn olds</w>
C. -
76 6</w>
canc ers,</w>
aor ta</w>
ex erts</w>
L s</w>
Author (s)
mercur y</w>
disturb ances</w>
H ung
appropri ately</w>
all ergy</w>
S even</w>
3 23
otechn ology</w>
39 ].</w>
Biosystem s,</w>
J enn
F eder
lac tic</w>
90 7
u si
sw ine</w>
synchron ization</w>
G PR
high er-
c et
LD H</w>
Found ation,</w>
head ache</w>
ang er
extr a-
Decre ased</w>
stimul i,</w>
as s.</w>
PA G
M eng</w>
Surpri singly,</w>
n n
—N 1</w>
mul tivariable</w>
39 7
Ka plan</w>
wh is
ap tam
Con ven
37 7
organis ms,</w>
Immunohisto chemical</w>
sc ann
contr ast
hybri ds</w>
me yer</w>
oth or
implic it</w>
cy st</w>
exec ution</w>
c f
recei ver</w>
Ag e,</w>
syndrome .</w>
test )</w>
F 4</w>
B ot</w>
12 0.0</w>
40 9
Networ ks</w>
e- mediated</w>
Paramet er</w>
y ”</w>
Chrom osome</w>
use fulness</w>
3 12
plic ity</w>
st on,</w>
schem es</w>
simult ane
[ 76
8 1.
longev ity</w>
monom er</w>
199 7).</w>
Sym posium</w>
68 ,</w>
Nr f2</w>
99 5</w>
Recombin ant</w>
(SI CI)
prolifer ating</w>
N a</w>
mg/m L</w>
77 6</w>
10.1002/ (SICI)
com mitte
Ferre ira</w>
Yo on</w>
60 9
Pati ent
G ad
hom es</w>
Berg er</w>
evalu ation.</w>
ann e</w>
Con struction</w>
coun ter</w>
wh ol
coll agen
Q ian</w>
d B</w>
line ).</w>
feel ings</w>
hemorrh agic</w>
tr unk</w>
N 3—C
T W
Par is</w>
Pol l
On col.</w>
cont empor
imag ing,</w>
H ud
circu it
B ass
excit ability</w>
re ds</w>
[57 ].</w>
79 0</w>
ish es</w>
interpre ting</w>
(P er
is in
Ch alleng
p ter
therm ia</w>
). 15
∗ ∗
RNA s.</w>
glyc emic</w>
K och</w>
F X
g ath
D uration</w>
el ective</w>
pattern ,</w>
− z
wind ow
Con sum
er che</w>
h ope</w>
et z
Rheumat ol</w>
Jos eph</w>
87 5</w>
is l
t g
99 7</w>
[ pii
CT C</w>
PE T/
c n</w>
py r
ordin ary</w>
M Y</w>
siz ing</w>
C EN
si de,</w>
est e
factor ial</w>
Sch e
mor tem</w>
Mic hel
neutroph il
G em
neuro pathy</w>
[12 ,</w>
top ical</w>
immun omod
hem odi
76 8</w>
ra ises</w>
probabil istic</w>
man -
inter genic</w>
77 2</w>
erro r.</w>
ep ic
(95 %
concep tu
Descri ptive</w>
CD C</w>
6 5,</w>
b ath</w>
oy ama</w>
13 -0
ti an</w>
Lev ine</w>
appli ed.</w>
F U</w>
CC A</w>
C ross</w>
re pos
Meas ures</w>
vox el</w>
Asth ma</w>
Al ter
La w</w>
J. H.</w>
System ic</w>
( s).</w>
aph rag
Ba x</w>
employ ees</w>
A ven
ag n
vari able,</w>
ref ine</w>
X X
inhibit ors,</w>
t- generation</w>
dat a-
remark ably</w>
clinic ,</w>
4 29
P- values</w>
nar r
anc ement</w>
ation -dependent</w>
mechanis m,</w>
describ ed.</w>
n d
D. J.</w>
Tur k
om icro
l ex
ch imp
L am</w>
hy ph
3 11
17 —C
T 1-
v o</w>
Flu or</w>
[3 1],</w>
in en</w>
6 —H
perc utaneous</w>
es i</w>
35 9
sp ray</w>
datas ets.</w>
lab elling</w>
S kin</w>
China 2</w>
N un
ex cited</w>
perpend icular</w>
piec es</w>
cardiomy ocytes</w>
magne sium</w>
L iter
Å ,</w>
Br .</w>
z hou</w>
famil ies,</w>
J. S.</w>
gov /
9. 8</w>
1.0 9</w>
micro arra
cerebro spinal</w>
absor bed</w>
infarc t</w>
pregnanc y.</w>
96 1</w>
Analy tical</w>
ycl ine</w>
cat s</w>
te ams</w>
dys regulation</w>
siv e.</w>
suppl ements</w>
H TL
osclero sis</w>
di electric</w>
ing estion</w>
10.1371/journal.pone.0 17
sto ichi
G PS</w>
iter ative</w>
Bir th</w>
(02) 00
Par t
olig os
pe er
om a:</w>
care :</w>
60 7
(http://creativecommons.org/licenses/by/ 3.0
tissu e-specific</w>
multic ent
Con clu
N as
cortex .</w>
flow ers</w>
In -
Ch al
87 1</w>
L ob
yn chron
g00 6
Mem ory</w>
Immunohisto chemistry</w>
chondro cytes</w>
d extr
Al b
Col e</w>
sul fat
lit ter</w>
—N 2—C
det ection.</w>
phim urium</w>
anal og</w>
Con sul
spik es</w>
estradi ol</w>
lic h
N P-
ultr a-
f i</w>
19 74</w>
Tor res</w>
p ir
reproduc ible</w>
70 6
2000 ,</w>
ar bon
- 20
iz ations</w>
Health .</w>
oper on</w>
L o</w>
exceed ed</w>
( white</w>
w t
( 45
rab bits</w>
lign in</w>
T en
heter ologous</w>
s- of-
comparis on.</w>
repeat edly</w>
T CA</w>
R. J.</w>
i j</w>
GL UT
96 7</w>
ci o</w>
interval .</w>
ist s,</w>
David son</w>
mas s,</w>
requ is
hear ts</w>
mis sense</w>
freed om</w>
k its</w>
pharmac ology</w>
H ]
bro ken</w>
av er</w>
34 8
vul g
nas oph
Intrac ellular</w>
on ey</w>
Conflic ts</w>
N Ac
G .,</w>
Ch an
MY C</w>
J. R.</w>
d ge</w>
4 2)</w>
pneum ococcal</w>
imag ing.</w>
who. int/
cm −1</w>
vas o
Pos sible</w>
7 20</w>
orth op
Sigma -Aldrich
K I</w>
vir tually</w>
Th er.</w>
br a</w>
@ un
illumin ation</w>
D —H
.201 6.0
week .</w>
the astern</w>
f ell</w>
Publ ished</w>
f asc
s oph
D unc
techniqu e.</w>
top ics</w>
antioxid ants</w>
homoz yg
( ∼
drug -resistant</w>
K eller</w>
G ong</w>
7 —H
ER I
low .</w>
Pere z</w>
D enti
adultho od</w>
C ari
99 0</w>
long ,</w>
is tically</w>
Jacob s</w>
- linked</w>
DISC US
sa w</w>
stem s</w>
as ome</w>
follow s.</w>
Cl a
Qi u</w>
ent ly.</w>
Hz )</w>
Hz .</w>
ectiv ely,</w>
Ther mo
Thail and</w>
ou x</w>
com position,</w>
alg al</w>
S s</w>
– 15</w>
article ’s</w>
S. -
CH D</w>
cat abol
es en</w>
A PA
neuro blastoma</w>
u .ac.
tor sion</w>
e tics</w>
5 36</w>
IL- 17</w>
000 -0000
A my
Inj ury</w>
g y
therap y:</w>
gl er</w>
g ers</w>
et ary</w>
Que ens
u ation</w>
M otor</w>
M. S.</w>
correc t
A ster
95 8
ov al</w>
2 (
sk ill</w>
sub sp.</w>
b ath
environ ments.</w>
Ug and
Inflamm ation</w>
ri sh
H s
inter neurons</w>
e ur</w>
è re</w>
(A m
5 16</w>
S 3
(0 ,</w>
Shangha i,</w>
pal mit
not ,</w>
▶ )</w>
6 25</w>
μ m)</w>
K Y</w>
algorith m,</w>
ren o</w>
vascul ature</w>
am en</w>
Poly morph
intern alization</w>
veget able</w>
Trans mission</w>
appe ti
non coding</w>
E U</w>
g in</w>
under lie</w>
B and
Treg s</w>
10.1016/S0 9
Mechanis m</w>
Lt d</w>
she ets</w>
* 1</w>
w ear
− 3.
blood ,</w>
mut ants,</w>
mal e,</w>
ac tu
respectivel y),</w>
sp read
13 ].</w>
rec ap
incorrec t</w>
off s</w>
gal acto
P neum
op y
ar ate</w>
inter pol
add ed.</w>
Method s.</w>
solub ility</w>
mobil ization</w>
Kau f
st ent</w>
98 7</w>
Kri sh
Pere ira</w>
Sh an
F W</w>
c ra
su ited</w>
10.1152/ aj
Australi a,</w>
Peo ple’s</w>
Fl av
Lin k
IC C</w>
D a</w>
m ).</w>
77 8</w>
Engl ish
Gram- negative</w>
Bo ul
fre ez
c rani
Cy tos
36 7
oc ean</w>
4 ±
F N</w>
76 -
79 6</w>
ot emporal</w>
assess ment,</w>
M ;</w>
Cop enh
Rec ur
ass ing</w>
chemo therapeutic</w>
angi ography</w>
Plat el
Y FP</w>
ere .</w>
mem ory,</w>
Lyn ch</w>
bod y,</w>
op ulmonary</w>
T as
T2 DM</w>
flex ion</w>
O thers</w>
D. A.</w>
2- fold</w>
SS R</w>
B auer</w>
40 ].</w>
ru g
c ure</w>
DISCUS SION</w>
( 20)</w>
aj ima</w>
DN MT
ure )</w>
ch .</w>
Man ag
bind ing.</w>
empha size</w>
neuro protective</w>
migr aine</w>
28 6
[40 ]</w>
super vis
lnc RNAs</w>
78 4</w>
edic ine</w>
coc aine</w>
radi ation,</w>
bi a,</w>
Con cer
oph ore</w>
sugges tions</w>
per oxidation</w>
sen ,</w>
pri mi
Oc t
f us
not es</w>
FL P</w>
bir th,</w>
2007 ),</w>
w ron
Rheumat ology</w>
10. 1200
At omic</w>
Immun ology
lab or</w>
R iz
3 T
formul ations</w>
photosyn thesis</w>
explan atory</w>
M S-
88 9</w>
phosphor us</w>
70 9
ur al
advant age
H CO
conflic ting</w>
a 00
B ax
ploid y</w>
clust ers.</w>
G rand
P 1
F( 1,
C 11</w>
spac es</w>
ar ises</w>
P om
requ est</w>
l ich</w>
approach es,</w>
Theore tical</w>
98 -
(3 2.
M S.</w>
88 0</w>
rí gu
Tet ra
B P-
interview ed</w>
S es
(M O
p i</w>
3 ’</w>
sched ule</w>
Radi ol</w>
exc ised</w>
as es:</w>
tet ram
answ ered</w>
96 3</w>
c ,
attrib ute</w>
st ance</w>
Man ch
Innov ation</w>
lay er.</w>
haz ards</w>
continu ing</w>
gre w</w>
— a</w>
at ed)</w>
n M)</w>
cool ed</w>
87 7</w>
Parti al</w>
[ Ca2+
vari eties</w>
M ei
DN ase</w>
p age</w>
G ut
t a,</w>
hepar in</w>
ov ine</w>
RE SULT
registr y</w>
refrac tive</w>
sub populations</w>
hon ey</w>
http://orcid.org/0000-000 2-
oste ogenic</w>
AB I</w>
Z ou</w>
14 ].</w>
( GA
distinc tive</w>
Q C</w>
ovas cul
V in
96 5</w>
ph asic</w>
3 +
B ill
draw ing</w>
onucle ase</w>
[3 2],</w>
CT -
[13 ,</w>
B ack
h ap
Y et,</w>
(Bas el
I PT
shif ting</w>
transp arent</w>
0.0 %</w>
Rh o</w>
2 A,</w>
in s.</w>
se q
W K</w>
ir rit
th y
ov ich</w>
37 6
m ),</w>
S er</w>
house keeping</w>
ion ization</w>
Hol mes</w>
T g</w>
cur cumin</w>
et ry</w>
inter mediates</w>
iodi de</w>
ul ates</w>
f uc
dish es</w>
am ni
E vent
Cz ech</w>
37 -
HF D</w>
ep sin</w>
R ad</w>
hydrox y-
acknowledg ed</w>
L uk
oper ate</w>
summar izes</w>
comor bidity</w>
Peter sen</w>
GC CA
fun gi
autonom ous</w>
76 2</w>
99 6</w>
increas ed.</w>
ph i</w>
[ 77
mol/ L)</w>
esc u</w>
mir ror</w>
er ad
( but</w>
Pro lifer
B ah
Ch romat
sh ips</w>
10.1037 /
surve y.</w>
r ational</w>
L au</w>
mosa ic</w>
famil ies.</w>
MET HO
T ag
ac hy
nam ely,</w>
ic ks</w>
L lo
Reg ulatory</w>
Peri od
98 9</w>
45 8
analog ue</w>
th ro
Com p.</w>
H ou</w>
D aily</w>
—H 9
endotheli um</w>
95 )</w>
B H
synucle in</w>
88 5</w>
os oph
98 1</w>
5 28</w>
insul in-like</w>
mo us
Gab ri
Ont ari
Trans plantation</w>
e. 200
G at
87 3</w>
re place</w>
L on
le sions.</w>
er ).</w>
inc ision</w>
Clin ic</w>
AS )</w>
sen ior</w>
Hydro gen-
– 28
MS E</w>
(X LS
pen icillin</w>
GG CA
BO LD</w>
+ 1
ri m
Rec ord
https:// www.
al an
dy sp
48 7
99 3</w>
Gre at</w>
ER P</w>
e osin</w>
S ex
Gener ally,</w>
B un
inf u
B ase</w>
infiltr ating</w>
89 1</w>
disc ord
76 4</w>
89 9</w>
chrom atin
transpos on</w>
n ish</w>
c ens
en ol
bi an</w>
threon ine</w>
ab s</w>
ell ,</w>
specific ally,</w>
Pl an</w>
n- 3</w>
P ho
are d.</w>
Wil d</w>
G N
re feren
institu tion</w>
19 77
ha us</w>
B .,</w>
ran k
year s).</w>
A ber
av es</w>
od or
con junc
Journ al
0. 2
Bar b
Aff iliated</w>
he at
K /
5 ±
oc k,</w>
G ron
dro p
ren ces</w>
A br
D ir
NA FL
papillom avirus</w>
Gil bert</w>
[58 ].</w>
P <0.00
(198 8</w>
ou l</w>
15 ].</w>
fashi on</w>
F DG</w>
e y,</w>
Psych ology
consum ption,</w>
Ch loro
fibre s</w>
Progr am
gen u
canc ers.</w>
(W HO
i ii</w>
Bail ey</w>
K I
par am
Frame work</w>
gene sis,</w>
progres sion,</w>
1 ·
3 C</w>
Br ain
Limit ed
distrib ut
Nucle otide</w>
dor m
W T,</w>
diar rho
z inc
j k
PM 2.5</w>
coll ected.</w>
p om
( Ac
Ab ra
plac enta</w>
stand s</w>
cham ber
22 ,
.0 1</w>
Predic ting</w>
limit ed.</w>
psych ometric</w>
reac tion,</w>
Pal mer</w>
Ta q</w>
ace ae)</w>
10. 217
or bit
los s.</w>
(B MI
lung ,</w>
all- cause</w>
out -of-
TNF- α,</w>
splic ed</w>
(b ),</w>
G ST</w>
aut o-
t ori
Val enc
examin ation,</w>
sym bi
propos al</w>
79 2</w>
). 20
bil irub
CO 2.</w>
sol ution
E I</w>
tac hy
C 26
R 2
me ier</w>
war m</w>
Mor i</w>
– 24</w>
op hi
TO F</w>
Y Y</w>
Stre ptom
Ch ip</w>
ab ,</w>
Le f
Ann exin</w>
o genetic</w>
89 7</w>
45 7
(C ),</w>
marg ins</w>
near by</w>
ü r</w>
conn ective</w>
B 6</w>
half- life</w>
w ash</w>
gran ules</w>
ov sk
le sions,</w>
ac tion.</w>
U C
rel ated
b ending</w>
inf est
A ir
pher om
R af
par simon
Thre e-
5 46</w>
substrat e.</w>
iv al</w>
K em
aug mented</w>
Cas 9</w>
degrad ing</w>
anth rac
lact am
at ax
( 90
meta- analyses</w>
Isl and</w>
K V</w>
H ot
Tuk ey
tra dition
C18 —C
stit ute</w>
emplo y</w>
H O</w>
exce ed</w>
adapt ations</w>
vill age</w>
ring ton</w>
Andre w</w>
pre dn
GA AT
TGF- β
Inter leukin
I CA
is :</w>
clud ed</w>
on line:</w>
c e,</w>
g004 Fig</w>
grad ing</w>
Rod rig
fresh ly</w>
j ob
g ut
homogene ity</w>
follow ing:</w>
B V</w>
bar s)</w>
mitogen -activated</w>
B ;</w>
200 6)</w>
pa ro
mor bid
ch ard</w>
F( 1,</w>
p 65</w>
anc e)</w>
5 22</w>
2. 4.</w>
19 73</w>
cre ates</w>
ris ing</w>
/J CO
6 30</w>
survi ving</w>
cons ent.</w>
Kim ura</w>
Sheld rick,</w>
ma st
str ands</w>
PD B</w>
78 2</w>
for -
9. 7</w>
Ell is</w>
ly so
Bul l.</w>
tin o</w>
Not ch
79 8</w>
B ang
. Table</w>
w illing</w>
spi king</w>
k s
W .,</w>
suc c
Conf idence</w>
an ic</w>
applic able.</w>
er /
d l
associ ates</w>
X R
10.1007 /
95 7
predic t
ultr y</w>
sp orts</w>
t m
Techni ques
PA R-
Last ly,</w>
Gen eva</w>
al s.
B 3</w>
b ad</w>
6 /j
89 3</w>
Min i</w>
vil le</w>
US P
(B ru
motiv ated</w>
; 8</w>
resp ir
T :</w>
addic tion</w>
Sch ol
Invol vement</w>
33 %</w>
plac ing</w>
pass ing</w>
plat es.</w>
78 8</w>
3 29
E h
gr ains</w>
expect ation</w>
k ill</w>
6 33</w>
Mg Cl2,</w>
J. J.</w>
(M c
Vic tor
ethan ol
000 1</w>
liter acy</w>
olog ies.</w>
Li e
Neurophysi ol</w>
M ammal
w ire</w>
refl ect
eosin ophil
1. 2
Z he
harv est</w>
Rod rígu
resc ued</w>
In si
phag ocytosis</w>
implic ation</w>
ri f
Mc L
mix ed-
– 29
prim e</w>
author s.</w>
88 3</w>
12 1.
cut ting</w>
K E
10 0.0</w>
synthe sis.</w>
Rem ark
Pro f.</w>
S par
Surve illance</w>
bif ur
im al</w>
pt on</w>
th eta</w>
thou gh,</w>
89 5</w>
(200 5)</w>
ic ity,</w>
asp ect
Mel an
ativ es,</w>
Sciences Anatomy
L A-
Alex and
88 7</w>
min /
br and</w>
88 1</w>
pri on</w>
Sim ult
mig rate</w>
5 24</w>
Co .</w>
ful ,</w>
a head</w>
Distinc t</w>
c age</w>
U AS-
munic ip
11 2.
Bacter ia</w>
R- factors</w>
it é</w>
neuropath ic</w>
Prof es
10.1371/journal.pcbi .100
altern ate</w>
all .</w>
67 .</w>
1 c</w>
5 26</w>
Par is,</w>
83 /jc
problem atic</w>
69 ,</w>
10.10 83/jc
F N
Fern án
filam ent
B U
conc ei
ro pol
Mi xed</w>
tog ether
Fern and
G 6
mat urity</w>
k ing
98 3</w>
le sion
phosphati dylin
Clin ic
questionnai re.</w>
benz o
39 9
3 20
Sch ro
positiv es</w>
B ox
in ase</w>
per it
ec on
deteri oration</w>
[ 78
10 —H
tel e
49 8
strateg y.</w>
son -
10.1126/science. 11
ori es.</w>
stand ardis
assum es</w>
) 900
PC a</w>
F on
revis ing</w>
pe a</w>
nod es.</w>
At g
odon tic</w>
osteoporo sis</w>
[4 1]</w>
cont act
200 ,</w>
anti- tumor</w>
Kn ight</w>
H ern
PI -
e ira</w>
ro le
49 7
F AM
ep ist
Provinc e,</w>
fail ure.</w>
h ).</w>
pre ferenc
Arch ae
hab il</w>
A Y
nan dez-
assemb lies</w>
aliz ation,</w>
A le
temper ate</w>
regul ations</w>
S ri
[14 ,</w>
Al on
E. M.</w>
Franc is</w>
duplic ated</w>
par a</w>
ti bial</w>
– 14</w>
opath ologic</w>
evol ution.</w>
be sides</w>
oglo bin
note worthy</w>
10. 7554/eLife.
10. 77
T ree</w>
c s,</w>
TP 53</w>
r 2</w>
Commun ication</w>
ch en</w>
maint ains</w>
earli est</w>
setting s,</w>
[33 ],</w>
T ot
2- 3</w>
[22 ,
(T ables</w>
neuro degeneration</w>
u el
l. s.</w>
B ach
til l</w>
im ported</w>
SP E
(R )</w>
prop yl
10.1200 /JCO
Pro to
O lym
C ox
87 9</w>
Le ung</w>
ful .</w>
( 40</w>
10.1158 /10
an astom
li ber
veget ables</w>
t00 3Table</w>
pol yn
glucos e-
over- expression</w>
( β
Mi x</w>
s cler
90 6
_ at</w>
mon ocyto
ID s</w>
5. x</w>
Re action</w>
epitheli al-
ie u</w>
D X
n en</w>
omencl ature</w>
anc e-
Protoc ol</w>
(00 )00
z en
re d-
(b ).</w>
cont our</w>
athlet es</w>
Psych ology,</w>
parti tioning</w>
prote om
post ural</w>
4 C).</w>
Bar re
robo t</w>
r umin
be ad
neuro trophic</w>
ge o
79 4</w>
W u
b ag
9. 9</w>
kn er</w>
9 ]</w>
g ar</w>
fos sil</w>
Plo S</w>
L I</w>
ex it</w>
ich i</w>
dist res
CD 34
ra -
invest ment</w>
inter cellular</w>
softw are,</w>
alog ue</w>
aro usal</w>
guidelin es.</w>
p ar</w>
seg mental</w>
en am
v ice</w>
H eter
remo ved.</w>
45 %</w>
fi es</w>
(2 ),</w>
N IC
sp oro
B la
1 H,</w>
inj ection,</w>
anomal ies</w>
vit amin
nan otubes</w>
hel ping</w>
tub er
g001 Figure</w>
55 -
ob sc
In clusion</w>
( R</w>
(3 1.
199 4;</w>
Reports 2045-
Reports2045- 2322
Reports2045-2322 Nature</w>
Rep Scientific</w>
Rep Sci</w>
12 ,
pre vent
pover ty</w>
di aphrag
(198 7</w>
sus pic
RCT s</w>
. ca
Bio informatic
ar um</w>
PD GF
R ang
in- depth</w>
physici an
ari es.</w>
SO X
Fer nandez</w>
Identi fying</w>
accurac y.</w>
P od
3– 4</w>
apol is,</w>
out puts</w>
( two</w>
weigh ed</w>
ser a
strok e,</w>
CT GT
b y,</w>
s agittal</w>
tr e</w>
Ep id
—H 11
orim otor</w>
46 8
a ard</w>
CC CA
der mat
os o</w>
Sampl ing</w>
Gmb H,</w>
repeti tion</w>
og a</w>
indi genous</w>
3 25
k appa</w>
ra ys</w>
200 4,</w>
ur able</w>
possi bilities</w>
9. x</w>
N ations</w>
d m
80 8
10.1016/j. mol
I q
ole ic</w>
RP E</w>
C t
b achi
87 0</w>
89 0</w>
.edu /
ic le</w>
anis otrop
Sens or</w>
ide as</w>
R O</w>
K ramer</w>
3 26
19 72</w>
AF M</w>
96 9</w>
vas odi
V iv
K v
G y
medi a.</w>
C oc
AP ,</w>
oid al</w>
New man</w>
46 6
sal i
divers ity,</w>
P BMC</w>
CN V</w>
M. C.</w>
( 46.
N J,</w>
Con st
conven ient</w>
H ap
El li
Trans actions</w>
E −
curv ature</w>
M ao</w>
asi a</w>
A edes</w>
deb ate</w>
(Qi agen
H 10
PC C</w>
met ac
veget ative</w>
circumst ances</w>
cancer ous</w>
B in
suic idal</w>
ow itz</w>
cytos ol</w>
Sig ma</w>
l ake</w>
E ight</w>
es '</w>
Immuno fluorescence</w>
contr asting</w>
95 6
86 ,</w>
8. x</w>
250 0</w>
– 30
chitos an</w>
af ter,</w>
“ I</w>
radi ological</w>
ear th
.200 3.0
au gh</w>
hund reds</w>
Cl oning</w>
en em
ig no
n. s.</w>
En zyme</w>
Neuro sur
dens it
Exampl e</w>
Au tism</w>
rel in</w>
Targ eted</w>
Hydrogen- bond</w>
at ri
ubiquit ous</w>
y d</w>
auth en
diseas e-
U s</w>
L 3</w>
– 2
. uk
3 16
ne y,</w>
ir on-
f ear
gon dii</w>
: 7
(4 2.
RESULT S</w>
abund ances</w>
Fish er’s</w>
Co unt
( 45.
Tob acco</w>
R ats</w>
- out</w>
n ets</w>
Hist one</w>
S 7</w>
frag ment
10. 5</w>
ad e
T ec
morph ology,</w>
coll ections</w>
C. M.</w>
Throm b</w>
sil enced</w>
( approximately</w>
immunoblo tting</w>
repor t.</w>
heim ,</w>
Mc Cl
9 37</w>
G le
­ ec
bi as,</w>
30 5
themsel v
de aling</w>
ation s;</w>
menstr ual</w>
Mo reno</w>
S. D.</w>
pregnanc ies</w>
Paul o,</w>
10. 18
cap ill
Re ed</w>
EM ,</w>
) )
– 50</w>
we ather</w>
anxi ety,</w>
tim ely</w>
[59 ].</w>
accor d
HEK 293</w>
K i-
id e.</w>
clud ing</w>
Trypan osoma</w>
Con di
r t
in soluble</w>
femal e,</w>
electroly te</w>
gluc o
pa ire
biomed central.
I BD</w>
frac tional</w>
applic ations,</w>
Mar yl
ulc er</w>
sc rap
Im plementation</w>
97 8
2008 .0
r al
B ene
98 5</w>
in trigu
arti facts</w>
16 ].</w>
con sequence,</w>
Al tman</w>
worl d.</w>
el ia</w>
ont ol</w>
MS M</w>
att ain
C en
FIT C</w>
ur gent</w>
Random ized</w>
6 B</w>
39 8
vibr ation</w>
( lower</w>
particul ate</w>
K lu
p ation</w>
pre- publication</w>
Follow -up</w>
trime ster</w>
gir l
d amp
; 9</w>
Iran ian</w>
materi als,</w>
ik a</w>
P relim
speci ation</w>
(1 −
pre pa
compon ent
ser um,</w>
distinguish able</w>
K ay
99 2</w>
brief ly</w>
48 6
38 7
enc h</w>
St a
hel ices</w>
Y el
form ulated</w>
G ST-
Hun ting
s. e.
element s,</w>
cost- effective</w>
D—H ···A</w>
the ory,</w>
cor onal</w>
nor th</w>
mod elled</w>
au t</w>
5 38</w>
max illary</w>
det ection,</w>
complic ations.</w>
al ong
Peder sen</w>
Fre eman</w>
MD PI,</w>
St one</w>
Rel ease</w>
ocr yst
condition s:</w>
Wal ter</w>
liv estock</w>
ess ler</w>
overn ight.</w>
i a
mg/k g/
conform ations</w>
I CD-
Bay es</w>
17 ].</w>
1 b
am er</w>
w /
ll o</w>
os copy</w>
carbon ate</w>
S ons</w>
Z in
h ands</w>
adap tor</w>
Fl ag
orim etric</w>
: 00</w>
5 44</w>
teach ers</w>
apprais al</w>
triglycer ide</w>
ous ly
K uro
test ed,</w>
post ulated</w>
P ass
K T
cardiomy opathy</w>
docum ents</w>
26 4
Sanch ez</w>
Oce an</w>
ro sis</w>
Str ong</w>
(G rant</w>
Re ad</w>
piec e</w>
campa ign
Pl an
myel in</w>
interleukin -
innov ative</w>
sp ores</w>
on o</w>
Tri s</w>
Thom son</w>
0.0 12</w>
.edu. cn
Sel ected</w>
-- --
lay er,</w>
Image J</w>
specific ,</w>
valu e
contr asts</w>
favour able</w>
ser o
iod ine</w>
techniqu e,</w>
Christi an</w>
categori es.</w>
suspen sions</w>
stat ements</w>
Red dy</w>
Gen Bank
a val
inser tions</w>
perf used</w>
flow s</w>
paclit axel</w>
cou gh</w>
2 1/
z ation.</w>
p ran
cytos keletal</w>
independ ence</w>
80 7
R iv
prot ecting</w>
C rop</w>
group ing</w>
hyper activity</w>
know n.</w>
Δ Δ
war r
PA -
( using</w>
h emi
Kar l
as a</w>
sen g</w>
lig and-
α /
en ni
2.0 0</w>
infra structure</w>
Pharmac o
Extrac ellular</w>
10.1186/1471- 2105-
fib rous</w>
0.0 25</w>
phospholip id</w>
heigh t,</w>
Po or</w>
0.0 15</w>
Pre- publication</w>
stress- induced</w>
gaz e</w>
Kw on</w>
88 6</w>
0.0 11</w>
minim ally</w>
Is su
2 G
glycoly sis</w>
45 6
ann i</w>
sedi ments</w>
accompl ished</w>
Den mark</w>
phot ograph
p n
A 1,</w>
200 5)</w>
of ,</w>
d ),</w>
F V</w>
Cere bral</w>
1 -</w>
stag es,</w>
R at</w>
asc o</w>
H &
– 40</w>
kidne ys</w>
GA CA
call ing</w>
68 8
me an,</w>
str al</w>
Initi ative</w>
ellip so
84 /j
19 70</w>
trad e-
46 7
iew icz</w>
bod y.</w>
Ri ver
Pe ak</w>
wor th
(L ond
compreh en
1 a
ie f</w>
– 21</w>
cis platin
glob ally</w>
instrum ental</w>
pap illary</w>
be fore
surround ed</w>
br u
Anesthe si
T AL
P <0.05</w>
M ou
Hen ry</w>
Car val
hydr ation</w>
nod al</w>
co ws</w>
Vienn a,</w>
tac tile</w>
K et
s @
R ay</w>
Effec tiveness</w>
H1 N1</w>
transpor tation</w>
multi disciplinary</w>
specific ity,</w>
CA P</w>
tryptoph an</w>
∑i =1
Uni variate</w>
AD AB
parti tion</w>
whole- genome</w>
Q ual</w>
5 34</w>
step .</w>
lap se</w>
lab our</w>
strom a</w>
Pl ant
98 8</w>
erg us
paire d-
differenc es,</w>
K ab
follic les</w>
sci ences</w>
quanti fying</w>
Syndrom e</w>
L ov
aver ages</w>
84/j em
2 —O
199 6).</w>
10.10 84/jem
; 7</w>
task s.</w>
mol ­ec
r in-
Ken y
S event
Neon atal</w>
cent ur
open ia</w>
Pro g</w>
Algorith m</w>
p 1</w>
Pathogen s
ner ves</w>
6. x</w>
mir ro
imag ery</w>
( 39.
precipit ated</w>
sic s</w>
k aryotic</w>
B all
dimer ization</w>
dat e.</w>
spac ing</w>
infec tion
N ec
na use
en e-
chem ic
Indi a
( Bi
18 S</w>
10.1128/J VI
vesi cl
po t</w>
Cra w
si li
RNA )</w>
me .</w>
el ly</w>
G m
IGF -1</w>
L Y</w>
B le
so und
om otor</w>
Hig gins</w>
discrepanc ies</w>
OR T</w>
sera dish</w>
II I-
afen ib</w>
- re
high- quality</w>
S et</w>
non- significant</w>
encour aged</w>
ation -based</w>
sec tions.</w>
98 6</w>
3 14
T IM
87 8</w>
f idelity</w>
super vision</w>
met al-
H ad
D 4</w>
O 3—C
T i</w>
est ers</w>
regener ative</w>
Mc Donald</w>
bur g
F low
j an</w>
Heidel berg</w>
2008 .</w>
(A –
(A ).</w>
mut ation,</w>
T .,</w>
10.1016/j. ej
E ph
author s;</w>
j ,</w>
children :</w>
Recomm end
BB B</w>
h ar</w>
10.1016/j. neuron
al loc
D end
separ ately.</w>
T Y
fu sions</w>
proced ures,</w>
96 2</w>
differen t.</w>
desc ending</w>
seas on
hum idified</w>
ap oli
[4 2]</w>
10.1161/ CIR
High ly</w>
Indon e
empha sized</w>
ass er</w>
Biomar kers</w>
96 6</w>
SC )</w>
96 4</w>
Mus cul
disequ ilibrium</w>
Vide o</w>
stat e-
enc er</w>
pat ernal</w>
[34 ],</w>
administr ation.</w>
hy stere
sourc es.</w>
Effici ent</w>
ot om
col i
is a</w>
cal /
Coll ectively,</w>
[ 79
pro vince</w>
imp acted</w>
r d
later .</w>
P a</w>
10 73</w>
recycl ing</w>
eclamp sia</w>
neuro log
n/ a</w>
FL AG
flur ane</w>
quasi -
[15 ,</w>
70 .</w>
( 48.
outcom e,</w>
conver t</w>
Mathem atical</w>
g ast
dropl ets</w>
Biochem istry
P ig
Rec ru
98 2</w>
In dex
4 2-
Est abl
depic ts</w>
– 60</w>
is let</w>
Cor relations</w>
schedul ed</w>
phot op
ba um
grav ity</w>
( 39
aut op
g ift</w>
Immun ob
CG A</w>
(M R
sug ars</w>
exer ted</w>
shor t,</w>
l ose</w>
S 1—C
oid s,</w>
moun t</w>
anti coagul
perform ances</w>
muscl e,</w>
(B er
10. 119
P ick
i us</w>
gi ven
Christ ensen</w>
B Y</w>
gr ams</w>
Public ations</w>
Afric a.</w>
hy giene</w>
ut ely</w>
( mm)</w>
gem cit
(A B
oxygen ation</w>
ra ising</w>
re z-
hum an-
ancest or</w>
judg ed</w>
cop i
Y a
tel omerase</w>
Fat ty</w>
aim ing</w>
re ef</w>
Isra el</w>
( green</w>
rec re
K ou
R est
Bure au</w>
D —H</w>
st ad
b ones</w>
transfer ases</w>
adult s:</w>
cross over</w>
F RET</w>
Kn ock
96 8</w>
fer ring</w>
2—C 3</w>
basel ine.</w>
aer t</w>
Gu ill
ar wal</w>
rearrang ement</w>
consum er</w>
al ).</w>
sen d</w>
se aw
Aut ophagy</w>
6 35</w>
18 ].</w>
5 42</w>
resourc es,</w>
comp act</w>
cent ros
preferen tial</w>
RA NK
sch er</w>
(4 4.
Hoff mann</w>
Singap ore</w>
am ento</w>
11 1.
(4 7.
ter ing</w>
ble ed
H in
99 4</w>
tic ks</w>
conf identi
(G ib
etc. )</w>
AA A</w>
10.1007/BF 00
i ally</w>
access ory</w>
Loc ation</w>
tem plates</w>
car d</w>
L ED
.201 6.
ardi al</w>
Ra w</w>
co valent</w>
µ m.</w>
fem ur</w>
W ester
plac ent
paramet er
10 000
Arch ives</w>
paraff in</w>
promis e</w>
Compl ement</w>
y t
Dig ital</w>
Brd U</w>
b allo
At las</w>
cen sus</w>
bl ank</w>
Sign al
Hay ashi</w>
( grant</w>
H 7</w>
reli ef</w>
physi ol
Ros si</w>
autophag ic</w>
ti i</w>
st af
atin g.</w>
bin omial</w>
atten d</w>
… ,</w>
Agric ult
A sc
comparis ons.</w>
2 );</w>
o val
medic in
assess ed.</w>
olog ica</w>
g n</w>
out door</w>
inform al</w>
tw in</w>
hu ge</w>
Sem in</w>
arg o</w>
distingu ishing</w>
Sal v
stake holders</w>
transduc er</w>
inequ alities</w>
B ai</w>
SU MO
purpos e,</w>
Hav ing</w>
orthog onal</w>
doxorub icin</w>
% );</w>
transcript omic</w>
quad ru
R BC</w>
S BP</w>
restrain ts</w>
(5 ′-
W an</w>
An dro
ari es,</w>
incre mental</w>
extr insic</w>
amph et
1/ 0
24 58-
im port</w>
dynam ical</w>
y ?</w>
88 2</w>
oscill ation</w>
mit ral</w>
Re habil</w>
V P</w>
fri ends</w>
Sch ist
vis ited</w>
( www.
pi per
pur ple</w>
IC )</w>
. edu</w>
a than</w>
Child hood</w>
Ri be
tes ticular</w>
oc rine</w>
test ;</w>
6 ]</w>
fl ap</w>
Willi am</w>
ligh t,</w>
ak ami</w>
lin gness</w>
perspectiv e,</w>
glucocortico id</w>
cyt ometric</w>
10.1016/j.b br
hyper sensitivity</w>
1—N 1—C
Ther mal</w>
lin e.
Re f</w>
# #
bacteri oph
X 3</w>
[11 ,12
( t</w>
f ür</w>
hepat ocyte</w>
and rogen
80 -
D G
ho us
hospit al.</w>
6 21</w>
ond s</w>
hypothalam ic</w>
S P-
contrac tile</w>
s z
flux es</w>
found ation</w>
her pes</w>
Pregn ancy</w>
obacter ial</w>
dys function,</w>
C ord
sit ting</w>
SA R</w>
87 4</w>
29 4
90 9
L ub
adver tis
modul us</w>
dich loro
Prelim inary</w>
Ander sson</w>
diamet ers</w>
c aries</w>
METHO DS</w>
N ev
Z ur
imp utation</w>
resus citation</w>
Helsin k
pul sed</w>
haem orrh
Dul bec
38 -
Or y
) ]
py re
morph ine</w>
el ds</w>
orb ent</w>
no ti
lamin a</w>
batter y</w>
Ad verse</w>
metastasi s.</w>
brom ide</w>
os aur
2 180
pae diatric</w>
syn ten
Trans f
5- fold</w>
no v</w>
Spec im
Bro oks</w>
D eri
sp in-
sourc es,</w>
interven tions,</w>
6 15</w>
J. D.</w>
sign al,</w>
S 4
17/ peer
1. 10</w>
nephro pathy</w>
Prog ress</w>
amplic on</w>
min u
Ne ither</w>
ro t</w>
tol u
R oth</w>
0.000 1)</w>
3 17
201 6,</w>
87 6</w>
si s;</w>
– 13</w>
per sist</w>
199 3;</w>
is ch</w>
S car
x /
P ir
Mad ri
lenti viral</w>
w ig</w>
Recog nition</w>
chem .</w>
ed i</w>
OR Fs</w>
D O</w>
web -based</w>
co il
Wol bachi
10.110 5/
mim ics</w>
A li
des tin
vesti bular</w>
Car p
supplement al</w>
6 29</w>
sen esc
ani a,</w>
87 2</w>
K ö
FAS EB</w>
dis k</w>
ac idi
N C,</w>
Obstet rics</w>
hydrol ase</w>
Hub er</w>
cl aim</w>
CA G</w>
os um</w>
wel fare</w>
cat ch
t ell</w>
experi ence,</w>
Cap e</w>
os a,</w>
12 —H
é n</w>
periph ery</w>
Compo und</w>
1 p</w>
1- 3</w>
polys accharide</w>
RT- qPCR</w>
M CA
Kat z</w>
mid line</w>
protein ;</w>
Nan os
D 2
Integr ative</w>
Che ung</w>
Per cent</w>
ultim ate</w>
– 25</w>
erythro cyte</w>
PK C
phot ographs</w>
As sist
G lob
sk ull</w>
Fac il
kin a</w>
emerg e</w>
rhyth ms</w>
C 13</w>
oder ma</w>
Ad am
G CG
h g
14 %</w>
In tra
li bit
K is
yth ing</w>
re alized</w>
h m
fu sion,</w>
en .
Wor ld
Tub erculosis</w>
K N</w>
| |
ran ,</w>
6 23</w>
at a,</w>
pair ing</w>
dispens able</w>
in ous</w>
amorph ous</w>
MR C</w>
Hay es</w>
de pri
88 8</w>
Yo ung
te g
comp ul
Resp ond
Americ ans</w>
Ol son</w>
F am</w>
(01) 00
200 6),</w>
f air</w>
) −
every day</w>
olig omers</w>
ph ages</w>
tri ang
S ed
2 X
here ditary</w>
inf ect</w>
T I</w>
Isl and,</w>
surge ons</w>
- P
S án
year s;</w>
x anth
col ors</w>
@ k
G 2/
tho roughly</w>
Stud ent</w>
M r.</w>
sh allow</w>
10.77 17/peer
on ia,</w>
11 3.
[60 ].</w>
Differenti ation</w>
d odec
Indi a,</w>
Entom ol</w>
co ff
a vir
19 79
acet one</w>
S anti
journ als</w>
⋯ A</w>
N -0
lig ated</w>
intak es</w>
bott len
Br assi
ancestr y</w>
Fr aser</w>
cock tail</w>
fol d,</w>
sent ence</w>
Tow ards</w>
Helsin ki</w>
Al tered</w>
ter ine</w>
st ool</w>
s rep
A th
anon ymous</w>
lipid emia</w>
S 2,</w>
1 −/−</w>
g002 Figure</w>
ation ic</w>
D —H⋯
insul in
Criteri a</w>
Ch il
11. 5</w>
moi ety</w>
10- fold</w>
ph i
D—H⋯ A</w>
U rin
30 4
B N
Ba um
ter al</w>
f .
16 1/
low ered</w>
soph istic
sulf on
post- translational</w>
ab a</w>
[24 ,
1- mediated</w>
Te h
erythro cytes</w>
observ ations,</w>
BC G</w>
chem istr
prin ting</w>
B lock</w>
cy sts</w>
applic ation.</w>
[ 1
80 9
2/ 0
LT P</w>
ad y
Canad a,</w>
Ophthalm ology</w>
an tr
id ase</w>
tw elve</w>
biotin ylated</w>
u is</w>
spl enic</w>
ae q
Arn old</w>
6 13</w>
Dom in
n ow
H3K 27
counter parts</w>
neon ates</w>
(C I
L :</w>
on as</w>
Bar nes</w>
To ol
refl ex
org .</w>
deacetyl ase</w>
13 %</w>
10.1371/journal.p bio
mil l</w>
inherit ance</w>
exerc ises</w>
thyro idis
habil it
och rom
an ese</w>
6 17</w>
sn ap
kind ly</w>
anc e;</w>
Well s</w>
R oz
Pro t</w>
ammon ia</w>
2 α</w>
inva sion,</w>
t c
background .</w>
igu chi</w>
– 22</w>
ab rog
extrem ity</w>
(0. 1</w>
19 71</w>
Graph Pad</w>
eu x</w>
C o</w>
0. 1,</w>
oc ol
Q T
SIRT 1</w>
E SCs</w>
co at</w>
D oh
occasion ally</w>
insuffici ency</w>
M r</w>
az one</w>
b p,</w>
1 201
2O 3</w>
V- infected</w>
leuc ine</w>
di -
w en</w>
gen y</w>
k l
I H</w>
beg ins</w>
O ber
Rh iz
mul tim
1. 12</w>
signal s,</w>
M eier</w>
10.1016/S0140-6736 (0
Preven tive</w>
manag ers</w>
3- 7
pol lu
10.1111/j. 1600-0
Sch ult
ot ec
sh ock
H ao</w>
( 2).</w>
Cal cul
tion al,</w>
[16 ,</w>
aspir in</w>
[12 ,13
enti ties</w>
configur ations</w>
cigarett es</w>
antibod y-
e 's</w>
con crete</w>
dr ying</w>
T ao</w>
om on</w>
triplic ate.</w>
O CT</w>
4 4)</w>
18 —C
Gu il
Subsequ ent</w>
em bo
Editor :</w>
V ),</w>
mut ant,</w>
O /
Hous e
Obj ectiv
10.1371/journal.pone.00 9
gu inea</w>
(100 %)</w>
trac hom
cou ple</w>
Re habilitation</w>
G EN
W en
Rich ards</w>
C ost</w>
pro po
(D E
hyper plasia</w>
ts bur
b order
Christ oph
AM P
I d
par ath
over t</w>
weigh ting</w>
19 ].</w>
follic le</w>
AB ,</w>
cl av
alg ia</w>
appear ing</w>
ac tion,</w>
A AC
Article Biology</w>
sp ines</w>
F U
reservo ir
depos its</w>
G au
st ore</w>
virus es.</w>
Phosphor ylation</w>
Matsum oto</w>
Di strict</w>
1. 11</w>
contempor ary</w>
Na Cl
so unds</w>
expect ancy</w>
stret ching</w>
here in</w>
si s)</w>
tic .</w>
ae dic</w>
Ze iss</w>
Wall ace</w>
But ler</w>
string ent</w>
2-s2.0- 7
ter son</w>
lo u
in ae</w>
epidemi ologic</w>
ques tion
f r</w>
switch ed</w>
Ab dom
– 16</w>
11. 2</w>
Cro hn
A part</w>
f ric
toler ated</w>
@ n
CD 44</w>
stud y:</w>
Ess ential</w>
Not e:</w>
(Qi agen,</w>
surve y,</w>
negativ e,</w>
Pakist an</w>
st ocks</w>
challeng e.</w>
ut a</w>
viscos ity</w>
az i</w>
Ter min
z yg
n ci
0.0 10</w>
lox acin</w>
aliz ation:</w>
En rich
Coron ary</w>
sativ a</w>
St u
AT M</w>
mit osis</w>
loc alize</w>
exist ed</w>
K ad
OR ,</w>
sensiti zed</w>
D il
0.0 13</w>
N eck</w>
th aw
lat est</w>
Bal d
Z an
[35 ],</w>
at ur
M ong
abdom en</w>
hospit al,</w>
ly tic</w>
conn ect</w>
stret ch</w>
http://www. biomedcentral.
[4 3]</w>
N GS</w>
K ov
cap sid</w>
stir red</w>
MA C</w>
element s.</w>
5 3,</w>
evalu ation,</w>
II I.</w>
10.1016/j. y
α .</w>
.n et
os ed</w>
ast- squares</w>
P b</w>
E li
att a</w>
89 4</w>
Fail ure</w>
perturb ations</w>
tong ue</w>
Re al</w>
ER ,</w>
charg es</w>
Gl asg
lin e-
pit ch</w>
Chol ester
W /
dos e,</w>
PF S</w>
I ron</w>
- .
vect or,</w>
I MR
89 2</w>
tex ture</w>
( u
chol er
k amp</w>
6 19</w>
Met ab.</w>
measure ment.</w>
0 ),</w>
it i</w>
27 3
24 /
98 4</w>
S A)</w>
simpl ex</w>
L up
potenti al.</w>
M ish
H3K 4
GT CA
dent ate</w>
( up</w>
Be yond</w>
cru zi</w>
E H
Xi ong</w>
ure ;</w>
E q
prim ed</w>
11 %</w>
coupl es</w>
dis charged</w>
Pres ence</w>
son i</w>
Gold stein</w>
Yam aguchi</w>
10.110 3/
y ang</w>
sil ent</w>
GTP ase</w>
fer ro
elig ibility</w>
stabil ity,</w>
men .</w>
Ha us
a ar</w>
restric tions</w>
5 48</w>
lith ium</w>
For ward</w>
C19 —C
ver s,</w>
diffic ile</w>
microtub ules</w>
Col or
L atin</w>
( 60
z .</w>
0. 1
M J
thres hold
be fore,</w>
t old</w>
M. L.</w>
6 10</w>
attrac ted</w>
78 ,</w>
b li
plat eau</w>
Mor rison</w>
is lets</w>
0.000 1).</w>
arri val</w>
nom inal</w>
rec tomy</w>
Amster dam,</w>
H es
Thir d</w>
om itted</w>
NH 4
Banglad esh</w>
ch al
Ro ot</w>
48 /
all er</w>
PK C</w>
Neuro logical</w>
Ca stro</w>
( The</w>
applic ability</w>
q vist</w>
α )</w>
cent ro
plast s</w>
(Basel )
36 9
el y
C erv
be st-
l id
compl eting</w>
hum oral</w>
vect or.</w>
1.0 )</w>
24 ].</w>
a sion</w>
6 11</w>
14- 3-
Bu il
expres sion
eli um</w>
10.1371/journal.pone. 000
gre en,</w>
evol ve</w>
Ampl ification</w>
nt d.
v el</w>
o ting</w>
chick ens</w>
Lar sen</w>
N T-
sel f
NL RP
K ne
TL R</w>
enn is</w>
ar abin
O st
P ai
abor tion</w>
inter personal</w>
V eg
on ian</w>
Ne asy</w>
bur n
syn cy
righ t.</w>
uniqu ely</w>
nor ms</w>
b act
aden ovirus</w>
ha k
ation s/
Hind awi</w>
au ,</w>
grow th
1. 15</w>
Liv ing</w>
tho rough</w>
calc ification</w>
tin nit
oste osarcoma</w>
dendrit es</w>
mo use,</w>
Beth es
Numer ous</w>
Bar s</w>
sens orimotor</w>
0000 00
MP s</w>
si al
a oka</w>
nod es,</w>
dis plac
Grou p
om s</w>
end points</w>
ti ps</w>
abov e-
multi drug</w>
psych ology</w>
serum- free</w>
antigen -
(4 3.
43 ].</w>
u ting</w>
89 8</w>
SO 4</w>
C. A.</w>
last ed</w>
bud ding</w>
high- fat</w>
echocardi ography</w>
sequ entially</w>
pre- treatment</w>
IS T</w>
volum e.</w>
t t</w>
depres sion.</w>
( θ
(201 5)</w>
asp iration</w>
GA ,</w>
somat osensory</w>
in set</w>
47 7
Ch ou</w>
10.10 53
resourc es.</w>
d an
ent ero
J. E.</w>
it able</w>
Ob es</w>
45 /
[13 ,14
re act</w>
Nig eri
10.1371/journal.p ntd.
C MR</w>
2 H
intens ity,</w>
F G
E y
ograph ically</w>
strateg ies,</w>
or f
in bred</w>
Rec over
her pes
explo ited</w>
ere n</w>
an no
39 -
bri le</w>
47 8
col i,</w>
19 76
Hun t</w>
diet .</w>
double- blind,</w>
ym a</w>
hyp oglyc
confir m
( black
F ergus
AT -
17 %</w>
ward s,</w>
promo ter.</w>
comor bidities</w>
F DA</w>
prot on
R ick
e −
ver ification</w>
4 1)</w>
navig ation</w>
hapl otyp
dep olar
arc tic</w>
6 55</w>
decad es,</w>
I ON
inf ant
ar ized</w>
ro v</w>
0.0 14</w>
te am
ab ul
V arg
Pr ad
C 0
clinic opathological</w>
(− )</w>
oscill atory</w>
reason ing</w>
trac tion</w>
8 ]</w>
Dulbec co
V all
6 40</w>
symb ols</w>
character izing</w>
target s,</w>
neutr alization</w>
tr ast
res cent
long est</w>
MC I</w>
n ap
[26 ,
AG E</w>
commun ities.</w>
po d</w>
r itor
S port</w>
origin ate</w>
16 %</w>
skill ed</w>
í a-
em er</w>
Endo thelial</w>
34 4
6 31</w>
ec ker</w>
adip ocyte</w>
fic ation,</w>
fibri ls</w>
(II I)</w>
adolesc ence</w>
vari ation.</w>
thi o
[6 1].</w>
O CT
l ;</w>
ej ection</w>
ir reversible</w>
Vand er
effici ency.</w>
RN P</w>
tit anium</w>
H2 AX</w>
be st
es el</w>
( IL-
ith s</w>
S PA
urb an
di lat
fraction ation</w>
ic os
non- parametric</w>
obser ving</w>
enti ty</w>
2-s2.0- 79
sc ar</w>
10.1101/ gad
program s.</w>
clinic ian</w>
Ont ario</w>
Interven tions</w>
6 37</w>
st ers</w>
vill ages</w>
IN T</w>
e water</w>
5 ],</w>
ori o</w>
89 6</w>
– 18</w>
ye ast
fibron ectin</w>
R H
(S T
Per ry</w>
physi ologic</w>
con ference</w>
bro ok</w>
Ar ray</w>
ch ori
sal ic
carri age</w>
4 3)</w>
und ers</w>
ig nor
D PP
re ality</w>
pl oy
88 4</w>
fu zzy</w>
el ution</w>
pepti de
lay ered</w>
T ou
mmH g)</w>
attenu ate</w>
go es</w>
ag ing,</w>
activ e,</w>
Con ver
B oc
Hor iz
ox al
( 75
bev ac
set ae</w>
myocardi um</w>
us er-
Gold berg</w>
immunoprecipit ated</w>
til ity,</w>
potenti al,</w>
0.0 16</w>
Wn t/
*** p</w>
u be</w>
Toxic ology</w>
P i</w>
Y F
Europ e,</w>
predic table</w>
y lob
Br us
5 1,</w>
H N</w>
ri bo
neuro muscular</w>
1. 13</w>
Neur onal</w>
[17 ,</w>
reac tions.</w>
pl ei
refer ring</w>
D na
I Q</w>
m erely</w>
ept .</w>
no ting</w>
5 10
(N O
10.7717/peer j.
sp ic
cham bers</w>
in sensitive</w>
unc er
ab is</w>
3- 4</w>
inc h</w>
– Whitney</w>
Meth yl
men tion</w>
Con focal</w>
aff erent</w>
assi gn</w>
inhal ation</w>
cl ip
18 %</w>
Malay sia</w>
Ver lag</w>
( upper</w>
ice- cold</w>
dam aging</w>
10.1038/n comms
H 11
ac a</w>
Ku o</w>
A uro
di r
F etal</w>
Res ol
201 1.0
( total</w>
o protein</w>
hom ocyste
– 32</w>
67 /
deliver ing</w>
amin e-
sub cut
mail .
Controll ed</w>
t- test,</w>
ost atic</w>
J ud
ed t</w>
Gen otype</w>
Ros enberg</w>
L ich
spi ro
cros ses</w>
recei ves</w>
re sis
ma il</w>
1. 73</w>
y ces</w>
Bur g
Pit tsbur
si de.</w>
norm al.</w>
pl u
capac ity,</w>
i NOS</w>
re activation</w>
E-0 3</w>
Pro ject
potenti ation</w>
mg/k g,</w>
– 0.9
Oste o
Ep ilep
s ons</w>
harv esting</w>
son ic
sh ak
br achi
S can</w>
@hotmail .com
lip ase</w>
Mac ro
ad duc
(righ t)</w>
(3 ,
exceed s</w>
prepar ation.</w>
hand le</w>
R al
Proper ties</w>
us ed:</w>
survi ved</w>
uncer tain</w>
W B
PR IS
Jord an</w>
inf ectivity</w>
[ 80
remain der</w>
Pres s,</w>
li o</w>
[44 ]</w>
: 8
H SC
women ’s</w>
ok i</w>
j uris
Hut ch
grad es</w>
strateg y,</w>
6 3-
ou ts</w>
ST AT</w>
Ca P</w>
low- dose</w>
X- 100</w>
V T</w>
Ne igh
6 51</w>
examin ation.</w>
acceler ate</w>
HP V-
distur bed</w>
uz umab</w>
analge sic</w>
Re id</w>
u plo
en umer
[Ca2+ ]
Indi a.</w>
situ ated</w>
ser oposi
Progr am,</w>
ij er
Br uc
f in</w>
CT CT
T O</w>
SA M</w>
; 6</w>
synchron ous</w>
Sou theast</w>
deliver y,</w>
mem b
ion ized</w>
Differen ce</w>
10.1111/j. 13
aegyp ti</w>
investig ator</w>
herit ability</w>
[36 ],</w>
17 56
epilep tic</w>
transf ection,</w>
MI ,</w>
e 1000
disord er.</w>
– 80</w>
V AS</w>
z om
– 11</w>
p /
Tw een</w>
i v</w>
(C l
m s)</w>
log 2</w>
compromis e</w>
carb ox
f alling</w>
res veratrol</w>
Com pan
6 1
teri or</w>
non specific</w>
10.217 4/
flavon oids</w>
doc toral</w>
P. R.</w>
si ella</w>
vox els</w>
6 45</w>
Joh ns</w>
B uc
requis ite</w>
kin et
degrad ation.</w>
aliqu ots</w>
Reg istry</w>
67 7
p ill
acid s.</w>
AP EX
dens ity.</w>
(200 4)</w>
catar act</w>
quer ce
anti- apoptotic</w>
H id
mut ually</w>
ser ological</w>
mis sion
bar a</w>
Gh ana</w>
Cam ero
ca p</w>
9 ±
fraction ated</w>
Estim ating</w>
nucle us,</w>
10.4 161/
40 4
L os
L AB</w>
intra operative</w>
A ud
S o,</w>
199 5).</w>
( λ
hu a</w>
http://dx.doi.org/10. 7554/eLife.
presum ed</w>
fac tion</w>
lingu istic</w>
6 27</w>
J us
i as</w>
show n,</w>
med ul
cad mium</w>
keratin ocytes</w>
Neuro path
mes oth
ach ,</w>
Hepat ol</w>
Impro vement</w>
Ch i-square</w>
offic e</w>
Wh il
Inter fer
sourc e.</w>
10.1093/nar /
preser ve</w>
Tur key</w>
docum entation</w>
con v
,15 ].</w>
xenog rafts</w>
Mu eller</w>
ess enti
acetyl choline</w>
; 10</w>
3—C 4</w>
transmis sion.</w>
sub scale</w>
prin ted</w>
Oc curren
V ol.</w>
Di am
AP 1</w>
– 72</w>
T OR</w>
Shim izu</w>
acu ity</w>
aden o
ethan ol,</w>
Ultras ound</w>
K Cl,</w>
low- density</w>
Al lo
as ks</w>
arrhyth mi
,16 ].</w>
F air
project ,</w>
Cru z,</w>
1 a).</w>
7 :</w>
j )</w>
Vinc ent</w>
round ed</w>
opter a:</w>
Con tribution</w>
co chemical</w>
tot ally</w>
un differentiated</w>
R ain
nex t-generation</w>
S asaki</w>
R omer
multipl e-
prim ates</w>
Al bert</w>
end a</w>
si veness</w>
consum ers</w>
hyper -
Dun n</w>
year s),</w>
ure tic</w>
t- tests</w>
B ent
l ectin</w>
dropl et</w>
68 -
Loc alization</w>
achiev ement</w>
Estim ated</w>
sh ares</w>
neuro endocrine</w>
el en</w>
CD ,</w>
30 /
toxic ity.</w>
Hipp ocamp
ex chang
on to
R. M.</w>
ful l
ro ad
ri an</w>
6 B).</w>
b m
plas min
illustr ating</w>
lymph ocytic</w>
e V</w>
CN T</w>
Ma ur
Fu ji
G 3</w>
advantage ous</w>
remo ved,</w>
(P =
ure th
det erg
exerc ise,</w>
D C,</w>
– 4.
P and
sh ot
L ess</w>
27 5
ho g</w>
sal mon
Cir culating</w>
Sim ple</w>
ar ing</w>
bio availability</w>
sequenc ing,</w>
numb er.</w>
sin k</w>
mod ular</w>
surve yed</w>
,17 ].</w>
oc al
gly cin
D ak
hon ey
(c m)</w>
dec lines</w>
Develop ing</w>
Cra ig</w>
replac ing</w>
far ms</w>
P PI
F 2,</w>
mon ey</w>
W ist
S mar
il es</w>
retro grade</w>
MAT ERI
lo ,</w>
D ay
I J</w>
hybridi zed</w>
en v
Ol sen</w>
vi d</w>
import ant.</w>
e e
activ ators</w>
Hoff man</w>
fluoresc ein</w>
complic ations,</w>
C ic
6 1.</w>
gly can</w>
de stro
precur sor
Sn y
Leuk emia</w>
PG E2</w>
43 2.
fo rec
amo eb
3 2].</w>
error s.</w>
K ow
ep er</w>
ation ”</w>
Lop ez-
é ri
hair pin</w>
bu d</w>
RT ,</w>
Colum bia</w>
qu i</w>
IL- 12</w>
D. M.</w>
depri ved</w>
tr aps</w>
olec ul
At l
phosphate- buffered</w>
genotyp ic</w>
obi um</w>
3 :
1 D
sic a</w>
P. J.</w>
neuro psychological</w>
inhibi tion.</w>
op sin</w>
a e:</w>
ylob acter</w>
clust ers,</w>
bic arbon
L or
Matthe ws</w>
– 64</w>
cy tic</w>
h os
le tic</w>
addres s:</w>
6 43</w>
frag mented</w>
P 4
juris dic
Bl an
lipopolys accharide</w>
in a,</w>
capac it
synthe size</w>
Spear man</w>
ol im
idop ter
wo unds</w>
34 5
assist ance.</w>
P 0
10.1158/0008-5472.CA N-0
Per sist
Cardi ology</w>
,18 ].</w>
prophyl actic</w>
medi a,</w>
l es.</w>
Guang d
J. W.</w>
Taq Man</w>
0. 5)</w>
Mas on</w>
anxi et
M Z</w>
id s
altern atives</w>
fis sion</w>
edi tion</w>
dec ide</w>
ac ial</w>
fish es</w>
un ic
ah ,</w>
vel oci
Appro ach</w>
200 4)</w>
li vers</w>
bil lion</w>
dro ps</w>
ship .</w>
D own</w>
us cular</w>
old )</w>
et .
energ etic</w>
argum ent</w>
pain ful</w>
blast ocy
asc ending</w>
van com
multi- scan</w>
http://dx.doi.org/10.13039/ 50110000
ch er
Kle b
( Th
( University</w>
cultures ,</w>
pathophysi ological</w>
IL-1 β,</w>
olig omer
anti- human</w>
n mol/
vic inity</w>
ett es</w>
T ul
GA AA
10.10 63/
N us
Im paired</w>
cur ative</w>
Wind ows</w>
chemo therapy.</w>
2 %,</w>
controversi al</w>
Rub in</w>
con vers
( 80
complex es.</w>
enz ie</w>
leg isl
disp arities</w>
B 4</w>
plat e.</w>
N g
ym an</w>
coll ag
48 9
http://www.biomedcentral. com/
E very</w>
E BP
sub population</w>
pul p</w>
fl or
Genev a,</w>
tax onomy</w>
10.1103/ Phys
1. 14</w>
quar ter</w>
mg/d L</w>
hor seradish</w>
Pro mot
neur ite</w>
y to
wil lingness</w>
id a,</w>
tamoxif en</w>
dismut ase</w>
44 ].</w>
Biom aterials</w>
deduc ed</w>
proce ed
K hal
Bar rett</w>
T X,</w>
E +
vi l</w>
disc arded</w>
establish ed.</w>
H ome</w>
(Sigma )</w>
NF-k appaB</w>
ff e</w>
Intere sts</w>
Ar ter
( average</w>
an :</w>
Mag n</w>
ic o
hydroph ilic</w>
D ro
,19 ].</w>
gl ab
6 ±
cl ient</w>
ap ine</w>
a _
iti s.</w>
Fus arium</w>
119. 9</w>
peopl e,</w>
import ant,</w>
t ome</w>
sin us
45 9
is land
blu e,</w>
6 -0
serot on
– 70</w>
ph o
Fl em
7 37</w>
schist osom
m M,</w>
ak a,</w>
spectiv e,</w>
op sis</w>
Ser v</w>
Deci sion</w>
PK A</w>
13 ).</w>
10.1103/Phys Rev
N ai
d en,</w>
uk a</w>
pharmaco kinetic</w>
al titude</w>
me ant</w>
su stain</w>
eno ic</w>
New cast
s ,
F ag
radi ol
N ij
bre ath</w>
im an</w>
lack ed</w>
8 ±
0.0 5%</w>
sign all
hypothe sis.</w>
200 3,</w>
SMA RT</w>
LO D</w>
tin el</w>
Car roll</w>
shor test</w>
fu sion.</w>
19 —C
N CI
6 41</w>
- independent</w>
att acks</w>
Z am
Ge ometric</w>
C unn
6 2.</w>
C 14</w>
MM P</w>
N ol
well- established</w>
vol ution</w>
u tions</w>
con idi
pre- existing</w>
protein ase</w>
b uc
10.1186/s 130
ca ution</w>
back ward</w>
k it
Fin land</w>
accept ability</w>
Questionn ai
Ac tu
). 26
shorten ing</w>
Acqu isi
Trans l</w>
recogn ised</w>
Dis rup
countr y.</w>
4—C 5</w>
Bar ri
dur ations</w>
mon oc
avi er</w>
S till
Organis ms
encapsul ated</w>
E-0 5</w>
re pl
cor rhiz
know n,</w>
AR C</w>
allo geneic</w>
s )
hor se</w>
repor ts,</w>
– 74</w>
roc k</w>
seg mented</w>
N- acetyl
10.1093/bioinformatics/ b
step s.</w>
am ent
S ca
Universit ä
second ,</w>
Je ong</w>
Andre ws</w>
[6 ,7
Per ceived</w>
J ain</w>
P eptide</w>
em ber
Black well</w>
M. R.</w>
m g)</w>
V- 2</w>
D Y</w>
Al me
synchron ized</w>
6 57</w>
dexamethas one</w>
prostagland in</w>
ve sicular</w>
kin ase,</w>
eukary otes</w>
I X</w>
peri -
Tox o
plan es</w>
nov el
Princi ples</w>
pd f.</w>
3 %,</w>
in o
e at</w>
minim izing</w>
trac er</w>
(0 %)</w>
carri es</w>
DR G</w>
one ’s</w>
J ay
Anti body</w>
j k</w>
May o</w>
pollut ants</w>
O pt.</w>
(6 6.
– 90</w>
Pre viously,</w>
ar ro</w>
I on</w>
macroph ages.</w>
appropri ate.</w>
socio- demographic</w>
At ten
.0b013e 328
peroxis ome</w>
avoid ed</w>
ori e</w>
[6 2].</w>
HMG B1</w>
anch ored</w>
tum or,</w>
addres s
al –
Car bohyd
volum etric</w>
dat a).</w>
(ANOV A)</w>
[27 ,
fal se-
Strateg ies</w>
ap ar
HIV- positive</w>
j /
Tim e-
ush ing</w>
c m.</w>
Th yroid</w>
[18 ,</w>
98 %</w>
– 23</w>
6 A).</w>
10.3 109/
NE S</w>
AG ,</w>
hi ,</w>
N om
lig ament</w>
Le i</w>
37 9
g ard
97 8-
c gi
F As</w>
EGF P-
suc ro
flow ,</w>
exce eding</w>
hol es</w>
del ay
L au
1 D).</w>
phen ols</w>
H- atom</w>
Z ambi
em ,</w>
consol idation</w>
diag onal</w>
P v
10. 16
ativ es.</w>
Re ich
ch ip
Ho ech
it u
Pow ell</w>
lim bs</w>
tion ),</w>
reas ons,</w>
dis sec
biomar k
ra d</w>
B yr
S tern
to uch</w>
nor th
health :</w>
c ement</w>
direc t
( l
tp c.
rh esus</w>
pow ered</w>
amin ase</w>
inhibit ors.</w>
Op in
carcinom a:</w>
F M
dynam ics.</w>
p ie
Thor ac</w>
Vas c</w>
,20 ].</w>
P ip
gath ered</w>
K ak
Ex press</w>
orig in,</w>
p H,</w>
Penn syl
H s</w>
frequenc y.</w>
at opic</w>
Defini tion</w>
Rech erche</w>
R &D</w>
N et</w>
(198 6</w>
ation ?</w>
compa res</w>
antidepress ant</w>
78 -0
intellig ence</w>
simul ations.</w>
( 46
undet ectable</w>
in ating</w>
commun ity,</w>
b 1</w>
bron cho
Auth ors</w>
CN Ts</w>
10.1105/ tpc.
defin ite</w>
compan ies</w>
( 48
ineph rine</w>
Effec tive</w>
6 49</w>
Me ans</w>
system :</w>
member s,</w>
ad ds</w>
st ell
i —
17 57
C >
C57BL/ 6
el e
14 —H
C. J.</w>
y 's</w>
mon o-
be am
0.000 0</w>
po l</w>
simil ar,</w>
h ir
t ensor</w>
[45 ]</w>
cri bed</w>
dys plasia</w>
amylo id
13 —H
Paul o</w>
at on</w>
m as</w>
Educ ational</w>
Aster is
Ar teri
0.0 17</w>
medic ine,</w>
10.1056/NEJMo a0
Univers al</w>
55 %</w>
diseas e
secre te</w>
pa d</w>
4 40
mal es.</w>
ch ew
d es.</w>
al ty</w>
M ori
fiel d-
deteri or
diamet er,</w>
insectic ide</w>
in tran
( 24</w>
transcrip tion,</w>
int oler
MD PI</w>
osi s:</w>
double- stranded</w>
inhibi tion,</w>
T ech</w>
http://www. ncbi.nlm.nih.gov/
Irel and</w>
1 b).</w>
K no
g003 Figure</w>
cont acted</w>
w rite</w>
sh aded</w>
co inc
f m
dou b
flow .</w>
tum or.</w>
he sion</w>
single- cell</w>
2 ·
pl eg
(x ,
O H,</w>
E-0 4</w>
s api
cap it
Carval ho</w>
sme ar</w>
nor m</w>
CH O</w>
pre fer</w>
A Y</w>
10.1016 /s
per mutation</w>
Wel fare</w>
nasoph aryngeal</w>
the sis.</w>
y clin
Ac tin</w>
off ering</w>
mut ation.</w>
transp aren
(H R</w>
Ne ill</w>
pharmac y</w>
Gu an</w>
M. M.</w>
rib os
stud y;</w>
aneurys m</w>
F en
10.1023/A :10
—N 2</w>
dise ased</w>
,2 1].</w>
E q</w>
eg ,</w>
thor ac
hemat oxylin</w>
glycos yl
11 12
) –
5 2,</w>
0. 33
tax on</w>
99 )</w>
episo dic</w>
ad y</w>
66 .</w>
ex -
tra it
Toxic ol.</w>
5—C 6</w>
migr ating</w>
ib ,</w>
counter part
ifi ed.</w>
3 B
( 500</w>
pack ed</w>
crystalli zation</w>
develop s</w>
k g/
R ous
helic ase</w>
2-s2.0-77 95
hear t,</w>
7 ±
energ y,</w>
Ac cum
Mill s</w>
Col on
ti ,</w>
ma ze</w>
C od
AD P</w>
sen se,</w>
immunos orbent</w>
mi st
bar s,</w>
effectiv en
y sm
homolog ue</w>
Hi erarch
purpos es.</w>
In c</w>
6 3.</w>
mon omeric</w>
fac ed</w>
synthet ase</w>
amplit u
tradition ally</w>
d es,</w>
en ever</w>
49 9
Datas et</w>
an ase</w>
evid ence,</w>
ent eri
C- terminus</w>
photop eri
27 ,
Dou gl
l is</w>
R ).</w>
Rodrigu ez-
F j
0.9 %</w>
al- based</w>
50 5
encephal itis</w>
Camp ylobacter</w>
(4 1.
[37 ],</w>
pan -
Thor n
Fung al</w>
slid ing</w>
ir relevant</w>
negativ e.</w>
USA 3</w>
P he
(A U
sensitiv ity.</w>
? ”</w>
slo pes</w>
Optim al</w>
0.9 900</w>
weak ness</w>
shed ding</w>
An g</w>
E O</w>
or )</w>
Y T</w>
Phot o
M r
Muse um</w>
B m
(N )</w>
neurotransmit ter</w>
200 5),</w>
E uk
German y.</w>
U su
def ence</w>
0. 3%</w>
oxy toc
L ank
6 59</w>
en stein</w>
self- renewal</w>
tissu e-
tr apping</w>
S cat
NA c</w>
theore tically</w>
– 42</w>
a -</w>
enhanc ers</w>
IU /m
Met S</w>
j p</w>
deliver y.</w>
pran dial</w>
cell- cell</w>
ent s
ANOV A,</w>
l us
complex es,</w>
Pae diat
protein )</w>
T we
( 44
Organ iz
Fin land
{ document
E SI
oxygen ase-
g b-
bo ost</w>
filament ous</w>
t RNA
s y,</w>
Con sensus</w>
isol ates.</w>
rec eptive</w>
ap oration</w>
Haw ai
sc arc
Predic tors</w>
AT T
AT ,</w>
obst etric</w>
6 39</w>
en i</w>
Ab normal</w>
( top
ren s</w>
dig it
thym ic</w>
co variate</w>
S 3.</w>
period on
tryp sin
G 0
allo steric</w>
hist ologic</w>
T il
6 5.</w>
qu e,</w>
or h
act or</w>
ch olec
(A D
3 000
prolifer ator
photo receptor</w>
i es:</w>
qualit atively</w>
Hend erson</w>
accurac y,</w>
Techn ology
represent atives</w>
Nuc l</w>
limit ations,</w>
ard .</w>
.. .
ce f
ot a,</w>
f unds</w>
a ’s</w>
L 4</w>
conduc ted.</w>
ter m,</w>
bund le</w>
ic /
S H-
har mon
ac ity</w>
Co om
g ation</w>
Bot .</w>
22 %</w>
Ne utroph
M 3</w>
Pro bl
Il lin
e in
11 4.
opharmac ol</w>
lin es)</w>
righ t:</w>
attend ance</w>
Twent y</w>
o ils</w>
st ores</w>
CR T</w>
Ab original</w>
Her re
Chin es
4 000</w>
– 31</w>
dic t
3 A,</w>
Zhe jiang</w>
work flow</w>
Micro scopy</w>
K Y
pres sing</w>
enroll ment</w>
E-0 2</w>
stimul atory</w>
2 a).</w>
Cari b
é ,</w>
out growth</w>
(5 2.
lipos omes</w>
ent ricular</w>
Ah mad</w>
6 5%</w>
Martin ez-
Wh ole-
thickn ess
task s,</w>
Diab etic</w>
Meta- analysis</w>
all i</w>
C li
unigen es</w>
out -
ES C</w>
person alized</w>
Streptom yces</w>
201 5),</w>
cle ared</w>
(D M
17 48
ak h
Prote ome</w>
119. 8</w>
er ra</w>
Ne utr
FIT C-
68 .</w>
L oh
(S O
D os
K up
complain ts</w>
even ly</w>
unit s.</w>
Col orectal</w>
normal ,</w>
sing ly</w>
surge on</w>
0. 44
σ 2
MY B
everth eless</w>
0.0 18</w>
fruc tose</w>
S ap
Pro portion</w>
com positions</w>
(Sigma-Aldrich ,</w>
45 ].</w>
children 's</w>
promp ted</w>
Ep igenetic</w>
itsel f.</w>
re ti
un folded</w>
Al drich
10.10 88
contrac eptive</w>
E rik
(5 4.
techn ological</w>
Collabor ative</w>
IP )</w>
as certain</w>
L il
bron chi
ong -
cytos ine</w>
F ont
way s.</w>
—H 15
Gi ov
post- operative</w>
tun n
b os
macro scopic</w>
desi re</w>
underg oes</w>
stress ful</w>
S A,</w>
(5 3.
cogn ate</w>
w ol
odem ographic</w>
tro n</w>
T 2-
22 /
po ultry</w>
ic a,</w>
PD- L1</w>
Invent ory</w>
. 26
o c</w>
ic ity.</w>
spec ulated</w>
6 60
A SC
spectro scop
7 ]</w>
Struc t.</w>
oper atively</w>
S 1)</w>
aff in
polym eric</w>
o a</w>
ev ent.</w>
Win ter</w>
H T-
AL Y
be ar</w>
background ,</w>
vi er</w>
manifest ation</w>
[19 ,</w>
resul t.</w>
C20 —C
ash ita</w>
dyst rophy</w>
H ul
( si
sex -
pred ation</w>
K o</w>
Com plementary</w>
micro fluidic</w>
fil es.
5- HT</w>
eng aging</w>
J or
encour aging</w>
institu tion
EQ -5
d res
ad a
Z )</w>
pat ent</w>
ag ency</w>
i ens</w>
function alized</w>
Technologi es)</w>
Arm strong</w>
ha u
F RA
V -1</w>
Sp inal</w>
[ 1.
dist ances,</w>
ar te
sequ estr
disc s</w>
ser otypes</w>
Brad ley</w>
Work shop</w>
7 11</w>
r us
hist ograms</w>
good ness</w>
set tl
encoun ter</w>
Excell ence</w>
pro biotic</w>
ine- rich</w>
St en
regard ,</w>
Ch eck
2 -</w>
ligh t.</w>
insul a</w>
(5 7.
mid ine</w>
Urin ary</w>
spectrophot ometer</w>
C2 1—C
CD 45
ag e;</w>
u y
pc DNA
standard .</w>
month -old</w>
tr ying</w>
ed ?</w>
Abstr act</w>
amplic ons</w>
conn ectiv
10.1136 /j
F os
fum ig
curv e.</w>
z on
ro genic</w>
op ened</w>
lo gg
Pro mo
Q .
expect ed.</w>
I E
27 4
overl apped</w>
(25 )</w>
pri mor
AT G</w>
bab y</w>
For d</w>
– 44</w>
1- 00
direc tion,</w>
Indi genous</w>
tool s,</w>
cyt omegal
Children 's</w>
tic ally,</w>
anti- cancer</w>
Pers onal</w>
D ual</w>
friend ly</w>
(A ,
belong ed</w>
aac qW
J /
; 5</w>
ap ple</w>
ov ar</w>
se al</w>
( number</w>
Combin ation</w>
5 49
at um
TT ,</w>
v ar</w>
D j
in habit
leuk emi
Analy sis
W O
S S,</w>
26 4.7</w>
spec ify</w>
thir ds</w>
h .
e 1</w>
Tris- HCl</w>
graf ts</w>
coll ected,</w>
al a,</w>
Sha o</w>
A de
Mal ar</w>
4 b</w>
un biased</w>
Psychiat r</w>
mom ent
k ern
Phil ip
P D.</w>
Sa unders</w>
Age ing</w>
compreh ension</w>
g005 Fig</w>
( <</w>
Ah n</w>
tel omeric</w>
H 14
B eg
p <0.05</w>
M. D.</w>
Bur ns</w>
. au
: 12
concer n
13. 5</w>
13 ,
outli ers</w>
sophistic ated</w>
(C R
al- Wallis</w>
His -
resili ence</w>
tex t.</w>
Garc ía-
redund ancy</w>
effici ency,</w>
child ’s</w>
ym en
T 3
C ass
mon ot
S. E.</w>
r P
out break
Pop ul
B AS
Viet nam
neo adjuvant</w>
ext ent,</w>
Sil ver
on ics</w>
10.12 10/
thromb ocyt
residu es,</w>
studi ed,</w>
a 3</w>
( 70
X BioMed</w>
: 11
.2 %)</w>
omet rics</w>
profil es.</w>
- level</w>
ship ,</w>
(C N
19 69</w>
a ec
L ati
conjug ation</w>
0.8 )</w>
k 2</w>
gel atin
ge hog</w>
Health care
analog ues</w>
monocyto genes</w>
G V</w>
29 5
T rin
S K-
trac ts</w>
Her nandez</w>
monom ers</w>
95 -
hear t
Mo vie</w>
ard t</w>
(P F
kin son
Proced ure</w>
de e
cal ,</w>
L ot
voc al</w>
negl ected</w>
Phar m.</w>
H au
(S NP
(2 1)</w>
grate fully</w>
GT P</w>
en es</w>
4 49
Sh and
it ’s</w>
bi ology,</w>
retro spec
ser ies,</w>
[6 ,
expres ses</w>
c ationic</w>
al o</w>
/ -
recogn izing</w>
pro karyotic</w>
UK ,</w>
O liver</w>
elong ated</w>
peopl e.</w>
Ru iz</w>
rigo rous</w>
diag nose</w>
E x</w>
D up
chemo therapy,</w>
co- culture</w>
( about</w>
Har t</w>
antigen -specific</w>
(W T)</w>
p o</w>
s ort</w>
consid ers</w>
sh aking</w>
mir -
bl a
man n,</w>
IL- 1</w>
c ili
formal in</w>
om ide</w>
Institu te
w ich</w>
an il
wor st</w>
ub ert</w>
debri s</w>
/ T
ord ering</w>
sc ene</w>
) 0
in qu
46 9
[6 3].</w>
genom es,</w>
standardis ed</w>
H aj
Jap an,</w>
graph ite</w>
verb ati
high .</w>
Good man</w>
Ca MK
nan ocryst
18 F-
wild type</w>
( 3).</w>
protocol s.</w>
pro stat
Dunc an</w>
Estim ates</w>
oph er
B ris
ti gu
ag ent,</w>
righ t,</w>
microw ave</w>
j as
dis solution</w>
Vi ol
s li
95 9
Web b</w>
– 100
Intro duc
Se as
A ar
I ow
K us
di morph
h ence,</w>
k an</w>
hor ses</w>
Predic ted</w>
66 -
G ill</w>
Adap tive</w>
homeost atic</w>
relig ious</w>
metastasi s,</w>
combin atorial</w>
C X</w>
19 60
spermat ozo
tures .</w>
PI )</w>
Electr ical</w>
ri t</w>
as tig
alumin um</w>
g ently</w>
De ep</w>
er to</w>
eli an</w>
d rough
Int es
H CC
(O R
AP )</w>
bor g</w>
x x
L ith
w inter
my c</w>
NA DH</w>
gi a,</w>
W ang,</w>
inf in
S RE
V K</w>
Adol escent</w>
be ad</w>
O 2,</w>
p 53
( 2.0
ak awa</w>
Af r</w>
Li ver
Rem ote</w>
ti bia</w>
pd f
epti n</w>
Pat terson</w>
P AT
1 a,</w>
Min imum</w>
AP S</w>
positiv e.</w>
seed ling</w>
CA R</w>
ten ,</w>
st ations</w>
is che</w>
recru iting</w>
( 47
Mon tre
Kir k
IFN γ</w>
Integr ation</w>
su r</w>
P 3
in ;</w>
con vul
∑ j
Sp ont
Thor acic</w>
A e.</w>
his tidine</w>
M ayer</w>
ing en</w>
wast ewater</w>
mas ked</w>
m ock</w>
hemodi alysis</w>
g ets</w>
1 ∶
26 ].</w>
66 8
speci es-
surfact ant</w>
chemot axis</w>
D od
ost asis</w>
hierarch y</w>
con dom</w>
Lev in</w>
vari ants.</w>
( g/
μ g)</w>
(200 9).</w>
pack aging</w>
ail ing</w>
o /
[46 ]</w>
le gs</w>
uni on</w>
ER α</w>
15 00
E sc
99 -
per m</w>
end ophy
10.15 90
ell s</w>
C 16</w>
78-0 432.
5 C).</w>
36 80
anthrop ometric</w>
sar co
(5 5.
thir d-
spe aking</w>
quanti tation</w>
co incid
B 1,</w>
pat ch
id i</w>
– 41</w>
vari ation,</w>
1. 16</w>
ul ic</w>
6 53</w>
consequ ent</w>
Path ol.</w>
phenotyp es.</w>
PET/ CT</w>
Ather osclerosis</w>
bond ed</w>
wh at
Recru it
on ts</w>
carb ons</w>
Mat rig
( )</w>
O VA</w>
chromat ography
A ust</w>
period s.</w>
some one</w>
con fo
percei ve</w>
educ ation.</w>
P E-
e GFR</w>
streng then</w>
Specific ity</w>
r y-
Real- Time</w>
nit ri
clust er.</w>
il in</w>
ass i</w>
adjust ments</w>
evol ution,</w>
vari ants,</w>
Gh osh</w>
A a
Cha o</w>
(IQ R)</w>
omorph ic</w>
strateg ic</w>
12 *
strept avid
I κ
6 16</w>
uni or</w>
Phil ipp
learn ing,</w>
member ship</w>
in clin
10.1158/10 78-0432.
sc oli
TER T</w>
PI K3
sit e-
files. Data</w>
[38 ],</w>
bur s
gran ular</w>
differenc e.</w>
an ova</w>
suit ability</w>
d k
1. 17</w>
( an</w>
constric tion</w>
ev aporation</w>
ow ska</w>
obser vers</w>
1, 3-
categor y.</w>
P un
oste oblasts</w>
lin -
D AS
control ;</w>
199 2;</w>
in ev
IC A</w>
sp ore</w>
requ ested</w>
ol ith
Str ains</w>
retin oic</w>
Mem orial</w>
2. 5.</w>
ten sile</w>
6 4.</w>
(P i
K och
targ et.</w>
as cul
approach ed</w>
Bur ke</w>
c ations</w>
tun ed</w>
well- defined</w>
ambul atory</w>
an .
L ess
re ared</w>
skin ,</w>
e as
tic um</w>
cl amp
Fl ex
In formed</w>
F it
ick i</w>
A Z</w>
8 23</w>
mo id</w>
Go og
( 5-
et to</w>
in o-
L ateral</w>
(Sigma ,</w>
detail s).</w>
Bl ast
super -
M n</w>
Lt d,</w>
Gen omes</w>
. 22
am ate</w>
q ,</w>
tra its.</w>
od om
e y-
TUNE L</w>
GT GT
(A mer
P aw
fac e-to-
sup posed</w>
N em
r um</w>
cal cin
S ie
pl ain</w>
Ex clusion</w>
far mers</w>
S emi
effici encies</w>
( β</w>
eli ac</w>
streng th,</w>
men tion
vari ances</w>
clean ing</w>
mo ves</w>
Vir gin
Joh ann
6 46</w>
glutam at
innov ation</w>
2. 5%</w>
is i</w>
GA AG
Pr as
99 ,</w>
b auer</w>
ques tions.</w>
Johan sson</w>
tures ,</w>
Whit e
T 2D</w>
2 b).</w>
symb ol</w>
Carolin a</w>
E .,</w>
2 1—C
apoli poprotein</w>
q -
species -specific</w>
normal ity</w>
D CS</w>
ds RNA</w>
caffe ine</w>
transcrip tion.</w>
10. 1</w>
le in</w>
b s
Polym erase</w>
S 5).</w>
(Mil lipo
NAFL D</w>
ur nal</w>
so y</w>
mo de.</w>
ey er</w>
B V
D all
0.0 1),</w>
categ ories,</w>
97 ,</w>
Jen kins</w>
year -
en rol
Wo ol
plac e.</w>
Mann –Whitney</w>
L IS
D ose</w>
orth olog</w>
(p <0.00
promo ter,</w>
combin es</w>
am yl
T CR
bil ayer</w>
M all
adipos ity</w>
1 100</w>
increas es,</w>
drin k</w>
memor y.</w>
K ane
Op en
intrigu ing</w>
I AI
2007 .0
co res</w>
lob es</w>
88 ,</w>
view ;</w>
inter net</w>
daugh ter</w>
int on</w>
w er
vers atile</w>
self- efficacy</w>
oli ve</w>
k g)</w>
X ML</w>
L −1</w>
straight forward</w>
lex ical</w>
U P</w>
stabil ity.</w>
Tre at</w>
– 34</w>
veter inary</w>
Acquisi tion</w>
*** P</w>
ijer ph
pr é
transpor t,</w>
enzym es.</w>
Mo z
ha i</w>
MH z,</w>
incub ating</w>
O s</w>
antenn a</w>
Ontari o,</w>
St res
Ros a</w>
[28 ,
IR S</w>
im er</w>
St able</w>
summar ize</w>
4- 00
mono therapy</w>
ob enz
n aph
inhal ed</w>
along side</w>
Chrom atin</w>
trabec ular</w>
initi es</w>
ol us</w>
7 27</w>
incom e,</w>
cle ft</w>
envel op
E ver
bot t</w>
trac ing</w>
B res
glomer ul
worl d,</w>
ei l</w>
pair s.</w>
ad hy
ae ti
Bu ff
ot rex
G ó
46 ].</w>
shap e,</w>
interval ,</w>
Buil ding</w>
st rial</w>
A mar
r ater</w>
phospholip ase</w>
initi atives</w>
ind ole</w>
10 th</w>
develop ed.</w>
ensu res</w>
k Hz</w>
facil itation</w>
sy .</w>
6 12</w>
CT L</w>
Q 8
ner -
he ads</w>
20 —C
Em ploy
Japan .</w>
(C am
public ation.</w>
( based</w>
phy s
k at</w>
– 54</w>
az awa</w>
1 H-
Flor ida</w>
Neurosur g</w>
res ected</w>
ho ods</w>
har bor</w>
as ci
research :</w>
rab bit
ax illary</w>
– S
solv ents</w>
o therap
jejun i</w>
phosphoryl ation,</w>
reac tions,</w>
vig orous</w>
proliferator -activated</w>
par adox
el is</w>
N ile</w>
sign at
z in</w>
Path og</w>
dis cover</w>
Rus sian</w>
97 )</w>
Doc um
necess ity</w>
con vinc
F GF</w>
@ med.
particl es.</w>
0.0 21</w>
- wise</w>
weigh t-
enam el</w>
analy sis
(C ol
U biqu
artem isin
inter ­
diseas e;</w>
28 ,
15 ).</w>
leth ality</w>
strength ening</w>
p m
E ff
d oxy
B if
mee tings</w>
prot otype</w>
10.1111/j. 146
c ar</w>
(19 7
sou th
mu sical</w>
Sch we
ex ud
co bal
10.1186/ gb-
C ov
B asi
S100 A
ass a</w>
Fish er's</w>
K F
I V,</w>
HO X
14 ).</w>
ipter a:</w>
Z r
triglycer ides</w>
ind ol
embry os.</w>
Obj ective</w>
sel ected.</w>
Sc and
plas ms</w>
Dist ance</w>
numb er:</w>
V J</w>
smar t
fic ation.</w>
Nil sson</w>
dis abl
organis ation</w>
aff ord</w>
ov sky</w>
al t
yn n</w>
manif est</w>
h ub
FL AG</w>
1. 18</w>
con tig</w>
11. 1</w>
chron ically</w>
7 15</w>
C 15</w>
Morph ological</w>
d ar</w>
G RP
mul tin
orig in.</w>
experi ence.</w>
– 26</w>
an s
Anti oxidant</w>
2 1%</w>
metagen omic</w>
end urance</w>
high- dose</w>
0.0 19</w>
gen sen</w>
ve ins</w>
4 Table</w>
Stand ardi
B es
pa w</w>
200 4),</w>
Sp an
Le ica</w>
occur .</w>
10 ;</w>
hall mark</w>
food ,</w>
[ M
Ph .
Combin ing</w>
ro ds</w>
un controlled</w>
A 0
meth oxy
bi of
channel s,</w>
War ren</w>
MA R
- 3.
condens ation</w>
ourn e</w>
but ,</w>
tr uly</w>
GF AP</w>
se )</w>
[20 ,</w>
( 55
ush ed</w>
surfac e-
pre n
m og
AN C</w>
I sup
WRK Y
II :</w>
comor bid</w>
1 B,</w>
Ber ry</w>
1 Δ</w>
G2/ M</w>
Ad ults</w>
ch air</w>
i /
V E
tic s:</w>
Comp any</w>
mening itis</w>
eutic als</w>
L S)</w>
pow er,</w>
Eb ola</w>
F .,</w>
29 /
tr ade</w>
T Y</w>
purpos es,</w>
μ M),</w>
de grade</w>
su ture</w>
inflamm asome</w>
B org
10.10 42/
OR s</w>
0. 1)</w>
tra its,</w>
H ung</w>
bre eds</w>
HCT 116</w>
(h )</w>
interpret ation,</w>
( 22)</w>
screen ing,</w>
acc ept</w>
ferenc e,</w>
administr ation,</w>
AL DH
ent ally</w>
preval ence,</w>
graph y</w>
rolog y,</w>
th at
syring e</w>
reas ons.</w>
um p</w>
ph r
2 D).</w>
TH P-1</w>
transl ate</w>
L ing</w>
( 16</w>
Min ist
ca vi
or in</w>
: 4
2) /
gly ca
Editor University</w>
ng/m l)</w>
as king</w>
Vir us
18 /
2- 1</w>
Gly co
ology /
Sny der</w>
Li k
Fac ult
archae al</w>
German y),</w>
ap ati
X RD</w>
Plas mid</w>
logarith mic</w>
dimer ic</w>
sec ure</w>
Re active</w>
L ept
Chem istry
adsor bed</w>
86 7
border line</w>
B ao</w>
im i</w>
genotyp es.</w>
go v</w>
T at</w>
Z ar
continu um</w>
hom o
equ iv
E in
har b
GS K3
couns elling</w>
complement ed</w>
environ ments,</w>
N ext</w>
Ass emb
fe brile</w>
ni g</w>
– 17</w>
Brazil ,</w>
mar king</w>
Mel bour
AC M</w>
stres sors</w>
sem in
form ations</w>
Kleb siella</w>
di dn
cochle ar</w>
high- grade</w>
d NT
D h
fail s</w>
epit op
55 8
dist ance,</w>
substrat e,</w>
78 /
leader ship</w>
he ur
Sch re
PAR P</w>
N os
clo ud</w>
middle- aged</w>
c e:</w>
10.1016/S0 30
In n
ren sic</w>
B IO
R e-
GA G</w>
Li b
1—C 2</w>
infer tility</w>
duplic ations</w>
Hemat ol</w>
[6 4].</w>
9 25
casc ad
refer r
H 16
4 34
larg e-
car d
man ’s</w>
(S p
ti r</w>
J in
Car b
55 7
19 50
2 190
10.1038/n bt
for d
H U</w>
ech an
Ab solute</w>
bl er</w>
retin opathy</w>
86 8
Stan ford</w>
sub scales</w>
ok en</w>
asp ec
th am,</w>
(C o
f ever,</w>
altern ating</w>
Lang e</w>
immuno assay</w>
detox ification</w>
can opy</w>
o com
ogen s</w>
C es
x ic</w>
judg ment</w>
er s;</w>
( group</w>
W ik
95% CI</w>
pro vi
ex ome</w>
t n
J acqu
- fold</w>
particip ates</w>
96 ,</w>
opath y,</w>
motiv ational</w>
glycoly tic</w>
erad ication</w>
Mi x
aden ine</w>
3 D-
C _
– 35</w>
. 14
TN M</w>
Tr k
omet er.</w>
or ical</w>
co w
Inter view</w>
unc ou
smo ker</w>
embol ism</w>
doc et
U/m l</w>
res orption</w>
Ros en</w>
no id</w>
var ic
Du an</w>
c ast</w>
Biochim .</w>
CH 2
n id
NA ,</w>
Web ster</w>
μg/m L)</w>
AR ,</w>
oste oblast</w>
protein s:</w>
unknow n,</w>
hydroph ob
Sil ver</w>
si er</w>
Microbi ology,</w>
S ect</w>
pl ayer</w>
.0 ,</w>
I ma
continu ity</w>
M. -
Le af</w>
Re agent</w>
Al t
.201 5
abin oid</w>
is other
addres ses</w>
HDL- C</w>
m am
intens ity.</w>
H ak
0.0 23</w>
trou t</w>
carcinom a,</w>
Stim ulation</w>
work place</w>
10.1074/jbc. 27
Incre ase</w>
locomo tion</w>
collap se</w>
L ine</w>
[47 ]</w>
mean .</w>
inter molecular</w>
d welling</w>
): 10
pip el
Hetero gene
peptid es,</w>
loc ked</w>
- in</w>
N ),</w>
Fe w</w>
en berger</w>
CR EB</w>
chloro form</w>
A PC
119. 7</w>
aliz ation.</w>
L ima</w>
sub cortical</w>
k u
g os
gau ge</w>
bi ologic</w>
G :</w>
ing ing</w>
F- actin</w>
qu it</w>
ac yl</w>
T AB
method ologies</w>
c ages</w>
2007 .</w>
omet ers</w>
invol ved.</w>
T f
3 -</w>
er ),</w>
con tigu
Cy clo
H ann
az i
R S,</w>
h m</w>
D ud
( where</w>
ther ing</w>
F 6</w>
Bra un</w>
Behavi our
a ”</w>
K 3</w>
Wolbachi a</w>
— the</w>
(5 8.
speci ally</w>
ij n</w>
C S-
M ell
77 ,</w>
4 %,</w>
cros stalk</w>
Tog ether</w>
D ;</w>
profil e.</w>
esthe tic</w>
Ha pl
10.1063/ 1.
1. 20</w>
incub ator</w>
t ent
profil e,</w>
di amin
Align ment</w>
287 5-
Indu strial</w>
w ang
im age,</w>
h u</w>
S inger</w>
F I</w>
Cogni tion</w>
fat ,</w>
flavon oid</w>
var .</w>
l ec
Arc tic</w>
ing a</w>
I de
Inc ,</w>
T X</w>
dis clos
H a</w>
min i-
consci ousness</w>
89 ,</w>
12 2.</w>
day -old</w>
gene sis.</w>
al ist</w>
@163. com</w>
pestic ide</w>
57 8
1 X
O G</w>
J ong</w>
hypothalam us</w>
T RE
assi e</w>
MALD I-
CD S</w>
pure ly</w>
heterozyg osity</w>
Simil arly</w>
co al
Grap h</w>
th en
cal ves</w>
y ch
lo v
Physi cs,</w>
monol ayers</w>
neigh bor</w>
Bri ef</w>
graph ic</w>
Ab cam
pup s</w>
H :</w>
(x )</w>
1. 19</w>
sp ond
d 1</w>
protein- coupled</w>
76 ,</w>
6 22</w>
1* 1</w>
diagnos tics</w>
inequ ality</w>
pl ed</w>
C 28
allerg en</w>
instruc tion</w>
T 7</w>
scal es.</w>
n ut
auto antibodies</w>
um /
1 Δ
c 1</w>
be at</w>
ro lim
ocy stis</w>
Neurolog y,</w>
(5 6.
T u</w>
pan el,</w>
bench mark</w>
C v
9 29</w>
Neurobi ol.</w>
spong e</w>
M. E.</w>
G el</w>
Pol and</w>
Shor t-
G >
index .</w>
MD R</w>
7 25</w>
19 68</w>
14. 5</w>
an o,</w>
− x+
acet ylated</w>
T z
fol ds</w>
res erve</w>
cat t
atten tion,</w>
ag ent.</w>
dem yel
Pres ent
patient s)</w>
diabet es:</w>
re flux</w>
electr on-
P2 X
zero .</w>
tun nel</w>
Fuj ita</w>
Sim on
[39 ],</w>
im ide</w>
enter ica</w>
So dium</w>
post- transcriptional</w>
SE )</w>
oc er
mer cap
chem istry,</w>
Micros oft</w>
pul s
immer sion</w>
cerebro vascular</w>
0.0 24</w>
ni e</w>
P ).</w>
MATERI ALS</w>
str ing</w>
ic ol
dig it</w>
200 2,</w>
aa aa
{ \
[ cited</w>
Gastro intestinal</w>
dis si
Recover y</w>
cyclo hex
N ative</w>
an atomic</w>
A gre
(200 3)</w>
A stro
( An
cycl es.</w>
al ign</w>
8 50</w>
c /
Luc iferase</w>
bi as
ker atin</w>
con i</w>
al t</w>
4 37
e ast</w>
Tok yo</w>
zo on
detect ed,</w>
c DNAs</w>
ment ary</w>
Com peti
Cor tical</w>
ferenc e:</w>
(C I)</w>
previ ously
at roph
CS )</w>
ethnic ity,</w>
IO P</w>
(198 5</w>
spl itting</w>
30 °C</w>
. 6
T rap
10. 7554/eLife.0
16 87
(Invitrogen ).</w>
h il
aer ob
obtain ed,</w>
load ,</w>
C 27
av i</w>
(http://creativecommons.org/licenses/by/3.0 /
[2 1,</w>
Pl anning</w>
Mo un
Epidemi ological</w>
c rest</w>
ac. uk
c uc
habit at
CD4 +CD
de t</w>
member s.</w>
asc ent</w>
elect romagnetic</w>
BM P</w>
.201 6
posi tions.</w>
CI F</w>
47 9
ed ness</w>
agg ression</w>
contr ary</w>
0.0 22</w>
-Al drich</w>
dis advant
O vari
4 12
i ri
10.1002/ art
HB s
5 4,</w>
RP 1</w>
69 .</w>
Nor way
ather ,</w>
shown ),</w>
TRA IL</w>
oc in</w>
Gr and</w>
unit .</w>
reason ably</w>
Recruit ment</w>
ol d.</w>
membran es.</w>
10.1099 /
Assum ing</w>
B en-
c ilia</w>
1. 21</w>
(A -
CA ),</w>
\usepackage{am s
shown )</w>
; 11</w>
18 :
97 %</w>
Li ,</w>
urac il</w>
Determin ants</w>
1000 ,</w>
sept al</w>
microtub ul
re model
Frank lin</w>
channel s.</w>
opin ions</w>
streptom y
distor tion</w>
gl ass
– 1</w>
fici ency</w>
S. L.</w>
F old</w>
infec ting</w>
S au
( Me
Optim ization</w>
Rah man</w>
deli ber
L er
termin als</w>
7 B</w>
spac er</w>
K s</w>
shap ing</w>
bre ed</w>
brain stem</w>
Ram os</w>
non invasive</w>
7 90
calci um-
– 52</w>
behaviour .</w>
sion s:</w>
plasmin ogen</w>
. cn
o j
epider mis</w>
pub med
bor ,</w>
Alme ida</w>
k e,</w>
[3 1,
7 10</w>
co st,</w>
as tically</w>
Har vey</w>
U pp
tub ules</w>
7 13</w>
mol bev
Sch l
1: :
illustr ation</w>
S ich
12. 0</w>
( vi
Concentr ation</w>
Ex cel</w>
ant )</w>
air ways</w>
MH z</w>
Elli ott</w>
Del etion</w>
per iv
counter stained</w>
(M ar
ran o</w>
eg awa</w>
comp iled</w>
Signific antly</w>
H and</w>
p ric
us a</w>
long- range</w>
7 th</w>
w ine</w>
ol arization</w>
constitu ent</w>
Barcel ona,</w>
( z
hyper trophic</w>
categori es:</w>
k s.</w>
manufact uring</w>
EM -
( day</w>
p inn
– 84</w>
(XLS X)</w>
ti les</w>
Tr an</w>
,24 ].</w>
(G O
( 49.
M ild</w>
(C ell</w>
Reson ance</w>
K rist
learn ing.</w>
EST s</w>
l er,</w>
' .</w>
Embr y
termin ated</w>
AC ,</w>
−z +
—H 16
Chi u</w>
G end
AT G
T ib
N es
ak u</w>
m é
week s)</w>
ri m</w>
disrup ts</w>
Abd ul
Character istic</w>
op s</w>
datas ets,</w>
b ad
act ors</w>
dyst roph
divi sions</w>
margin ally</w>
1- dependent</w>
biom echanical</w>
us ),</w>
analy sing</w>
rot ational</w>
cin .</w>
Expl oring</w>
37 8-
cell- mediated</w>
mic ro</w>
R in
spac ed</w>
T AR
20 45
( solid</w>
SE ,</w>
modific ations.</w>
micro RNA-
synchron y</w>
Belgi um</w>
U tili
Biom ed.</w>
Q 1</w>
transcrip tionally</w>
ocataly tic</w>
RT )</w>
cho ic
neuro science</w>
galacto sidase</w>
im mort
tin ent</w>
K P
tiv e-
os ystem</w>
K end
Ch ag
mess enger</w>
4 30
® ,</w>
gri p</w>
n ar</w>
har monic</w>
separ ating</w>
C —C
– 33</w>
– 51</w>
ris k-
a Ga
sk i
kg/m 2</w>
Pro j
Ga g</w>
ü n
const antly</w>
chim er
Chi ang</w>
o o</w>
S A-
inj ecting</w>
val v
Mob ile</w>
is otype</w>
e ,
Schul z</w>
Pere z-
ar tic
quadr atic</w>
Per in
anch or</w>
Autom ated</w>
ultras onic</w>
67 8
ar s,</w>
aliz ations</w>
CA R
anisotrop y</w>
v om
pen et
Dep ending</w>
ass en</w>
24 58
2- 00
hyperglyc emia</w>
threshol d.</w>
Oxy gen</w>
im per
Pro motion</w>
an en</w>
st ock
Micro RNA</w>
s pro
allo y</w>
proto zo
nit rite</w>
erythemat osus</w>
demograph ics</w>
CO G</w>
su ite</w>
kidne y,</w>
equ ilibri
reinforc ement</w>
ELIS A.</w>
10.1186/1471- 2458-
ON ,</w>
0.9 )</w>
chemil uminescence</w>
gh relin</w>
TLR 2</w>
techn ology,</w>
imprin ted</w>
ic ide</w>
( 88
ag ing.</w>
—H ···
80 .</w>
perfect ly</w>
capac ities</w>
Gen .</w>
Epidemi ology,</w>
op posing</w>
compar atively</w>
pancre atitis</w>
remo val
19 /
sub clinical</w>
er g</w>
copi es/
HR P</w>
Gonzal ez-
unc h</w>
7 51</w>
7 19</w>
efficac y,</w>
Mammal ian</w>
20 56
K ik
predat or</w>
co don
2. 00
s ular</w>
n. d.</w>
p el</w>
Bh attach
surve ill
psych osis</w>
6 )
specim ens.</w>
et ter</w>
Ad heren
LPS- induced</w>
together .</w>
flu id
Mo on</w>
12 ),</w>
4 36
compens ated</w>
Hsi eh</w>
Al most</w>
prospec tively</w>
K aro
am a,</w>
review ing</w>
illness es</w>
Inter pre
98 )</w>
Tod ay</w>
L aser</w>
spot ted</w>
M P-
qual ified</w>
4 This</w>
scre ens</w>
C W
ChIP- seq</w>
14 ,
classifi ers</w>
care er</w>
M ali
permeabil ized</w>
opre valence</w>
fut ure,</w>
nat ure,</w>
res emble</w>
Activ ated</w>
47 ].</w>
vag in
ri ed</w>
6 3,</w>
A. A.</w>
agen ic</w>
accommod ate</w>
Sh annon</w>
5 b</w>
Ch ir
dynam ics,</w>
Shap iro</w>
Oce an
Anth rop
elimin ating</w>
micro plate</w>
ana emia</w>
7 21</w>
23 %</w>
carbohyd rates</w>
p edic
ij ms
M Z
m l.</w>
ity /
disord ers:</w>
Bethes da,</w>
1. 23</w>
prepar ing</w>
ures :</w>
.0 2</w>
secre ting</w>
Heidel berg,</w>
recogn izes</w>
P ater
r )</w>
agg ed</w>
Liter ature</w>
Rodrig ues</w>
O ak
mac aque</w>
nois e.</w>
to ur
1 R
Immun ology,</w>
10.1128/ IAI
acet yl-
V I.
59 8
Teh ran,</w>
ill ness,</w>
ri st</w>
waveleng ths</w>
ses sion.</w>
0.0 26</w>
opportun istic</w>
US ,</w>
caregi ver</w>
classific ation.</w>
isol ates,</w>
T ).</w>
7 17</w>
ophil a</w>
[6 5].</w>
(rang e)</w>
t ner</w>
ques tion,</w>
Whe eler</w>
b at</w>
pestic ides</w>
co x
oc ellul
C ode</w>
d /
B eng
sex es</w>
criteri a:</w>
bloc kers</w>
Hum an
Nan op
immunob lot</w>
Mid d
Li ber
lnc RNA</w>
erv ation</w>
ev ic</w>
0.0 28</w>
simul ations,</w>
Cog n</w>
K amp
D er</w>
intr au
Bar ker</w>
17 45
ag encies</w>
( 49
thermod ynamic</w>
qu ick</w>
GO: 000
4. 8
occup ation</w>
ell i
sol id-
- A
paren ting</w>
stom atal</w>
arthro plasty</w>
10.1007/ 978-
atten tion.</w>
Ras mus
glu con
Su peri
reduc tas
cryp tic</w>
mechanis m
H 15
Pro fil
gel .</w>
compon ent,</w>
PC 3</w>
bi ophysical</w>
K ath
μ mol</w>
restric t</w>
Spont aneous</w>
cost s.</w>
Fin anc
Engl and
log 10</w>
60 °C</w>
resol ution.</w>
item s,</w>
propi dium</w>
TA G</w>
Evalu ating</w>
squ are
B PA</w>
6 56</w>
; 4</w>
O f
V D</w>
war ran
tre e.</w>
i ve</w>
6 58</w>
Ad am</w>
67 %</w>
datab ases.</w>
evolution arily</w>
0.0 35</w>
titr ation</w>
ta p</w>
V on</w>
is m.</w>
ultra violet</w>
C ec
Dru g
id en</w>
“ The</w>
encomp assing</w>
Nutri tional</w>
glycos ylated</w>
enzyme ,</w>
PA P</w>
SHELX L
J ang</w>
( clone</w>
Qu antum</w>
% ]</w>
syno vi
er s'</w>
CL US
ch lamy
0.0 27</w>
U K.</w>
7 23</w>
therap ies.</w>
sl ud
[ Internet
– 36</w>
malari al</w>
Frac tional</w>
dec arbox
ari d</w>
M aking</w>
H V</w>
ascor bic</w>
For m
face-to- face</w>
axis )</w>
migr ated</w>
M BP
an son</w>
Del ta</w>
( top</w>
0.0 32</w>
(M olecular</w>
MA P
12 0.1</w>
em ens</w>
extrac tion,</w>
ass er
Shar p</w>
th is.</w>
itsel f,</w>
A udi
4 48
ass o</w>
PD -1</w>
3. 4.</w>
replic ation.</w>
ro v
C22 —C
1 =
Schult z</w>
Pres sure</w>
modul ators</w>
l un
omyel itis</w>
log- rank</w>
sc rat
18. 5</w>
– 48</w>
recept or.</w>
te eth
are n</w>
Hum ph
colon y-
lip id-
li ver.</w>
cub ic</w>
@163. com
(I L
5. 8
leav es,</w>
D oy
Simult aneous</w>
loc ations.</w>
ch in</w>
am eric
well- be
Con nell</w>
Resour c
carbon yl</w>
meas urable</w>
[48 ]</w>
Syn thetic</w>
rein forced</w>
N ick
primi tive</w>
g004 Figure</w>
Wist ar</w>
( lane</w>
6 14</w>
newbor ns</w>
F AD
10.1371/journal.ppat .100
Hep atic</w>
transmis sion,</w>
7 1
E pi
coun t
10.1128/ MC
Man u
I g</w>
PC Rs</w>
Foc us</w>
UN IT
A ro
Å .</w>
). Figure</w>
simpl e,</w>
ó g
wean ing</w>
N 4</w>
tre ad
mCher ry</w>
M ec
cost s,</w>
5 25
mon ophy
polys accharides</w>
hydro gel</w>
bi oge
b :</w>
O tol
om i</w>
C 21
res er
gam es</w>
de fl
Jiang su</w>
9 86
1. 22</w>
Engl .</w>
– 55</w>
b q
Ac cession</w>
qa aiab
17 18
at las</w>
– 92</w>
replic ation,</w>
@ 126.
10.10 55/
(C F
immuno reactive</w>
c- Myc</w>
GS K-
Contro l
branch ed</w>
se a
classific ation,</w>
10.1055/ s-
79 ,</w>
amid e,</w>
compa red.</w>
bac ks</w>
an eu
(P E
initi ative</w>
B all</w>
O 5
Ak t
3- phosphate</w>
7 55</w>
G est
– 1.0
Abdom inal</w>
insp ired</w>
99 9
E stro
i x
A 5</w>
Bec k
11 ),</w>
retrospec tively</w>
subcut aneously</w>
manuscript ;</w>
N 4
un necessary</w>
Lond on:</w>
pepti de,</w>
– 62</w>
Se att
degrad ation,</w>
Belgi um
inform ation;</w>
cross- validation</w>
Bern ard</w>
Ch ou
analog s</w>
7 47</w>
Be ing</w>
seaw ater</w>
L ec
Ex tern
nemat odes</w>
issu es,</w>
cl ath
bio sis</w>
24- well</w>
S my
Ul tra
Y .,</w>
(bot tom
Chlamy dia</w>
Nor m
subtrac ted</w>
(Bru ker,</w>
prote olysis</w>
model :</w>
g ;</w>
manufacture r</w>
Par asi
10.1016/S00 92-8674
78 .</w>
0 2
ell ites</w>
Cholester ol</w>
Nic o
[29 ,
compet e</w>
special ists</w>
24 %</w>
LT R</w>
V ig
6 44</w>
7 35</w>
fol d)</w>
ic i</w>
Organis ation</w>
om e
vap or</w>
a, b).</w>
Lipo fect
Arti ficial</w>
I to
Geriat r</w>
u b</w>
energ y-
thalam us</w>
[40 ],</w>
r uc
mammal s,</w>
in consist
e uc
PU FA</w>
( defined</w>
bio tin</w>
h ill</w>
10.12 10
3 );</w>
GG CT
dil ated</w>
ju ice</w>
D M,</w>
s ain</w>
Transi ent</w>
sc in
issu es.</w>
ad os</w>
blood .</w>
Endoc rine</w>
,26 ].</w>
Mod elling</w>
G Y</w>
- 9</w>
S ag
L x
pro- apoptotic</w>
Trans genic</w>
out line</w>
break ing</w>
air d</w>
ha v
Phen otypic</w>
aid ed</w>
0.0 31</w>
intr onic</w>
Pharmac y,</w>
pro static</w>
3 a).</w>
al ),</w>
Griff in</w>
sugg estion</w>
ord er.</w>
ot o,</w>
aberr ations</w>
co ast</w>
− ,</w>
199 1;</w>
w itz</w>
tiv ity,</w>
prepar ation,</w>
Sup pression</w>
Rel at</w>
ace ae,</w>
Sur g.</w>
bi variate</w>
° C).</w>
index es</w>
SC I</w>
studi es
Ste phen
compu ter-
è s</w>
Massachuset ts</w>
rot ating</w>
P X
4 27
ml −1</w>
9 p
pros thetic</w>
al do</w>
Xi ang</w>
H ence</w>
an ol
). 12
D ensity</w>
d um
Dou ble</w>
CB 1</w>
6 38</w>
Hu a</w>
+ +
fol d-
ec z
William son</w>
Daw son</w>
conver gent</w>
Y K</w>
measure ment,</w>
communic ate</w>
Coun ty</w>
owner ship</w>
immun ology</w>
om ic
impl ied</w>
Li qu
ot actic</w>
ath ers</w>
ac s</w>
modul ator</w>
mes enteric</w>
B AL</w>
20 ).</w>
hard ly</w>
H im
baum anni
opo rous</w>
der m
F e-
scram bled</w>
cal modul
computer ized</w>
N- terminus</w>
overl ap
0.9 9
). 11
V p
t led</w>
oder mal</w>
ech .</w>
H ey
tool s.</w>
( 4).</w>
ro le.</w>
experiment s;</w>
manip ulated</w>
N HE
dissem inated</w>
catal ase</w>
to oth
plas tid</w>
eIF 4
compos it
V V</w>
inform atic</w>
Wil kinson</w>
Re tin
is otrop
Compl ex
6 18</w>
low- income</w>
Assemb ly</w>
a *
Relationsh ips</w>
preser ving</w>
homolog ues</w>
but ter
η 2</w>
an ag
Sch mid</w>
40 5
resembl es</w>
1– 1.
( 86
000 4</w>
Vog el</w>
em aker</w>
H SV
2, 3-
fac ulty</w>
concor d
(0 ,
element al</w>
intro g
ch est
G o</w>
( 23)</w>
th a</w>
4 24
[22 ,</w>
blot ting.</w>
il ty</w>
preced ed</w>
e tine</w>
[ 2-
Fin nish</w>
Jan sen</w>
.ac.uk /
ow icz</w>
mechan ics</w>
ann u
Col or</w>
R é
Communic ations</w>
2-s2.0- 337
extrac tion.</w>
(C ,</w>
c is</w>
pharmaco kinetics</w>
ul o
tr apped</w>
ple 's</w>
K M
Er n
Emo tional</w>
AM D</w>
nitro cellulose</w>
T ap
12 2.
M y</w>
P 1,</w>
Gom ez</w>
Ar rows</w>
om o</w>
Cam eron</w>
9 28
– 45</w>
recap it
p 38
Gram- positive</w>
AD C</w>
selen ium</w>
yc lo
mut ant.</w>
an ore
L O</w>
hol deri
Put ative</w>
immun ogenicity</w>
4 35
pro tr
estim ates.</w>
per ,</w>
L und</w>
– 61</w>
Garc ía</w>
small- cell</w>
phosphatidylin ositol</w>
cath epsin</w>
en sis,</w>
multipl ied</w>
anth ropo
vo ice</w>
[ 87
glut ar
Ca val
regi ster</w>
H2 O,</w>
ell ing,</w>
bar :</w>
S 0
ris h</w>
ff i
Col eman</w>
(D MS
st ack
constitu tion</w>
(3 ),</w>
em e</w>
K es
ity ).</w>
bl add
6 26</w>
(F D
or o</w>
er tal</w>
L and</w>
10. 2</w>
w and
es c</w>
E AE</w>
she ath</w>
ferri tin</w>
reac ted</w>
ly sin
hydrox ylase</w>
cardi a</w>
K la
} ,</w>
Pharmac ological</w>
pre pub</w>
residu als</w>
function :</w>
educ ated</w>
gent am
genom e
dec on
10.1053 /j.
uncertain ties</w>
Opin ion</w>
pyrid ine</w>
PE G-
p y</w>
so di
– 63</w>
conjug ates</w>
0.0 20</w>
Ory za</w>
al ine</w>
mus h
ocy te-
P rat
present ations</w>
X ing</w>
related ness</w>
isot opic</w>
else where
check list</w>
n ow,</w>
Whil st</w>
ti tu
aut ocor
incen tives</w>
I ’
( 56
x eno
Y =
Gen otyping</w>
Fergus on</w>
1. 27</w>
Sc anning</w>
Typ ical</w>
[3 2,
Reli ability</w>
Ange w.</w>
Krusk al-Wallis</w>
CF U</w>
In g
Alvare z</w>
Cycl in</w>
factor s
exp iratory</w>
ophthal m
produc t
Suc cess
Cur tis</w>
My ocardial</w>
Po int</w>
ev ent,</w>
S S)</w>
Sof t</w>
Nanj ing</w>
mechan ically</w>
sent ences</w>
g00 7
Inv asive</w>
- and-
al s:</w>
coff ee</w>
pa i
re )</w>
inst ant
µg/m l</w>
7 33</w>
La ur
d ying</w>
52 /j
age- matched</w>
Acc eler
eal ing</w>
un common</w>
herbi v
PC )</w>
Mal ign
G ru
Y F</w>
Lou is</w>
2 c</w>
( Di
thrombo tic</w>
Isol ated</w>
8 96
resp ect
bi ology.</w>
(Roch e</w>
Targ ets</w>
− 4.
} {
6 42</w>
ur ,</w>
as ynchron
H ex
ol ia</w>
3 0.
Endocrin ol.</w>
c ari
sc -
kin je</w>
ging i
(- )</w>
re im
19 67</w>
interfac e.</w>
Li kert</w>
6 52</w>
0.0 29</w>
10.11 52/j
sh ire</w>
rif amp
person -
referenc e.</w>
hemat ological</w>
Trans fer</w>
F ati
ser um.</w>
Tak eda</w>
tor que</w>
- N
An ticancer</w>
mem ories</w>
Symptom s</w>
J ol
B ates</w>
sibl ings</w>
dis placed</w>
(P DB</w>
quin one</w>
ond a</w>
* /
ren sen</w>
The or</w>
7. 4)</w>
e at
16 ).</w>
bi o</w>
(c f.</w>
disrup ting</w>
U A</w>
( 87
( C</w>
sic kness</w>
7 41</w>
25 °C</w>
Hierarch ical</w>
( 14</w>
mal nutrition</w>
toxic ity,</w>
11. 0</w>
Gard ner</w>
( Wang</w>
str y,</w>
cur ved</w>
29 ,
adj unc
HR V</w>
cl aud
ultras ound
Hoech st</w>
R ad,</w>
Neuro chem</w>
− y+
cri sis</w>
Gib bs</w>
z yn
dys function.</w>
P ain
6 28</w>
lead ers</w>
control ler</w>
Q O
st ace
green house</w>
J. F.</w>
vehic le-
Inf ra
-0 15-0
p. )</w>
residu es.</w>
intr insi
Val id
norm ative</w>
cop olym
p assi
F let
n ev
multi dimensional</w>
22 —C
– 36
red )</w>
observ able</w>
discus sed.</w>
Develop ment,</w>
mil itary</w>
edi c</w>
( 89
Th al
CL L</w>
IO NA
Sm ir
St ability</w>
2 p</w>
Ki- 67</w>
behavi ors.</w>
lo t
com pres
Nit ric</w>
cent roid</w>
Laborator ies</w>
pluripot ency</w>
– 82</w>
mon t</w>
PC 1</w>
iter pen
Mal es</w>
6 5-
nod ule</w>
Q u</w>
K U
.0 4</w>
strok e.</w>
metalloprotein ase</w>
mei osis</w>
(k g/m
a- 3</w>
29 58.
1. 33</w>
ter ms,</w>
tur ns</w>
pathogen s.</w>
it ely</w>
Au gu
10.1016/j.c ub
str and
ad ec
CC T</w>
carcinom a.</w>
Brad ford</w>
(198 3</w>
Dougl as</w>
micro graphs</w>
Log istic</w>
li poly
dehydr ation</w>
P. A.</w>
physi cochemical</w>
Prolifer ation</w>
MMP- 2</w>
s ap
6 24</w>
(9 4)
(201 6).</w>
Sch ae
endor f</w>
H ahn</w>
dat e
P age</w>
bas ed,</w>
li d</w>
German y,</w>
gemcit abine</w>
ext ant</w>
.0 3</w>
1 %),</w>
incre ment</w>
bene fici
Produc ts</w>
B ay</w>
p s,</w>
ac tion
– 71</w>
(http://creativecommons.org/licenses/by/4.0/ ).
EM EN
3. 9
TH E</w>
R 1,</w>
6 36</w>
MC P-1</w>
A- induced</w>
Mil lipo
mm 3</w>
P ent
F ow
pois oning</w>
C is
dat a
O hi
casc ades</w>
C s)</w>
mm ;</w>
bri ght
CD 44
4.0 )</w>
bus iness</w>
Min nes
Bal ti
induc er</w>
Car los</w>
Her cul
ch i-
sp ort</w>
coun t,</w>
Cent r
– 34
Ltd.201 3
Stat es
67 9
ses sion,</w>
Cong ress</w>
behavi ors,</w>
Prog .</w>
platin um</w>
Sur ge
1 ×
star ved</w>
poly (
201 0.0
cat ast
E ber
Endo genous</w>
organ elles</w>
B NP</w>
0.0 33</w>
pri s
sh rink
enzyme -linked</w>
V A
De an</w>
iz z
R X
2 Department</w>
lo os
MR ,</w>
8 —H8
cur ve
– 35
% -
Y on
Fem ales</w>
acid )</w>
evid ences</w>
sp aw
predic tor
I o
Sp ace</w>
6 th</w>
physi ologically</w>
necess it
M ER
i ,
cour t</w>
http://www. who.int/
pherom one</w>
min ;</w>
Strateg y</w>
Lam bert</w>
E W
-- -</w>
Orig in</w>
0.0 34</w>
2-s2.0-79 95
M d
rem ia</w>
10.1186/s 129
(v )</w>
1 Department</w>
i on,</w>
2 B,</w>
ter ritor
f im
dy es</w>
bas ement</w>
inst ar</w>
rever si
Carl son</w>
( 24)</w>
pow er.</w>
S age</w>
co factor</w>
Tum our</w>
7 45</w>
as ka</w>
Post operative</w>
specific ity.</w>
disp arity</w>
acchar id
( without</w>
Americ a,</w>
Online Acta</w>
scre w</w>
en j
(200 2)</w>
– 53</w>
umb er</w>
bact ere
as an</w>
- cell</w>
work ers,</w>
6—C 7</w>
in som
2 *
b 9
ig ma</w>
—N 3—C
( 18</w>
Sp encer</w>
du plex</w>
immunoblo t
immer sed</w>
Bern stein</w>
w rit
L s
un o</w>
morph ologically</w>
AD -
sh ut
euthan ized</w>
det ects</w>
capac ity.</w>
15 16
i :</w>
β 2</w>
N az
AM PK
3 D).</w>
iter ations</w>
Mach ine</w>
reflect ance</w>
clean ed</w>
phot ons</w>
Bi ob
( Mo
im pu
oy a</w>
credit ed
c ac
xyl ose</w>
Tsu k
os si
abstr act
1 d
.edu. au
lav age</w>
D C-
20 ].</w>
muc us</w>
(Ag ilent</w>
read ings</w>
Di stric
vol ati
J as
11 5.
200 3)</w>
Ech ocardi
Rep ublic
PE ,</w>
low er-
dee ply</w>
arthri tis,</w>
cor ti
B au
List eria</w>
L AS
( 2,</w>
circul atory</w>
W I,</w>
fe b
questionnai re,</w>
A. S.</w>
T issu
nucle us.</w>
10 9.0
[66 ].</w>
B ,
conside red,</w>
reli ed</w>
6 54</w>
tabl ets</w>
ent ;</w>
medi um-
76 /
oc clu
MD D</w>
– 43</w>
ifi ed,</w>
E X</w>
Ab del
wh el
wav egu
R ating</w>
ME Fs</w>
scienc es
Cl on
0.0 36</w>
1. 24</w>
199 9
z adeh</w>
trans mit</w>
Burk holderi
3. 5
10.1016/j.bbr c
0.0 38</w>
En erg
effectiv e,</w>
Psychiat ry,</w>
S ri</w>
discrimin ant</w>
2 100</w>
glutamat ergic</w>
muscl e.</w>
cell- free</w>
CM V-
us ch
parac rine</w>
48 ].</w>
S ung</w>
( 57
O ld</w>
test :</w>
A _
m RNA,</w>
tic al,</w>
Gl ass</w>
A xi
( p-
form at
MCF 7</w>
scenari o,</w>
Y ou
vulg aris</w>
depart ments</w>
expl ored.</w>
twent y</w>
es a</w>
agon ist
phy sem
Toxo plasma</w>
is m
le gen
irrig ation</w>
ed e</w>
Hab it
MI T</w>
refl ective</w>
inter cept</w>
abnormal ity</w>
9 34
satis fy</w>
h ept
Z ie
8—C 9</w>
ropol itan</w>
og roup</w>
27 %</w>
mo de,</w>
15 ,
(5 1.
en burg</w>
M ind
Y er
7 16</w>
for th</w>
T OR
AM ,</w>
– 3</w>
prior ities</w>
p re</w>
atic s,</w>
hyper cholesterol
Hu i</w>
sym biotic</w>
Cunn ingham</w>
consol id
prom pt</w>
gam ma
cardi opulmonary</w>
H h
3 —
antim al
MD )</w>
res sive</w>
pol y</w>
OD 600</w>
10.12 42/
Chem otherapy</w>
br ation</w>
Y P</w>
Wol f
consum ption.</w>
co- transfected</w>
devic e.</w>
( ></w>
over load</w>
v able</w>
n omenclature</w>
divid e</w>
Af ter
H +</w>
them e</w>
log e
pr ag
sp as
< 1</w>
Biotechn ology
i ber</w>
Co operative</w>
C row
Ple ase</w>
tempor ally</w>
he ad,</w>
migr ation.</w>
parench yma</w>
m ant
H ack
Ass ays</w>
– 81</w>
eng ,</w>
controll ed,</w>
M amm
28 %</w>
re constituted</w>
e NOS</w>
ovari es</w>
hum an,</w>
4 11
Struc tures</w>
(03) 000
us u
Particip ant</w>
I tem</w>
r ing.</w>
Austri a</w>
HER 2-
0.0 45</w>
analge sia</w>
asth ma,</w>
po ie
s −1</w>
Reg istr
al ”</w>
unit s,</w>
3– 5</w>
G ang
gen it
My D
< .001</w>
V H</w>
tur ning</w>
ultr af
at ed-
37 °C,</w>
Ana esthe
2000 )</w>
myco bacterial</w>
bir th.</w>
sal v
rest or
k le
end otox
Ue q</w>
cited. A</w>
self- este
[49 ]</w>
oc ap
threshol d,</w>
F 2
su red</w>
k m
μ l)</w>
A R-
comput ationally</w>
– 65</w>
tb 00
Microbi ol
di thi
Repor ting</w>
ush ima</w>
dis agre
Y eh</w>
circuit ry</w>
R UN
work shop</w>
3- 00
is ser
devic es.</w>
ac in
D BP</w>
B G
again ,</w>
vari ance.</w>
contribut or</w>
Cum ulative</w>
D og
Parkin son</w>
Syd ney,</w>
I ch
nation wide</w>
PP V</w>
Mc Cor
Sh erman</w>
Ex ec
6 34</w>
self- management</w>
s p</w>
6 32</w>
(N H
19 %</w>
Agric .</w>
8 27</w>
P reci
( high</w>
war far
10. 13039/
ym ph
inter section</w>
antagon istic</w>
clinic al,</w>
CR E
( ref
signal -
ali ve</w>
si t</w>
ut y</w>
Y ears</w>
rhe umatic</w>
F -1</w>
4 70
hy nch
dop ing</w>
98 9
astro cyte</w>
CI S</w>
K L
orient ations</w>
R ing
Depend ent</w>
E ast
5 11
progno sis.</w>
pro hi
loci .</w>
4 18
altern atively</w>
Luc as</w>
( on</w>
conveni ence</w>
ch ick</w>
sy phil
tetra hydro
medic ine.</w>
[ 86
ques tion.</w>
S. H.</w>
S ok
MA ).</w>
d as</w>
Ol der</w>
Craw ford</w>
w rap
sion /
loc ate</w>
ent :</w>
em itted</w>
con caten
Insi ghts</w>
Wh at
scienti fic
N ine</w>
Mexic an</w>
D 1,</w>
8 :</w>
An no
9 68
Griff iths</w>
describ ed,</w>
) 70
tw ard</w>
distinc tly</w>
Coun try</w>
S ang
An ten
phy t
8 15</w>
T CT</w>
A D.</w>
Ac inet
temperat ure
Sus cepti
Ik eda</w>
behaviour ,</w>
K CN
W ij
veloci ties</w>
119. 6</w>
B ond</w>
E PI
lit term
H er</w>
in- embedded</w>
0.4 %</w>
women :</w>
lev er</w>
Suppl ement</w>
A c</w>
RF P</w>
p al</w>
biosens or</w>
periph er
enc es,</w>
b ate</w>
3 b).</w>
( ref.</w>
ors al</w>
ligh t
brid ging</w>
10. 39
Wal tham,</w>
bevac izumab</w>
[4 1],</w>
defici encies</w>
(D ).</w>
l uminescence</w>
l 1</w>
ig e</w>
Fel lowship</w>
M s.</w>
l on</w>
17 -0
S. C.</w>
rul ed</w>
Sen s.</w>
Scri pt</w>
oper ation.</w>
an timicro
0.0 37</w>
pair s,</w>
sub optimal</w>
one uro
Percep tion</w>
6 48</w>
resi ding</w>
V 3</w>
Goog le</w>
ocarcin oma</w>
Sciences Physiology
phan tom</w>
nocic eptive</w>
ero sion</w>
10− 3</w>
cultiv ar</w>
Result s:</w>
K LF
dos e.</w>
perme able</w>
osom es,</w>
ass emble</w>
Gó me
clust er,</w>
bio chemistry</w>
Invit rogen</w>
low -</w>
immobil ization</w>
4 25
– 28</w>
T SS</w>
A. L.</w>
5 '
il i</w>
Yo o</w>
determin istic</w>
25(OH) D</w>
Sol ub
0.0 41</w>
ess e</w>
rad ic
is ed,</w>
i ).</w>
blast s</w>
ili ac</w>
TGF β</w>
Financ ial</w>
ocom ial</w>
7 43</w>
am ylase</w>
her b
c iliary</w>
y b
Ber kel
B 12</w>
haz ard
O il</w>
L un
CT .</w>
n em
re organization</w>
quanti fi
0.0 42</w>
19 66</w>
Ex pres
ab rup
fluctu ation</w>
RE M</w>
fav our</w>
e u</w>
Q L</w>
n ing,</w>
200 1,</w>
spati otemporal</w>
sul fox
Romer o</w>
B enz
d er,</w>
br ady
C ub
leuk emic</w>
T un
DEN V</w>
B eta</w>
C att
bre ad
neuro logic</w>
A. C.</w>
posit ron</w>
.ac. uk</w>
x- ray</w>
m 1</w>
add en</w>
Otol aryng
Ab s
(198 4</w>
scaff old
li que</w>
En s
ol ine</w>
no thing</w>
ä r
distor ted</w>
transcript s.</w>
subtrac ting</w>
P ou
2, 000</w>
V eget
E I
biom ateri
agric ulture</w>
special ty</w>
199 4).</w>
c as</w>
dep olarization</w>
7 39</w>
acetonitri le</w>
10.1111 /j
7 31</w>
weigh ing</w>
con ferred</w>
ent ric</w>
chemo attrac
S rin
depic t</w>
st ern
seas ons</w>
My el
K ondo</w>
Be il
tripl e-
ques tions,</w>
p est</w>
si RNA-
I tem
1 x
Y )</w>
V es
q GG
compart ment
Hash imoto</w>
ro ta
T DP-
e g</w>
0.0 39</w>
D x</w>
P Y</w>
– 91</w>
McCar thy</w>
D airy</w>
H NSC
Com merci
For mal</w>
yo to</w>
( open</w>
end otoxin</w>
peri operative</w>
an ze
provid ed.</w>
C 1,</w>
stero idal</w>
ory z
an /
LC 3</w>
: 3
ine al</w>
Bost on</w>
9 50
tro pic
ne ovascul
e q
abet h</w>
T amura</w>
( mg/
k ens</w>
comm ens
col y
Ish ikawa</w>
; 3</w>
str ained</w>
SF- 36</w>
ement s,</w>
Wal es</w>
S 8</w>
RNA- binding</w>
69 8
us o</w>
mTOR C1</w>
FEV 1</w>
Brassi ca</w>
10.12 42
ak ,</w>
Com ment</w>
re modelling</w>
10. 3</w>
basi s.</w>
tumorig enic</w>
qu art
6 56
arch ives</w>
ad or</w>
Schwar z</w>
PR ,</w>
steat osis</w>
co- expressed</w>
– 19</w>
Steph en</w>
SN R</w>
in- house</w>
Ovari an</w>
Oc cup</w>
We ek</w>
PA H</w>
200 6.</w>
(R 2</w>
medi as
Di az</w>
Behavi our</w>
clear .</w>
100 1</w>
. ).</w>
-0 11-
Pur kinje</w>
A. R.</w>
consum e</w>
19 65</w>
choler ae</w>
sit e-specific</w>
ét é</w>
ic k,</w>
scri pts</w>
GT T</w>
6- well</w>
pe an
ib a</w>
gluc an</w>
P ure</w>
I H
pe dia</w>
33 ,
exacerb ation</w>
HD AC</w>
1 aa
en anti
gener ation,</w>
hyper methylation</w>
rhyth mic</w>
tr n
inf ective</w>
electro cardi
Hol land</w>
10.1002/ c
year )</w>
m Glu
A j
gr am-
Bi op
idi d
bas e-
po ros
loci ,</w>
P asc
K ah
Intes tinal</w>
Rich ter</w>
V ries</w>
Syn ech
b are</w>
b ank
miRNA s,</w>
G astric</w>
Transcript ome</w>
China 3</w>
y le
immun e-
s. d.</w>
al do
id ae,</w>
Tow ard</w>
Arti cl
7 49</w>
exercis e.</w>
MD S</w>
Condi tions</w>
N ,
sen tinel</w>
band width</w>
pon in</w>
g 1</w>
e ks</w>
min ).</w>
is ms</w>
4 000
i =
produc t.</w>
erythro poie
( 58
regim es</w>
particl es,</w>
cl ay</w>
Parasit ology</w>
allog raft</w>
Biochem istry,</w>
worldwid e.</w>
Alon so</w>
Up date</w>
; 2</w>
difficul t.</w>
k ur
1. 26</w>
CA A</w>
Se oul
cult uring</w>
top ography</w>
room s</w>
pathogen s,</w>
wa it</w>
bruc ei</w>
CA 3</w>
° C;</w>
og on
ore dox
4 C</w>
Test s</w>
26 %</w>
confound ers</w>
43 %</w>
syn ergy</w>
group :</w>
Physici ans</w>
item s.</w>
practition er</w>
Psych ol
– 73</w>
ard -
Rac 1</w>
C SCs</w>
diagram s</w>
gli omas</w>
CC 1</w>
η p2</w>
str ate</w>
im e</w>
H5 N1</w>
po pl
) ],</w>
H ox
visi ting</w>
al- like</w>
500 ,</w>
clinic i
mimic king</w>
each .</w>
Al together,</w>
Y ang
cross- linking</w>
0.9 8
sec tions,</w>
respond ent</w>
10.3 109
semiconduc tor</w>
α 1</w>
ad here</w>
st aphyloc
1. 5%</w>
Recommend ations</w>
at us,</w>
v ,</w>
simil ar.</w>
construc ting</w>
F AB
sourc e:</w>
Cy s</w>
In ser
cortico steroids</w>
V or
0, 0
Upp sal
c on</w>
Transp ort</w>
G MP</w>
cell- derived</w>
gran ted</w>
v q
un favorable</w>
An terior</w>
k cal/
(6 2.
cent red</w>
1. 28</w>
sion ).</w>
H 13
ah i</w>
NM _0
2-s2.0-8 49
4 _
regres sion.</w>
os mol
[3, 4].</w>
cytomegal ovirus</w>
co .
be half</w>
1471- 23
Mich el</w>
(S )</w>
me -
p ag
an ov</w>
Y W</w>
Ha as</w>
Casp ase-
7 60</w>
ati d</w>
a us</w>
—O 1</w>
read ers</w>
CO ,</w>
antimicro bi
10.1146/annure v-
ent ers</w>
emerg ent</w>
GG GT
mo s</w>
7 50
matrix :</w>
et ra
dose- response</w>
4 16
fron t
phosphati dyl
β )</w>
[23 ,</w>
Di xon</w>
pl aqu
hom ogenous</w>
1. 35</w>
− 1)
N 4—C
1097 -0
SEM ,</w>
M PT
98 ,</w>
tinnit us</w>
b are
P eptides</w>
dissoci ated</w>
statin s</w>
pat rick</w>
accumul ating</w>
(S te
ad er</w>
analysi s;</w>
Scand in
fas ci
diagnos ing</w>
si o</w>
CC CT
7—C 8</w>
on e)</w>
[67 ].</w>
Gonzále z</w>
ID ,</w>
mol )</w>
W ir
; 14</w>
Prot ective</w>
Or g</w>
ax ,</w>
F ine</w>
( if</w>
judg ments</w>
lead er</w>
en tion</w>
contrac t</w>
capt uring</w>
Fig s.</w>
2 R</w>
bol us</w>
10 6.
PE G
refu ge
b p.</w>
Sol omon</w>
7 29</w>
RA GE</w>
174 3-
Viet nam</w>
D W
Ch ow</w>
49 ].</w>
single- stranded</w>
o facial</w>
L. M.</w>
glob ulin</w>
3T 3-
28 5
deep -
U B
[2, 3].</w>
UNIT ED</w>
tas k-
E F-
concentr ate</w>
m ock
e o</w>
7 57</w>
met azo
id eal
H ö
os se
bro mo
(M )</w>
.200 1.
sporo zo
war a</w>
re ment</w>
trac ks</w>
leishman iasis</w>
a str
; 12</w>
dor f</w>
10− 4</w>
ur us</w>
(B ,</w>
paired- end</w>
98 8
10.1038/n g.
wri st</w>
BM P
sc F
auto immunity</w>
RO Is</w>
11 6.
0.0 43</w>
vasodi l
observ ations.</w>
GF P,</w>
e ing</w>
@ mail.
an yl</w>
(S PSS</w>
transc ranial</w>
tt e</w>
verte bra
abstr acts</w>
( 13</w>
path ologies</w>
CC C</w>
H2 PO
u j
MS A</w>
issu e.</w>
IT S</w>
N W
robo tic</w>
descript ors</w>
cl ass,</w>
V anc
de y</w>
don 't</w>
C RA
oc ked</w>
mat ory</w>
inf requ
spir al</w>
ing ?</w>
CD34 +</w>
0. 22
divers ity.</w>
k =
In s
ti zing</w>
Her r
ph lo
herbi vo
Posi tion</w>
10.2337 /d
rem n
nod ul
t a-
Intellig ence</w>
1990 ;</w>
7 %,</w>
.0 6</w>
Compon ent</w>
idi s</w>
S yl
warran ted</w>
Ue q
me als</w>
al im
screen ing.</w>
m −3</w>
measure ment
Cron bach
Eng el
R elev
H3K 9
campa ign</w>
2– 1.
+ =
t ance</w>
her ni
asth matic</w>
Initi ally,</w>
10.3109 /0
Inter -
2. 5,</w>
Car ri
38 %</w>
1 i</w>
gonad otrop
immun ity.</w>
ot to</w>
chir al</w>
e sis</w>
off ,</w>
10.10 5
Cha in</w>
invasi veness</w>
20 35
communic able</w>
fibrin ogen</w>
Mor an</w>
B i</w>
Nanos cale</w>
C P-
U tre
House hold</w>
2 0.0</w>
ess en</w>
worsen ing</w>
T CF
A P-1</w>
rever se-
Ver te
Micro be</w>
graf ting</w>
fish .</w>
Moder n</w>
y- induced</w>
ah ed
molbev /m
gro ove</w>
PC NA</w>
9—C 10</w>
transform ations</w>
2 ×
( 5).</w>
200 2)</w>
10.1093/ molbev/m
st er,</w>
rec ti
cu ff</w>
olig o
2 R
sti n</w>
er ly</w>
rh am
N b
13. 0</w>
O 4—C
78 9
sal ts</w>
Z a
K ut
[50 ]</w>
sem inal</w>
local isation</w>
N k
nucle ation</w>
bur den
brain -
migr ant</w>
Tec n
ter rit
10.1128/A AC
TR IM
red ox
o ter
bre cht</w>
multi functional</w>
1 ×</w>
– 83</w>
multi level</w>
11 11
( 2010).</w>
one- third</w>
200 3),</w>
(S 2</w>
T au
10.1016/j. aj
persist ed</w>
access ing</w>
DS B</w>
ec tions,</w>
boot str
2 a,</w>
(C T)</w>
2 1].</w>
sum med</w>
PMC PMC
( 60</w>
A 3
80 5
2, 0
10 10</w>
two- step</w>
categor ization</w>
neut rop
miner alization</w>
G es
X S</w>
7 30</w>
(T ak
7. 5,</w>
Le an</w>
sp end</w>
1- 4</w>
SNP s,</w>
ur onic</w>
normal ised</w>
H. J.</w>
[ see</w>
hand -
anon ym
Inter face</w>
0.0 47</w>
Mo ti
sl ex
exec uted</w>
Wat ers</w>
p is
ac ia</w>
deploy ment</w>
Path ways</w>
Onc ology
7 53</w>
chem oradi
ag on</w>
(WHO )</w>
depend ed</w>
class es.</w>
Low e</w>
transi t</w>
Th rough
obes ity.</w>
fa ecal</w>
Sens ory</w>
phot o-
address ed;</w>
we ed</w>
righ t
j et</w>
; 13</w>
ch ow</w>
(L )</w>
map .</w>
ater n
ort ex
Proced ures</w>
79 -
un translated</w>
Person ality</w>
rele ase.</w>
at e/
hard ware</w>
an ks</w>
ococc i</w>
situ ation,</w>
Ann a</w>
IN E</w>
10.1007/s 110
mo use.</w>
mat ric
K ok
Cont ent</w>
cl aimed</w>
an a.</w>
umin escent</w>
aff eren
ed d
W N
C 30
H g
AT TT
C23 —C
ann exin</w>
dis location</w>
de )</w>
ot ube</w>
at tr
0.0 30</w>
e id
infl ammat
S iv
associ ative</w>
contrac tions</w>
201 2-
Te aching</w>
10.1186/1475- 2875-
NCT 0
detail .</w>
ord er,</w>
conve x</w>
vast ava</w>
ent on</w>
Mon te
Francis co</w>
Dis ability</w>
X- linked</w>
resol ution,</w>
Pancre atic</w>
De c</w>
L ight
countr y,</w>
2015 This</w>
6 2,</w>
invent ory</w>
6 5)</w>
h b
AB CG
attit ud
T au</w>
stac king</w>
neighb ors</w>
conduc tive</w>
col orimetric</w>
Ne il</w>
4. 1.</w>
ket amine</w>
el ey</w>
Rol es</w>
comfor table</w>
9 60
ch enko</w>
assembl y,</w>
ratio ;</w>
En zy
pro kary
od ynamics</w>
fig .</w>
ement s.</w>
vin yl
B W
BM ,</w>
Fu chs</w>
ef f</w>
Bir d</w>
= h
Hu h
kinet och
amy otrophic</w>
inc i
Bu ffer</w>
rh initi
cap tures</w>
form aldehy
MH C-
sk i,</w>
curric ulum</w>
HO -1</w>
5- 00
skew ed</w>
Zh ang,</w>
sens ation</w>
I CAM-1</w>
well )</w>
post ure</w>
Jan ssen</w>
8 11</w>
10.1016/0 16
loc us.</w>
D ong
consult ations</w>
F ST</w>
201 1-
d g
– 75</w>
bar k</w>
(P O
gl acial</w>
J uan</w>
” ),</w>
grow th-
Y A</w>
CA C</w>
1, 4-
wron g</w>
0.0 48</w>
– 27</w>
fi l</w>
ad er
W es
Ret ri
aug mentation</w>
act yl
meta- analysis.</w>
immunomod ulatory</w>
h ou
de er</w>
Sanch ez-
Guangd ong</w>
5 35
C 1-
PD E
si sed</w>
on itis</w>
St ol
5 40
-0 15-
on ;</w>
U R
2 110
marrow -derived</w>
dis advantage</w>
12 0.2</w>
poly ethylene</w>
identi ties</w>
Cac o-
1 c
O H-
dehydr ated</w>
F le
ti bi
insul in,</w>
acet yl</w>
[ 3-
differen t,</w>
EGF R-
cyclo phosph
[24 ,</w>
H 6
re habilit
neo plasms</w>
Su gi
M og
is sion</w>
Se par
5 2)</w>
if ier</w>
aden oma</w>
gluc uron
error ,</w>
F AK</w>
sing .</w>
se eding</w>
13. 3</w>
relationship s.</w>
ser ies.</w>
w as,</w>
Po ol
M ig
com mitted</w>
Mov ement</w>
f le
p en</w>
Philadelph ia,</w>
pre defined</w>
( a,
EC D</w>
20 °C</w>
− 16
possess ed</w>
10.1128/J VI.
4 13
st ory</w>
miR- 34
(S ee</w>
numb ers.</w>
os it
T GA
thou ghts</w>
p K
Benj amin
fail ures</w>
Carcin ogenesis</w>
Author (s).</w>
4 A,</w>
Rasmus sen</w>
J es
s-of- function</w>
acquisi tion,</w>
Y 1</w>
D yn
87 ,</w>
µ M)</w>
inser ts</w>
pertur bed</w>
0.0 44</w>
cruc i
stat us:</w>
ci prof
X I
Lar son</w>
a- associated</w>
J ).</w>
ric ,</w>
Cent ro</w>
cer amide</w>
N ame</w>
C -1</w>
ging ival</w>
Sch izophren
S. K.</w>
77 8
┬ á
ten ed</w>
assembl y.</w>
Mg 2+</w>
Re stric
brain /
initi ates</w>
disord er:</w>
siz es.</w>
C ann
ch ool</w>
bacterioph age</w>
p g
10.1128/JVI .0
pro vo
Stud ents</w>
PA 1</w>
relax ed</w>
Dun n
microscop y,</w>
hab it</w>
af er</w>
weigh t
A ward</w>
fibr in</w>
j ima</w>
G in
fru it
T ool</w>
foc us
Ty phimurium</w>
(C V
symmet ry.</w>
Se o</w>
confid ent</w>
T in
genotyp e.</w>
Mo tiv
migr ants</w>
-0 12-
or us</w>
coll ectively</w>
(P T
dis comfort</w>
vas opres
molecul e,</w>
hydr ated</w>
te zom
Mono clinic,</w>
techn ology.</w>
Fig u
1. 29</w>
overl aps</w>
ill ed</w>
Melbour ne,</w>
os cl
b ats</w>
grad e,</w>
( ω
.0 8</w>
(T )</w>
st ar</w>
E hr
10.1039/ c
Sh own</w>
ot ted</w>
inferen ces</w>
esophag us</w>
lymph oblastic</w>
L BP</w>
retard ation</w>
fav ored</w>
m ell
Bas al</w>
ei x
activ ations</w>
chemistr y.</w>
Angel es,</w>
arg u
X /
Som e
: 0
osteocl ast</w>
(I F
e ae</w>
phon ological</w>
hu b</w>
gr am
fa ult</w>
Stephen s</w>
T av
Nat ur
interrup ted</w>
Pearson ’s</w>
O E</w>
166 4-
glyco proteins</w>
(P ar
[4 2],</w>
S ons,</w>
aspec ific</w>
Thir ty-
97 9
10. 4</w>
U.S. A</w>
Q ing
O B</w>
hetero chromatin</w>
NF κB</w>
5 ’</w>
B *
10.116 4/
5 1)</w>
mand atory</w>
19 75
St ere
0.0 46</w>
wh enever</w>
P. O.</w>
5 4)</w>
cin nam
ace ae
el even</w>
an e,</w>
6 %,</w>
Intr a-
over whel
ay an</w>
CN Vs</w>
eptid ase</w>
ation s).</w>
12. 1</w>
NA S</w>
infl amed</w>
dem eth
spe ed,</w>
Fer nandez-
SC s.</w>
gr and
ab b
SO CS
[ 4-
Gul f</w>
Fac ility</w>
T ong
S ous
H& E</w>
Bu ild
iz awa</w>
ic an</w>
explo it</w>
c 2</w>
LN CaP</w>
profil es,</w>
rend ering</w>
Sub ject</w>
( more</w>
ok es</w>
al ia</w>
dou bling</w>
candi dat
substrat es.</w>
element ary</w>
describ ed
in ositol</w>
mas s.</w>
el y-
fe et</w>
( three</w>
repres ses</w>
Kin ase</w>
rid ae</w>
conn ect
50 ].</w>
8 25</w>
7. 00
Pat rick</w>
10.1590 /S
un complicated</w>
lact ation</w>
/ 0000
P rec
S ib
ram anian</w>
gi |
fl asks</w>
expl ants</w>
ill on</w>
c ba
depic ting</w>
Cha ud
hydrox yl
cave ol
recru its</w>
Ex erc</w>
Ep stein-
rc cm
meth otrex
op to
M cl
produc t,</w>
aff inities</w>
K C
Hom o</w>
ø r
inter rog
Lic ence,</w>
De k
(B ar
angi ogenesis,</w>
program s,</w>
L LC</w>
scal es,</w>
predat ors</w>
d X
house hold
discrimin ating</w>
– 94</w>
Sand ers</w>
PT H</w>
[ 89
Rep air</w>
Bren ner</w>
stri at
ga str
cataly sts</w>
Z en
Seoul ,</w>
col d-
re produced</w>
0.000 2</w>
Ar tem
Remark ably,</w>
double- blind</w>
[33 ,
ses sions.</w>
Du ff
z ip
Y ing</w>
Un til</w>
per id
Se ed</w>
En d</w>
co- localization</w>
war m
vim entin</w>
– 46</w>
G US</w>
th )</w>
pl ating</w>
classific ations</w>
CT S</w>
ver tex</w>
6 17
y r</w>
alb um
c e.</w>
tax onom
mark eting</w>
f ast-
PD )</w>
AS A</w>
AC A</w>
dru g,</w>
O reg
Ch u
b one,</w>
L es</w>
ent om
Gre enberg</w>
i es
sulf ide</w>
D. C.</w>
Po ul
sh i</w>
201 6)</w>
guarante e</w>
ther ,</w>
reson ant</w>
(L O
siz es,</w>
Ter m</w>
thym us</w>
embryo genesis</w>
Mes enchymal</w>
individu al,</w>
Anti biotic</w>
angi o
my ocytes</w>
58 8
ot i</w>
direc tion
[ 88
tetrac ycline</w>
bicarbon ate</w>
pro spective,</w>
complement ation</w>
N o.
0.0 49</w>
P HO
activ ity-
telom eres</w>
N Z
elucid ated</w>
uc in
accurac ies</w>
S ax
µ g/
depend ent,</w>
Per haps</w>
– 29</w>
gu ardi
rem ind
V G</w>
Soci et
9 —H9
guidelin es,</w>
V 9
Meh ta</w>
proce ed</w>
D s
ligh t/
Martin s</w>
Econ om
( medi
popul ation-
ho st.</w>
Lif e
repres s</w>
lo id</w>
J. B.</w>
war ning</w>
4 45
rele ase,</w>
commun ities,</w>
En v</w>
Acinet obacter</w>
1 A1</w>
spectro scopic</w>
T GT
ensu red</w>
5 12
shor tly</w>
form ic</w>
Prac tic
Co ff
amino transferase</w>
glycer ol,</w>
BP )</w>
on set,</w>
110 1</w>
Medic inal</w>
N GF</w>
M ast
ris ky</w>
p R
n y
ac ulture</w>
Re as
Ow en</w>
7 60
mu si
Ram ire
1. 30</w>
U rology</w>
56 8
endos ym
F og
CD C
Isl and
1. 32</w>
valu e)</w>
o- temporal</w>
N d
mac ul
hyper alge
cap ita</w>
F f
Lu x
(6 4.
− 80</w>
E di
DNA )</w>
dec lining</w>
manif ested</w>
swe et</w>
acceler ometer</w>
Ma the
Lim ited</w>
author ities</w>
0. 6)</w>
co- mor
b ent</w>
angi os
( shown</w>
N .,</w>
Con fir
fic ations</w>
at es
0. 2)</w>
thyroidis m</w>
L. A.</w>
Fis ch
D res
Ac ross</w>
ann ually</w>
ag g</w>
om as,</w>
Afric a:</w>
issu e,</w>
Ka iser</w>
Hol m
os i</w>
transplant ation.</w>
provinc es</w>
are a-
[68 ].</w>
Sch er
ain ed.</w>
read s.</w>
n b
F O</w>
co stly</w>
Q L
F ast
affec ted.</w>
fram esh
63 2/
( mmHg)</w>
a es
( of</w>
( eg,</w>
m RNA.</w>
reduc ed.</w>
mas king</w>
7 40</w>
re side</w>
Predic tive</w>
bund les</w>
sal ient</w>
admis sion,</w>
P into</w>
ti um</w>
3 *</w>
dig ree</w>
transcript s,</w>
Q Ds</w>
princ ip
flagell ar</w>
c- Jun</w>
glyc ans</w>
enti a</w>
Ig G1</w>
1 H
qui escent</w>
c ock</w>
relationship .</w>
HEPE S</w>
E e
s 8
10.1021/ bi
od d
characteris ation</w>
Inf ant</w>
Micro RNA-
fet us</w>
36 %</w>
be h
anti hypertensive</w>
CT G</w>
ec a</w>
l ak
big ger</w>
I v
ograp hi
– 100</w>
ut ,</w>
notic eable</w>
10- year</w>
const ant,</w>
I K</w>
Ok ada</w>
table t</w>
GM- CSF</w>
0.0 40</w>
19 64</w>
plan es.</w>
cal oric</w>
bloc ker</w>
de ad
R are</w>
L oz
10. 6</w>
C. L.</w>
conclu sive</w>
Wo ods</w>
soci ally</w>
ro idal</w>
19 68
f ishing</w>
y li
targ et,</w>
gover ning</w>
thickn ess,</w>
man soni</w>
suc ces
e _
aeros ol</w>
e —
ballo on</w>
T max</w>
K od
extr av
H R-
C2—C 1—C
mac aques</w>
(200 1)</w>
C un
.0 7</w>
decl ared.</w>
sk aya</w>
d yn
em ail</w>
arti fact
chec king</w>
Por ter</w>
Wiscon sin,</w>
sol itary</w>
ide an</w>
w ing
G and
L ine
dens ely</w>
C57BL/6 J</w>
ic ate</w>
moun ting</w>
di urnal</w>
dis abilities</w>
I ;</w>
H 5</w>
t ut
post- treatment</w>
Meth ylation</w>
Behaviour al</w>
7 59</w>
co w</w>
ph ones</w>
contigu ous</w>
E liz
55 9
bab ies</w>
E 7</w>
25 /
h ang
SP R</w>
ingredi ents</w>
anthropo genic</w>
[4, 5].</w>
Crystallograph ica</w>
rish nan</w>
p B
ad vised</w>
AC )</w>
© 2012</w>
peak ed</w>
poly unsaturated</w>
– 93</w>
on c.
Adol esc</w>
10.1093/ h
Q T</w>
Gu tier
imid azol
174 1-
I –
metalloprotein ases</w>
catech ol
isol ation,</w>
Don nell</w>
no ise,</w>
E Y
toc opher
SO C</w>
di methyl</w>
Ad vis
Si O2</w>
(m )</w>
ion izing</w>
Hercul es,</w>
10.1371/journal.pntd. 000
” ;</w>
nanow ires</w>
eu chi</w>
Sal z
se em
rac e,</w>
induc tion.</w>
CC s</w>
1.0 ,</w>
Prote omic</w>
Hsp 90</w>
Bur den</w>
en ey</w>
HIV ,</w>
organ s,</w>
5 3)</w>
equ als</w>
10. 8</w>
oc ul
co al</w>
L AM
end ocytic</w>
sen s</w>
R Neasy</w>
Victor ia</w>
de ionized</w>
0. 54
hom odi
si a
mid gut</w>
dis closure</w>
wash es</w>
buty rate</w>
vit re
ell a,</w>
D. R.</w>
thor ax</w>
pe er-
) b</w>
J av
knowledg e.</w>
Bis hop</w>
vari able
Zin c</w>
pre requisite</w>
Si egel</w>
Flet cher</w>
anc ies</w>
15. 5</w>
96 %</w>
micron utri
cataly zes</w>
inoc ulum</w>
S -1</w>
10.1002/ ij
GG T</w>
car bo
trast uzumab</w>
g t
p5 3,</w>
col i.</w>
NE T</w>
A ph
2– 4</w>
pe diat
index ed</w>
SY 5
defici enc
29 %</w>
A 2,</w>
pyro sequencing</w>
coll ection:</w>
CCR 5</w>
p A</w>
Shand ong</w>
F AN
ar a,</w>
u yama</w>
W ink
priv acy</w>
langu ages</w>
4 3-
categor y,</w>
.200 2.
inten tional</w>
small .</w>
high- performance</w>
J p
(4 ,
Ribe iro</w>
200 5.</w>
wavel et</w>
aliqu ot</w>
,3 1].</w>
( δ
olip id</w>
Oncotarg et</w>
Franc e)</w>
em physem
chaper ones</w>
pal m</w>
eu w
Pet ri</w>
5 15
6—C 5</w>
grap e</w>
P. M.</w>
corrhiz al</w>
att ained</w>
G IS</w>
EZ H2</w>
RT s</w>
in sky</w>
-0 10-
J ing</w>
miti gate</w>
Paren tal</w>
(5 9.
char ts</w>
Fluoresc ent</w>
ischa emic</w>
dynam ically</w>
Al f
PC I</w>
frag ile</w>
11—C 12</w>
4 95
trans activation</w>
raf t
orph an</w>
. "</w>
top -down</w>
cann abis</w>
bo th,</w>
happ ens</w>
eukary ot
ech t</w>
K ay</w>
Soci o-
[ 95%</w>
p ect
cath eter
Stock hol
sol id
achiev ed.</w>
I van
nano structures</w>
fel lowship</w>
intak e.</w>
Olym pus</w>
stud ents.</w>
end- stage</w>
hist amine</w>
000 -000
Migr ation</w>
bar s:</w>
individual ’s</w>
V :</w>
osom es.</w>
Post erior</w>
compon ent.</w>
localiz es</w>
iz e,</w>
inclu de:</w>
subject .</w>
X 4</w>
fore brain</w>
Sec re
micro sat
Res on</w>
D uc
broad -
co de:</w>
(H D
facil ities.</w>
neuro toxicity</w>
V eh
Mar .</w>
Concep tu
Sh eng</w>
10 24</w>
R il
sk a-
bil ater
Arti cle</w>
phosphoryl ates</w>
y mo
discontinu ation</w>
er ing.</w>
( range,</w>
Hz ),</w>
coun ty</w>
GL P-1</w>
I -1</w>
0. 7)</w>
practic es.</w>
lay ing</w>
RK 2</w>
N ever</w>
inc is
n ul
Hunting ton
covers lips</w>
9 27
empir ically</w>
Mi R-
hum id
Micro RNAs</w>
enlarg ement</w>
10 11</w>
gen .</w>
fluo roph
P ha
16 ,
Anim .</w>
ch ap
ber gh
colle agu
min ),</w>
7 12</w>
in osi
PV DF</w>
94 °C</w>
z ig
co s</w>
W Y</w>
(L i</w>
record s.</w>
ST I</w>
(G raph
1 A)</w>
pa re
10.1038/sj. onc.
0.8 %</w>
° C/
rot ated</w>
AC CA
repos itory</w>
solu tions.</w>
recover y.</w>
PA C</w>
2. 1.
az zi</w>
[5 1]</w>
Lu c</w>
n igr
optim izing</w>
bilirub in</w>
integr ins</w>
34 ,
intui tive</w>
bal ancing</w>
Carib bean</w>
Red ox</w>
high- level</w>
ep igene
Wer ner</w>
enc e)</w>
sequestr ation</w>
IC S</w>
Ga em
Success ful</w>
head ach
com position.</w>
S ach
Ne umann</w>
araj an</w>
; 15</w>
nov .,</w>
ob a</w>
develop ed,</w>
SA INT</w>
R PL
ari ,</w>
HEK 293T</w>
receptor- mediated</w>
5 30
av ec</w>
P 5</w>
rat h</w>
D SM</w>
AL P</w>
morph ogenetic</w>
present ation,</w>
E 6</w>
cur ated</w>
gen es)</w>
1—N 1</w>
l u</w>
ent es</w>
(S E
4 38
15 35
accoun t.</w>
C ag
Moh amm
ace a</w>
MO I</w>
Dis order</w>
ulf ite</w>
haem oglobin</w>
( [
AE s</w>
AD H
4. 2.</w>
Epstein- Barr</w>
8 45</w>
– 37
7 5)</w>
Sh el
applic ation,</w>
resourc e-
AS P</w>
Ex trem
K K
P all
R 0
[25 ,</w>
Pl anta</w>
Hoch berg</w>
II I)</w>
7 5,</w>
New ton</w>
gh um</w>
fici ally</w>
multipl ex
CB T</w>
MT ,</w>
law s</w>
es e
bi directional</w>
stabil izes</w>
Bio diversity</w>
to ol.</w>
os pi
eri o</w>
chemo therap
Be au
spec ts</w>
phosph ate,</w>
TRPV 1</w>
23 ,
includ ed,</w>
s as</w>
ca ve</w>
8 17</w>
cu ti
9 29
double- strand</w>
Diag n</w>
(6 3.
De b
ou d</w>
Sciences Biochemistry
(S ADAB
circl es)</w>
Vie w</w>
Pl anc
noc tur
proced ural</w>
mark er,</w>
X i</w>
(d ashed</w>
E d.</w>
dil em
dur ation.</w>
hemisph eric</w>
P MS
Repor ted</w>
GC CT
st at</w>
MI R
in contin
steril ized</w>
increas es.</w>
temperat ures.</w>
Lin k</w>
work shop
10− 5</w>
(Promeg a,</w>
37 5
1. 31</w>
8 10</w>
sy n</w>
I schem
Asteris ks</w>
osyn thesis</w>
‐ 1</w>
ol or</w>
n ut</w>
E arth
sub stitute</w>
FLAG -
4 47
M anc
On line.
σ )
CF TR</w>
J A
(RO S)</w>
Ep stein</w>
119. 5</w>
L us
Mah on</w>
Cha k
ho od,</w>
rin i</w>
P R-
are r</w>
St ation,</w>
zer o-
0. 4)</w>
sh ore</w>
n ascent</w>
field s.</w>
post prandial</w>
guid ing</w>
amin ogly
NO 2</w>
out lier</w>
[4 3],</w>
Ex amin
9 11</w>
10.1098/r sp
organiz ation,</w>
D RE
metabol omics</w>
de sic
shorten ed</w>
F ts
sc or
neo plasia</w>
—H 17
ph ar
Mar sh</w>
practic es,</w>
j n
tub ule</w>
pig ment
Ex on</w>
HO MA-
on /
D ex
1. 50</w>
down ,</w>
burg dor
is omerase</w>
fix ed-
ag lia</w>
Mil li
st un
r po
quench ing</w>
(I R
sc ul
Em pir
feed ing,</w>
4 D).</w>
ö n
Ki 67</w>
6 a</w>
Tel :</w>
Ar g</w>
Deli very</w>
ec ond</w>
ov á</w>
gr ain
clos por
hr an</w>
8 13</w>
Knock down</w>
4 26
tob ac
restric tion.</w>
ob ac
col oured</w>
2 230
fo under</w>
deploy ed</w>
list en
y @
ER G</w>
( GF
Produc t</w>
Inv est.</w>
t ul
nois y</w>
ens ch
gener alization</w>
Sol ution</w>
Di vision,</w>
impu ted</w>
O M
Daw ley</w>
7 14</w>
St ur
narr ative</w>
inter cal
P ang</w>
All erg
m ec
at ology</w>
5 C</w>
chimp anze
v eg
n evertheless</w>
icillin -resistant</w>
reduc tion:</w>
analyz ed,</w>
Con struc
10.1038/n meth
ov ol
ñ a</w>
tre e,</w>
G ip
K 562</w>
12 3.
y ol
B P,</w>
10.1002/ij c.
(SADAB S;</w>
( in
S as
g omer
communic ation,</w>
ter m.</w>
cycl ine</w>
infec tion:</w>
assimil ation</w>
Veter ans</w>
Burkholderi a</w>
adhy ay</w>
S Z</w>
oxid o
adhe sion,</w>
E ich
Ec on</w>
S. S.</w>
tw ins</w>
ost at</w>
fo am</w>
acqu iring</w>
R ank</w>
110 5</w>
10.1037/ a00
Ab bott</w>
8 21</w>
el o</w>
__ __
material s:</w>
dr astically</w>
V os</w>
dep ths</w>
C M)</w>
Og awa</w>
below ,</w>
Method ology</w>
4 39
sp ur
(2 )
Pre operative</w>
Pap er</w>
Bi oge
pac e</w>
hospit als.</w>
SO D1</w>
anth in</w>
Statis tically</w>
d anger
anti psychotic</w>
9 45</w>
local ity:</w>
e- derived</w>
19 67
F 1,</w>
le pt
h ),</w>
(S er
Conven tional</w>
7 3.</w>
3- fold</w>
sho ots</w>
smo ked</w>
bod y-
sh rim
per im
induc tion,</w>
includ ed:</w>
blood- brain</w>
[69 ].</w>
pa rous</w>
govern mental</w>
at ed;</w>
refin ement.</w>
middle- income</w>
W all</w>
descri p
contin ental</w>
Perspectiv es</w>
f K
R Y
hospit als,</w>
B it
A be</w>
previ ously,</w>
six th</w>
OT U</w>
psori asis</w>
L af
Eag le
gener ation.</w>
NK T</w>
G α
-5 p</w>
prob ing</w>
interpret ation.</w>
colli sion</w>
T SC
Antoni o</w>
ch itin</w>
T 1,</w>
4 23
gr as
IU /
Balti more,</w>
M emb
B ai
Australi a.</w>
10.1038/n g
19 40
atern ary</w>
Gre ater</w>
U 2
Present ation
HR QoL</w>
un ified</w>
st s,</w>
patient s;</w>
Prac tical</w>
rej ected</w>
fa ther</w>
stero id
10. 7</w>
Rho A</w>
myo genic</w>
Cr ude</w>
transp osition</w>
(N ational</w>
β 3</w>
itud in
9 39</w>
R im
am e
thous and</w>
en )</w>
PK M</w>
mod al
utili zes</w>
o k,</w>
Srin iv
(P )</w>
month ,</w>
backg rounds</w>
pert us
uter us</w>
observ ation,</w>
lip idemi
( 59
repair ,</w>
rough ness</w>
step s,</w>
n cia</w>
nucle oside</w>
promo ter
H ei
.0 9</w>
cyan obacteria</w>
— P
9 g
T CM</w>
speci es:</w>
R MS</w>
algorith ms.</w>
TR PM
tail s</w>
k ing.</w>
T SH</w>
M IN
micro biological</w>
Reduc ing</w>
Dis co
dis appeared</w>
reduc ed,</w>
su t
hk l</w>
pepti de-
ant a,</w>
top -
3- D</w>
allevi ate</w>
Na OH</w>
peptid es.</w>
1 ev
9 17</w>
( adjusted</w>
twent y-
rub ber</w>
prim ers.</w>
): 11
opter a</w>
an other.</w>
M ae
37 %</w>
fibro sis,</w>
Blo od
8 39</w>
psychiat ry</w>
k d
147 5-
( 30)</w>
H eg
; 1</w>
V et.</w>
com pressed</w>
datab locks</w>
sis- related</w>
numb ers,</w>
muc os
earli er,</w>
autis tic</w>
q i</w>
se e,</w>
cm −
cap sa
Enrich ment</w>
horiz ont
M. P.</w>
elect roph
chi o</w>
obacter ia,</w>
Pres s.</w>
och romat
as cribed</w>
Arth ur</w>
9 vq
80 6
trac ked</w>
otox ins</w>
(6 ).</w>
M T-
phen yl-
ling ual</w>
ion s,</w>
tel em
ME G</w>
viri ons</w>
M. H.</w>
Ac t
(mg/d L)</w>
W agen
id o</w>
Bacteri ol.</w>
membran es,</w>
other wis
opath ies</w>
limit ed,</w>
Ban er
160 0</w>
A w
Bar n
B ic
in e:</w>
K NO
Physi ology,</w>
os el
fir stly</w>
T AS
15. 0</w>
G ent
mis sions</w>
fol ic</w>
co val
ur o</w>
( after</w>
Agu il
9 70
/ her</w>
Compo unds</w>
blo t.</w>
K ud
us ).</w>
occur rences</w>
incorpor ates</w>
9 000
querce tin</w>
Z ool</w>
Feld man</w>
( 300</w>
ar m,</w>
Cast ell
M uch</w>
Argen tin
z ek</w>
z u</w>
( between</w>
og r
ed ly,</w>
Rus so</w>
10.1111/j. 157
Q S</w>
U 12</w>
( –
valu ed</w>
(6 8.
Don n
B rom
10 78
min is
Dis crimin
Health care,</w>
1 199
in es.</w>
gen i
res or
Add ress</w>
conjunc tiv
Numer ical</w>
′ ,</w>
le gi
ren dered</w>
R up
an os</w>
e– control</w>
8 29</w>
– 56</w>
44 %</w>
in effective</w>
Reg ard
Lip ids</w>
joint ly</w>
acces si
posi tions,</w>
st ack</w>
index ;</w>
Ca uses</w>
– 85</w>
de structive</w>
F at</w>
mer ic</w>
Head ache</w>
T rem
Challeng es</w>
Categ ory</w>
[ 90
18 00
Y d
10 B</w>
. 13
larg er.</w>
Br uce</w>
Go to</w>
(S igma</w>
n is
organ izing</w>
) **</w>
epithelial- mesenchymal</w>
cent er,</w>
cour se.</w>
D n
paradig ms</w>
ar u</w>
vom iting</w>
ting er</w>
R- 2</w>
Equ ations</w>
smar t</w>
Sever ity</w>
es arean</w>
(C T
extrac ting</w>
error s,</w>
al di</w>
load ings</w>
[5, 6].</w>
R P-
min i
vie we
8 2
encephal opathy</w>
Ethi op
Sal t</w>
bas e,</w>
3′ )</w>
emb l</w>
embry os,</w>
L H
A co
K. M.</w>
Clust ering</w>
el eph
Ker r</w>
freez e-
li st.</w>
in- hospital</w>
– 38
radi o</w>
an ’s</w>
p eren
1. 34</w>
11 2–
H 18
A A,</w>
[34 ,
IN TER
plasm on</w>
s ]</w>
s Biology</w>
om a
eng u
op olys
Regi ons</w>
thick ening</w>
R az
peptid ase</w>
low- grade</w>
ant s:</w>
A C-
wild life</w>
sec ,</w>
load .</w>
hyp oc
plan e.</w>
ucl idean</w>
Christoph er</w>
bo ost
test es</w>
Yel low</w>
F la
Depart amento</w>
Su stain
occur red.</w>
Pal e
.uk /
and ro
an thus</w>
le i
dec lar
sub species</w>
anomal ous</w>
h ler</w>
Con served</w>
P c
O 2/
3 2%</w>
zz o</w>
normal ize</w>
8 47</w>
O V</w>
g r</w>
R IP
G av
hypo thes
N =
sil enc
ric e,</w>
ST S</w>
schem e.</w>
plex us</w>
IS )</w>
ju n</w>
inter ior</w>
SC s)</w>
± 2.
8 19</w>
T AM
Greg ory</w>
1– 4</w>
eth idium</w>
19 20
hydro carbon</w>
contex t-
L j
GA GT
19 66
http://dx.doi.org/10. 7554/eLife.0
200 1)</w>
omet ry,</w>
necess ary,</w>
) —
cer vi
Ho use</w>
Vanc ou
Sour ces</w>
MD M2</w>
or /
5 20
tread mill</w>
panc reas
Boy d</w>
90 .</w>
( control)</w>
( per</w>
G az
t or,</w>
ag o
m s-
skel eton</w>
ren der</w>
sex .</w>
econom ically</w>
anc y,</w>
plac e,</w>
Z NF
l ever
retur ning</w>
(H 2O
for ti
199 3).</w>
(M E
C s,</w>
23 —C
10.1093/ brain/
46 ,
histor ies</w>
ro stral</w>
in fo
5 16
Paren ts</w>
3. 1.
fluo rescent
mAb s</w>
1, 2-
AA AA
assign ments</w>
R it
10.18 632/
plei otropic</w>
HUV ECs</w>
erg er</w>
ill ness.</w>
pro lac
land er</w>
SP s</w>
He ight</w>
magnit u
ophosph ate</w>
Extern al</w>
Pri vate</w>
statis tics.</w>
fail ing</w>
Mal awi</w>
( τ
LDL- C</w>
Bl anch
5- di
O F
long- lasting</w>
iz ation
7 70
L ad
rab ies</w>
equilibr ated</w>
gl it
sem en</w>
audi t</w>
1- year</w>
p 0
10.4 10
collo idal</w>
Wo und</w>
k .
int ubation</w>
epidem ics</w>
associ ation.</w>
sid er
sav ing</w>
transcriptom es</w>
L ah
thal ass
content /
8 43</w>
paren ts,</w>
CG H</w>
thou gh
E mail:</w>
ex ported</w>
8 %,</w>
ver n
2 240
Mari e</w>
Bacter oid
miR- 21</w>
arti fact</w>
intra ocular</w>
9 %,</w>
ar te</w>
R -</w>
9 60</w>
stud ents,</w>
per tinent</w>
K ie
ophysi ology</w>
ill ,</w>
f low-
end onuclease</w>
(6 5.
− )</w>
intrinsi cally</w>
Har a</w>
vent r
frame work,</w>
15 68
duoden al</w>
di esel</w>
Yam ashita</w>
beli ef
loc us,</w>
ir y</w>
– 39
17 46
( B</w>
Se ph
- C
alcohol ,</w>
7 26</w>
15 46
denat uring</w>
Cv AU
ent re</w>
om ,</w>
AG A</w>
2 150
baumanni i</w>
P are
1. 38</w>
pros thesis</w>
st able,</w>
specim ens,</w>
discord ant</w>
simul ation.</w>
A st
hyperten sion.</w>
end osomal</w>
– 95</w>
eo rological</w>
PG C-
In form</w>
drin ks</w>
t DCS</w>
hist ones</w>
R. L.</w>
lymph aden
0.0 50</w>
HA ART</w>
super imposed</w>
2 147
2- mediated</w>
Wild life</w>
vacu ol
catabol ism</w>
NLRP 3</w>
restrain t</w>
ine- induced</w>
immun ity,</w>
genotyp e,</w>
at CvAU
9 33</w>
gra zing</w>
( standard</w>
ure r</w>
numb er
12 A</w>
u v
occa sional</w>
ev ing</w>
Z A</w>
B aj
H eli
chol angi
Om ni
[5 2]</w>
PB S-
1. 45</w>
K ag
8 53</w>
ow ed</w>
tri es</w>
Isra el
CT LA-
Vi j
(201 5).</w>
X P
ist a</w>
el bow</w>
5- FU</w>
( 26)</w>
Bet a-
unit ,</w>
i. p.</w>
Counc il
EF @
ran ks</w>
Clear ly,</w>
lac Z</w>
0. 3)</w>
en ’s</w>
N 0
Gold man</w>
manipul ations</w>
C ock
rip ening</w>
pub ertal</w>
F L,</w>
11. 3</w>
ot ,</w>
capacit ance</w>
Math Typ
2 H,</w>
e@ MT
e@MT EF@
e@MTEF@ 5@
e@MTEF@5@ 5@
e@MTEF@5@5@ +=
MathTyp e@MTEF@5@5@+=
Hern án
D ab
oxytoc in</w>
▸ ).</w>
Rec ord</w>
q F
cell -based</w>
em al</w>
pa uc
post traumatic</w>
] .
la un
under graduate</w>
s ac</w>
F 1
Abra ham</w>
go tic</w>
evid ence.</w>
particip ation.</w>
oz one</w>
Schist osoma</w>
7 24</w>
ap ic
appro val
( -0.
drug .</w>
yl ed
reconstruc tions</w>
re aring</w>
in gen,</w>
M ous
9 39
den si
bu r</w>
contrac ep
NP ,</w>
pip ette</w>
β- caten
intra -</w>
life- threatening</w>
weigh t/
or bidity</w>
2 170
common ,</w>
4 1-
yl transferase</w>
8 37</w>
ati a</w>
V B</w>
P ari
xy lo
17. 5</w>
S 9</w>
Pal ae
10.100 6/j
not ed.</w>
Jur kat</w>
vehic les</w>
chrom atic</w>
poly aden
ful filled</w>
(2. 5</w>
pseud om
d ;</w>
rev ascul
paramet ers:</w>
.. .</w>
S J
Annot ation</w>
micro biology</w>
9 21</w>
co- cultured</w>
art 1ev
relationship s,</w>
F an
h ow
I ST
i yama</w>
ba 9
201 3-
sh am-
7 18</w>
2+ ,</w>
15 N</w>
ent ral</w>
sal t-
): 12
s ong</w>
E uc
(k g)</w>
C s.</w>
Benj amin</w>
magne tization</w>
onc otarg
4 2%</w>
ligh ts</w>
fi x</w>
IN K
transf ection.</w>
par ity</w>
Diff rac
sustain ability</w>
6. 00
el ite</w>
Pro file</w>
h ad
I :
amat su</w>
D w
paraff in-embedded</w>
dem and
Mad ag
J oll
ig a</w>
am phen
i que</w>
phosphoryl ation.</w>
Quin n</w>
mercap to
mis sion.</w>
J o</w>
plant ar</w>
St ock</w>
fist ula</w>
resembl ing</w>
opoul ou</w>
d well</w>
t00 4Table</w>
Char l
PC 12</w>
Inhibit ory</w>
ag her</w>
20 ),</w>
L enti
add ed,</w>
hippocamp us,</w>
vari ability.</w>
aa fi
N ation
F SH</w>
k /
k as</w>
V F</w>
ds DNA</w>
[26 ,</w>
star v
dec oding</w>
Nep al</w>
standardi zation</w>
CH 3
sampl ing.</w>
fe aafi
feaafi art1ev
MathType@MTEF@5@5@+= feaafiart1ev
nat ri
adv anc
s perm
clar ified</w>
a ort
D ens
Ens embl</w>
Research ers</w>
fruc tos
soci etal</w>
p ene</w>
Ad el
(rang e:</w>
7 1.</w>
100 %.</w>
w all,</w>
1 H),</w>
cyt ology</w>
amphet amine</w>
Bo eh
(1 H,</w>
Cy ber
chang ed.</w>
K yoto</w>
ar )</w>
ut z</w>
A bo
a em
g eriat
S 5
F all
te t</w>
Cl ay
( a).</w>
control :</w>
H ain
agglutin in</w>
Cen sus</w>
( 27)</w>
Pediat rics,</w>
[70 ].</w>
St aining</w>
up -</w>
kD a)</w>
Sh am
1/ [
sever ity,</w>
approxim ated</w>
i ya</w>
( χ2</w>
phag ocytic</w>
carboxyl ic</w>
(S i
devic es,</w>
C 29
( 68
li thi
9 13</w>
Fe atures</w>
Fab ric
59 -
t an</w>
Se id
quer ies</w>
chemo kin
g006 Fig</w>
tin s</w>
[6,7 ].</w>
X at
U M</w>
s 1</w>
1- induced</w>
prospec ts</w>
jurisdic tional</w>
atom s.</w>
M N,</w>
10.1016/j. bb
fix ed,</w>
u W
Sc en
Neurophysi ol.</w>
Mont gomer
Com position</w>
stimul us.</w>
,2 1,
8. 00
G ae
non parametric</w>
spe eds</w>
cylind rical</w>
Copy right:</w>
partner ship</w>
200 2),</w>
E GT
pass ages</w>
Nik ol
low- level</w>
ser ous</w>
– 40
tt a</w>
Sigma -Aldrich</w>
Z EB
MT )</w>
20 50
L ock
in- dependent</w>
Y et</w>
(Ab cam
assum p
en k
For sch
F MR
Sp in
1aa atCvAU
9 49</w>
g005 Figure</w>
35 ,
Rel ation</w>
memb ered</w>
Jos e,</w>
4 28
10.1002/ p
ult on</w>
voc abul
arach id
24- h</w>
ev in</w>
phyl um</w>
beta- catenin</w>
© 2011</w>
enc e/
re distribution</w>
precipit ate</w>
. br
incid ence,</w>
MR S</w>
, t
vi k</w>
pro fit</w>
aj i</w>
θ max</w>
: 0</w>
1. 36</w>
ur a,</w>
Iran .</w>
transpos ons</w>
ci tiz
N ab
Fir mic
air ,</w>
ty ph
17 55
1 j
coar se</w>
Cam bodi
Mut ant</w>
fl ask</w>
ari ans</w>
db ba9
9vq ai
a is
en @
ag r
S alu
M eij
mo ie
at es:</w>
soci odemographic</w>
iv a</w>
ho uses</w>
comm and</w>
{document }</w>
lo ok
form ally</w>
Sh u
12 0.3</w>
M our
AL K</w>
—N 3</w>
inten tions</w>
Pur ified</w>
9 15</w>
8 95
(200 0)</w>
predn isol
( age</w>
G d
arre sted</w>
pre- treated</w>
orch estr
BRCA 2</w>
spermatozo a</w>
slud ge</w>
ci f</w>
25 ,
Na 2
co re
—H 18
defin ed.</w>
MathType@MTEF@5@5@+=feaafiart1ev 1aaatCvAU
H 17
(201 2).</w>
U 11</w>
happ en</w>
2 1,
uptak e,</w>
equiv oc
ch a</w>
10. 22
Chic ago</w>
3- kinase</w>
a, b</w>
sup 1.
EC 50</w>
7 52</w>
os kel
plat form.</w>
Th ai</w>
Mo ro
mes ench
detach ment</w>
nick el</w>
oper ation,</w>
R out
mov ement.</w>
[44 ],</w>
Lópe z-
autop sy</w>
fec und
tion ally,</w>
(c ),</w>
Ma eda</w>
CD4+CD 25
p <
Y un</w>
Ag ric</w>
Han son</w>
Addic tion</w>
L inc
AT )</w>
Wo o</w>
Hodg kin
Epith elial</w>
P er</w>
ar s.</w>
absc ess</w>
an tic
C tr
ver s.</w>
k w
Ji ao</w>
del im
cor ner</w>
gu anine</w>
Women 's</w>
Feder ation</w>
E-Mail s:</w>
In corpor
Hy giene</w>
ter a</w>
Tum ors</w>
cycl ase</w>
b uck
9 MD
min i</w>
in breeding</w>
9 41</w>
uW rP
arthri tis:</w>
adi s</w>
S pit
retur ns</w>
β 2
HIF- 1
Apop to
skill s,</w>
pa stor
b Iq
Sym ptom</w>
tt Lear
fK ttLear
Mich igan</w>
bIq V9
bIqV9 2A
MBP bIqV92A
H5 MBPbIqV92A
9MD H5MBPbIqV92A
7 34</w>
. ;</w>
8 41</w>
sedi mentation</w>
Bro ad
k h</w>
acceler ates</w>
identifi able</w>
es ds</w>
11 —H11
macrom olecular</w>
10.1016/j. s
V ).</w>
T ac
Lx BI
LxBI 9g
** P<0.0
en th
(P I
w k</w>
is omer
ae Xat
aeXat LxBI9g
Pier re</w>
hydro thermal</w>
uWrP 9MDH5MBPbIqV92A
uWrP9MDH5MBPbIqV92A aeXatLxBI9g
fKttLear uWrP9MDH5MBPbIqV92AaeXatLxBI9g
con sequently,</w>
k u</w>
depend ent.</w>
(m mol/L)</w>
GA A</w>
Cult ures</w>
- ,</w>
ch t,</w>
Alter ations</w>
e w</w>
diseas e-free</w>
ischem ia-
phospholip ids</w>
Fe 3
mit es</w>
Wel ch</w>
S cor
rac ial</w>
hyd rate</w>
( less</w>
ic in,</w>
carb ap
10. 9</w>
ch ia</w>
U F
Concentr ations</w>
Caco- 2</w>
DR B
sci sic</w>
bud get</w>
ulcer ative</w>
V II</w>
X X</w>
9 23</w>
sal in
di pl
Le ast-squares</w>
.edu. cn</w>
Com plications</w>
16. 5</w>
10.15 42/
IR F
Provinc ial</w>
( 50)</w>
8 51</w>
Seas onal</w>
er lo
ere bral</w>
Resol ution</w>
19 47
Re qui
immun ogenic</w>
Col on</w>
9 38
met amorph
S erg
efficac y.</w>
su n</w>
biosyn thesis,</w>
pack ages</w>
V N</w>
(P BS)</w>
N ie
C. S.</w>
plant .</w>
audi o</w>
Enter ococcus</w>
g ig
Ab use</w>
2. 4
as )</w>
R. S.</w>
In surance</w>
H C)</w>
decad e,</w>
8 57</w>
l li
MO )</w>
Par kin</w>
R 5</w>
ñ o</w>
Brazil .</w>
T CGA</w>
event -related</w>
p H-
clo ud
( low</w>
Ag arwal</w>
6 4)</w>
be c</w>
lo resc
Oste oporo
U 22</w>
q 8
at ech
detach ed</w>
Mar co</w>
interpret ations</w>
histor y.</w>
SI )</w>
– 66</w>
diarrho ea</w>
un adjusted</w>
scho ol,</w>
class es,</w>
or rho
chi tin
pic ked</w>
wave form</w>
un folding</w>
fl ash</w>
Ch ris
4 D</w>
S ay
abs ent.</w>
U 13</w>
Ch eng
1. 37</w>
off spr
sel ectiv
2 120
D ah
cell- cycle</w>
Committe e.</w>
3- 1</w>
esc ens</w>
Jim ene
R int</w>
CA TT
Gyn aec
multi modal</w>
110 7</w>
. org</w>
ph aryngeal</w>
lay ers.</w>
extrac t,</w>
ak in</w>
( a,</w>
201 2.0
propag ated</w>
nit ros
harv est
Madri d,</w>
C24 —C
2014 This</w>
Autom atic</w>
inter specific</w>
9. 00
90 5
C 19</w>
(198 2</w>
Zim bab
U 23</w>
disc er
con es</w>
8 58
me ets</w>
MA T</w>
C are,</w>
6 50
“ the</w>
10.1016/j. p
os copic</w>
S ai
4 a).</w>
[ 100
f gas
and er
in distinguishable</w>
(H 1N
parti te</w>
brain res
moun tain</w>
11. 4</w>
bb nr
fif Hh
fifHh DY
fifHhDY fgas
fifHhDYfgas aac
bbnr fifHhDYfgasaac
Muscul oskeletal</w>
K ha
(b p)</w>
e ip
hom e,</w>
ym e</w>
cl ass.</w>
v /
pre clud
: 13
penetr ating</w>
displ ay
q ing</w>
4 20
Method s:</w>
C 17</w>
r d</w>
Na ir</w>
D. L.</w>
immun o-
ab and
panel .</w>
Kore a
possess ing</w>
loc ations,</w>
estim ator</w>
IC D</w>
Prob ability</w>
chloro quine</w>
en bach</w>
communic ations</w>
Am bi
polyn omial</w>
Shi b
Iκ B
intrau terine</w>
A id</w>
gener ator</w>
CI s</w>
er adic
ed ’</w>
Vit ro</w>
seas on,</w>
Y outh</w>
z on</w>
e =
( 67
avi r</w>
as parag
M CT
CO 2,</w>
ward ,</w>
Are as</w>
Rec ently</w>
10. 210
ste in,</w>
atic a</w>
s an</w>
6 1,</w>
one ph
IQ R</w>
Carp enter</w>
– 37</w>
attrac tion</w>
155 3-7
' )</w>
phenotyp es,</w>
(t )=
p ale</w>
C Q</w>
affili ations.</w>
U t
Sciences Cell</w>
B ob
13. 1</w>
Lar sson</w>
coloc alization</w>
aper ture</w>
chromat ographic</w>
Sh an</w>
brain :</w>
(L .)</w>
ge fi
140 0</w>
smooth ing</w>
em itting</w>
Women ’s</w>
76 .</w>
) 60
galact ose</w>
complet eness</w>
2 199
(Δ /
chromosom es.</w>
l on
L ed
heter os
till o</w>
AC SE
Neurosci ence,</w>
tri angl
immun ocyto
clos ing</w>
Car r
vi ro
derm atitis</w>
chamber .</w>
° C),</w>
pre mis
it e,</w>
PL A</w>
b ard</w>
B C,</w>
mov ement,</w>
editor .</w>
m A</w>
S. R.</w>
200 8-
(7 ).</w>
z ot
V ag
diseas es:</w>
Eng el</w>
u ve
mal on
10.1038/ 350
11. 8</w>
dem ethyl
− .
let -7
er ron
E d</w>
D ell
pol es</w>
mot or
meas les</w>
Pal li
p ink</w>
sle eping</w>
R W
1, 4
ach and
v )</w>
rick son</w>
mom ents</w>
Concer ning</w>
MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAU fKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9g
(bot tom</w>
laborator y.</w>
dist ance.</w>
Ok amoto</w>
eng ag
certi fic
formul a:</w>
squ ares
6- month</w>
datas et
10.1016/j.mol cel
prin ts</w>
an e-
her d</w>
require d,</w>
in ol
8 40</w>
200 4.</w>
F ib
c argo</w>
sup1. cif</w>
10 5.
PA S</w>
– 300</w>
Ethi opi
e 2</w>
bov is</w>
Gl u</w>
E Acta</w>
9 35</w>
student s’</w>
S ham</w>
ri ding</w>
no ,</w>
alk yl
R ates</w>
Sec ret
3 1–
influ ential</w>
principl e,</w>
Nak agawa</w>
U 33</w>
Elect rophore
tumorig ene
AI C</w>
b l</w>
CR ,</w>
ta x</w>
J ah
wall .</w>
c c</w>
8 33</w>
physi cs</w>
P p
eg al
Jac ob</w>
7 32</w>
t ack
8 35</w>
interven tion
10.3389/f psy
pig mentation</w>
Cy an
there after</w>
ne apolis,</w>
e igh
check CIF</w>
4 A
long itudin
lipid s,</w>
sp ring
lac tis</w>
argum ents</w>
osteocl ast
7 44</w>
incen tive</w>
Ee eu
μ L)</w>
fr Fj
dbba9 frFj
0x b9
z ak</w>
1. 75</w>
regul ated,</w>
h s.
dy slex
eli hood</w>
aa ake
Rab bit</w>
0x X
S tern</w>
Eeeu 0xX
Eeeu0xX dbba9frFj
(p .
know ing</w>
ing s
Ec ology
ond er
la id</w>
—H⋯ O</w>
enzyme .</w>
c rown</w>
ass urance</w>
Fre ed
CB F</w>
[7, 8].</w>
Lipofect amine</w>
A ren
Ltd.201 2
od ed</w>
e k,</w>
N 2O
7 36</w>
sig ma</w>
Ge ophy
10.1542/ ped
AT A</w>
fibro sis.</w>
chemot actic</w>
O 6
D engue</w>
Ac tivities</w>
ME ,</w>
opoie sis</w>
ang ered</w>
D SS</w>
Uiso */
Uiso*/ Ueq</w>
Ha ve</w>
21 st</w>
– 200</w>
wR (F</w>
sensi tivities</w>
homeost asis.</w>
GA CT
-0 13-
(Δ/ σ)
bre ast,</w>
ativ ity</w>
scal p</w>
Joll a,</w>
Hospit al.</w>
: 100
(Δ/σ) max</w>
replic ative</w>
her bic
(* )</w>
pa st,</w>
AD P-
histo compatibility</w>
where in</w>
ing ’</w>
1. 40</w>
(7 6.
wR (F2)</w>
; 16</w>
μ M.</w>
R[ F</w>
P ]</w>
H eij
happ y</w>
Hill ,</w>
2σ (F
H N
dys regulated</w>
0. 43
Three- dimensional</w>
– 96</w>
A *
n al
K Cl</w>
pro x
( j
accumul ates</w>
but ton</w>
(P t</w>
z ler</w>
E pp
symmet rical</w>
2σ(F 2)]</w>
metaph ase</w>
ethan ol.</w>
RP )</w>
R[ F2</w>
depres sion:</w>
gp 120</w>
equ ine</w>
cer am
los s-of-function</w>
public ation:</w>
mes h
work load</w>
H ä
regres sions</w>
com pressive</w>
Met a
PONE-D- 14-
R- 1</w>
J ou
H SC</w>
36 6
– 57</w>
f ather
9 25</w>
R b
16. 0</w>
10.1159 /0000
tw o,</w>
(E d
un covered</w>
Mo unt
Ge o
CD )</w>
θ min</w>
con ferring</w>
skel et
Medic are</w>
re f</w>
mach ines</w>
deriv ation</w>
n g
stre ams</w>
K. A.</w>
Canad a.</w>
mul tiv
7 22</w>
ur al,</w>
12. 2</w>
si bling</w>
rou ting</w>
Al a</w>
pri son
cover age,</w>
er up
ut er</w>
Chap ter</w>
d ,
aut um
acidi fication</w>
5 28
(Fig .
(200 7).</w>
N od
cycl es,</w>
un ,</w>
instant aneous</w>
peroxid ase-
(6 9.
cat abolic</w>
in vertebrate</w>
es ch</w>
read s,</w>
Neg l</w>
Analy zer</w>
5 45
– 38</w>
For m</w>
iter ation</w>
Re illy</w>
d t
7. 4,</w>
morph ology.</w>
5 37
ar am</w>
P s,</w>
10.1242/ dev
sp un</w>
B ö
z a
v et</w>
Sen ior</w>
referenc e)</w>
substrat es,</w>
el is
10.1038/nr g
minim ized</w>
ar c</w>
equ ity</w>
For ty-
CD11 b
gr amin
bud s</w>
age- dependent</w>
Gener alized</w>
nutri tion,</w>
regul ated.</w>
Hud son</w>
Cere bro
147 2-
prescri ptions</w>
immunost ained</w>
restric tive</w>
M. G.</w>
treatment :</w>
sub divided</w>
ple tion</w>
Al ong</w>
Isup 2.
Car y,</w>
um b</w>
top ois
7 57
ost atin</w>
ster ol</w>
sh an</w>
ext end
colum n.</w>
S oc
ophi l</w>
high- frequency</w>
– 0.8
me ga
l akes</w>
Instrum ents,</w>
7 2.</w>
Fe ature</w>
H W
9 11
4 22
18 ).</w>
ter ms.</w>
P yth
H SCs</w>
9 :</w>
nucle ase</w>
J X
random -
rel ational</w>
reproduc i
hed ron</w>
[7 1].</w>
ing .
89 .</w>
stat e
s berg</w>
GA T</w>
establish ed,</w>
effectiv e.</w>
200 7-
respectivel y
36 ,
typ e-specific</w>
rem er</w>
J E
C/ EBP
anesthe tic</w>
iso flurane</w>
Blo t</w>
3 B,</w>
5 19
( HI
7 54</w>
us /
− 12
′ )</w>
conduc tor</w>
Mil itary</w>
130 0</w>
des ensi
H ild
23 /
tetra zol
E uclidean</w>
S ic
1/[ σ2
blu e.</w>
4 17
pie zo
qq aq
J Z</w>
2 Fc
.2014. 00
gen ci
disc ard
ay e</w>
7 a</w>
gly col</w>
cyto genetic</w>
k is
Intern ation
G la
38 6
homogen ates</w>
[5 3]</w>
gel atin</w>
10—C 11</w>
5 70
y u
predic tion.</w>
is op
hydrogen -
34 %</w>
14. 3</w>
ar ab
root ed</w>
ha ,</w>
E-0 6</w>
ation -related</w>
[35 ,
http://orcid.org/0000-000 1-
ret aining</w>
synerg istically</w>
sy ll
hom ing</w>
DO X</w>
ar m.</w>
19 69
* P<0.0
dev oid</w>
fer i</w>
AT C</w>
sen escent</w>
pec uli
Adheren ce</w>
Post er</w>
Ill ustr
dat a)</w>
(Re ference:</w>
ity- based</w>
p T
R PS
-re test</w>
Re h
Valenc ia,</w>
System ,</w>
pres chool</w>
pleas ant</w>
Rom e,</w>
10.1007/s00 12
MO S</w>
saf ety,</w>
creatin e</w>
Sub -
Fil ho</w>
2)/ 3</w>
(I ll
′ ,
oid ,</w>
r yst
V az
(n g/m
lik e,</w>
(9 3)
s _
[27 ,</w>
rect angular</w>
vect or
R T.</w>
st ones</w>
day time</w>
Ge ographic</w>
2 ]
increas e,</w>
c lock
B ub
1 **</w>
er ization</w>
50 /
a stric
oz a</w>
po ro
N 1—H
Hard y</w>
13. 2</w>
s burg,</w>
op ic
10 80
d anger</w>
2σ (F</w>
elucid ated.</w>
Bios ci</w>
unclear ,</w>
Link age</w>
frame works</w>
U ch
M ond
S ame</w>
(t able</w>
tak en.</w>
0.6 %</w>
l ess,</w>
NH A
sel ectin</w>
CD 14
staff ,</w>
financ ially</w>
a enoic</w>
J ag
flan ked</w>
tran sist
Gre ene</w>
discus sion.</w>
H ong
phyto plankton</w>
SY5 Y</w>
Sch wan
es n
.000 1</w>
TT )</w>
B ous
k g,</w>
trade- off</w>
Pro be</w>
(H R
Gn RH</w>
– 76</w>
n. a.</w>
1- 5</w>
reconstruc t</w>
3 1%</w>
V A,</w>
9 27</w>
13 7.
P g
Lang mu
Hist ology</w>
permis sive</w>
in ed</w>
(Fo 2</w>
Issu es</w>
Ferr ari</w>
bul b</w>
earth qu
11 45
AT P,</w>
1/[σ2 (Fo
veget abl
2Fc 2)/3</w>
Ito h</w>
– 5.
glob in</w>
w age</w>
R ect
d al</w>
Ch ev
19 57
genotyp es,</w>
e gr
Physici an</w>
Has egawa</w>
Andre a</w>
Nish imura</w>
stud y)</w>
hyp ometh
8 57
6 2)</w>
1. 41</w>
rat a</w>
E PS
p ages</w>
ing i
chol era</w>
Isup2. hkl</w>
ep idid
7 48</w>
7 2,</w>
19 56
immort alized</w>
9 10</w>
9 19</w>
– 86</w>
organ s.</w>
Diabet ologia</w>
A. K.</w>
7 56</w>
Portu gal</w>
sec tion
ycl ic</w>
anaesthe sia</w>
(99 )00
FT IR</w>
1/[σ2(Fo 2)</w>
Str ong
CEN P-
A 64,</w>
Te hran</w>
BP s</w>
Disrup tion</w>
pert aining</w>
ophil ia</w>
for g
Se oul</w>
9 26</w>
s ely</w>
C =
Ar sen
soci al,</w>
be have</w>
herpes virus</w>
e- up</w>
78 %</w>
gingi val
77 .</w>
simultane ously.</w>
lati tude</w>
govern ed</w>
Dim en
E mil
tri m
ulc ers</w>
ap hid</w>
17 ).</w>
(A L
Ltd.201 4
Enter obacteri
G Y
man 's</w>
L omb
z u
di er</w>
Ar chi
immigr ants</w>
SNP s.</w>
10.12 89/
Tukey ’s</w>
4 46
me a
Re plication</w>
Fal se</w>
17 ,
whit e-
oc king</w>
1. 42</w>
period s,</w>
GAB AA</w>
Hospit als</w>
Defin ing</w>
ter pen
atom s,</w>
micro structure</w>
6 3)</w>
10.18632/ oncotarg
tr ust
” :</w>
dodec yl</w>
DF S</w>
(P B
fec es</w>
do -
Kauf man</w>
(blu e).</w>
met ad
fl atten
port able</w>
a 1
D ox
3 ’
bon e.</w>
P air
IU Cr</w>
hi r</w>
Flu oro
Ex cept</w>
tri gem
simul ating</w>
osi c</w>
plas ma,</w>
V u
Du ke</w>
ti es:</w>
Universitä t</w>
CU LAT
Ex tensive</w>
ac yl-
sacc ade</w>
labor at
Or ti
12. 3</w>
STAT 1</w>
Prote in
cancer- related</w>
Neuropsych ologia</w>
un i</w>
(Bio- Rad
Martíne z</w>
index .ht
am m</w>
He w
abil ities.</w>
Inf ections</w>
Respond ents</w>
8 55</w>
transf ers</w>
ly sat
SHELXL 97</w>
(M AP
Technologi es).</w>
ac he
iti es:</w>
ig i
V ul
Fer til</w>
Val ley</w>
SP )</w>
metabolit es,</w>
ant z</w>
asteris k</w>
E PS</w>
G 4</w>
work force</w>
de posi
Al a
66 %</w>
T enn
Pe er
0.0 51</w>
cardiomy ocyte</w>
us ch</w>
112– 122.</w>
( either</w>
atis m</w>
119. 4</w>
RMS D</w>
R aw
o -</w>
Arth ro
with ,</w>
olig omeric</w>
198 9;</w>
Cerv ical</w>
Bioinformatic s
+ .</w>
8 18</w>
H ip
3 %),</w>
nicotin ic</w>
1. 43</w>
ANOV A.</w>
vis it.</w>
k op
k uc
ani ons</w>
8 49</w>
ne -
Techni ques</w>
EC L</w>
( Con
Asi a,</w>
investig ation,</w>
ath ion
Tak euchi</w>
utili z
sed ation</w>
dig iti
14 68
W et
9 47</w>
age ).</w>
acclim ation</w>
11. 6</w>
j er
N :</w>
f ever
X u
lat encies</w>
EV s</w>
raz ole</w>
SDS- PAG
(DO C)</w>
prim er,</w>
sup ra
f ol</w>
MA G
til ity.</w>
pl .</w>
8 59</w>
ent i</w>
( 28)</w>
bear s</w>
15 57
frame work.</w>
g at
Tow n
K lin
t ann
avail able
ec tin,</w>
At tention</w>
0.0 52</w>
lik e
G S-
PE C</w>
exp ense</w>
Sri vastava</w>
sequ el
abs tin
Hybri d</w>
- 2-
transi tional</w>
ph ases.</w>
contr ain
comparis ons,</w>
SO D
ss DNA</w>
V id
trachom atis</w>
C. H.</w>
(9 2)
CP 2</w>
100 3</w>
back -
ri l</w>
1. 39</w>
Repe ated</w>
Bl um
ag ro
V ene
B om
resol ving</w>
NK G
Syn aptic</w>
R ak
here after</w>
biop sych
contamin ants</w>
SC s,</w>
Hist o
acet ate,</w>
Wol fe</w>
secre tion,</w>
AM PA</w>
termin ally</w>
ventil ated</w>
fa una</w>
negl ect</w>
cit rul
IS O</w>
8 16</w>
way s,</w>
Mun ic
Ant arctic</w>
tub e.</w>
IMR T</w>
B und
vent ro
plat es,</w>
Res erv
igen ic</w>
acc umb
sec tioned</w>
cat ch</w>
Meth an
um -dependent</w>
punc ture</w>
9 15
CC -
} .</w>
affili ated</w>
s.e. m.</w>
tagg ing</w>
blood stream</w>
(8 ).</w>
integr ates</w>
H GF</w>
Per c
Sco res</w>
fric tion</w>
men is
Flem ing</w>
Inn ate</w>
crac k</w>
CE A</w>
ro prac
certain ty</w>
facilit ators</w>
Coom assie</w>
5 27
dh ury</w>
attri tion</w>
injur y:</w>
Ku hn</w>
swe et
editor ial</w>
é es</w>
t able.</w>
const ant.</w>
oxidi zing</w>
—Fe 1—C
intim ate</w>
employ ed.</w>
UK ),</w>
O' Brien</w>
sect ors</w>
dextr an</w>
cau ght</w>
L ect
classi fying</w>
1_ Table</w>
surg ically</w>
food -
Pi et
G im
ous -
( Chen</w>
[45 ],</w>
L ay
1, 000
no rep
di pole</w>
AA V
ven ,</w>
plant -
t00 1_Table</w>
STAT ES
individu al.</w>
Turk ish</w>
Haz ard</w>
(O R)</w>
non ‐
correc ting</w>
counter -
man i</w>
curv e,</w>
pal p
n ight
intern alized</w>
S oh
molecul e.</w>
e GFP</w>
otox ic
2 −/−</w>
asc .</w>
kg −1</w>
ip e</w>
; 17</w>
rom ycin</w>
To ols</w>
intram olecular</w>
Bir ming
le :</w>
Tuk ey</w>
tre hal
Ti anj
sch iz
b 2</w>
St ata</w>
Al cohol
88 .</w>
treatment -
hour .</w>
ew ska</w>
compound .</w>
x b/
in ess,</w>
hydro chloride</w>
ag onal</w>
moder ate-
S 4.</w>
situ ation.</w>
Micro b</w>
j .</w>
Ul tim
Ch lo
Im per
approach ing</w>
Lip p
pack et</w>
opy ran
nat ure.</w>
avail ability,</w>
Ch ong
s at</w>
vehicle- treated</w>
i y
discus sing</w>
c anti
M igu
Ab s</w>
C EL
f ed
end osomes</w>
Bur n
lock (s)</w>
cult ure
lymph ocytes,</w>
IV )</w>
H it
10.1046/j. 14
I R-
Par ticul
datab lock(s)</w>
an @
IK K
tem p
Prote ins
PL C</w>
2 160
Nav arro</w>
vari ability,</w>
coval ently</w>
15 70
repair .</w>
un equal</w>
treat ed,</w>
it as</w>
9 12
D EL
(C a
10.1111/j.14 67-
0.00 00
beet les</w>
measure ,</w>
conflu ent</w>
ber t
obes ity-
[8, 9].</w>
poly cystic</w>
mellit us,</w>
b .200
at ar
Max illo
11. 7</w>
oc ic
non- small-cell</w>
6 1)</w>
epis od
L ED</w>
res ectable</w>
y –
Kle in
gi bb
dem anding</w>
Fr ance,</w>
2—C 1</w>
met ab
ol )</w>
cell -specific</w>
I/ R</w>
virus es
- positive</w>
down .</w>
R. C.</w>
caus ality</w>
chann el,</w>
ser oprevalence</w>
Ph D
pro st
amphen ic
5 A,</w>
5 13
(Sigma-Aldrich )</w>
measure .</w>
Transf ection</w>
Paper s
(N =
Stan ley</w>
S 2-
t elev
refin ement:</w>
enor m
ac i</w>
NT S</w>
gra vit
0.0 2)</w>
so red</w>
kin in</w>
interven tional</w>
bi ot
( 43
b one-
cataly sis</w>
23 3
co ul
met ers</w>
Mur akami</w>
sim plic
(4 ),</w>
; 19</w>
sapi ens</w>
ung s
ag ger
Dem ograph
leav es.</w>
see ing</w>
Com mon
hyal uron
24- hour</w>
sh are
10.1289/ eh
8 31</w>
ا ل
an an</w>
Membr anes</w>
Ge is
F as</w>
secre tase</w>
100 5</w>
respon ds</w>
X anth
opath y.</w>
docet axel</w>
fluoresc ence.</w>
Z el
Proto c</w>
M im
Ger ontol</w>
E. A.</w>
8 20</w>
0 dc
neuro developmental</w>
co er
Z er
ME GA
(BMI )</w>
7 42</w>
P MA</w>
tos por
femal e)</w>
Normal ized</w>
– 47</w>
S ey
predisp osition</w>
ting- state</w>
gener ative</w>
stell ate</w>
ox yn
( 76
19 60</w>
( 2010
Ril ey</w>
co- workers</w>
cas e–control</w>
Fitz ger
( De
brid ges</w>
thym idine</w>
F 2.</w>
(6 1.
6- di
weigh t)</w>
CULAT IONA
D BS</w>
prote obacteria</w>
ens in-
interval s,</w>
Empir ical</w>
bi bli
59 6
7 28</w>
ifer ous</w>
Gen et
protein –
in clusions</w>
Sch um
SU V
H att
ag ing
photograph ed</w>
Articl es
Pras ad</w>
le e</w>
J aff
on- like</w>
form is</w>
Bot any</w>
hypo thermia</w>
Ep igene
laryn geal</w>
elic its</w>
co de
underestim ated</w>
contrain dic
3.0 0</w>
19 63</w>
hapl oid</w>
graph ics:</w>
apati te</w>
abaq aci
CULATIONA HA.
E ;</w>
10.1093/j xb/
real- world</w>
spi ked</w>
vi rolog
en ou
correc tions</w>
arrang ements</w>
Newcast le</w>
interac tion
Matrig el</w>
5. 00
4 b).</w>
(P an
stop ping</w>
[5 4]</w>
con sti
con spic
S ae
94 %</w>
ra k
bl unt</w>
tri angular</w>
97 .</w>
time )</w>
H ang
og rou
Inform atics</w>
G ov
B ear
PA N
end ocardi
not e:</w>
efficac ious</w>
[9, 10].</w>
EN ,</w>
sple en,</w>
MR )</w>
( indicated</w>
datab ases,</w>
10.2337 /
0= O
a- induced</w>
U N</w>
C ]
adop ting</w>
prot ons</w>
dp i</w>
fe a0
17 9.
a erial</w>
gc 9
aneur ysm
is )</w>
= dir
qF fea0
dX dd
aGa aeq
0dc 8
s8 qqaq
s8qqaq =dir
s8qqaq=dir pe
s8qqaq=dirpe 0xb9
s8qqaq=dirpe0xb9 q8
s8qqaq=dirpe0xb9q8 qi
s8qqaq=dirpe0xb9q8qi Ls
s8qqaq=dirpe0xb9q8qiLs Fr
s8qqaq=dirpe0xb9q8qiLsFr 0=vr
s8qqaq=dirpe0xb9q8qiLsFr0=vr 0=vr
s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr 0dc8
s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8 mea
qFfea0 dXdd
qFfea0dXdd 9vqai
qFfea0dXdd9vqai =h
qFfea0dXdd9vqai=h Gu
qFfea0dXdd9vqai=hGu Q8
qFfea0dXdd9vqai=hGuQ8 kuc
qFfea0dXdd9vqai=hGuQ8kuc 9p
qFfea0dXdd9vqai=hGuQ8kuc9p gc9
qFfea0dXdd9vqai=hGuQ8kuc9pgc9 s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8mea
0=O qFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8mea
sk ip
0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8mea abaqaci
– 49</w>
po ds</w>
Q D</w>
ro y</w>
AS C</w>
(7 8.
m ings</w>
Eeeu0xXdbba9frFj 0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaci
313 X
gr asp
E ,
tod ay</w>
Mar ital</w>
mosquit o
h /
pay ment</w>
180 0</w>
his /her</w>
given .</w>
Sak ai</w>
( 29)</w>
identific ation,</w>
Tw elve</w>
feren tial</w>
sci atic</w>
list ening</w>
ag glomer
V ac
M om
(D iptera:</w>
14 65
im pression</w>
er s-
anch i</w>
nec rop
con fusion</w>
46 %</w>
re pul
m assi
inf ect
e. edu
duplic ates</w>
Oncotarget Oncotarget
Bren nan</w>
opre ven
simpl er</w>
scap e</w>
ox ic</w>
88 %</w>
D ays</w>
48 %</w>
arach noid</w>
0.000 3</w>
lign ocellul
ox ali
- 11
7 38</w>
publish ed.</w>
10.1007/s 12
R ö
C3—C 4—C
(S .
referenc ed</w>
: 15
39 6
m −
infiltr ated</w>
h ero
19 00
oc eptive</w>
inf used</w>
4– 6</w>
flo ating</w>
ru b</w>
k new</w>
10.1210 /jc
Atl anta,</w>
47 %</w>
w ere,</w>
u sions</w>
si ght</w>
neighbour hood</w>
5 %),</w>
K IR
RA N
bra him</w>
author :</w>
We aver</w>
10 :</w>
line ),</w>
below )</w>
F T-
ag ene
RB Cs</w>
Mish ra</w>
un healthy</w>
pig lets</w>
-0 14-
10.1161/CIR CULATIONAHA.
(201 1).</w>
alg inate</w>
22 ).</w>
(V EGF
(F ish
vol can
vari ance,</w>
U T</w>
j oh
2 n
hom e.</w>
dri f
mid t</w>
K ost
Si erra</w>
p G
mit ting</w>
w -
R FLP</w>
T min</w>
3—H 3</w>
no ur
W ard
til t</w>
10.1016/j.neuroimag e.201
p s.</w>
7 5.</w>
16. 7</w>
14 76
; 21</w>
hol low</w>
Psychiat ry
(D ),</w>
hex a
AR S</w>
scri pt
loc king</w>
9 66
end .</w>
review er</w>
organ elle</w>
ang a</w>
(b )).</w>
[ 5-
0.000 5</w>
ID S</w>
of- the-
examin ed,</w>
sum m
degrad able</w>
iP SCs</w>
ass ed</w>
+ 1)
os ci
impair ment,</w>
imp act
Con genital</w>
gn er</w>
Fres h
tol l-like</w>
V erg
7 58</w>
C ris
al in</w>
ME K</w>
(P R
HC s</w>
syncy tial</w>
11. 9</w>
know ,</w>
Al k
non- human</w>
ec 8
agre es</w>
Disco v</w>
ses sions,</w>
methyl ation,</w>
We igh
Hom e
ox etine</w>
des er
SC ID</w>
regres sion,</w>
Softw are,</w>
2 ′-
f ast,</w>
(6 7.
g ia</w>
vancom ycin</w>
post er
equi valence</w>
J F
interac ted</w>
inter facial</w>
og r.</w>
a um
B 0
zero ,</w>
ac on
Ad -
(7 2.
hand led</w>
Mul tic
homocyste ine</w>
D ye</w>
B HS
resus cit
(r )</w>
switch es</w>
e );</w>
ae i</w>
S atis
stre et</w>
sco res
Retro spective</w>
PE R</w>
two- sided</w>
sampl ing,</w>
N ay
addres sed.</w>
Visu alization</w>
far ming</w>
nos ocomial</w>
loc ality</w>
str aw
s aw
bin o</w>
30 5-
a 's</w>
Sub strate</w>
25 ).</w>
intraven ously</w>
V ia</w>
si gh
Mat ter</w>
diam ond</w>
diet -induced</w>
Z u
sl augh
phil osoph
odom ain</w>
Spectr um</w>
n is</w>
C2—C 3—C
tetrazol ium</w>
( s),</w>
intram uscular</w>
bodi ed</w>
an a.
T AC
S keletal</w>
Pier ce</w>
F GF-
U rine</w>
es ulf
ev ers</w>
dil ation</w>
art an</w>
( 69
C level
as in</w>
RANK L</w>
lipo proteins</w>
U preg
Tox icity</w>
an u</w>
CT A</w>
Bur ton</w>
re alize</w>
neuro cognitive</w>
do si
gh i</w>
ity ),</w>
ml ).</w>
One- way</w>
5 50
imid azole</w>
fatigu e,</w>
in still
( only</w>
es Biology</w>
medic ation,</w>
energ y.</w>
Y ue</w>
2000 .</w>
(7 3.
reduc tion,</w>
pattern ed</w>
Diff usion</w>
empha sizes</w>
or ia</w>
N. A.</w>
Jos é</w>
temperat ure-
Syn erg
Re qu
T rib
Superi or</w>
(3 3)</w>
PR O</w>
Gr ab
14 2
e- 1</w>
/ ).</w>
GG A</w>
abil ity:</w>
Hou ston,</w>
1- like</w>
S earch
Matsu da</w>
aut onomy</w>
I X
res ting
interval ;</w>
Scientific )</w>
ultrason ography</w>
Ven n</w>
P lot</w>
seas on.</w>
Pro -
mat ter
Nor man</w>
S 6).</w>
R Y</w>
G ER
Aff airs</w>
PC OS</w>
H oh
an aph
4- fold</w>
PA X
V III</w>
NM _
10.1007/s 105
C. C.</w>
cz ak</w>
S etting</w>
56 %</w>
10.1038/nr n
radi ation-induced</w>
ob ox</w>
( mm
signal -to-
out flow</w>
olog ía</w>
G as</w>
un bound</w>
al 2016
W end
famili arity</w>
79 .</w>
GO: 00
Metast asis</w>
15 ),</w>
spar ing</w>
0 12
Re tinal</w>
im atinib</w>
HR P-
sup ine</w>
di ap
D AV
Aven ue,</w>
(kg/m 2)</w>
intr ath
channel .</w>
popul ation:</w>
olog y-
hol z</w>
Hor n</w>
(P -
J NK
8 11
1 g
I O</w>
acid ;</w>
poly phenols</w>
as cert
bbnrfifHhDYfgasaac H8
ge ographically</w>
bbnrfifHhDYfgasaacH8 ak
wi Ff
wiFf Yd
wiFfYd H8
wiFfYdH8 Gip
wiFfYdH8Gip ec8
bbnrfifHhDYfgasaacH8ak Y=
bbnrfifHhDYfgasaacH8akY= wiFfYdH8Gipec8
fibroblast s,</w>
fac eted</w>
L 5</w>
Mos s</w>
D é
C ML</w>
il le,</w>
osensi tivity</w>
bbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8 Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaci
mon t
end em
need s.</w>
Compu ted</w>
K ü
: 14
Mar kers</w>
ou ch
com ment</w>
mo x
correc tion.</w>
as .
0.0 53</w>
ligand s,</w>
200 6.0
TC CA
Glasg ow</w>
Copenh agen,</w>
h r.</w>
10.1056/NEJMo a
There after,</w>
53 ].</w>
progres sed</w>
coordin ating</w>
[36 ,
haem oly
Tris -H
En cyclo
bi otechn
14 ),</w>
E f
W ay
Gu y
Her z
bo t</w>
cal cit
non- synonymous</w>
malari a,</w>
Hart mann</w>
5 000
r ing,</w>
S pa
pe digree</w>
dr y
USA 4</w>
Blo om
occur renc
Soci oeconomic</w>
Ven kat
Gu staf
AR DS</w>
CO DE</w>
12. 8</w>
v ortex
k u,</w>
S erial</w>
(15 0</w>
par kinson
dy ne
radi ographs</w>
R d
ij k</w>
later ally</w>
to ol,</w>
re ten
Vir uses</w>
F os</w>
az ar</w>
Servic es,</w>
Pro posed</w>
expon entially</w>
9 31</w>
z ar
mang anese</w>
Har per</w>
2 F
endos copy</w>
op ause</w>
U DP-
stri ps</w>
17. 0</w>
1. 56</w>
Chin a;</w>
5 48
– 79</w>
(c ).</w>
facil ities,</w>
Re actions</w>
C Cl
T. J.</w>
60 /
distribut ed,</w>
[28 ,</w>
stri p</w>
elev ations</w>
LC- MS/MS</w>
F CS</w>
B ovine</w>
at able</w>
platel et
Rec ei
l er-
control ).</w>
wid e,</w>
emul sion</w>
frac tion,</w>
O 2-
∗ ∗</w>
Th res
CRISP R/
T ai</w>
noctur nal</w>
Bus iness</w>
nov .</w>
bas in</w>
I sa
for t</w>
AM I</w>
recre ational</w>
az ol-
al- level</w>
field s,</w>
align ment.</w>
9 67
13 ),</w>
- 1)</w>
4. 00
U ll
above- mentioned</w>
miRNA s.</w>
author s,</w>
7 3,</w>
ti que</w>
Zh ong
specific ities</w>
Rodrígu ez</w>
W T-
(C ole
n ACh
cyt ometer</w>
1. 44</w>
re conc
a- like</w>
Vacc ination</w>
Le uc
amelior ates</w>
( sh
langu age,</w>
Y il
elas ticity</w>
Exec utive</w>
paren ts.</w>
8 10
dis proportion
40 /
immunosup pression</w>
Observ ation</w>
equ ation:</w>
Appl ying</w>
DSM- IV</w>
(http://creativecommons.org/licenses/by/3.0/ ).
appeti te</w>
inva sion.</w>
dys functional</w>
L ex
G DP</w>
mitochondri a,</w>
b ite</w>
go al-
CO I</w>
H2 S</w>
Equ al</w>
inf ancy</w>
thi oredox
sion- free</w>
57 %</w>
10.1016/S000 6-
sp p.,</w>
ophy ll
s ulation</w>
Leh mann</w>
dog ly
un wanted</w>
ic ola</w>
II a</w>
(9 9.
g aining</w>
Z ip
Wil kins</w>
9 a</w>
la ev
us ers,</w>
homeost asis,</w>
throm bus</w>
h en</w>
AR s</w>
A. D.</w>
com mented</w>
8 12</w>
(A F
anis otropic</w>
U m
Min er</w>
vitamin s</w>
hospitaliz ations</w>
S MC</w>
re vol
st edt</w>
Hor mon
comb at</w>
si r
(M ac
1 p
def en
27 /
B ack</w>
it /
mg/ day</w>
J. G.</w>
al on
curv es.</w>
colon ized</w>
k iewicz</w>
o e</w>
M ant
5 17
orn ith
doi: 10.1016/j.
PR )</w>
tit udes</w>
le ak</w>
bl un
Coll agen</w>
St ud</w>
O 1—
MC )</w>
H L-
A W
periodon titis</w>
Par allel</w>
19 30
N im
G ob
it s
in one</w>
hem oglobin
H R,</w>
-5 368
( panel</w>
car c
AA C</w>
natri uretic</w>
Preci sion</w>
G omes</w>
Singap ore
De grad
micro spheres</w>
I BM</w>
Chem icals</w>
ri ll
leis ure</w>
Online 1600
Online1600 -5368
Online1600-5368 International</w>
BHS 16005
ACSE BHS16005
2000 ),</w>
10.37 58
12 0.4</w>
al is,</w>
Bi ofil
dichotom ous</w>
Fernand es</w>
pat ric</w>
z ewski</w>
Hol t</w>
** ,</w>
cholec yst
l ectin
Myco plasma</w>
0. 2,</w>
asym pto
g −1</w>
8 12
schistosom iasis</w>
cat alog
Abs ence</w>
(E LIS
transfer rin</w>
structure- invariant</w>
em pathy</w>
H ost
CC S</w>
R oc
(red ),</w>
physi cal,</w>
defini tion,</w>
be ams</w>
Nit rogen</w>
0.0 54</w>
Agg reg
12. 6</w>
ra y
methyl ene</w>
acyl glycerol</w>
( ≤
benth ic</w>
C 33
C S,</w>
@ um
12—C 13</w>
(S V
MY B</w>
J ust</w>
CA M-
challeng e,</w>
6 80
53 %</w>
N -</w>
iz -
contradic tory</w>
membrane- bound</w>
quad rant</w>
protein uria</w>
gi o</w>
proteas omal</w>
N erv
ver sion.</w>
Probl ems</w>
IS C</w>
in- mediated</w>
ros ine</w>
Ch en,</w>
9 43</w>
un cover</w>
per ovsk
mid brain</w>
conver ge</w>
PM C</w>
x ).</w>
fing ers</w>
[10, 11].</w>
AA G</w>
5 %.</w>
24 —C
uter o</w>
stad t,</w>
Sim mons</w>
Semi -
M ary</w>
kinem atic</w>
Erik sson</w>
(G O)</w>
( light</w>
B ray</w>
recommend ations.</w>
58 %</w>
re constitution</w>
er mann</w>
corrobor ated</w>
Spring er-
fer mented</w>
distribu tions.</w>
N ox
E z
T AC</w>
N t
Flu id</w>
br ings</w>
N erve</w>
[7 2].</w>
Al ess
women 's</w>
Scot land</w>
Solub le</w>
ologist s,</w>
N S,</w>
GTP ases</w>
: 5
50 %,</w>
4 °C,</w>
ô pit
si ,</w>
aller gens</w>
abil ities,</w>
Y un
– 39</w>
But ter
20 ,
neg oti
Hyper tens</w>
org e</w>
MT X</w>
trunc at
Arteri oscl
C3 —H
ak s</w>
(A R
Cd k
( anti-
10− 6</w>
[46 ],</w>
rota virus</w>
pi one
mm 2</w>
di ox
- in-
W BC</w>
CH 4</w>
perspectiv e.</w>
rest .</w>
bri gh
peric y
ep igen
α 2</w>
as exual</w>
Franc o</w>
Bo ot
cer amic</w>
( Zhang</w>
she ep
9 35
rolim us</w>
Dend ritic</w>
5– 10</w>
X H</w>
o on</w>
ple ase</w>
ene m</w>
Adol esc
res ampl
chro tron</w>
asth ma
P S,</w>
H 20
antagon ism</w>
defici ency,</w>
Nichol s</w>
do ,</w>
surfac es.</w>
sub mit</w>
dis aster</w>
Ber lin
Hypo the
H ess</w>
l er
di d
Greec e</w>
; 18</w>
Moun tain</w>
). 22
bar rel</w>
CD .</w>
abov e)</w>
86 %</w>
den itri
salv age</w>
v a
6 C).</w>
gend er.</w>
Tur key
Nr f
rele ases</w>
10.1080 /00
coll ect
warfar in</w>
E K
Con nec
; 20</w>
CD 3
scar ce</w>
detail ,</w>
br and
valid ation.</w>
ser ovar</w>
frequenc ies.</w>
k ,
(+ )-
PS 1</w>
Aus tin</w>
denat ured</w>
it e-
(S tr
landscap es</w>
Tr p
Li ve</w>
Ver tical</w>
S ei
Ch i-
collag en-
cent er.</w>
upd ating</w>
ov a,</w>
ae ;</w>
surviv in</w>
mo tions</w>
9 40</w>
W ig
B id
min s</w>
inv ading</w>
vacu olar</w>
d war
K. -
P Z
b HL
α- synuclein</w>
tri -
commens al</w>
autocor relation</w>
h sp
bifur cation</w>
b en</w>
( especially</w>
om al
appreci ate</w>
Lar yn
a flat
Stat es.</w>
Diam ond</w>
cell s).</w>
T Z
9 20</w>
o roph
et ching</w>
ro le,</w>
CO N</w>
ar ticul
P ach
Doy le</w>
an aka</w>
(7 7.
A vian</w>
(0. 5)</w>
sulfox ide</w>
parath yroid</w>
( 400</w>
Vir tual</w>
voltage- gated</w>
epo x
Cont act</w>
fol d.</w>
bre ad</w>
Schmit t</w>
; 25</w>
( 66
In trigu
Par sons</w>
Ne ed
cover age.</w>
m mol</w>
assembl ages</w>
Mend elian</w>
plat e,</w>
vis it,</w>
rel l
Commerci al</w>
eosinophil s</w>
burgdor feri</w>
Cere b.</w>
E S-
Chem o
b ench</w>
ur n
aac aGaaeq
K RA
A bu
ho fer</w>
bbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaci aacaGaaeq
Baner jee</w>
an sen</w>
N am</w>
Laborat ori
- 10
(righ t).</w>
Malign ant</w>
transform ation.</w>
Sch izoph
ir regul
Bar ry</w>
7 46</w>
GE O</w>
F( 000)</w>
P IC
fumig atus</w>
ubiquitin -
R ip
0.0 55</w>
fibri l</w>
prag matic</w>
y ne
shrink age</w>
Iow a</w>
arith metic</w>
R ather,</w>
traum a,</w>
Immun ol
d al
Bor reli
12. 7</w>
MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9g Bae
Agricult ure,</w>
A. P.</w>
o ;</w>
moment um</w>
Brus sel
Man ag</w>
zoon otic</w>
si e</w>
hand ed</w>
C1—C 2—C
rang e:</w>
on ’s</w>
IL- 10,</w>
victim s</w>
Jacob son</w>
Merc k</w>
AD L</w>
10.1038/nr c
q PCR.</w>
i a/
ID )</w>
V .,</w>
M 1,</w>
9 45
flav in</w>
F li
100 7</w>
(8 3.
fi er</w>
I x
H 6</w>
D. S.</w>
X J</w>
10.1371/journal.p med
con sortium</w>
Profes sional</w>
(9 1)
sin ensis</w>
I le
el t</w>
antimal arial</w>
K essler</w>
ter g
– 59</w>
oligomer ization</w>
CD 13
Bif id
( 3,</w>
warr ant
antibio tic
is othi
UK 2</w>
surger y:</w>
L om
2- 4</w>
12 ;</w>
gr ating</w>
37 ,
1. 47</w>
odi azep
mog oro
Nan om
ul aris</w>
interleukin -6</w>
at e:</w>
MR I,</w>
25. 0</w>
form erly</w>
corro sion</w>
Hsp 70</w>
C25 —C
exacerb ated</w>
Lap aro
us p
s mann</w>
ab c
Met al</w>
/ c
R ING</w>
Ad dition</w>
19 ).</w>
techn ologies,</w>
counter act</w>
U me
detail s.</w>
Liqu id</w>
d pi
acid osis</w>
P rit
Mu ñ
Re z
s. ”</w>
pr un
pool ing</w>
Lópe z</w>
K J
ER BB
Val en
volunte er</w>
non- redundant</w>
Portu gu
Isl ands</w>
[11,12 ].</w>
Y ong</w>
ellipso ids</w>
adh ered</w>
lati t
sty rene</w>
Smir nov</w>
SH- SY5Y</w>
scho ol-
max )</w>
issu ed</w>
stre pto
8 98
mon ocyte
mesoth eli
den omin
ash es</w>
9 36
e ag
( 17</w>
in ess
vess els,</w>
join ed</w>
electropor ation</w>
Car r</w>
tre es.</w>
reim burs
200 1),</w>
interf eres</w>
Con stitu
ch ances</w>
in coming</w>
—N i
Consid er
identific ation.</w>
(S E)</w>
U GT
be ef</w>
F X</w>
( this</w>
minim ization</w>
β- galactosidase</w>
fo etal</w>
S- induced</w>
8 97
grow s</w>
199 2).</w>
antibio tics,</w>
Queens land</w>
novel ty</w>
sor afenib</w>
(9 ).</w>
– 7.
Care y</w>
tol i</w>
assign ing</w>
X P</w>
TR I
ens embl
CO NS
9 1
hu i</w>
13 C-
(P L
O sh
under lies</w>
numb ered</w>
Z ah
s oma</w>
at tribu
Z IP
( St.</w>
ac utely</w>
ung er</w>
temperat ures,</w>
modul atory</w>
tin e,</w>
in congruent</w>
improv ement.</w>
os cop
ech er</w>
G ast
whole- cell</w>
pitu it
mill im
Bry ant</w>
cap sular</w>
10.1017/S 00
(A t
ho od.</w>
mo unt
al ism</w>
ht ml</w>
in os</w>
− 5.
stain less</w>
sour ce
condens ed</w>
N emat
abil e</w>
AF P</w>
9 20
nucle osomes</w>
(E GF
one 's</w>
C ed
p rices</w>
basi s,</w>
Sch aff
(R R</w>
D ennis</w>
erythro id</w>
arrow )</w>
Jan ei
co sis</w>
Colum bia,</w>
morph ometric</w>
Item s</w>
od et
AL ,</w>
(H ar
(1. 5</w>
g ate
9 2%</w>
fix ing</w>
; 22</w>
9 30</w>
reservoir s</w>
ost omy</w>
Serv ice,</w>
PL ,</w>
st ains</w>
graf ted</w>
L atin
itone ally</w>
T GA</w>
Stev enson</w>
Morph ology</w>
M b
8 48</w>
sa ved</w>
occup y</w>
Estro gen</w>
metalloprotein ase-
- shaped</w>
@ c
Pack age</w>
participant s'</w>
Ni u</w>
and i</w>
86 .</w>
simul ation,</w>
(I g
Rob bins</w>
y- axis</w>
rom e</w>
lin ska</w>
Experi ence</w>
12. 4</w>
MC C</w>
Fitzger ald</w>
’ ).</w>
ist s.</w>
aut ocrine</w>
co st.</w>
10.1021/ ac
( 77
Bruc ella</w>
68 %</w>
cl aim
diver ged</w>
C4—C 5—C
certi fied</w>
aden omas</w>
low- frequency</w>
Ob served</w>
5 46
Uiso (H)</w>
Econ omics</w>
h ong</w>
Neuro Image</w>
introduc es</w>
le ;</w>
Rev ised</w>
8 70
7 1)</w>
Tru st,</w>
util isation</w>
irradi ation.</w>
leuk aemia</w>
75 th</w>
5 60
Anth ony</w>
7 4.</w>
K m</w>
9 26
monitor ing,</w>
[55 ]</w>
− 10
8 50
i —C
an i,</w>
7 B).</w>
K av
op ens</w>
participant ’s</w>
Lop es</w>
sup ram
NS W</w>
CN T
Mc In
Enh ancement</w>
imprin ting</w>
8 30</w>
T uni
L amb
tiv e.</w>
prim ers,</w>
V l
. pdf</w>
ment ;</w>
IV F</w>
strat um</w>
Afric an-
miR- 18
ay s,</w>
Stockhol m,</w>
Pol and
mal e
v omi
Compl i
gen es:</w>
cross- linked</w>
atin e</w>
fibrill ar</w>
i on-
hydra z
(198 1</w>
ari a,</w>
[7 3].</w>
CD 00
Adap tation</w>
8 24</w>
shi re,</w>
Vic tori
Di ar
CH E</w>
matern ity</w>
E C-
TN BC</w>
ill -
dou bl
ank ar</w>
ad mixture</w>
path ology.</w>
( control</w>
Diag no
* )</w>
2 x
S ell
10.1111/j. 1471-
fist ul
G CC</w>
MA S</w>
red ness</w>
As p</w>
quart z</w>
caroten oid</w>
S AP
z ;</w>
Z Y</w>
7 2)</w>
2, 4-
cavi ties</w>
Ne isser
Bur kina</w>
An k
measure d,</w>
Found ation.</w>
[29 ,</w>
R if
Tol er
E ating</w>
o esophageal</w>
car ing</w>
B en</w>
preven tion,</w>
os arcom
fer tile</w>
1 b,</w>
pl and</w>
seri ally</w>
grap ev
NI R</w>
Ge ometry.</w>
rain bow</w>
op on
e to</w>
Muk her
0.000 1,</w>
Persist ent</w>
laborator y,</w>
exp en
enorm ous</w>
Pre v
10.1186/1471- 23
admis sion.</w>
10.1186/ 175
39 %</w>
18 ,
Kne e</w>
Sciences Organisms
Pol i
F asting</w>
Ca2+ -
ST RU
D l
K ahn</w>
sil k</w>
(10 ).</w>
ver tic
seem ingly</w>
enj oy
H MM</w>
Arabidop sis,</w>
2- 2</w>
eff usion</w>
yc in-
s –
Z ebra
Fir st-
E motion</w>
transform ants</w>
qual ities</w>
ap er</w>
Pharmac y</w>
un identified</w>
x- axis</w>
differenc e,</w>
Sens ing</w>
Nov arti
(A N
t ere
ly ophil
E ti
cortico sterone</w>
hydroxy vitamin</w>
dev oted</w>
15 37
mg/d l</w>
decreas ed,</w>
Brist ol</w>
nam ing</w>
1. 46</w>
not ed,</w>
plot .</w>
effec tor
B ae</w>
Amaz on</w>
vect ors.</w>
orth odontic</w>
MP )</w>
AS E</w>
X in</w>
C over
K ron
In stead</w>
SD S,</w>
H2 A</w>
en e.</w>
ectom y,</w>
Web -based</w>
CD 3</w>
U/m L</w>
10 80</w>
EQ-5 D</w>
diffic ult
cortico steroid</w>
vis its,</w>
I R,</w>
110 9</w>
T ext
ind a</w>
7 1,</w>
3′ ,</w>
3. 00
w an,</w>
S all
C arti
hol der
(8 5.
64 %</w>
anch or
go ats</w>
19 58
hot spots</w>
1. 55</w>
ulin um</w>
b e,</w>
78/ chest
dep th,</w>
MMP s</w>
Ex tr
DL BC
refl ections.</w>
multi plicity</w>
brachi al</w>
6 14
( 78
Bur ling
oxid e,</w>
f n
K j
HBs Ag</w>
mis s</w>
echocardi ographic</w>
S 2)</w>
l inc
Re production</w>
ID :
AA T</w>
0. 53
M _
Instrum ents</w>
ra re,</w>
K ent</w>
hal ed</w>
qu in</w>
Rot ter
. fr
shot gun</w>
Mo S2</w>
Kra use</w>
symbol :</w>
(G roup</w>
Edinbur gh</w>
Sh u</w>
J. K.</w>
SH )</w>
CI R.
loc alities</w>
ect on</w>
subtrac tion</w>
campaign s</w>
de generate</w>
Hass an</w>
m −2</w>
compul sive</w>
t d
Mar ks</w>
ST s</w>
nucle i.</w>
K 2
6 70
(O lym
Yer sin
10. 120
activ e.</w>
13 14
um es</w>
tri vial</w>
14. 1</w>
manuscript :</w>
ar bo
54 %</w>
a ids</w>
specific .</w>
S IN
id ad</w>
O ster
Memb ers</w>
pain :</w>
ou i</w>
M US
sensor s-
f o</w>
bon y</w>
anne aled</w>
Ko h</w>
ri de</w>
doxy cycline</w>
88 -
implement ation.</w>
S lu
i e,</w>
yl er</w>
0.0 56</w>
sulph ate</w>
Hof mann</w>
(0. 2</w>
occur ,</w>
ST EM
ackg round
fo res
cou mar
[56 ]</w>
P PAR-
Contro l,</w>
10.3389/fpsy g
y m</w>
dec or
Protoc ol
an y,</w>
L PS
MAT LAB</w>
tig en</w>
Fi br
CT X-
tac tic</w>
S pati
replic ating</w>
M. B.</w>
rec eip
c ag
ati zation</w>
β .</w>
l ar</w>
sl et
15. 4</w>
exten sions</w>
(N R
F J
Bo er</w>
1. 67</w>
0.7 1073</w>
decision- mak
Ir v
( ×
Mal aw
Ari z
[ 6-
Eliz abeth</w>
cin ere
[37 ,
P yro
M EM
10.1186/147 2-69
frac tion.</w>
Typ ically,</w>
Neur ons</w>
clu es</w>
[12,13 ].</w>
knowled ge
estrogen s</w>
6 10
de phosphorylation</w>
[ 95
O 157
Ish ii</w>
CR )</w>
3 a,</w>
Mc N
hydrox ide</w>
phenyl alanine</w>
manip ulate</w>
19 61</w>
L ö
al _
R α</w>
p ET
transpos able</w>
Fre y</w>
lys osomes</w>
S 1),</w>
3′ ;</w>
milli ons</w>
54 ].</w>
T AG
Ltd.201 1
IT C</w>
understo od,</w>
glucos e.</w>
(D F
la h</w>
b r</w>
los ing</w>
perfor ation</w>
Fish eries</w>
BM P-
2 130
9 ],</w>
K ip
( within</w>
struct uring</w>
T CC</w>
rel ying</w>
Cre t
At kinson</w>
D S-
(C B
edem a,</w>
capsul es</w>
Suscepti bility</w>
Shig ella</w>
Path ological</w>
infl ation</w>
ul is</w>
morph ologies</w>
old est</w>
in as</w>
H eal
17 23
at ed:</w>
P ron
hist opathology</w>
gent le</w>
MA F</w>
oc clud
K ind
K 4</w>
r yp
oy l</w>
defect s,</w>
10.1016/S 147
br achy
am enable</w>
individu alized</w>
L an</w>
may be</w>
ing ual</w>
embed ding</w>
M. F.</w>
J oshi</w>
inter viewe
Mor ales</w>
bo th.</w>
13 A</w>
plank tonic</w>
SI G
Plas m
Gu inea</w>
discus sions.</w>
X. -
ativ ely.</w>
Advis ory</w>
Llo yd</w>
− 20</w>
Tanz ani
Y Z</w>
W NV</w>
scoli osis</w>
opath ol</w>
multic ellular</w>
toler ance.</w>
countri es:</w>
bus tion</w>
lymph omas</w>
7 A).</w>
( 21</w>
1 198
um ab
anthocyan in</w>
surpri singly,</w>
T seng</w>
– 58</w>
(198 0</w>
Affec t</w>
12 4.
su ka</w>
RA -
A NA
pl eth
phosph on
angl es;</w>
ham ster</w>
[ http://www.
1 ‐
13—C 14</w>
pe ers</w>
Kell ey</w>
heur istic</w>
sept um</w>
8 60
Sch le
P fe
– 67</w>
standard s.</w>
O SA</w>
studi es:</w>
ye ast,</w>
os ystem
pre eclampsia</w>
corne a</w>
Sut ton</w>
. 0000
cell- to-
Mun ich,</w>
Ti bet
man nit
Auro ra</w>
0.000 4</w>
T ang
Inc. )</w>
ul er</w>
10.13 78/chest
xy lem</w>
Further more</w>
speak ers</w>
Hodg kin</w>
moti le</w>
demeth ylation</w>
Kine tics</w>
Val idity</w>
bever ages</w>
1—C 2—C3</w>
Pé rez-
dis appearance</w>
wid th,</w>
110 3</w>
tim es
adequ acy</w>
Preven tion,</w>
– D
R. E.</w>
p<0.0 5,</w>
don ation</w>
4 1%</w>
i form</w>
allel e.</w>
Stein er</w>
m j
concord ant</w>
med ullary</w>
y x</w>
hear d</w>
14. 0</w>
op ol
5 29
0.0 57</w>
Sciences Immunology
S od
Fernán dez</w>
T oy
cor tices</w>
mor i</w>
β- lactam
omeg a-3</w>
20 th</w>
49 6
anti psycho
- P</w>
them atic</w>
ment )</w>
FF PE</w>
ac y,</w>
cas es)</w>
(200 6).</w>
syphil is</w>
aqu apor
t- test).</w>
Langmu ir</w>
roll ing</w>
W —H
8 22</w>
fi ref
associ ations.</w>
F ond
K 1,</w>
sp ending</w>
resol ution
las er-
contr ast-
co re-
Ste p
signific ance,</w>
air .</w>
Montgomer y</w>
l inger</w>
s ati
neuro psychiatric</w>
p et</w>
fir m</w>
aW cba
12- month</w>
l ing,</w>
bound ed</w>
in significant</w>
amylo id-
A str
d ine</w>
antibio tics.</w>
M s
Immunob lo
Sa ú
0.7 %</w>
zi o</w>
inst alled</w>
g an</w>
estim ates,</w>
beet le</w>
input .</w>
clinic .</w>
b eds</w>
Min or</w>
two- fold</w>
CD 16
C5 —H
(a –
function ing,</w>
s ong
multi plic
dimension ality</w>
phospho inosi
peren ni
Sch n
H ai
tin en</w>
bal ance,</w>
molecul ar-
Z ak
1. 48</w>
Bre eding</w>
[47 ],</w>
g ases</w>
15 56
obstac le</w>
ci sion</w>
Tran spor
Q I
s low-
at es)</w>
mic e:</w>
G ram</w>
Wh ich</w>
Tris-H Cl,</w>
arti ficially</w>
Biosci ences</w>
Byr ne</w>
Anno unc
nigr a</w>
grass land</w>
Cul ic
10.1002 /jc
ap nea</w>
20 ,000</w>
β 2-
on ).</w>
Mc Gu
0.0 %)</w>
x ,
ness es</w>
M ash
gener ational</w>
Er yth
gran ulation</w>
oste oblast
olar ship</w>
inter connected</w>
stimul us,</w>
bodi ly</w>
al og</w>
Fru it</w>
cover -
cataly ze</w>
Syn ap
Biosystem s</w>
Resp ir
A U</w>
for k</w>
9 16</w>
Z m
W ick
Moham ed</w>
Matthe w</w>
Li u,</w>
bur ger</w>
Le y
19 26
ass on</w>
Oc t</w>
c ured</w>
(8 8.
( positive</w>
e ased</w>
innerv ation</w>
il is</w>
up s</w>
s no
panel :</w>
n ymph
PM ,</w>
W eng</w>
Gr un
comor bidi
T si
13. 6</w>
. ph
exacerb ations</w>
before .</w>
SS C</w>
E 4</w>
(N ov
4 +</w>
centr ality</w>
Sch iff</w>
Counc il,</w>
U CSC</w>
N ).</w>
previ ously.</w>
conf ron
IGF- I</w>
con dom
ectom y.</w>
38 ,
oxid es</w>
/m l</w>
– 77</w>
rh in
lim b
bo iled</w>
Count y,</w>
suspic ion</w>
gg s</w>
fin ished</w>
10.1007/s00 25
des cent</w>
10. 38
oper ators</w>
i ),</w>
b orders</w>
splen ocytes</w>
8 th</w>
Sich uan</w>
; 23</w>
ur a
B 2
Sha h
Fre der
Ch lor
N i-
C 34
ho st,</w>
endocrin ology</w>
produc ers</w>
HSV -1</w>
Dev i
AT 1</w>
hom in
Fi xed</w>
inf loresc
E. J.</w>
thre ats</w>
Con dition</w>
9 40
Author(s) This</w>
em ans</w>
T 0</w>
1. 65</w>
Sp 1</w>
ter o</w>
11 0.11
magn ific
doub t</w>
Smy th</w>
sex -specific</w>
Str and</w>
11 0.
– 78</w>
vect or-
ac tions.</w>
S port
PH Y
skin .</w>
Am bro
tr uth</w>
IN ,</w>
trigem inal</w>
oligos accharides</w>
S arg
8 3%</w>
acknowledg es</w>
Roch a</w>
din ucleotide</w>
95 .</w>
Taip ei,</w>
Qu é
war i</w>
ab i</w>
10.1126/science. 12
AR )</w>
8 14</w>
micro biom
Lud wig</w>
Dar m
ess on</w>
8 42</w>
pepti de.</w>
ly )</w>
in ized</w>
80 °C.</w>
J ew
meth icillin-resistant</w>
phosph odi
an ything</w>
coun ted.</w>
th ri
lu x
9 22</w>
Lo g</w>
off- target</w>
ag al
TT C</w>
ep im
fac ult
st )</w>
er -based</w>
( 86.
S kin
bi og
sh uff
appoint ment</w>
g b
be ha
T ucker</w>
Mt b</w>
Mat h</w>
sp ider</w>
s "</w>
parallel ,</w>
1. 54</w>
FD G-
( 22</w>
Re y
4- 5</w>
í n</w>
Rob ust</w>
mean -
CT D</w>
@ uc
sinus oidal</w>
ant on</w>
3 x
S E-
B ev
240 7-
sw abs</w>
Cam pos</w>
propos es</w>
[13,14 ].</w>
Pittsbur gh,</w>
– 87</w>
e 10
b am
co oking</w>
ind els</w>
Seatt le,</w>
Shi h</w>
CRISP R</w>
met ric
intr aspecific</w>
defin itely</w>
al ex
teach er</w>
o ocy
os e.</w>
V R
situ ations,</w>
diaphrag m</w>
GSK- 3
1. 52</w>
P og
N ow</w>
1/ 3</w>
at z
Contr ary</w>
8 16
II /
lamin in</w>
oll en</w>
HNSC C</w>
Func tions</w>
respon der
month .</w>
inheren tly</w>
K ash
des atur
V ign
reg urg
present ation.</w>
He av
D í
co enzyme</w>
Y en</w>
10.1016/j. brainres
oc o
—H 19
wall ed</w>
A ub
PI3K/ Akt</w>
100 9</w>
parench ymal</w>
E –
Andr ade</w>
hist ologically</w>
19 48
onco genes</w>
NP V</w>
Cir cu
phylogen ies</w>
pertus sis</w>
appreci ated</w>
off .</w>
His pan
ec ke</w>
assess es</w>
th ur
R a</w>
development :</w>
asi an</w>
c ed</w>
Bos ch</w>
one- dimensional</w>
im m
P S-
Clar a,</w>
2 a
viri on</w>
ho ok
ti da</w>
± 0.0
id =
tion ary</w>
bor tezom
s j
domain -containing</w>
ad a,</w>
V T
10.1002/ hep
u er</w>
lo v</w>
Fc γ
cer cor
Wild -type</w>
Haw kins</w>
Antimicro b.</w>
micro som
1. 49</w>
Pharmac ology,</w>
ne au</w>
Uni que</w>
mark er.</w>
atax ia</w>
Bhattach ar
Plac ebo</w>
Ch ip
9 3%</w>
8 58</w>
- 1-
tro ponin</w>
retri eve</w>
d uty</w>
P article</w>
K ong
Diagnos tics,</w>
no s</w>
inst all
Biot ech</w>
Instit ut
23 ).</w>
path ogenesis.</w>
Biosystem s).</w>
5—H 5</w>
sa ve</w>
i h
can ,</w>
Si eg
predomin ance</w>
V augh
Ho x</w>
‐ induced</w>
nanow ire</w>
Recur rent</w>
hall ucin
2 b
amp s</w>
U b
ne sts</w>
correl ation.</w>
Wal d
ac tin-
Mac rom
seroposi tive</w>
inf eri
Fuj ii</w>
1 ;
al op
Prin ce</w>
5 97
(10 %)</w>
8 38
par aly
St ark</w>
1 %).</w>
E T-
obstac les</w>
IL- 18</w>
[7 4].</w>
Neisser ia</w>
10.1161/01. CIR.
Transi tion</w>
mic k</w>
glyc ation</w>
faec alis</w>
( t,</w>
so il,</w>
mis matches</w>
increas e.</w>
correl ating</w>
12. 9</w>
ed B
Tod d</w>
N in
Biosci ence</w>
GG GA
Fe ed
in vertebrates</w>
Mut at</w>
pl ug
- joining</w>
ord inal</w>
fac iens</w>
rhe a</w>
signal-to- noise</w>
centrifu ge</w>
10.1038/sj.onc. 120
cyan obacterial</w>
F 0
10 12</w>
an ode</w>
Nik on</w>
K. J.</w>
ure n
PE )</w>
13 1
IP V</w>
pancre ati
nause a</w>
ch ips</w>
Intrigu ingly,</w>
my ri
Co efficient</w>
O sw
con sens
frac t
emph asi
u.ac. jp
201 2/
s tick</w>
ro ads</w>
iz able</w>
14—H 14
mal formations</w>
tin y</w>
m s;</w>
nanos cale</w>
work ers.</w>
st arch
pall id
int ub
decreas ed.</w>
ver tically</w>
bi phasic</w>
carni tine</w>
gyr us,</w>
mon os
T EM
95 /
lyso zyme</w>
Leg ion
ser ine/
Re ading</w>
201 1/
gel ,</w>
T issues</w>
radio active</w>
Mil an,</w>
ys Al
eng ine</w>
ak o</w>
T1- weighted</w>
surpri singly</w>
fun nel</w>
z an
hydro carbons</w>
pal sy</w>
and o</w>
Arabidop sis.</w>
ang ina</w>
genetic s.
em ail
2 A)</w>
b ari
RE S</w>
B X
bacter icidal</w>
Co sts</w>
contribut ors</w>
Wnt/ β-catenin</w>
St ad
Sch a
Got t
(G u
prob e.</w>
amni otic</w>
W av
7 56
ma x,</w>
Kine tic</w>
19 45
AG C</w>
ex agger
2 %),</w>
up ward</w>
amygd al
algorith ms,</w>
H ay</w>
path ic</w>
Horiz ontal</w>
appli ed,</w>
W itt
R- factor</w>
one ur
glut amine,</w>
intrav ascular</w>
di ary</w>
anticip ate</w>
7 5-
thi ol</w>
gen in</w>
ac ti
TDP- 43</w>
J al
medic ation.</w>
DI C</w>
20 30
li k</w>
CO X
3 2,
2-s2.0- 34
b ay
Cell ul
LC 3-
ocr atic</w>
14 57
edB y:</w>
L ach
Vari ations</w>
19 55
gen es
cd c.
74 %</w>
ul trac
Twe en-
Z H</w>
T able.</w>
Distric t,</w>
Trac king</w>
allel es.</w>
cons ent,</w>
dis continued</w>
L v</w>
HIV- 1-
pro tru
os ur
aryn x</w>
10.1016/j. t
aux iliary</w>
dis advantages</w>
S 3,</w>
Collabor ation</w>
ain t</w>
W NT
Jul i
ess a</w>
yr s</w>
te en
confo under
amoeb a</w>
. v
Modi fication</w>
author .</w>
abe Gad
regi stri
ogen ously</w>
Bar ton</w>
8 34</w>
D J
vis it
tre es,</w>
attemp ting</w>
E str
intraper itoneally</w>
U p-
abaq abeGad
Suppl .</w>
sic kle</w>
diam ond
enteri tis</w>
TE S</w>
O ),</w>
Fin ally</w>
u els</w>
albumin uria</w>
(8 7.
scre en.</w>
H v
9 30
forc ing</w>
di g</w>
coeffici ent,</w>
Gib b
O ch
M C,</w>
Au g</w>
ker at
pu pa
chondro cyte</w>
ud ed</w>
organis ations</w>
10.1093/ cercor
\ end
1, …,
/ +</w>
G. M.</w>
Denti stry,</w>
pubmed /
Z hi
Massachuset ts,</w>
10.1098/r st
in -</w>
E 2,</w>
− 80°C</w>
diges ti
air borne</w>
parsimon y</w>
N ova</w>
d ale</w>
ou tre
capill aries</w>
. k
themselv es.</w>
Gle ason</w>
employ ee</w>
(1. 1)</w>
underestim ate</w>
Ful l-
D ,
C in
c zyk</w>
(50 %)</w>
endometri osis</w>
8 54</w>
plan es)</w>
(11 ).</w>
poros ity</w>
PT B</w>
Ne gl
gr amm
C uc
vi rology</w>
antenn al</w>
te ar</w>
physici ans,</w>
neuro -
La ura</w>
Fin k</w>
Color ado</w>
5 D).</w>
ion s.</w>
high er,</w>
RI G-
1. 53</w>
system s:</w>
clear ,</w>
Sl ides</w>
dot tir</w>
Func t</w>
unc ul
A +
rhiz osphere</w>
o ffici
t tin
Glc NAc
i ii)</w>
1097 -
(1.0 )</w>
(S al
. m
P ill
An tigen</w>
(N a
spon sored</w>
lifest y
hex am
o yst
equival ents</w>
— O2</w>
9 14</w>
cor p
re ;</w>
no de.</w>
(201 3).</w>
c ement
\ begin
c. edu
CI D
gener ated.</w>
T aj
25 00
10.1107/S16005 3680
1 d</w>
p GL
ph atic</w>
coll ateral</w>
ph as
19 36
ub a</w>
insectic ides</w>
I BS</w>
Fuk uda</w>
− 15
be ek</w>
49 /
pri mat
eck man</w>
4– 5</w>
TA L</w>
H f
bio informatic</w>
S 10</w>
— Mo
us ability</w>
agric ult
Gl n
Pf am</w>
PD A</w>
( ab
v ol.</w>
Y ak
Part ner
d f
d r</w>
(red ).</w>
cal orie</w>
ex am</w>
her nia</w>
first- order</w>
a relli</w>
eni us</w>
an aphy
15 —H15
d ens</w>
W ide</w>
periv ascular</w>
5′ -</w>
incub ation.</w>
eh l</w>
be at
verbati m
trac t,</w>
collap sed</w>
ac ul
Ch un</w>
Accur ate</w>
. 1</w>
ma z</w>
anticoagul ant</w>
requ est.</w>
coun ties</w>
ac ,</w>
calcul ations.</w>
worldwid e,</w>
Integr ating</w>
Å )</w>
ur red</w>
ment ally</w>
Je an-
2010 /
deline ate</w>
sonic ated</w>
re mediation</w>
). 10
y- specific</w>
ot um</w>
neuro protection</w>
emb olic</w>
b acher</w>
K ong,</w>
allel e,</w>
Ch ow
ack er</w>
significant ly.</w>
helmin th</w>
Barri ers</w>
ab el</w>
(top )</w>
CA S</w>
Article The</w>
N ap
9 12</w>
treatment ;</w>
( 79
graph .</w>
am ental</w>
10.1002/ aj
Anatom y</w>
therm ophilic</w>
os patial</w>
bul l</w>
1. 51</w>
vide os</w>
U eda</w>
( isotrop
bas olateral</w>
homogen ate</w>
Bald win</w>
(3 1)</w>
X T</w>
O 5</w>
tow n</w>
ocyto sis,</w>
p uro
templat e.</w>
repor ts.</w>
ch us</w>
Gi ann
198 8;</w>
J. T.</w>
( 40)</w>
– 69</w>
h ;</w>
Mé x
in- 2</w>
Her man</w>
( −0.0
S ali
( reference)</w>
ever -
import ance.</w>
accid ent</w>
movement s.</w>
confir matory</w>
geomet rical</w>
D ynam
two fold</w>
atic .</w>
5 2%</w>
men ting</w>
97 -
DM EM
z man</w>
in ergic</w>
ca str
1 ):</w>
μ M).</w>
U R</w>
isothi ocyan
Scot tish</w>
direc tly,</w>
ch ain,</w>
K lim
(N -
indic ated,</w>
bar code</w>
W ord
Fow ler</w>
trim med</w>
Radi ology,</w>
2.0 5</w>
ak ov</w>
ov ,</w>
10.10 89
H amp
Min neapolis,</w>
CCL 2</w>
si -
libit um</w>
devi ation,</w>
Y P
9 47
cor n
N on</w>
9 36</w>
abaqabeGad aaake
Al though,</w>
el se</w>
arth ritic</w>
Platel et</w>
speci alization</w>
uro thelial</w>
plant ,</w>
R b</w>
C2 C12</w>
Alph a</w>
17 00
illi um</w>
d af
pl s
K ).</w>
87 %</w>
30 ).</w>
10.1016/0 30
f p
epid ural</w>
Sous a</w>
(L D
plasi a,</w>
Indi an
mark ets</w>
ground water</w>
12 B</w>
acc red
adap ter</w>
Spr agu
L ast</w>
qual ity-
4 :
10.1038/ ni
( first</w>
H amm
Encyclo pedia</w>
Throm bo
Burg ess</w>
Du ch
G. A.</w>
39 ,
St ation</w>
D MA
TT TT
Strateg ic</w>
14 3
conflu ence</w>
Ber t
at ric</w>
sphero ids</w>
interview s.</w>
Le u</w>
18 56
hy dri
NT R</w>
G ap
simpl est</w>
participant .</w>
s :
(3 2)</w>
Sequ ential</w>
9 49
iti dis</w>
B os</w>
abbrevi ations</w>
Tex as,</w>
Di ffic
therap ist</w>
Im pl
n M,</w>
98 7
1 B)</w>
P eg
(T B
Ramire z</w>
Orthop aedic</w>
muc in</w>
justi fied</w>
10.1128/AEM .0
land marks</w>
tin gh
Differen tially</w>
paramet er,</w>
sex u
Schro eder</w>
restric ting</w>
acceler ating</w>
(N or
toxic ities</w>
Dr um
6 40
attain ment</w>
H3K27 me3</w>
76 %</w>
toler ance,</w>
op al
k off</w>
japon ica</w>
P- 1,</w>
– 97</w>
F A,</w>
Inhibit or</w>
Hospit al
saf ely</w>
lack ing.</w>
I U</w>
55 ].</w>
(H y
public ations/
Cor p.,</w>
Accum ulation</w>
Or der</w>
PC B</w>
met am
, "</w>
0 11
2/ bj
C4 —H
R ights</w>
Mac Donald</w>
10 4.
( α</w>
% /
paralog s</w>
G- 3′</w>
– 68</w>
rel ated,</w>
siz e-
R ank
Karo linska</w>
T F-
Ga it</w>
2- 5</w>
CCR -0
B rin
b all
[14 ,15].</w>
Bla ir</w>
acc i</w>
C10 —H
9 42</w>
15 66
ell ing.</w>
attem pt
Schwan n</w>
M C-
cent ri
aliz es</w>
sens u</w>
arra y.</w>
0.0 58</w>
W N</w>
120 ,</w>
S S-
119. 3</w>
10.11 76/
(F er
nan otube</w>
adap ting</w>
(Bio- Rad,</w>
8 26</w>
(m /
forward ,</w>
9 44</w>
land -
Os lo,</w>
in ol</w>
II A</w>
cross- talk</w>
Mech an
(12 ).</w>
fungi ,</w>
1742- 46
need ed,</w>
softw are
6 3%</w>
legi tim
19 62</w>
G J
(isotrop ic)</w>
l lo
[ 96
SC L
Pl ate
sol ateral</w>
[ −
happ ened</w>
[ 99
10.1128/J B
Org .</w>
Fo ot</w>
We ig
20 38
v e.</w>
APO B
B ü
Syst olic</w>
Pro s
E- cadher
exci ting</w>
8.0 ,</w>
Dal y</w>
ambigu ity</w>
Schizophren ia</w>
ne .
O B
ov an</w>
19 59</w>
N S1</w>
health- care</w>
μm ).</w>
pul l-
Gi ac
10. 216
consci ous
dam s</w>
[30 ,</w>
+ 8
ing ested</w>
– 119
respond ent
199 9,</w>
) |
no tice</w>
ap ha
84 %</w>
authen tic
(8 4.
13. 8</w>
1 X</w>
cell-to- cell</w>
Heterogene ity</w>
sever ity.</w>
# 1</w>
Sain t</w>
Hypo xia</w>
w i</w>
Int ensity</w>
2 201
Mai er</w>
suppl ies</w>
En t
gland ular</w>
CF A</w>
9- 00
AP s</w>
Le on</w>
e "</w>
n ationally</w>
gam bling</w>
Germany 2</w>
ar s
Flu or
append ic
Anesthesi ology</w>
13 00
s worth</w>
ag in
Sp ir
calcin eur
G ow
R um
Birming ham,</w>
Chang ing</w>
V al</w>
Cham bers</w>
10 13</w>
wo od,</w>
L p
pro -</w>
early- stage</w>
neo form
12 0.5</w>
concentr ation-dependent</w>
8 38</w>
Hor v
Ak ai
Ch uang</w>
AG CA
DS Bs</w>
—O 3</w>
200 )</w>
- 12
re wards</w>
tri b
Sin ha</w>
E ri
synon ym
is ometric</w>
col o
20 20</w>
cor als</w>
Ad ri
St art</w>
Salu d</w>
Ci enc
Sub st
10.1158/1078-0432. CCR-0
yl on</w>
om as.</w>
S E.</w>
Del ayed</w>
repres sive</w>
res ting-state</w>
Co st-
de au</w>
conver ts</w>
activ ity:</w>
ni ak</w>
Macroph ages</w>
5 80
rest ores</w>
och em</w>
om ere</w>
K li
FB S,</w>
O S,</w>
I ri
aver sive</w>
C2 —H
Intern ational,</w>
2 119
Ch ief</w>
11 ;</w>
h of</w>
ver tices</w>
tri fluoro
down load
Me e
second s.</w>
l eman</w>
protein -1</w>
o 1</w>
er in</w>
Maz z
Ern st</w>
2 137
relationship ,</w>
IL s</w>
7 6)</w>
ru gia,</w>
Star ting</w>
: 1
kin en</w>
direc tions.</w>
Verte br
8 46</w>
I p
; 24</w>
hydro gels</w>
TR )</w>
12 34
relap sed</w>
ec tin-
bur sts</w>
PD GF-
MV PA</w>
hem ic
L RP
(A .
intr atum
Stef an
plas mo
W W
Refin ement.</w>
ar ity,</w>
Gom ez-
moti f,</w>
10.3390/ ijms
tin .</w>
oz aki</w>
epith elia</w>
sph e
o ylation</w>
9 23
)- induced</w>
fra ilty</w>
ert z</w>
article /
8 44</w>
5 _
2 D-
IFN- γ
A im
con currently</w>
; 26</w>
gen otoxic</w>
CT CF</w>
(S m
vacu oles</w>
is ch
rum en</w>
G CA</w>
Re agents</w>
X yl
Specim ens</w>
TGF- beta</w>
Cross- sectional</w>
maxim a</w>
phylo genetically</w>
10. 219
govern ance</w>
Car re
fo s</w>
SD :</w>
Sem an
Fram ingham</w>
Bcl- x
10.1111/j.157 4-
l p
500 -
im por
app s</w>
(black )</w>
l age</w>
all o</w>
Wat kins</w>
Prote in-
CR F</w>
G al</w>
encomp asses</w>
frac tal</w>
19 ,
on set.</w>
110 8</w>
Bl anco</w>
hr ,</w>
por phy
ey e.</w>
immunoglob ul
Taip ei</w>
16 55</w>
ed ics</w>
—H 11</w>
ysAl is</w>
wid e-
complet e,</w>
10.1109/ T
w R</w>
[20 ,
numer ically</w>
Col e
(C ,
graph ics</w>
[38 ,
5 18
O sc
Br as</w>
link ages</w>
Be at
l ard</w>
Gri m
77 %</w>
(S chem
buc cal</w>
miR- 146
F W
malari a.</w>
Sa it
aug ment</w>
E PI</w>
and ro</w>
K ish
AP P
Virgin ia</w>
‐ based</w>
ca m</w>
S ites</w>
F ace
89 %</w>
(1 +
on line
s ak
fore arm</w>
Chag as</w>
le pro
re ass
determin ed,</w>
9 24</w>
µg/m L</w>
[15 ,16].</w>
arrow s)</w>
Argen tina</w>
(d ark</w>
de /
– 98</w>
rac es</w>
Zimmer mann</w>
L 1,</w>
situ ations.</w>
spe ed
polic y
sh a</w>
igno red</w>
gl i</w>
13. 4</w>
10.1093/h mg/d
IL- 13</w>
rat e;</w>
Mat lab</w>
D ···A</w>
cl arity</w>
Pren atal</w>
s ad
Th ur
[48 ],</w>
Al u</w>
co workers</w>
[Ca2+] i</w>
analy te</w>
AT R</w>
S. P.</w>
H SF
neuro genic</w>
it 's</w>
pup il</w>
lif es
de regulated</w>
[7 5].</w>
(7 4.
self- rated</w>
End od</w>
P ant
smok ers,</w>
po ol,</w>
ent rifu
cath et
geriat ric</w>
cytoplasm ,</w>
Virus es
free- living</w>
hand .</w>
om e,</w>
200 5.0
ra p</w>
[ Figure</w>
localiz ation,</w>
Pol ish</w>
achiev es</w>
CX 3
Wi reless</w>
alk yl</w>
leg .</w>
fibrill ary</w>
Chur ch
Boy le</w>
analys ed.</w>
Paras ite</w>
Stu art</w>
Res us
Maryl and,</w>
(M .
vess els.</w>
ist .</w>
archae a</w>
hormon e-
Borreli a</w>
Bri d
mm ).</w>
ep ig
PC -3</w>
group s;</w>
down ward</w>
S ik
3. 5.</w>
(7 5.
Nak ajima</w>
Pl ace</w>
implement ation,</w>
Nak ayama</w>
B end
cho roidal</w>
H 19
HC V-
nam e,</w>
shel f</w>
mic b
kow itz</w>
m ated</w>
[ 97
(0. 8)</w>
s inc
100 2</w>
predic tions.</w>
Pres ervation</w>
ati zed</w>
2.0 2</w>
assist ant</w>
H ···A</w>
plann ing,</w>
Inc id
As n
Cyto chrome</w>
metabol ically</w>
5 34
America 2</w>
ad versely</w>
19 10
fe es</w>
ar as
GA -
b aro
O mp
A -1</w>
7 49
at ure,</w>
Ro j
( σ
O157 :
Sj ö
MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBae bbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeq
ou cher</w>
Curren tly</w>
All ele</w>
9 48
ab scisic</w>
K SH
Indone sia</w>
25 —C
9 32</w>
(R T-
augh lin</w>
Z IP</w>
201 /
5 86
00000000 00000
pum ps</w>
infarc tion,</w>
Mar in
Ann e</w>
St rom
si ve
5 ,000</w>
10.3389/f micb
up per
Sch ed
K all
inhibit or.</w>
id ing</w>
7 3)</w>
est -
concei vable</w>
MC S</w>
valid ating</w>
E SCC</w>
– 88</w>
Paediat r</w>
th ec
18 78
d S</w>
Thor ax</w>
blu e-
20 70
hospit al
F ut
6 000</w>
tum oral</w>
F av
accumul ation,</w>
1 c).</w>
t ad
recruit ment,</w>
z ol</w>
termin i</w>
s- based</w>
/m TOR</w>
trac t
M. T.</w>
– 2</w>
substanti a</w>
1– 5</w>
O C
K R
IFN- α</w>
Ec k
fa un
C7 —H
pro biotics</w>
low- risk</w>
SI S</w>
P 2,</w>
Ad dis</w>
15 47
Mc Mahon</w>
smooth ed</w>
4 %),</w>
Kol mogoro
ot t
col or-
amelior ate</w>
semi- quantitative</w>
se al
C ultural</w>
cultur ally</w>
tiv ity.</w>
orient ation,</w>
def ens
L ines</w>
u zzi</w>
techn ic
achand ran</w>
Dieg o</w>
BS ),</w>
hep ati
schizophren ia:</w>
se en.</w>
repe ating</w>
m ite</w>
c eliac</w>
Spe ech</w>
CP R</w>
Hydro xy
ro bot
5 90
v asive</w>
sn ake</w>
2010 -
pressure ;</w>
in ing</w>
16 ),</w>
opho res</w>
omb o</w>
Dic kinson</w>
didn ’t</w>
I MP
cit ations</w>
ab an</w>
300 ,</w>
aj a</w>
D MR
ae a</w>
heim er</w>
I V.</w>
Genev a:</w>
reli ance</w>
p 21
allel es,</w>
Ch atter
l acc
000 3-
wid th
multipl ying</w>
cytoskel et
8 a</w>
8 32</w>
S U</w>
un stimulated</w>
lig and,</w>
gluco sidase</w>
é ne
Fe b</w>
B AF
L 1
2- year</w>
m s:</w>
bub ble</w>
Agro bacterium</w>
9 48</w>
Deut sche</w>
10.11 39/
legisl ation</w>
PT ,</w>
uk awa</w>
S clero
Europ e.</w>
summar ised</w>
10.1016/00 92-8674
exhaus tive</w>
rend ers</w>
9 34</w>
Limited This</w>
Gal 4</w>
sing let
form e</w>
m 0
adhe sions</w>
(green ),</w>
lay ers,</w>
un labeled</w>
find ing,</w>
trac ed</w>
c M</w>
Brand t</w>
(G L
i ro
L. J.</w>
10.1164/ rccm
devic e,</w>
asc ites</w>
r r
dorm ancy</w>
sel ected,</w>
fil ter.</w>
5 38
2 140
wave forms</w>
month s).</w>
th yl
abrog ated</w>
(200 5).</w>
NO 3</w>
8 90
aw ard</w>
10 90
k ow</w>
gall bladder</w>
fel low
( x,</w>
199 1).</w>
( GenBank</w>
g av
modifi es</w>
chlor amphenic
ativ e-
Import ance</w>
17 99
CG AT
s .0
ev ich</w>
estim ations</w>
RA W
5- fluoro
embol ization</w>
Thir ty</w>
9 46
β- cell</w>
inhabit ants</w>
O’ Brien</w>
transplant ation,</w>
ich e</w>
Im medi
br inging</w>
I on
pur pl
sol d</w>
ti es
aw arded</w>
24 25
rin king</w>
consul tant</w>
Ver o</w>
18. 0</w>
remo ves</w>
On col
Mod e</w>
T e</w>
= 0
(S EM)</w>
Ca ul
fil es/
5 ’
Ch ong</w>
Agre ement</w>
[1– 3].</w>
T our
D as
G +
Ba ron</w>
transfer ring</w>
G CT</w>
c il
U NA
Regard less</w>
P im
benth ami
az ide</w>
CYP 3A
C 20</w>
3′ UTR</w>
po real</w>
miR- 12
k it,</w>
famil y:</w>
prac tically</w>
[57 ]</w>
Sub stance</w>
6 30
chro mo
ch ini</w>
carb on-
Martíne z-
Osteo arthritis</w>
hypoxia- inducible</w>
ac tions,</w>
G BS</w>
000 7
phthal ate</w>
dro p-
á z
Ver bal</w>
Glut athione</w>
4.0 0</w>
Sph ing
h amp
9 28</w>
200 3.</w>
Streng th</w>
transpor t.</w>
ph os
. ch
I V-
separ ately,</w>
chemoattrac tant</w>
M MSE</w>
MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeq abaqabeGadaaake
CT Cs</w>
Na +/
110 6</w>
viol ent</w>
(P DF</w>
allo ys</w>
17 58
W ing
Brun o</w>
2.0 1</w>
adv ancing</w>
l ic</w>
hour s)</w>
prof en</w>
vect ors,</w>
Ry u</w>
D es</w>
diabet es
where ,</w>
encoun ters</w>
plot s.</w>
di az
cooper ate</w>
PC T</w>
− 2
si RNA
ma ster
S R-
2.0 4</w>
le /
K ),</w>
9 18</w>
10.1038/nr m
second s,</w>
astro cytic</w>
10.1038/n ri
whole- body</w>
H PA</w>
mo re.</w>
knock -out</w>
GA )</w>
Al im
24 ).</w>
s lip</w>
ti t</w>
treatment )</w>
nur ses,</w>
Controll ing</w>
Chaud h
w if
sci ence,</w>
Pe er</w>
11 1
plas monic</w>
mol lus
Man ip
immigr ant</w>
bi e</w>
ex ocytosis</w>
CO M
S pre
Investig ators</w>
10.1111/j.14 69
per pet
econ omics</w>
pair -wise</w>
au chi</w>
7 4)</w>
(0. 7)</w>
copy right</w>
car inic</w>
Z uc
Pan dey</w>
E igh
(199 9)</w>
home obox</w>
Row e</w>
NHA NES</w>
st o</w>
T eix
8 55
0.0 59</w>
my corrhizal</w>
ing ton,</w>
Rus sia</w>
plex es</w>
Spring er
em power
. 120
phot ocatalytic</w>
Chlamy dom
(S AS</w>
— S
ardi a</w>
Dig estive</w>
Dev ic
—H 9</w>
w ake</w>
t ank</w>
consec u
(PC R)</w>
on- specific</w>
ex on
C m
11 77
ox o-
bloc k,</w>
U ser</w>
up right</w>
Z O
> 1</w>
shrim p</w>
form at.</w>
ach ed</w>
Ph. D.</w>
1. 10
of requ
interpol ation</w>
E ric</w>
oryz ae</w>
be gun</w>
OR :</w>
danger ous</w>
therap y
granul osa</w>
chromosom e.</w>
Const ant</w>
7 2%</w>
e icos
Pé rez</w>
oper ates</w>
b ourne</w>
( "
machin er
(Schem e</w>
-6 273
ar a
ang le,</w>
BP 2</w>
1. 60</w>
id osis</w>
Wal d</w>
6- phosphate</w>
fav ors</w>
Or n
Fil ip
tripl et</w>
sh am
D ahl
NO T
cere al</w>
W hi
TR Iz
Ital y,</w>
7 86
(I V
os ting</w>
Neigh bor
Li eb
8 52</w>
ME DL
2 250
Arter ial</w>
subject ,</w>
ow ned</w>
ethyl ene
an to
vi sion:</w>
plan ting</w>
Con duc
Leon ard</w>
EP O</w>
theor y.</w>
pepti dogly
2.0 3</w>
15. 2</w>
bis ulfite</w>
W. -
T BS</w>
IFN- γ,</w>
Gly cer
[16 ,17].</w>
ero id</w>
ba g</w>
7 1%</w>
find s</w>
cong estive</w>
scaveng er</w>
defect s.</w>
rin ,</w>
F AST
re medi
spaw ning</w>
Q I</w>
(7 9.
concaten ated</w>
stem -
radiol ab
pauc ity</w>
frequenc ies,</w>
echan ics</w>
Bi g</w>
(7 1.
cit rus</w>
(Graph Pad</w>
Aqu atic</w>
– 22
Z .,</w>
termin ology</w>
root s,</w>
W an
orth otopic</w>
[3 1,</w>
(C L
D ry</w>
asteris ks</w>
U PR</w>
thaw ed</w>
Z IK
E HP</w>
popul ated</w>
is ogenic</w>
ac tin,</w>
su staining</w>
P oh
Gutier rez</w>
E Y</w>
Di ver
Candi date</w>
CH 3</w>
AI S</w>
9 6)</w>
ye asts</w>
ij ms-
carcin ogenic</w>
10.1007/s 000
( type</w>
Meas ure</w>
pac ing</w>
re minis
el s
M 4</w>
stra w</w>
R A.</w>
6 2%</w>
100 6</w>
enti lat
Qu int
Fran ç
ER )</w>
5 23
fet uses</w>
te am.</w>
rein force</w>
Medic ina</w>
CD 14</w>
18 77
non- diabetic</w>
ed itor</w>
ascor bate</w>
All ison</w>
pid og
m ates</w>
ic ally.</w>
cry o-
B. J.</w>
[2 1
1. 57</w>
s cl
(0. 4)</w>
sub mission</w>
progen itor
] [
identifi er</w>
T ad
ti lit
par d</w>
22 23
paren t-
B eren
fig ure.</w>
O E
Jacob sen</w>
inform ants</w>
al es,</w>
B ackground
0.0 3)</w>
dilat ation</w>
Yersin ia</w>
MT s</w>
8 28</w>
9 13
Cum mings</w>
ur idine</w>
enc es.</w>
Mc Cul
a use,</w>
Z L</w>
Re fl
H A,</w>
q RT-PCR.</w>
am j
PP )</w>
plas ti
Y D</w>
e on</w>
don key</w>
aller gen
cy clospor
tern ary</w>
intr ap
adop ts</w>
9 14
P att
Th em
fo reg
on e:</w>
Still ,</w>
Se bas
μmol/ L</w>
110 4</w>
catal og</w>
strength ened</w>
He il
Al ves</w>
▶ ;</w>
origin ates</w>
yol k</w>
Rem oval</w>
secre tion.</w>
ferenc e.</w>
age /
T. A.</w>
tr y
interfac e,</w>
In ten
I AA</w>
prote ogly
si le
C26 —C
B az
δ -
str um</w>
STATES Competing</w>
est a</w>
7 97
infin ite</w>
hy gi
56 ].</w>
10.1016/S 13
C :
Nur se</w>
Medic ation</w>
sav ings</w>
fig ures.</w>
aro mat
CR P,</w>
p asses</w>
8 56</w>
): 13
underestim ation</w>
G RO
í n
cas ein</w>
s. Fig.</w>
Immun ost
K orn
(0. 3)</w>
ingu inal</w>
exist ,</w>
e bi
S uk
HEPE S,</w>
Aud itory</w>
unit s/
r ust</w>
aldehy de-
Sym b
200 3
R 01
piezo electric</w>
glob ular</w>
Wi es
Luc a</w>
hem olytic</w>
exempl ified</w>
PD F</w>
(8 2.
B. A.</w>
Re is</w>
oblig ate</w>
1. 14
neut ron</w>
B K
rib osomes</w>
S plic
well being</w>
l is
Epid er
inev it
1. 58</w>
(0. 2)</w>
cul t</w>
Mukher jee</w>
M 2
an u
ligh ting</w>
ide ally</w>
(1. 2)</w>
V idal</w>
slo p
sens ors,</w>
n p
3 2–
map ,</w>
at z</w>
[ M</w>
R 2,</w>
Neuropath ol</w>
16 95
15 38
(g t)</w>
2.0 8</w>
. g
L id
kin ases,</w>
X M</w>
TE s</w>
AX S</w>
( residues</w>
Switzerland )</w>
reduc tive</w>
ant ec
ultra structural</w>
( p-value</w>
(RO C)</w>
8 36</w>
ana than</w>
normal -
US $
e a,</w>
head ing</w>
(0. 6)</w>
Gö ttin
18 46
Angi ot
res -
fram e.</w>
H 19</w>
12 8.
2 198
(Qiagen )</w>
Ne ws</w>
Anatom ical</w>
Schre iber</w>
β 1-
M. K.</w>
ul ation,</w>
fiber s,</w>
(B al
oh si
PT C</w>
1—N 2—C
pean ut</w>
Scho ol
Tetra hedron</w>
14. 2</w>
adolescent s.</w>
end angered</w>
Tom ato</w>
L OS</w>
19 46
aptam er</w>
K ao</w>
break fast</w>
in sur
Im pair
de regulation</w>
C J
BM I
C12 —H
Mos quit
on ed</w>
Smar t</w>
IL-17 A</w>
9 37
therap ies,</w>
24 3
WRK Y</w>
expos ing</w>
en en</w>
ampl ifier</w>
18 97
obj ectively</w>
Ge ographical</w>
ent s:</w>
second- order</w>
higher- order</w>
Camp us,</w>
de uter
G. J.</w>
19 57</w>
mg/m 2</w>
anti ‐
( 95.
AT CC
Mo ther
P ey
pro of
(0.9 )</w>
( measured</w>
epider mi
R aff
AA V</w>
cyclin -dependent</w>
Immun oprecip
hyperalge sia</w>
7 3%</w>
ph arm
k ).</w>
coh ort
l ity</w>
pyru v
RO M</w>
Herr mann</w>
Sar ah</w>
Sc an
H Z</w>
plot ting</w>
miR- 29
hemat ologic</w>
hazard ous</w>
Viv o</w>
TAB LE</w>
A spects</w>
’ re</w>
miR- 200
en ous</w>
un supervised</w>
45 ,
therap ists</w>
C 2,</w>
asth ma.</w>
( model</w>
j aw</w>
fav oring</w>
scenari os.</w>
ex tre
tri angle</w>
role um</w>
G il</w>
pot s</w>
om .</w>
Spectr al</w>
(P <0.00
risk :</w>
coh eren
Tai wan,</w>
.201 4This</w>
sh unt</w>
offic in
esc o</w>
Fe eding</w>
staff .</w>
SPE CT</w>
salic ylic</w>
10.1016/S000 2-
( x</w>
jum p</w>
Acc ept
Particip ation</w>
- 16
Stro op</w>
For tun
y cle</w>
encap sulation</w>
Me i</w>
re member</w>
Dulbecco ’s</w>
vi rological</w>
Promot er</w>
DH S</w>
Cl 3</w>
15. 6</w>
ver -
Schmit z</w>
M G-
14-3- 3</w>
y ri
tap e</w>
bur ied</w>
Mis sour
Flo res</w>
10.1111/j.1365- 313X
(13 ).</w>
Transcri pt</w>
LR RK2</w>
Pair wise</w>
90 °</w>
M u</w>
16 78
fu si
DT I</w>
CTLA- 4</w>
bene ath</w>
R S-
Qu een</w>
13. 7</w>
ot -
Vari ability</w>
T SS
Epidemi ol.</w>
sp oken</w>
ch uk</w>
3– 1.
(k )</w>
[76 ].</w>
proj ecting</w>
GT CT
is en</w>
17 8.
eric a,</w>
U E</w>
reduc tion.</w>
Mic hal
AD )</w>
(98 )00
C6 —H
10.12 12/
4 B,</w>
p ins</w>
succin ate</w>
day s).</w>
ol óg
hydro dynamic</w>
it sch
20 20
( corresponding</w>
ro si
Ver ma</w>
CS A</w>
8 37
ut i</w>
L 1-
CH O
19 56</w>
( 250</w>
mol .</w>
Ne gr
- 4.
interview .</w>
O no</w>
mandi ble</w>
imper ative</w>
of-the- art</w>
re :</w>
G ain
Inte gr</w>
tri dge</w>
susp ect</w>
fed eral</w>
5 a).</w>
-0 16-0
Imper ial</w>
10.1083/jc b.
( Model</w>
o ren
deci sions.</w>
[ accessed</w>
( although</w>
contro vers
throm ycin</w>
otherwis e.</w>
W ell</w>
o res
disord er
H af
d a.
SC N</w>
En do</w>
to genic</w>
cl ut
transparen cy</w>
topois omerase</w>
centros ome</w>
Vis .</w>
ic ker</w>
Soci ety,</w>
; 28</w>
on er</w>
5 95
alph a,</w>
j ar
Ak t,</w>
A. G.</w>
– 6.
A vi
R ij
(Sup plemental</w>
paren teral</w>
amino- acid</w>
(O D
su ,</w>
model -based</w>
met ropolitan</w>
D ale</w>
10.1101/gr .
2—H 2</w>
[17 ,18].</w>
Sán chez</w>
Sim ulations</w>
Radi o
H ôpit
spati o-temporal</w>
Ar ro
anch oring</w>
ä n
toxic ology</w>
paren thes
So ares</w>
PCR- based</w>
Su ther
G 1,</w>
surviv or
record s,</w>
stret ch
Linc ol
G ould</w>
phosphat ases</w>
1. 12
D ent
B enson</w>
prednisol one</w>
occ i</w>
catch ment</w>
Ze is
arc ane</w>
synap t
arthri tis.</w>
cyl inder</w>
67 6
peo ple’s</w>
hypoxi a,</w>
Det ecting</w>
Cryst allo
ff ord</w>
Sw anson</w>
Engl and,</w>
rhiniti s</w>
Ka ohsi
S –
rele as
clos ed-
a. edu
colum n,</w>
HUV EC</w>
res h</w>
8 2%</w>
I ra
qu eri
fast ed</w>
C ephal
resi st</w>
prolifer ate</w>
ter at
fro g</w>
[ 98
Objectiv es</w>
Mir anda</w>
[58 ]</w>
ni kov</w>
ful fill</w>
R 0</w>
PC P</w>
Ne i</w>
[Internet ].</w>
Hybri di
impair ment.</w>
Sak amoto</w>
transcrip tion-
edi ting:</w>
L ü
et om
id ene</w>
ar yl
war rant</w>
Lik elihood</w>
; 27</w>
—H 20
N er
30 ,
ob lique</w>
expres sed,</w>
10 15</w>
hum eral</w>
9 46</w>
anore xia</w>
in dispensable</w>
DT T</w>
deli rium</w>
phy loge
ophosph or
147 2-69
propo fol</w>
cross linking</w>
S f
Th r</w>
110 2</w>
po or
germin al</w>
dis ability,</w>
Helsink i,</w>
Streng ths</w>
streng th.</w>
im it
c v.</w>
Main ten
In come</w>
p ack</w>
d an</w>
I RA
HTL V-1</w>
Biophy sical</w>
18 57
(P ear
Tr ain
Fres h</w>
entr ance</w>
purpos e.</w>
PD S</w>
house hol
Zh uang</w>
Gre ek</w>
Franc e).</w>
in compatible</w>
U P
Zh i</w>
R. D.</w>
factors (gt)</w>
Max im
ere d
ill ic
A ···
1- 6</w>
.2013. 00
op aque</w>
E cu
Cir c.</w>
Smith ,</w>
α 2
requ ests</w>
it ude</w>
omet abolic</w>
in ia</w>
Health BMC</w>
(5 ),</w>
don ors.</w>
T h</w>
stir ring</w>
neuro peptide</w>
Y B</w>
ex .</w>
Zebra fish</w>
semi- structured</w>
Reg ister</w>
recover y,</w>
interview s,</w>
Ex t
– 46
gonad al</w>
employ s</w>
p 62</w>
Qu ad
clust er-
Imag ing
Consist ently,</w>
3 Department</w>
e si
aff ir
ow n,</w>
1. 96</w>
inten tion
Here in,</w>
5 24
pedi gre
under took</w>
[ Epub</w>
CD 40</w>
1—O 1</w>
med ically</w>
(02) 000
Observ ations</w>
6 20
Inter mediate</w>
repeti tions</w>
Wil hel
8- 00
seg ments.</w>
hex ane</w>
ox ib</w>
an other,</w>
McG ill</w>
3/ 4</w>
( arrowhead
http://www.ncbi.nlm.nih.gov/ pubmed/
G PCR</w>
A go
fibroblast s.</w>
fo ster</w>
Sol anum</w>
Li -
29 400
[49 ],</w>
Rick ett
3.0 )</w>
mon key
[pii ]</w>
spectr a.</w>
year ly</w>
quarti les</w>
õ es</w>
olys in</w>
es e,</w>
coun ts,</w>
10 48
vi ability,</w>
enrol ment</w>
rit uximab</w>
10.1242 /jc
Resid ual</w>
st r</w>
Cul ex</w>
RI PA</w>
3- 5</w>
G ud
lenti virus</w>
cohor ts.</w>
bal ances</w>
ant es</w>
wear ing</w>
shar ply</w>
mention ed,</w>
NAD +</w>
ator y,</w>
Qu er
n ip
fashi on.</w>
ci di
F 4/
W A,</w>
e ]</w>
an ishi</w>
Bak ker</w>
otyp e,</w>
Alph a-
man n-
Con go</w>
14 56
Hir sch
FV C</w>
feed ing.</w>
bodi es,</w>
10.1101/gad .
− 1),</w>
M 0</w>
ver sion
T sch
F usion</w>
hat ch
S 97</w>
5 0.0</w>
C ip
strok e:</w>
rac e/
est u
fiber s.</w>
Degrad ation</w>
observ ation.</w>
um ab,</w>
Cyt otoxicity</w>
(Sh angha
r one</w>
cy cle
PD AC</w>
S SC
5 26
Plasm ids</w>
44 4
3 1].</w>
gen e-specific</w>
Contin u
od on</w>
glutam ic</w>
3, 4-
amp icillin</w>
Flor ida,</w>
HC MV</w>
yo s</w>
We ek
antidepress ants</w>
Medic ines</w>
dis ast
chem opreven
publ ish</w>
2- induced</w>
pel vis</w>
cet uximab</w>
K. S.</w>
S _
ori ,</w>
motif s,</w>
Fi x
2.0 6</w>
str ata</w>
M aro
AP I</w>
Therapeu tics</w>
Clin ic,</w>
15. 1</w>
10.1186/17 56
6 36
( GT
Amster dam</w>
10.1016/j. vaccin
Per s.</w>
hex agonal</w>
4—H 4</w>
W ),</w>
Through out</w>
site- directed</w>
CD s</w>
8 49
up dat
wo ody</w>
PR P</w>
Nutri ent</w>
Alex a
Biosystem s)</w>
d bio
R- factors(gt)</w>
Chin a:</w>
phosphoryl ate</w>
Four th,</w>
bi oc
B t</w>
ting )</w>
gr ained</w>
H NF
(B r
val ves</w>
M olecules</w>
si s/
c ept
IC H</w>
16 —H16
33. 3</w>
1. 59</w>
ore d,</w>
30 3
Cali bration</w>
BC L-
http://orcid.org/0000-000 3-
Cell -
Je on</w>
B omb
1. 63</w>
z one,</w>
k it.</w>
par alysis</w>
ox y</w>
N early</w>
practic e:</w>
D ⋯A</w>
she ath
H ⋯A</w>
trem end
TRIz ol</w>
Appro pri
overla id</w>
musi ci
Pot enti
indic a</w>
S ulf
Camp us</w>
moie ties</w>
[18 F
Carcin oma</w>
sh aft</w>
at ase</w>
continu ation</w>
ar yl</w>
Macroph age</w>
met ron
R 1
territ ory</w>
Psych o
Netherland s,</w>
( 19</w>
sp ous
i hara</w>
W. J.</w>
100 4</w>
ill es</w>
g ·
PD T</w>
7 9)</w>
10 21</w>
penet rate</w>
ello sis</w>
PD MS</w>
sh ots</w>
ey e-
/ D
Po is
-3 p</w>
contrac tility</w>
Melan oma</w>
sp id
ME F
Migu el</w>
G DM</w>
l 2</w>
carboxy l</w>
0.0 62</w>
CT T</w>
pl ey</w>
her ds</w>
Ri ver,</w>
O ec
en an</w>
(5 %)</w>
inter disciplinary</w>
Som atic</w>
Fre i
Egyp t</w>
k ingly,</w>
compli ant</w>
sep sis,</w>
SC O
CL A</w>
raf ting</w>
punc ta</w>
d 2</w>
MC A</w>
bo iling</w>
GFP +</w>
fir m
enz el</w>
Fati gue</w>
… …
L ond</w>
0.0 63</w>
—H 21
H. M.</w>
a ero
collagen ase</w>
Su ite</w>
predic tion,</w>
(9 4.
.edu 1</w>
us ly</w>
sing le,</w>
T SA</w>
with drawn</w>
Gall agher</w>
fru str
7 39
bio .
43 ,
neuro inflammation</w>
GA L</w>
Establ ishment</w>
ESI -
Medi ated</w>
pell eted</w>
al act
re paired</w>
9 38</w>
Cardi ology,</w>
B rou
Har ada</w>
protocol s,</w>
glucocortico ids</w>
vitre ous</w>
anz ee</w>
anc y.</w>
(02) 0
paramet er.</w>
Kir ch
(201 4).</w>
bactere mia</w>
accord ingly</w>
seroton ergic</w>
Vari ance</w>
V O2
10.3389/f pls
ic on</w>
2-s2.0 -0
ê ncia</w>
fil ari
Diff er</w>
adipo genic</w>
gentam icin</w>
< 5</w>
pe g
1. 62</w>
emerg es</w>
id ou</w>
[ GenBank
H enn
Arch itect
opo dia</w>
H Q
( mean
pres ently</w>
Dow n-
( Liu</w>
pharmac ologic</w>
infiltr ate</w>
mmol/ l</w>
hepat oma</w>
denti n</w>
A. E.</w>
A do
s ner</w>
BC R-
America *</w>
Springer- Verlag</w>
10.1021/j f
Pre viously</w>
Bra un
13. 9</w>
mil k,</w>
7 58
out patients</w>
Phil osoph
D ere
SO 4,</w>
Ple ist
Vis ser</w>
B ever
4 *</w>
cholin esterase</w>
gr and</w>
Mc Gra
phlo em</w>
as u</w>
a ult
depend ently</w>
an in</w>
NA )</w>
Mor ton</w>
Med ina</w>
st s.</w>
alb opic
PA M</w>
hybri dis
rib avir
1.0 %</w>
particip ate.</w>
introg ression</w>
SR C</w>
ron utri
ste in
d ating</w>
auth ority</w>
3 This</w>
test -retest</w>
[18 ,19].</w>
L C3
—N 4—C
es h,</w>
p yo
BM SCs</w>
16 77
s. Table</w>
appropri at
abnormal ities,</w>
SI V</w>
15 86
10.1289/eh p.
food .</w>
ri ll</w>
Cryp t
APO E</w>
oti ana</w>
lef t,</w>
high- affinity</w>
vers a.</w>
f athers</w>
Ag os
- infected</w>
d ac
8 25
ot o
D rop</w>
10.11 13
th am</w>
Can ber
sing ular</w>
; 30</w>
6 97
Dem entia</w>
sor b
photo receptors</w>
comp elling</w>
Min imal</w>
De ath
Cat aly
19. 0</w>
i o
de af
son ication</w>
evapor ated</w>
nich es</w>
Targ et
(C or
Thorn ton</w>
mar in
Imp act
F ah
v ant</w>
my x
deterg ent</w>
[ 8-
Pearson 's</w>
row ski</w>
am end
γ δ</w>
n ac
ak rishnan</w>
Spe ed</w>
Sid di
ven a</w>
par ap
invol ved,</w>
glucon e
(9 6.
β- D-
spe ak</w>
6- 00
15. 3</w>
at tract</w>
1, 2</w>
Pop ulus</w>
10.1111/j.14 69-
,26 ,
v s
ul ing</w>
Hel m
Bil ateral</w>
4- 2</w>
R 01</w>
Pil ot</w>
receip t</w>
1. 64</w>
0. 125</w>
(1. 3)</w>
abund ance,</w>
Co de:</w>
Cal culation</w>
– 120
Nak ano</w>
Pri mer
(un published</w>
draf t:</w>
K ast
read out</w>
RN F
man eu
T empl
neovascul arization</w>
O 6</w>
hetero dimer</w>
CI -
20 97
i ;</w>
Gonzále z-
Bi as</w>
trans well</w>
two- thirds</w>
hol istic</w>
parti tioned</w>
strepto zot
Kaw asaki</w>
http :
Doh erty</w>
C. R.</w>
it sch</w>
; 29</w>
v ign
(B ur
n a,</w>
i er,</w>
bi ology
aa S
arrow s).</w>
5 14
O le
bo oks</w>
S en</w>
R ach
In org.</w>
2. 6.</w>
vi ability.</w>
Cor nell</w>
4 1–
n ad
her bs</w>
actin .</w>
troph oblast</w>
mon etary</w>
lim bic</w>
Compli ance</w>
person n
ir in
initi ation,</w>
ble aching</w>
69 %</w>
impul se</w>
http://www.biomedcentral.com/ 1471-
Ch it
20 39
16 56
ow ners</w>
(H B
resting ly</w>
p 27</w>
chain .</w>
87 .</w>
2 H</w>
17 47
toler ability</w>
Pl ast</w>
130 1</w>
( yellow
sum i</w>
my oblasts</w>
0.0 61</w>
GA C</w>
—H 8</w>
syndrom ic</w>
dor solateral</w>
Z M</w>
og o</w>
m ere</w>
dimin ish</w>
defin ed,</w>
local ised</w>
17 39
sin s</w>
sand wich</w>
Polym er</w>
He ath</w>
C M,</w>
10.3 201/
K e</w>
P 1-
(S PS
pre conditioning</w>
w ings</w>
Edinbur gh,</w>
5 S</w>
ly ase</w>
18 66
habit ual</w>
HE K</w>
sim plicity</w>
g ill</w>
S PAR
plat e
gen et</w>
en :</w>
t on-
p. i.</w>
5 3-
radi ation.</w>
stoichi ometry</w>
Effici ency</w>
cytokin es.</w>
Standardi zed</w>
ins ular</w>
lox ac
manag er</w>
SC D</w>
ing -related</w>
ascert ained</w>
defici ency.</w>
mo tion.</w>
ste adily</w>
(14 ).</w>
z umab</w>
reach ed.</w>
Pro long
Nucle i</w>
journ al
H 9</w>
F K</w>
X- 100,</w>
ST R</w>
M HC
Ig G,</w>
( compare</w>
ting ;</w>
opath ogenic</w>
ca esarean</w>
diamet er.</w>
Guang zhou,</w>
GT G</w>
3 '-
ro ve</w>
ax i
M au
ophy te</w>
gr .</w>
el an</w>
rec al
centrom ere</w>
Th ym
path ology,</w>
el et</w>
K aj
k on
R hyth
PPAR α</w>
n ation</w>
new er</w>
far .</w>
Helsink i.</w>
so .</w>
Ma astric
se au</w>
mis classification</w>
20 ;</w>
ud ine</w>
tri age</w>
sam e.</w>
identi ty,</w>
od ys
si aly
CD4 +
ques tioned</w>
P HC</w>
phyl a</w>
Ev ents</w>
fl avi
8 4)</w>
Ro ad</w>
Camero on</w>
mm /
and ra</w>
g us</w>
b es
ES RD</w>
18 80
obst et
n ;</w>
1990 ).</w>
ity ?</w>
(8 9.
T V
24 ,
transfer ase,</w>
b inge</w>
of- life</w>
Sub stitu
Cap acity</w>
physi otherap
Per ox
os ki</w>
Hemat ology</w>
10.3201/ eid
afford ed</w>
revis ited</w>
random ised,</w>
1. 68</w>
(K )</w>
14. 4</w>
lo ose</w>
L é
MIC s</w>
G- protein</w>
(20 %)</w>
201 6;</w>
bloc k.</w>
coeffici ent.</w>
su b</w>
A 6</w>
w n
logarith m</w>
S oy
1. 38
ut z
C5—C 6—C
hall marks</w>
3 2/
1 β</w>
0.0 2,</w>
neo plasm
sec ur
p <0.000
V ec
ev ening</w>
inspec ted</w>
11 40
Sh h</w>
explo iting</w>
sh ir
J r,</w>
penicillin ,</w>
oligodendro cyte</w>
ofrequ ency</w>
tolu ene</w>
PIK3 CA</w>
purch ase</w>
ab d
198 7;</w>
sub si
Disord ers
chloro plasts</w>
Mich ig
Am b
insom nia</w>
explo itation</w>
al arm</w>
synten y</w>
[77 ].</w>
Pennsyl v
time ;</w>
as best
1. 61</w>
gefi tinib</w>
Z ul
Se e
in i,</w>
co- infection</w>
D id</w>
6 13
20 57
langu age.</w>
Pay ne</w>
@ m
trunc ation</w>
oc rit</w>
lo us</w>
28 4
( normal</w>
(R &D</w>
spin ning</w>
nm ).</w>
North west</w>
L '
al o
rin t</w>
M urine</w>
H eu
multi factorial</w>
Ig G-
Fer mi</w>
tub e,</w>
accoun t,</w>
an ;</w>
0.0 64</w>
Bel ow</w>
3- year</w>
15 29
.2015 This</w>
fertili zer</w>
17 40
11 11</w>
id ol</w>
4. 3.</w>
propyl ene</w>
gingival is</w>
g006 Figure</w>
Depart ments</w>
2 1).</w>
bare ly</w>
CD 25
( 35)</w>
Hos p</w>
15 34
nanoparticl es.</w>
Ap r</w>
valu es)</w>
succ ess.</w>
cytoplasm .</w>
nucle i,</w>
: 00
sch ol
counter part</w>
10 ]</w>
merg ing</w>
Compan y,</w>
por a</w>
ey ama</w>
8 5)</w>
Gill esp
Larg e-scale</w>
w ig
vis its.</w>
jud ge</w>
10.1093/ embo
hol tz</w>
− 1).</w>
12 5.
Rom an</w>
H AD
J M
D M.</w>
yiel d.</w>
19 58</w>
K. L.</w>
B att
n if
lar va</w>
g00 8
10.1098/rsp b
investig ated,</w>
Import ant</w>
(15 ).</w>
ali er</w>
At mosph
HSP 70</w>
♂ ,</w>
– 89</w>
tri phosphate</w>
Cycl er</w>
standard ,</w>
smo ker
. de</w>
C NA
I '
2 +/
moder ate,</w>
draf ts</w>
HPL C-
each ,</w>
seri ously</w>
benz odiazep
N 1,</w>
(V )</w>
j our
en de
ag lip
sil k
for ,</w>
bread th</w>
57 ].</w>
ng/m L)</w>
i. v.</w>
[39 ,
toler ate</w>
fluoresc ence,</w>
TE C</w>
In direct</w>
melan in</w>
P )2</w>
Chem other.</w>
B ond
c 0
High- resolution</w>
68 7
blot ted</w>
Compon ents</w>
9 18
(0 5)
Mar ker</w>
arrhythmi as</w>
th in-
9 24
met as
2.0 7</w>
ob ank
output .</w>
sof t-
nap us</w>
el ap
[3 2,</w>
RA W</w>
H ick
Fi elds</w>
align ment,</w>
Aβ 42</w>
mat ter,</w>
IS S</w>
9 4)</w>
Sur g
sial ic</w>
diamet er)</w>
MI R</w>
bel t</w>
H 2-
Ex tended</w>
10 1
ip er</w>
(C al
vig il
direc ts</w>
y ’</w>
break points</w>
Conceptu alization:</w>
Ab und
l man</w>
ec o
Sh en
Min im
10 17</w>
2 c).</w>
un met</w>
T. M.</w>
NE T
son ’s</w>
T ah
8 56
referr als</w>
agg ing</w>
expos e</w>
Pa rent</w>
ces arean</w>
10.3390 /s
(3 )
enni um</w>
bat ches</w>
chol est
Zimmer man</w>
sh un
r m
attr activ
M K-
go od,</w>
f on
ec ki</w>
201 4-
119. 2</w>
deliver ies</w>
AR F</w>
14. 8</w>
Netherland s)</w>
common .</w>
Cl os
inf ants.</w>
pseudom alle
inv ade</w>
Sup port
5 39
N ah
Ed mon
6 12
(T a
( 4,</w>
T os
identifi ers</w>
14. 6</w>
s angu
phon on</w>
antigen ,</w>
(E D
nitrogen ,</w>
Sil v
– H
mo tility,</w>
kary otype</w>
Ne f</w>
kinem atics</w>
spe aker</w>
em argin
r 1</w>
epidemi ology,</w>
b out
age ),</w>
201 3/
a ad
by stand
SS Rs</w>
D. E.</w>
arachid onic</w>
S AGE</w>
Ne to</w>
2. 3
Nichol son</w>
( each</w>
en closed</w>
Tri glycer
oglyc ans</w>
hp f</w>
Cryp tospor
fib romy
blu e)</w>
44 ,
( sub
en counter
heterogene ity.</w>
F ;</w>
i ak</w>
V 5</w>
Mar cus</w>
artemisin in</w>
Se p</w>
un explained</w>
GA P</w>
D. W.</w>
2-s2.0-00 36
14—C 15</w>
quin tile</w>
predisp osing</w>
j un
cuti cle</w>
neutrophil s,</w>
aro us
Philadelph ia</w>
Func tion
Endoc r</w>
8 86
medic ations,</w>
Biosci ence,</w>
A lo
revers es</w>
10 27</w>
age -</w>
[ t
inde ed,</w>
Crohn 's</w>
/ E
jo in</w>
ot te</w>
L eptin</w>
Har bor</w>
Lie ber
rest oring</w>
recurrenc e.</w>
le sion.</w>
Aber rant</w>
panel s)</w>
0.0 1%</w>
line ages.</w>
NY )</w>
femal es)</w>
2. 25</w>
vi als</w>
prot ection.</w>
osteocl asts</w>
lymph o
hom os
14. 7</w>
ell um</w>
N SCs</w>
18 38
TL C</w>
7 47
bim odal</w>
16 70
U re
HR s</w>
ml ,</w>
land mark</w>
se en,</w>
muscl es,</w>
0.0 65</w>
myel ination</w>
1. 85</w>
mild ly</w>
Ag e-related</w>
mis sion,</w>
arbitr arily</w>
H3K4 me3</w>
man nos
28 ).</w>
16 50
acet ab
Pot ter</w>
10 50
ato ire</w>
Inf ected</w>
1. 11
sch aft</w>
pen alty</w>
Fon sec
– 50
Su h</w>
Mo unt</w>
20 36
S MC
PL C
mann ose</w>
(Am bi
GSK3 β</w>
Psych opharmacology</w>
Chrom osomal</w>
orb id
amm e</w>
L RR</w>
depres sion
F 10</w>
mitochondri a.</w>
10 19</w>
(9 3.
hydra ulic</w>
br ush</w>
es );</w>
ear -
chromosom es,</w>
A. B.</w>
PONE-D- 15-
3 G
miner als</w>
vacu ole</w>
re- suspended</w>
(E qu
int ent</w>
Ga N</w>
9 90
research es</w>
child ,</w>
She pher
19 39
8 8)</w>
patient s
methotrex ate</w>
feren ce
D CM</w>
2, 3,
rh o</w>
8 1
S cr
Ohi o</w>
2.0 ,</w>
H SD
vi sion
et us</w>
HIV/ AID
percep tion,</w>
EG CG</w>
rh abdom
mel t</w>
Mü ll
10.1016/j. biopsych
0.000 6</w>
week )</w>
ec onomy</w>
NSC L
( re
B ast
repeat ability</w>
deoxy chol
organiz ation.</w>
C rop
5 36
comparis on
d ly,</w>
am el
Pu erto</w>
p or</w>
B AT</w>
2- phenyl
(19 79</w>
Fo od
co existence</w>
Con tig
6– 8</w>
uptak e.</w>
bi otechnology</w>
18 48
(IQ R</w>
(9 8.
kn ocked</w>
T B,</w>
l ub
pig mented</w>
omyc et
Sch r
Ray mond</w>
Pediat r.</w>
Research .</w>
lamin ar</w>
59 %</w>
on- line</w>
justi fy</w>
drin k
care rs</w>
Four th</w>
AL A</w>
[50 ],</w>
Dis soci
49 %</w>
( $
perenni al</w>
in- releasing</w>
fertili zed</w>
Fund amental</w>
Ex act</w>
3T3- L1</w>
( relative</w>
superi ority</w>
anomal y</w>
provinc ial</w>
mi a,</w>
eal e</w>
W ada</w>
TG G</w>
( mal
transfer .</w>
http: /
slow ing</w>
Zur ich,</w>
0.0 60</w>
SI ,</w>
L itt
k ir
ci vil</w>
T A-
10.1113 /j
eng raft
D rag
fol ia</w>
RA )</w>
44 /
Ur ban
child 's</w>
multicent re</w>
excep tions</w>
trem or</w>
el ic</w>
co atings</w>
al ert</w>
shap e.</w>
( lanes</w>
[59 ]</w>
4, 5-
River a</w>
Min i-
Ber man</w>
9 2)</w>
K appa</w>
(B e
it us</w>
brid ge,</w>
18 45
pro to-
Sel f</w>
co- occurrence</w>
Crohn ’s</w>
anti coagulation</w>
) ***</w>
sens or.</w>
(P K
ET S</w>
(H ymen
movement s,</w>
Squ are</w>
adduc ts</w>
10.1023/A :100
p ad
G amma</w>
79 %</w>
arthri tis
Per kins</w>
E spin
(9 2.
centrom eric</w>
Sub group</w>
10.1113/j physiol
degener ation.</w>
2 Δ
th et
Ass ess</w>
Laure nt</w>
C K-
techni ques
o plankton</w>
melanog ast
hamp ered</w>
Immedi ately</w>
Process es</w>
1 e-
60- 95
luc ifer
h 1</w>
sens ors.</w>
d rain</w>
Ab b
Pf ei
B –
Well -
35 S
f lip</w>
– 45
ST RO
1. 83</w>
st able.</w>
segreg ated</w>
maxim izing</w>
cal orim
Mos er</w>
2. 50</w>
0. 1–
form ats</w>
1 C,</w>
(0. 1)</w>
am ol</w>
or poreal</w>
st yl
6 b</w>
warrant ed.</w>
as ep
W I
exhaus tion</w>
Na HCO
Abstr act
o sides</w>
non- canonical</w>
g all</w>
25 53
pollut ant</w>
E del
(C S
bio tin-
2 p
cover- date
Occurren ce</w>
Immun .</w>
r ance</w>
di ode</w>
Dav is,</w>
Gynec ology</w>
ul ph
16 45
100 8</w>
P 0</w>
N J
organis m.</w>
medi ans</w>
ag han</w>
M BP</w>
endos cop
Mag ne
hus band
39 -0
An a</w>
rot ary</w>
sol ids</w>
olig o</w>
yiel d,</w>
short age</w>
Wein er</w>
Ot to</w>
Cere b</w>
c ach
PL A2</w>
intoler ance</w>
cel lo
need s,</w>
aw ake</w>
C P,</w>
skill s.</w>
11 57
ol ean</w>
sum ,</w>
cal end
(T ri
2 200
glit azone</w>
Lam b</w>
97 /
ari us</w>
propag ating</w>
mon ocytes,</w>
er us</w>
spectr um.</w>
Stre et</w>
Adju st
si al</w>
manufact ured</w>
D ry
magnit udes</w>
[19 ,20].</w>
S M-
P ru
spir it
pneum onia,</w>
P s)</w>
tri mm
11 18</w>
ten e</w>
P ie
: 16
(200 4).</w>
centr ally</w>
pu zz
prev ailing</w>
PV )</w>
RPM I-
11 35
(N E
c ran
1. 5,</w>
gr ati
ar ine</w>
N oc
( 36)</w>
P sy
A s,</w>
smok ers.</w>
Wal es,</w>
prob es.</w>
poly po
10 14</w>
ul a,</w>
further ,</w>
Ste ff
19 34
p 16
further .</w>
control ),</w>
Wol ff</w>
De fic
c qW
On g</w>
16 38
ol ly</w>
ab o</w>
SE T</w>
Y X</w>
1. 13
Disord .</w>
junc tional</w>
Over weight</w>
1—N 2</w>
I rish</w>
coinc ides</w>
Y AP</w>
rel ay</w>
r ation</w>
modific ation,</w>
dol ph
(a )).</w>
ag ne
6 55
14 97
abov e).</w>
Ott awa,</w>
199 7.
17 70
t zer</w>
Super nat
(p<0.0 5)</w>
á ,</w>
El ement
b c</w>
Pet ro
IC s</w>
Fernán dez-
l ass</w>
ay o</w>
> 10</w>
an s:</w>
10 23</w>
manag ement
Ca Cl2,</w>
10 61</w>
re trac
ha user</w>
St even</w>
Innov ative</w>
independ ent,</w>
domin ate</w>
No ise</w>
B ard
blind ness</w>
mis folded</w>
go .
dri ll
AG AT
( 23</w>
tetra ploid</w>
are t</w>
a ç
CF S</w>
require ments.</w>
Al am
t x
fluctu ating</w>
apopto sis-
over- expressed</w>
Method ology:</w>
id es.</w>
caroten oids</w>
ani onic</w>
web sites</w>
ud inal</w>
tool box</w>
Rou x</w>
Appro aches</w>
Ad ler</w>
D A,</w>
hynch us</w>
TT P</w>
mic a</w>
PL S</w>
C M.
18 95
10.1038/sj. bj
CRISP R-
(MR I)</w>
chlor inated</w>
vi sion.</w>
par v
an is</w>
ann an</w>
ble m</w>
dis similarity</w>
UTR s</w>
P A.</w>
(G re
pow der
US -
Ly 6
par at
j aw
intra epithelial</w>
bron chos
progno sis,</w>
frag ments.</w>
Bioscienc es)</w>
euro pa
10.1155/201 4/
/ N
poly vinyl
conc eal
Non linear</w>
Gol den</w>
ing ly.</w>
heigh tened</w>
mi R</w>
Ri ed
ak i,</w>
D S,</w>
Tra ffic</w>
magn ification.</w>
f ),</w>
model s:</w>
reac tors</w>
adi um</w>
Neuro biology</w>
Pr P</w>
ul li</w>
endosym bi
4 –1.
e. org/
Janei ro,</w>
vox el
whis ker</w>
z ia</w>
c I
bo y</w>
at- risk</w>
ampl ification,</w>
[7 -
LP S,</w>
root -
RT I</w>
1/ m
Maastric h
(t ),</w>
y ,
CH OP</w>
199 8,</w>
pre processing</w>
Jeff rey</w>
S amp
Nichol as</w>
F 1-
re ro</w>
Qi ao</w>
− 13
pul l</w>
ill u
f an</w>
tri s
ti m</w>
Trans forming</w>
oscill ator</w>
(S 3</w>
phot onic</w>
m M),</w>
V ;</w>
recogni tion,</w>
it abine</w>
oc ephal
cont ours</w>
Organ ization,</w>
K IF
out let</w>
G ha
8 48
+ 1-
NF AT
iz a</w>
G Cs</w>
Ch ik
comprehen sively</w>
X ho
vari ably</w>
low er,</w>
AM )</w>
in consistency</w>
(1. 4)</w>
BM -
context s.</w>
S im</w>
do esn
( accession</w>
19 38
10.1128/MC B
sw ab</w>
afferen ts</w>
dys lipidemia</w>
Bar ber</w>
Typ es</w>
P PL
G ai
pur ine</w>
ig o</w>
def enses</w>
muscl es.</w>
Hus sain</w>
(99 )000
stres sor
Transl ation</w>
transmit ter</w>
Wein stein</w>
SN P-
Other wise,</w>
Rh odes</w>
L al
F az
19 74
su re
Osc ill
(mg/d l)</w>
Mainten ance</w>
C. E.</w>
Duff y</w>
sn ail</w>
migr ain
Ca Cl2</w>
sp .,</w>
Micro bes</w>
libr ary.</w>
Fe in
nat ur
is sa</w>
Tax on</w>
Neuro surgery</w>
4- 6</w>
micro b
rect um</w>
9 3)</w>
2000 –
diseas e-specific</w>
10 %,</w>
an non
O 2)</w>
AA CA
25 3
( when</w>
MA ),</w>
Li a
u gg
no de,</w>
0 30
0 ;</w>
20 80
Medic ine.</w>
8 45
bot tle</w>
search ,</w>
ect op
15 ;</w>
Canad a)</w>
899 3
r z
obut y
ment -
correl ation,</w>
caud ate</w>
G K
M ST
15 12
Shib ata</w>
uc i
microsat ellites</w>
L. -
of :</w>
norep inephrine</w>
manipul ating</w>
S. E.M.</w>
A d</w>
o il,</w>
fecund ity</w>
– 99</w>
at us.</w>
acad em
psych opathology</w>
false- positive</w>
ve z</w>
metast ases.</w>
Editor 1</w>
on 's</w>
n s.</w>
St aff</w>
polyp s</w>
CS F,</w>
on ous</w>
nat ural
): 14
ff ,</w>
y- to-
De ep
ol /
edi ble</w>
Wo j
17 30
includ ing:</w>
casp ases</w>
PS I</w>
PC V
Br and</w>
ocor tex</w>
hybridi z
electro spray</w>
Ham mond</w>
Determin ing</w>
C- 3′</w>
br ac
H 22
6 47
ag enc
10.1001/jam a
phag ocyt
fim bri
20 40
ri b</w>
hystere c
Brad y</w>
27 7-
t RNAs</w>
–10 ].</w>
B PD</w>
ac o</w>
Flag -
ER S</w>
et an
schizophren ia.</w>
ot ta</w>
B 2,</w>
AG G</w>
transpor t
Bay er</w>
.ac. jp
review :</w>
orient ation.</w>
H anc
multi locus</w>
immuno compromised</w>
( pre-
(1. 5)</w>
wash ing,</w>
des orption</w>
in- plane</w>
12 0.6</w>
midw ives</w>
se /
magnet o
10.1111/j.1365- 2958.
whe el</w>
agg rav
T >
− 14
cov ered.</w>
Aco us
− 0.001</w>
S mol
Eth anol</w>
C alg
oper ation
ampl ification.</w>
G ay
Oc ular</w>
z one.</w>
state- of-the-art</w>
9 1%</w>
myco bacteria</w>
mol­ec ules</w>
8 2)</w>
Grand e</w>
im etic</w>
N est
Wat ts</w>
Mali k</w>
Bet ter</w>
sucro se,</w>
brack ets</w>
monophy letic</w>
met eorological</w>
5 );</w>
K and
ens son</w>
wa x</w>
persist s</w>
Ag ain
1. 70</w>
partner s,</w>
18 ),</w>
rel lo</w>
Spear man’s</w>
B uk
pyri midine</w>
zi k</w>
R itch
- 10</w>
each )</w>
B CA</w>
si ll
DRB 1*
g ates</w>
1. 66</w>
G- CSF</w>
transl ation,</w>
self-este em</w>
or :</w>
1. 95</w>
en burg,</w>
6—H 6</w>
hat ching</w>
15 36
r /
meri stem</w>
8 40
consider ation.</w>
MI M</w>
stac ks</w>
e QTL</w>
al id
7 68
in ward</w>
extrav as
c AMP-
(10 0.0)</w>
S AT
HE V</w>
5 :
flu ency</w>
Per u
D us
az za</w>
sleep ,</w>
random isation</w>
GAL 4</w>
G Q
19 50</w>
Mi ao</w>
el .
Medic ago</w>
18 39
rat e)</w>
8 1.</w>
parasit aemia</w>
W E
A Q</w>
on es
10 3.
6 95
prot ect
j unior</w>
experiment er</w>
U MR</w>
conn ects</w>
simpl ify</w>
function alization</w>
Y ale</w>
isot op
in efficient</w>
aden os
16 60
forc e,</w>
Hist opathology</w>
5- 6</w>
thrombocyt openia</w>
litterm ates</w>
Bri an</w>
— Ru
17 98
415 9.
con du
bro od</w>
val l</w>
l amp</w>
(p g/m
Inc. ).</w>
extrac t.</w>
So rensen</w>
T2- weighted</w>
G b
+ ;</w>
RT- PCR,</w>
18 55
10.11 67/
rati os.</w>
Ltd. 2010
Fel low
tun able</w>
light/ dark</w>
fl ank</w>
U pt
G ;</w>
(9 7.
Jon athan</w>
10 81</w>
break point</w>
[20 ,21].</w>
Y G</w>
B oth
CB 2</w>
11 75
il o
El ements</w>
12 78
[33 ,</w>
L od
ch etti</w>
un im
le aching</w>
immun i
detect ors</w>
5 b).</w>
W as
tom ography
dr astic</w>
Chlamydom onas</w>
whe e
col or,</w>
ground ed</w>
dou bled</w>
F RE
y u</w>
ref used</w>
nucle olar</w>
effici enc
n ect
(S an</w>
ec to
z- score</w>
Chur ch</w>
sali ence</w>
IC T</w>
s in-
C oding</w>
10 47
12 45
servic e.</w>
After wards,</w>
Func t.</w>
C14 —H
37 4
SS I</w>
transf er,</w>
cl ub
azi one</w>
TC CT
ME P</w>
(16 ).</w>
tim ulatory</w>
olip ids</w>
22 29
Blo om</w>
K ari
5– 6</w>
n h
mad e.
Shim ada</w>
N2 O</w>
5 Table</w>
Zambi a</w>
rin ted</w>
neuro troph
mes oporous</w>
Guid eline</w>
Gi org
C2—C 3</w>
17 50
phenotyp ing</w>
10 50</w>
18 50
- O
(M erc
22 -00
omet rically</w>
st yles</w>
12 47
map s.</w>
cross- section</w>
panel ),</w>
head .</w>
chi roprac
12 p
10.1046/j. 15
ph ases,</w>
Mexic o,</w>
ut ter
set -up</w>
Georg ia</w>
10 25</w>
expl ain
1. 69</w>
v eld</w>
Clin ical
single- nucleotide</w>
Distribu tion.</w>
2.0 9</w>
(H &
bond s.</w>
Gh an
endomet rium</w>
C and
Phil ip</w>
A MA
0. 3,</w>
fir st
factor -1</w>
calci um,</w>
Illin ois</w>
D AR
(Millipo re,</w>
un fortun
seed ling
UN IC
ne o-
G ambi
mo tion,</w>
H ori
ad one</w>
4 -</w>
19 13
SU MO</w>
IC P</w>
7 98
PC S</w>
bur ning</w>
PRIS MA</w>
ren ess</w>
5—C 4</w>
15 97
dex tro
D orsal</w>
architect ures</w>
0.8 ,</w>
well- characterized</w>
macroph ag
CH ,</w>
Co V</w>
16 46
recogni tion.</w>
g e.</w>
ev acu
18 30
H add
25 th</w>
Path og
Le one</w>
8 2.</w>
accumb ens</w>
Guang zhou</w>
j =
col on,</w>
27 ).</w>
ampl ifying</w>
- sensitive</w>
; 31</w>
reminis cent</w>
1. 39
( negative</w>
sou th-
2 B)</w>
a ?</w>
– 500</w>
munic ipal</w>
mut ans</w>
hist ogram
di vor
com be</w>
oh ep
accumul ation.</w>
pg/m l</w>
10.1126/science. 28
knock -down</w>
ex ha
W ech
Her b
bec ,</w>
Studi es,</w>
Polymorph isms</w>
Fron tal</w>
P am
A SCs</w>
search .</w>
adipo genesis</w>
26 —C
go s</w>
ere ll
Mat t
ur ic
construct s.</w>
9 1)</w>
M MR</w>
20 48
.0b013e318 1
fine- focus</w>
expres sed.</w>
cellul ase</w>
TL R-
sor ghum</w>
p <0.001</w>
Sim ulated</w>
Ara b</w>
Nutri tion,</w>
plan e,</w>
Gabri el</w>
sub families</w>
new s</w>
to v
Hypo thesis</w>
Er ro
10.1242/dev .0
stere otyp
o flagell
Bo ok</w>
3 d</w>
130 7</w>
intra hepatic</w>
cann abinoid</w>
bl inding</w>
alg a</w>
VEGF ,</w>
2 C
© 2010</w>
Com posite</w>
( 5,</w>
c :</w>
aneurys ms</w>
T SP
16 36
schizophren ia,</w>
de ;</w>
acquisi tion.</w>
H ip</w>
ad e,</w>
10 88
disp os
adi a</w>
photoperi od</w>
p as</w>
bright ness</w>
b and,</w>
at ro
j ac
anim al.</w>
in ts</w>
V DR</w>
S char
att ain</w>
(Ill umin
p mol</w>
irradi ation,</w>
6 1%</w>
ath y</w>
G ig
5.0 0</w>
18 98
proceed ed</w>
covari ates.</w>
chang e
app i.
96 .</w>
stem /
Ha user</w>
G Hz</w>
C3—C 4</w>
Mann heim,</w>
0.0 75</w>
18 36
don e.</w>
8 78
,4 1].</w>
surfac es,</w>
bl y
[4 2,
SS T</w>
micro lit
B eli
± 3.
sub arachnoid</w>
I brahim</w>
58 ].</w>
C13 —H
kD a,</w>
ish ,</w>
HC C.</w>
(M at
outre ach</w>
mot t</w>
level )</w>
10.1007/978- 1-
4 );</w>
SHELX S97</w>
All an</w>
over coming</w>
An s
an di
input ,</w>
sequ est
fel dt</w>
cited. The</w>
infest ation</w>
Limit ed.</w>
ro z
cho ice.</w>
radi ology</w>
mind fulness</w>
10.1176/ appi.
ectom ized</w>
[78 ].</w>
Bri g
cere us</w>
att ach</w>
ase- free</w>
B and</w>
hypot ension</w>
17 97
buff ers</w>
2. 15</w>
Bl ake</w>
pol ice</w>
occur s.</w>
99 .</w>
t ants</w>
polar iz
mot oneur
Mg Cl2</w>
(L ep
M MC</w>
1 K
initi o</w>
whit e,</w>
emul si
Mi ura</w>
8 1)</w>
time- series</w>
11 55
Cas tillo</w>
Be ad
16 88
ung -
again .</w>
detail s,</w>
11 80
W ass
Sec urity</w>
7 48
mut ant
10.1016/j. ne
eri e</w>
corrobor ate</w>
chlor ide,</w>
modific ations,</w>
ev asion</w>
T C,</w>
silic one</w>
FL I
v re</w>
ker man</w>
dar k.</w>
Y ates</w>
SI V
T oc
2- dependent</w>
AA )</w>
character ized.</w>
threat ened</w>
ne ocortical</w>
Jenn ifer</w>
destin ation</w>
7 4,</w>
morph ol
aeti ology</w>
( 38)</w>
hyph ae</w>
hard ness</w>
upreg ulates</w>
st i</w>
PO 4</w>
Nag y</w>
put atively</w>
far m
17 60
1 E).</w>
0.0 67</w>
Kr as
El mer</w>
plasm id,</w>
ciprof loxacin</w>
10.1158 /
solu tions,</w>
or y.</w>
S Q</w>
Mit o
mou th
g ren
femal e.</w>
14 70
counterpart s.</w>
Sam uel</w>
fil m.</w>
pat ern
smok ing.</w>
10 60
tumorig en
transpor ter
saf er</w>
elucid ation</w>
8 ],</w>
enc eph
0.000 1),</w>
event ual</w>
PM L</w>
20 88
10.1056/NEJM 199
paren theses</w>
endos perm</w>
10.1128/J CM.
xy gen
R ich</w>
Griff ith</w>
clinic opathologic</w>
(C E
ater .</w>
14. 9</w>
100 %,</w>
righ t).</w>
T ron
MALDI- TOF</w>
siv e-
Ch ick
vaccin ation.</w>
n ard</w>
lipop h
extern ally</w>
( 34)</w>
it ori
big g
visi bility</w>
rac h
osp inal</w>
Intr insic</w>
Syd ney</w>
us .
[1- 3].</w>
5 1%</w>
lin oleic</w>
cn emi
CP )</w>
mo vi
etc. ).</w>
Sch iz
6 27
Consid er</w>
Cal ab
(Sup pl</w>
m t</w>
cou gh
Diagnos tics</w>
coly tic</w>
Wa ve</w>
–11 ].</w>
scaff ol
MP O</w>
M R-
8 3)</w>
cis- regulatory</w>
M. W.</w>
ti -
az -
re tic
p ens
formal in-
under take</w>
as par
Prog ressive</w>
2 C,</w>
Again st</w>
N oti
Karl sson</w>
10.1177 /00
kov á</w>
(M L
he al</w>
cirrho tic</w>
diver genc
B L-
10 40
uniform ity</w>
al- to-
dec ap
16 67
( 2/
matur ation,</w>
anxi ous</w>
neuro physiological</w>
Pharmac eutic
D urb
0.0 26
align ing</w>
18 27
( xi
et ch</w>
deci ph
(H e
non alcoholic</w>
L ys</w>
Cere bell
inv aded</w>
host s.</w>
old er,</w>
pub erty</w>
23 ]</w>
C MA
She a</w>
- 80°C</w>
vis c
199 9)</w>
miR ‐
er ine</w>
rat ,</w>
Pro blem</w>
z ir
righ t)</w>
Mar ried</w>
Cronbach ’s</w>
fr in
all y;</w>
establish es</w>
P P-
progres sion-free</w>
trypan osom
ab sol
Reg ular</w>
(M in
mo vie</w>
dend rite</w>
Build ing,</w>
1. 80</w>
incorrec tly</w>
op eptide</w>
heterogene ity,</w>
N ov</w>
La us
Car l</w>
130 3</w>
–9 ].</w>
ul os</w>
47 ,
APOB EC
ol ium</w>
It ali
Ty r</w>
R IN
complet e.</w>
robu stly</w>
Mic hi
G 12
19 65
Hap Map</w>
ato h</w>
et te,</w>
Peo ple's</w>
Scientific ).</w>
H. S.</w>
Car bon
ym ents</w>
sequel ae</w>
od ynam
F lin
−x+ 1,</w>
reli ability,</w>
G 3
physi ology,</w>
Cir cadian</w>
quanti le</w>
frac tions.</w>
discrimin ative</w>
direc ting</w>
cid in</w>
(P M
tri methyl
secre tions</w>
co t</w>
F au
1. 72</w>
CD 28</w>
O' Connor</w>
N aj
C 21</w>
kan amycin</w>
aw ara</w>
F g
AS M</w>
group ),</w>
C igarett
M us</w>
H 2,</w>
BAL F</w>
15. 8</w>
10 33</w>
signal- regulated</w>
RO S-
ag itation</w>
surger ies</w>
controvers y</w>
com positional</w>
Ed ward</w>
deform ity</w>
anti- malarial</w>
AR T
cervi x</w>
w )</w>
clon es.</w>
( Lee</w>
meta- analysis,</w>
co ol</w>
ac y
Foxp 3</w>
(8 1.
Sak ur
Liv ing
monitor ing.</w>
( no.</w>
Man age</w>
El der
Cat ar
e. ”</w>
SA H</w>
Epilep sy</w>
10.1038/n cb
ly :</w>
Schae fer</w>
ity ”</w>
dre w</w>
D. G.</w>
ec tion)</w>
10. 33
spe ed.</w>
8 46
P- g
mL −1</w>
e ight-
ME S</w>
1 S
antigen s,</w>
,24 ,
gen ol</w>
th ink
4 ·
17 38
10.1016/S00 22-
6 1/
un desirable</w>
Inhibit ors</w>
N RF
Anti viral</w>
14 99
(T NF
flu id,</w>
adv ent</w>
18 70
- 2,</w>
Ori gin
+ ),</w>
P d</w>
membr ane
P ;</w>
10.1093/embo j/
0.000 7</w>
un modified</w>
curren t,</w>
Th in</w>
str .</w>
j ian</w>
H ok
w asting</w>
accid ents</w>
P ec
non sense</w>
adapt ation,</w>
NP s.</w>
satis fi
c GMP</w>
g ain,</w>
multi drug-resistant</w>
fertili z
bub bles</w>
( excluding</w>
fel low</w>
child .</w>
15 77
induc tive</w>
S S.</w>
b out</w>
A A-
19 49
se k</w>
incre ments</w>
Q 2</w>
metabolit es.</w>
as y
Alber ta</w>
er ing
L A,</w>
A or
model )</w>
erc a</w>
5 %).</w>
syring ae</w>
Ham burg,</w>
repres sing</w>
ag ers</w>
S AL
15 50
1. 76</w>
conidi a</w>
Andre as</w>
(d ),</w>
(Roch e,</w>
electrophore tic</w>
R. H.</w>
z y</w>
mmH g,</w>
O wing</w>
trac t.</w>
densit ometry</w>
of ron
10.15 34/
10 86
Sciences Genetics
K ane</w>
EB V-
concept ,</w>
Clust al
ser v</w>
ap ia</w>
6 ],</w>
S M,</w>
): 15
j ,
ver t</w>
Sil encing</w>
Irel and
mean s,</w>
Des ai</w>
Mo roc
Enzym atic</w>
typ e)</w>
896 -6273
10.1534/ genetics.
M M,</w>
(95% CI)</w>
lat tic
aw ay,</w>
af ric
um an</w>
soy be
breast -
–8 ].</w>
carboxyl ate</w>
S- phase</w>
8 1%</w>
ven ess,</w>
OP N</w>
(S EM
@yahoo. com</w>
com ment
contain er</w>
es er</w>
proce eds</w>
mic elles</w>
H 1,</w>
18. 2</w>
16 55
aa ale
Carolin a,</w>
d ity</w>
(T NF-
Hir sch</w>
ost om
occa sions</w>
10.1016/j.neuro science.
1. 17
2007 –
6 34
Dn mt
16. 1</w>
mind ,</w>
di ol</w>
Dal ton</w>
r b
12 31</w>
def ensive</w>
Author s.</w>
preced es</w>
soci eties</w>
interrup tion</w>
dam ages</w>
Tra it</w>
ch ord
subunit s,</w>
ag ron
ab use,</w>
in activating</w>
stere otactic</w>
mammal s.</w>
ing er
inf ants,</w>
Investig ation:</w>
san itation</w>
chemo resistance</w>
amphi bi
Ear lier</w>
C ER
9 th</w>
dec im
amin oph
G 1/
significant ly,</w>
Sciences Neuroscience
retin as</w>
elabor ate</w>
gro ov
desc end
Omni bus</w>
Neutr al</w>
ult i</w>
caroten e</w>
Sep sis</w>
D. H.</w>
numb ering</w>
ket o
ch en
V v
( =</w>
vari ant
intrac ellul
7 80
D ate</w>
decarbox ylase</w>
(P CA)</w>
ik i</w>
aes tiv
[60 ]</w>
Wil ey-
11 56
(Å )</w>
ol aryng
MI S</w>
determin ations</w>
8 13
16 90
extrapol ated</w>
ch ez-
Re yes</w>
Vi ability</w>
c apped</w>
inf anti
10 43</w>
stoichi ometric</w>
H PA
– 47
(199 8)</w>
multi tude</w>
[ 110
tetrac yclin
de oxyn
V os
Dou ble-
( (
Se k
Quanti fying</w>
Slo ven
@hotmail .com</w>
3 ·
to .</w>
Orti z</w>
plas ma.</w>
plasm id.</w>
midd le
at o,</w>
19 23
um -based</w>
t ast
high er.</w>
6 90
com mission
6 25
pow er-
plic ate</w>
ST D</w>
Recon struction</w>
h al</w>
fre e,</w>
two- stage</w>
Bi el
– E
bond s,</w>
alkal oids</w>
S AS
PM ID:</w>
Americ a.</w>
ide a,</w>
19 36</w>
CA N</w>
poly styrene</w>
10 37</w>
SEM )</w>
A chi
Min i
59 9
USA :</w>
princip ally</w>
identi ty.</w>
Se di
− 11
controversi al.</w>
h es
str e</w>
promis cu
mes oderm</w>
est ri
o o
Suther land</w>
21. 3</w>
11 68
partner s.</w>
ogl ut
all ine</w>
vol unt
f en</w>
plas ma
Path ogenesis</w>
SA T</w>
Wink ler</w>
M ab
Law son</w>
Fuk u
F ever</w>
de w</w>
questionnai res.</w>
Arterioscl er</w>
10.1038/n n
Montre al,</w>
warr ants</w>
Tri als.
C1—C 2</w>
Ag ra
2 b,</w>
wee p</w>
ang -
1— figure</w>
wid ths</w>
ob vi
dr aining</w>
7—C 6</w>
200 2.</w>
arrow ).</w>
Vand en
veloc ity,</w>
pos tin
[21, 22].</w>
1 k
lob ular</w>
T 0
Reas ons</w>
CON CLUS
Archi ve</w>
(E uro
electrophore sis.</w>
Grou p.</w>
li m</w>
Ques tions</w>
aw ak
Hyper ten
fri end</w>
transform ation,</w>
atic s
un ambigu
flo ur</w>
fluoro quinol
d ing,</w>
co hesion</w>
.201 7
T- DNA</w>
optim ally</w>
( four</w>
4 0.
0.0 66</w>
crow ding</w>
conclu sions.</w>
Ji an
colony- stimulating</w>
Glo b</w>
Bec kman</w>
cath ode</w>
Sar kar</w>
MI P-
trans located</w>
I PA</w>
organ ell
intern ally</w>
RO S,</w>
10.1016/000 6-
util ised</w>
erlo tinib</w>
hu is</w>
16. 3</w>
.... ....
sub tropical</w>
potenti ates</w>
b ak
RAW 264.7</w>
N 0</w>
upreg ulate</w>
ros s
os ac
ST M</w>
ey e,</w>
ch ur
car in
D 3
ten -
orthop edic</w>
j u</w>
M aster
0.000 8</w>
(F F
60-95 68.
ol iv
m g.
IP F</w>
mush room</w>
h ans</w>
ff man</w>
activ ated,</w>
I cel
room .</w>
custom -
Inde ed</w>
( van</w>
(AU C)</w>
gu l</w>
∑j =1
long- lived</w>
p ro</w>
cell s),</w>
imp ur
regener ation.</w>
Sigma-Aldrich ,</w>
Ser rano</w>
2 2.5</w>
escal ation</w>
tim escal
research ers,</w>
In d
O G
domestic ation</w>
acet yl-CoA</w>
Cardi othor
15 78
10.1007/s 120
10 35</w>
symb olic</w>
soil .</w>
aromat ase</w>
a pro
l enses</w>
S. B.</w>
MC L</w>
Indu stry</w>
1. 71</w>
( compared</w>
Pre sid
11 70
17 29
PP 2A</w>
Co oke</w>
Bow man</w>
17 35
ph allo
anastom osis</w>
B -1</w>
ATP- binding</w>
tur bul
Psych osocial</w>
Lym ph</w>
DLBC L</w>
12 9.
no xi
mant le</w>
As sem
tumor- associated</w>
itch ing</w>
dend ri
S1- P
pp m)</w>
1. 78</w>
ob arb
elimin ates</w>
Sha red</w>
Nico tine</w>
basi cally</w>
Tran sc
R ath
Par k
themselv es,</w>
E -1</w>
CAT CA
40 ).</w>
nephro path
Stra uss</w>
A :
Darm stadt,</w>
IS H</w>
ag enda</w>
[5 1],</w>
X Y
E 0
Gillesp ie</w>
/ n
custom ized</w>
sme ars</w>
respect ,</w>
block s.</w>
an od
C4—C 5</w>
ae v</w>
Meas ured</w>
IF T</w>
articl es.</w>
( containing</w>
uc a</w>
provid ers,</w>
inte ger</w>
electro des.</w>
contrast- enhanced</w>
at su</w>
m RNA
fos sil
encephal omyelitis</w>
mo use
Lif est
metabol ized</w>
ph or
is man</w>
F lag</w>
/ k
G an</w>
CB S</w>
Pro xim
I +
Nob le</w>
D aph
1- /-</w>
Cl −</w>
–12 ].</w>
hemic ellul
12 77
ak umar</w>
Sen eg
D E-
it ation,</w>
T rom
8 7)</w>
cru stace
[ a
l ad
distribu tions,</w>
Rodrígu ez-
L umin
extrac ts.</w>
u ated</w>
NSA IDs</w>
vertebr ates,</w>
finger print</w>
challeng es.</w>
Self- reported</w>
10 70
yel low,</w>
w on
(I ),</w>
time- lapse</w>
g adol
bin ,</w>
mening i
ex changed</w>
Pen ic
CD 133</w>
10 71</w>
8 A</w>
degre e,</w>
bleed ing,</w>
J ava</w>
centrifug ation,</w>
Biob e
12 88
ent rap
Interpre tation</w>
respon der</w>
lifes pan
Throm b
T anner</w>
ol ate</w>
bo red</w>
amp utation</w>
-0 14-0
(M al
dis closed</w>
8 9)</w>
MR I.</w>
19 37
[79 ].</w>
Phylo geny</w>
Pe king</w>
la p</w>
W AS
morbid ity,</w>
y am
en thal</w>
pollin ation</w>
m n
= −
v entilat
2 100
intrac erebral</w>
B CI</w>
ax anthin</w>
She ffi
Prote obacteria</w>
12 58
-3 '</w>
Ban ks</w>
factor ;</w>
cells/ well</w>
. ),</w>
Dic t
co he
Tri zol</w>
communic ation.</w>
10 18</w>
gene tics,</w>
W inter
Bro ad</w>
credited. Background</w>
C im
rang e)</w>
circumst ances,</w>
cho roid</w>
Pl ates</w>
10.1016/S016 8-
instrum entation</w>
q )</w>
ju x
Repe at</w>
Kane ko</w>
AP 2</w>
t ect
M U</w>
10.109 4/
.0 –
op reserv
m aph
sub types.</w>
capsa icin</w>
H AM
adenocarcin omas</w>
Donn elly</w>
g ag
SD -
IR B</w>
herit able</w>
TLR s</w>
O 7
5 ×
ex osome</w>
Et OH</w>
in- based</w>
wit ness
st e</w>
obarb ital</w>
flo x
Si emens</w>
uni tinib</w>
de oxy-
ap o</w>
CA SP
genc y,</w>
depend encies</w>
Ch amp
B olog
j h
ultrac entrifu
min or
D TT,</w>
disadvant aged</w>
a );</w>
(B o
bo om</w>
Par a
12 7.
tre s</w>
su e-copyright-statement©</w>
V ern
Sriniv asan</w>
investig ations.</w>
thic ker</w>
mol/ L</w>
i ano</w>
distinguish es</w>
c f.</w>
[22, 23].</w>
10.1097/ 00000
hydrox y</w>
satis factor
Er k
6 45
mortal ity:</w>
M ö
Immunost aining</w>
SS c</w>
el d,</w>
TM EM
C a-
( En
t ang
exp and
[ 0.
Hard y-
Ch at
15 55
ó n
11 23
rib osom
olog ically,</w>
N2 —H
bro iler</w>
pin ning</w>
oxygenase- 2</w>
immun ologic</w>
tes un
sing le
m PFC</w>
e- binding</w>
Thir dly,</w>
Syn chron
coc ain
Isl am</w>
IPT G</w>
Hear ing</w>
20 90
1. 88</w>
poly g
Canc ers</w>
C 35
is awa</w>
C L-
23 14-
transi tion.</w>
ja und
U 0
MD CK</w>
15 99
repos itor
ag h
M X
ION S</w>
emo tion
biosens ors</w>
199 9.
human ized</w>
arrhyth mia</w>
Tri s,</w>
In ner</w>
rel uc
environment ally</w>
Mar se
normo xic</w>
V asi
Bu en
10.1128/J B.
sig moid</w>
elic iting</w>
Zeal and
post- infection</w>
occur s,</w>
qu orum</w>
SA P</w>
Neuropsych opharmacology</w>
M X</w>
In d</w>
< 10</w>
articl es,</w>
Ver me
10 29</w>
-0 16-
don or
ac rom
protein /
medul la</w>
d ap
O SCC</w>
Consum ption</w>
oz ol
TRA IL-
M 2-
20 60
Jp n</w>
whol e,</w>
orthop aedic</w>
ner t</w>
im ed
duc ts</w>
IL- 8,</w>
self- administered</w>
pal ate</w>
Wh o</w>
8 80
sul cus</w>
4- 39
arg ues</w>
CA :</w>
(2 %)</w>
( ed
Le e,</w>
[4 3,
olec ule</w>
mee ting
miR- 30
individual 's</w>
clo t</w>
7 37
M ech</w>
ur ia,</w>
organ ize</w>
acquisi tion:</w>
so m</w>
Ethn icity</w>
bou ts</w>
He id
10.1084/jem .200
RA M</w>
inc ap
biol uminescence</w>
T G,</w>
thro at</w>
– 48
aly pt
Ph e</w>
Cor al</w>
3 c</w>
10.1016/S0 95
pro gnos
Vect ors</w>
P Q
M ent</w>
Gre y</w>
30- day</w>
radio activity</w>
lei omy
[34 ,</w>
ed ullary</w>
over all,</w>
(25 %)</w>
re strained</w>
black ,</w>
(B ,
2. 10</w>
ta it</w>
CT AT
19 24
(P A
bio reactor</w>
(17 ).</w>
ous )</w>
ischem ia/
P PAR</w>
s s</w>
T ie
Pap ad
ich er</w>
anti proliferative</w>
Sal mon</w>
120 3</w>
C 22</w>
APA CHE</w>
59 ].</w>
50 ,000</w>
ly l</w>
appreci ation</w>
ov an
or de
W LED
Arab ia</w>
15 95
pre- mRNA</w>
Planc k</w>
L ing
Inj ection</w>
2. 11</w>
fore st,</w>
0.6 ,</w>
−0. 1</w>
Ph D,</w>
4 —
ine ),</w>
Silver man</w>
Neph rology</w>
A ron
i ke</w>
0.0 4)</w>
administr ation:</w>
Pai red</w>
4- 3</w>
Dic er</w>
8 3.</w>
15 58
16 47
Sh enz
p 27
Tom as
4—C 3</w>
10.1053/j. gastro
Metast atic</w>
10 65</w>
Con serv</w>
eosin ophilic</w>
emb er,</w>
R igh
K og
AL Y</w>
en ess,</w>
u to</w>
bo ards</w>
abstin ence</w>
In f</w>
15 96
Parasi t</w>
(1 ∶
Kre bs</w>
idae ).</w>
c ott</w>
an ey</w>
R. W.</w>
chron ological</w>
16. 2</w>
ML ST</w>
hed gehog</w>
new ,</w>
(I CD-
drug -induced</w>
al pine</w>
Trac e</w>
Manch ester</w>
; 32</w>
5 1-
– 400</w>
miR- 155</w>
vis co
US )</w>
F 5</w>
CH -
11 28
reimburs ement</w>
Teix eira</w>
11 33</w>
s ay,</w>
mamm ography</w>
elig i
co- ordin
Protoc ols</w>
Can .</w>
CO 3</w>
fin ally,</w>
di zz
B alk
( α-
s. )</w>
MI F</w>
Ch ond
1. 87</w>
ey es,</w>
Dani els</w>
Mcl -1</w>
Ch en
2 /j
ep sil
Man s
v ow
PA D</w>
.gov /
Prog ression</w>
Ch ile</w>
16 48
T eng</w>
Sn ail</w>
[ F
12 57
sum mation</w>
ane k</w>
Peri od</w>
MT HF
CONS ORT</w>
EB P</w>
op ac
mat ters</w>
membran ous</w>
vin yl</w>
tr ains</w>
encomp ass</w>
spur ious</w>
Sto ch
13 B</w>
J u</w>
u th
hun ting</w>
administ ering</w>
param agnetic</w>
analy ses
pig ments</w>
mech ano
excep tional</w>
epitheli um,</w>
adolescent s,</w>
Met z
10 20</w>
medias tinal</w>
Sim ons</w>
report edly</w>
M ing</w>
rein hard
frag ments,</w>
Varg as</w>
virus- infected</w>
V O</w>
Heav y</w>
lumin ance</w>
Eco RI</w>
b et</w>
contin gency</w>
bec ause,</w>
Nij me
D ial</w>
challeng es,</w>
NL R</w>
CI N</w>
App endi
: 000
em an
P ham</w>
ubiquitin ated</w>
7 67
segreg ating</w>
lin son</w>
Bill erica,</w>
18 60
15 45
xenog raf
stake holder
W ay</w>
V ri
Ob viously,</w>
PC 2</w>
drin kers</w>
L AMP</w>
end e</w>
anth ra
11 21</w>
20 95
th ered</w>
decad es.</w>
Dop amine</w>
per itone
electr icity</w>
T 2,</w>
C MR
10.1186/ cc
t 0
Jim éne
lo oks</w>
bot ulinum</w>
Pres cri
run .</w>
mam mal</w>
12 35
Short- term</w>
feedback .</w>
10.1002/(SICI) 10
au b</w>
sulf ur
10.1002/ cn
main land</w>
E dition</w>
( ρ
lay out</w>
L MP
19 59
18 37
1 A—C
V TE</w>
SN Vs</w>
Intr aven
] {
St em
HB V-
SP S</w>
Phen otype</w>
< .0001</w>
Bar th
incontin ence</w>
Y az
Kauf mann</w>
O FF</w>
F inding</w>
W AT</w>
10.1016/j.j acc
in s:</w>
si tis</w>
se m</w>
character ization,</w>
ad -
(S ol
rec tom
motif s.</w>
Con trac
i @
ent rain
I CO
–13 ].</w>
microbi ot
associ ation,</w>
E ste
3—C 2</w>
parag rap
3 %).</w>
predn is
Y N</w>
W ed
plant s:</w>
period ically</w>
(I S
w ir
Sto kes</w>
6 49
panel s).</w>
AC h</w>
1986 ;</w>
Cow an</w>
ne ocortex</w>
des ert</w>
construc tive</w>
mas cul
hystere sis</w>
framesh ift</w>
( grey</w>
eri ,</w>
11 73</w>
CD 40
E C,</w>
China Correspondence</w>
employ e
Hutch inson</w>
15—C 16</w>
10.210 5/
Japan ),</w>
C i</w>
. eu
Plo s</w>
D ip
Cyto kines</w>
Cle ar</w>
S ander</w>
Manch ester,</w>
h TERT</w>
brow ser</w>
prevent able</w>
Sch ä
. 2</w>
MA X</w>
serine/ threonine</w>
—H 15</w>
. .</w>
ak k
Clust ers</w>
frequenc y-
box .</w>
Kn own</w>
How ell</w>
190 0</w>
(DE 3)</w>
organis ational</w>
a esthetic</w>
aminogly co
(1– 2</w>
empha sizing</w>
hear t.</w>
only )</w>
Gr ants</w>
bottlen eck</w>
comp ani
C MS</w>
8 17
Boc a</w>
10.1001/jama. 28
Portugu ese</w>
A mi
hyp ere
ew icz</w>
Dulbecco 's</w>
vocabul ary</w>
t ones</w>
polyaden ylation</w>
Mer cur
C leav
narrow ing</w>
meg a</w>
Nic otiana</w>
H D-
T ip
ric ians</w>
[6 1]</w>
7 59
(DO CX</w>
n um
lik ely,</w>
19 51</w>
al.201 6
ae us</w>
gli oblast
−0.00 2</w>
n ing
is ome</w>
11 86
1. 92</w>
other wise,</w>
10.1152/j n
T am</w>
− 6
t able,</w>
2 200</w>
O ra
(I N
spor ulation</w>
ac ro
low ers</w>
log- transformed</w>
Wal ters</w>
Utili zation</w>
N SC</w>
Ster il</w>
Ar gin
Ag -
immunol ab
9—C 8</w>
arter ly</w>
10 31</w>
15. 7</w>
10 47</w>
call us</w>
Expl or
lin i</w>
W ad
Entom ology</w>
generaliz ability</w>
S now</w>
Progr ams</w>
19 ),</w>
osh ita</w>
di ure
top ographic</w>
Kir sch
as awa</w>
Ram achandran</w>
Mol ina</w>
CD Cl
PE S</w>
illic it</w>
combin ation.</w>
og lit
intestin e,</w>
Pal o</w>
Hay nes</w>
biosyn thesis.</w>
21. 1</w>
14 67
un rav
ul d
ub er
narrow er</w>
1. 77</w>
sug arcane</w>
isol ation.</w>
intran asal</w>
t ed
normal izing</w>
S ø
examin es</w>
Coun t</w>
B ord
war ding</w>
spermat ogenesis</w>
settl ement</w>
T AS</w>
sacc ades</w>
bigg est</w>
10 1,</w>
Bam HI</w>
20 47
M ent
7 26
In ference</w>
μm ;</w>
deline ated</w>
,3 1,
expos ure
T ir
R GC</w>
gu ard</w>
N 9</w>
ton ian</w>
os ito</w>
laun ched</w>
it es,</w>
gon orrho
ra re.</w>
emphysem a</w>
stimul us-
p S
ik h</w>
Numb er:</w>
A nest
(m mol/
tin ib
nitrogen .</w>
myc in</w>
bl ade</w>
red :</w>
quad ric
pd f/
Rob o
E-0 1</w>
th at:</w>
De ficiency</w>
multi plication</w>
H r
asynchron ous</w>
10 16</w>
Queens land,</w>
; 33</w>
12 67
deriv atives,</w>
http:/ /j
d =
divi sion,</w>
Graph ical</w>
S1 P</w>
t es,</w>
pharmac ists</w>
equ ality</w>
Os aka</w>
Er l
chec ks</w>
A IC
s ):</w>
low- cost</w>
Sus an</w>
Glc NAc</w>
9 1-
Treat ments</w>
cryp t</w>
Zh an</w>
199 8.
10 67
(18 ).</w>
X PS</w>
Haem ophilus</w>
legen d</w>
infer ring</w>
Re es</w>
G ly</w>
bl att</w>
Instrum ent</w>
O sp
CR 1</w>
ogly ca
genu ine</w>
Ro os</w>
7 40
10 2.
Notch 1</w>
blastocy st</w>
van ia</w>
M olecul
py raz
201 4.
com mis
Will is</w>
un methylated</w>
Nor dic</w>
ri ger
Micros at
KNO WLED
n ag
l b
0.0 68</w>
seg ments,</w>
score )</w>
Kik uchi</w>
Bre ak
pul led</w>
Geophy s.</w>
10 69</w>
1/m bc.
U sed</w>
10.109 1/mbc.
1. 89</w>
B lock
Embry onic</w>
chimp anzee</w>
Jor gensen</w>
10.1002/ ej
il eg
−17 9.
ont ologies</w>
g007 Fig</w>
constitu ting</w>
1. 82</w>
17 ),</w>
time :</w>
incid ences</w>
Str ati
hypoglyc emia</w>
(S R
combin ation,</w>
Stri kingly,</w>
Hal f</w>
T m</w>
rel ativ
H PR
Fo rensic</w>
10 53</w>
(d ).</w>
ret ains</w>
atin ,</w>
amin idase</w>
CD 56
kin es
discrimin atory</w>
Dek ker</w>
Ca ir
Found ation
16 35
al. This</w>
Z J</w>
time- consuming</w>
ep end
Shepher d</w>
Interfer on</w>
17 88
(N CB
dig est</w>
over represented</w>
1. 86</w>
hot spot</w>
W ah
Abstr acts</w>
P ter
Le ip
E le
7 95
so aked</w>
ex foli
(19 78</w>
spectr um,</w>
. 27
( Version</w>
trans genes</w>
telev ision</w>
confidenti ality</w>
PS II</w>
10—C 9</w>
tet rap
ga thering</w>
Tr ue</w>
techn ically</w>
Di ast
Del phi</w>
Gr und
gradu ates</w>
inclu sive</w>
Moham mad</w>
Lym e</w>
V oc
Rosen thal</w>
Bro ok
near- infrared</w>
grapev ine</w>
mal e-
Netherland s.</w>
Theore m</w>
Revie wing</w>
be i</w>
streptavid in</w>
Def ense</w>
22 —H
(S L
N 2,</w>
(G er
second- line</w>
rhe um
CXCL 12</w>
3 A)</w>
10 39</w>
Co operation</w>
An at</w>
TG AT
6 57
0.0 2).</w>
10 55</w>
s now</w>
prop yl</w>
anc e/
Mon th
K B
wi res</w>
illumin ated</w>
cryst al,</w>
Mor ita</w>
12 39
.00 1,</w>
(Gib co
( 80</w>
ligand s.</w>
A. H.</w>
dep olym
STRU CT
NA -
1. 16
Inter views</w>
Famil ial</w>
22 ]</w>
17. 2</w>
10.1104/pp .10
lea fl
confound ed</w>
10.1177 /10
post- test</w>
am ides</w>
2 ‐
10 63</w>
[5 2],</w>
( χ
t s:</w>
nor th-
need les</w>
ch ic
Pra k
ou tward</w>
p an</w>
manufacture r.</w>
sc ru
ke y,</w>
Nan otechnology</w>
Anest h</w>
are as
Bo olean</w>
(1. 6)</w>
head -
e Health</w>
Mitochond ria</w>
ser otyp
Z ap
Chap el</w>
1 Research</w>
benefit s,</w>
G root</w>
BC R</w>
20 55
(G r
insp iratory</w>
hyper insulin
Universit à</w>
( In</w>
level s:</w>
fu sion
0.0 29
ver m
S war
Genomics BMC</w>
DPP H</w>
propos ed.</w>
Immunob lot</w>
development ally</w>
Mar qu
(I V)</w>
women )</w>
oxid ants</w>
8 15
lo ff</w>
Prolong ed</w>
1. 74</w>
oligodendro cytes</w>
committe es</w>
- /-</w>
(r 2</w>
Biol BMC</w>
m L,</w>
Specim en</w>
p ectin</w>
170 0</w>
bl ad</w>
nanom aterials</w>
az a</w>
Bar tel</w>
l c
facil ity.</w>
album in,</w>
mas tig
Ol sson</w>
10.1093/j nci
(q RT-
Gu ine
19 54</w>
x n
8 4.</w>
10.1083/jc b.200
hormon es,</w>
Oreg on</w>
( 3/
[80 ].</w>
bo unds</w>
Qi agen</w>
no )</w>
Commun ities</w>
negativ ity</w>
Conclu sion:</w>
-0 10-0
fat ality</w>
T m
Ful ler</w>
200 5–
suppress ors</w>
men opause</w>
con gen
rat e:</w>
influenz ae</w>
cit ric</w>
plat form,</w>
q 0
promo ter-
More ira</w>
HE R</w>
re ject</w>
expon ent</w>
eosin ophil</w>
ar y)</w>
Bre ast
11 15</w>
10. 73
10 59</w>
0.0 25
h c
Zn 2+</w>
Par am
ty phimurium</w>
con azole</w>
10 59
um ),</w>
ward s.</w>
Ar bor,</w>
re generating</w>
om e.</w>
AC L</w>
19. 5</w>
lipidemi a,</w>
NO ,</w>
Al ab
. Figure</w>
cli ffe</w>
fund us</w>
cent ers.</w>
univers ally</w>
discharg e.</w>
( 20–
–7 ].</w>
communic ating</w>
cav ity.</w>
Sub ramanian</w>
é tait</w>
incid ental</w>
Z ol
dep th.</w>
af ter.</w>
Cent er.</w>
smart phone</w>
p est
mill is
e ir
osi s
eh an</w>
sclero sis:</w>
in expensive</w>
Ab sent</w>
Sh ock</w>
rain y</w>
Nor ton</w>
particip atory</w>
Di as</w>
A oki</w>
l ens
De pletion</w>
2_ Table</w>
1. 79</w>
10.1093/cercor /b
More over</w>
t00 2_Table</w>
su is</w>
recommend s</w>
discipl ines</w>
MD R-
10.2105/ AJ
O157: H7</w>
MP a</w>
(blu e),</w>
CO PD
23 56
zy gotic</w>
Thail and
curv es,</w>
or is</w>
sec tion).</w>
1000 000
contain ers</w>
IC F</w>
( Ne
ES R</w>
7 69
SV R</w>
miti gation</w>
hn RNP</w>
thickn ess.</w>
sm ith</w>
ay -
Ill umin
11 23</w>
adolescent s:</w>
1. 81</w>
S ow
PL GA</w>
A wa
400 ,</w>
sev en-
.2012. 00
en ol</w>
8 5.</w>
surve y
D en</w>
revi sions</w>
pre- clinical</w>
ess el
Bru ker,</w>
): 1</w>
si g</w>
iner tial</w>
á s</w>
rati os,</w>
Tr p</w>
HTL V-
hemat oxy
uncou pling</w>
tw ist
solubil ized</w>
8 30
Mis sis
Ag e-
12 70
(Lond )</w>
scho ol.</w>
th igh</w>
pa x
macrom olecules</w>
ent ry,</w>
N. S.</w>
AT T</w>
10.1016/j.j mb
TLR 9</w>
transi tion,</w>
k +
acqu i
10 95</w>
(4 %)</w>
Super vision:</w>
G og
plot ,</w>
dis co
( °C)</w>
rid ine</w>
antagon ist,</w>
ma y,</w>
Bo oth</w>
Foxp 3+</w>
17 36
y og
Ni em
tubercul ous</w>
rog ram</w>
Legion ella</w>
12 50
c .,</w>
assembl ing</w>
un predictable</w>
Drum mond</w>
B 3
19 27
10.1002/cn cr
High- throughput</w>
—N 4</w>
enc e;</w>
au r</w>
Sán chez-
–14 ].</w>
28 36
im pres
tor .</w>
ch ief</w>
k V</w>
L TR
Bio- Rad</w>
12 80
ont s
erron eous</w>
4 E-
Vie ira</w>
Elev en</w>
119 9</w>
ref riger
German y;</w>
F ong</w>
10 55
fo relim
TNF- alpha</w>
KNOWLED G
C> T</w>
7 %),</w>
Lu is</w>
AB L</w>
vertebra e</w>
localiz ation.</w>
an tine</w>
[35 ,</w>
C ous
peri plasmic</w>
energ etics</w>
Fuji wara</w>
tachy cardia</w>
ron ate</w>
as ub
0.000 9</w>
W F
CG CA
2 This</w>
pu tida</w>
pom be</w>
15. 9</w>
ox ia</w>
en in</w>
W heat</w>
Ko en
absc ess
Op portun
Cx 43</w>
AC KNOWLEDG
mol ars</w>
St om
us e:</w>
Cret aceous</w>
V A)</w>
F 1,
ubiquit ously</w>
expendit ures</w>
Oh ta</w>
C5—C 6</w>
12 38
37. 5</w>
zinc -
mg/m l)</w>
month s;</w>
A zi
sub merged</w>
con sequences.</w>
Hol m</w>
Enterobacteri aceae</w>
10 83</w>
q GH
modific ation.</w>
re v</w>
le sion,</w>
oxygen ,</w>
1. 200
phenomen on.</w>
Th anks</w>
Foc al</w>
1. 90</w>
micro particles</w>
exampl e.</w>
(6 ),</w>
C L,</w>
120 5</w>
119 0
displac ements</w>
119 1</w>
yo st
0. 25%</w>
ag ed.</w>
sph inc
ME K
AN G
allo dy
S. W.</w>
P. C.</w>
hi k
H S-
15 88
S MS</w>
NMD AR</w>
C at</w>
(S il
T 4
W ur
B ush
window .</w>
elucid ating</w>
Ru an</w>
17. 1</w>
contrast ed</w>
Investig ating</w>
I gn
resc ues</w>
bir ds,</w>
impul sivity</w>
or bit</w>
deline ation</w>
[23 ,24].</w>
M PS</w>
( ±0.
schem e,</w>
14 00
syn tactic</w>
mad e,</w>
auth ors'</w>
O 5—C
K IT</w>
ax on
X F</w>
SN s</w>
70 /
10 58
ori b
appropri ate,</w>
11 17</w>
forc ement</w>
0.00 2)</w>
B rink
aut oradi
BY )</w>
coun ts.</w>
2. 0.CO;
modifi er</w>
Yok oyama</w>
Inter val</w>
IFN- β</w>
symbi ont</w>
Ly on</w>
av oids</w>
an abolic</w>
D 6</w>
reason ed</w>
25 ]</w>
inter vertebral</w>
g ado</w>
dep th
109. 3</w>
referenc e,</w>
19 55</w>
transi ents</w>
1. 84</w>
nanos he
glyca emic</w>
U G</w>
di ac
( Gen
pack age.</w>
discard ed.</w>
al.201 5
partner ships</w>
end ers</w>
33 ).</w>
un aware</w>
pur ifying</w>
20 86
17 59
(i e,</w>
as certain
ophy tes</w>
Princ eton</w>
Nor ris</w>
Bor n
heigh ts</w>
gg er</w>
Cover age</w>
(M F
Swed en,</w>
N TR
16 98
Re eves</w>
Arti cles</w>
11 ,12
Ischem ic</w>
Ex tinc
6 37
x )
amid ino-
cd c
ac ros
1: 100</w>
(Ph il
ation —
L PA</w>
( di
disabl ed</w>
am ar
Oct 4</w>
reinforc ing</w>
far -
requ est
r y:</w>
ischemia- reperfusion</w>
Firmic utes</w>
10 39
post mortem</w>
A gn
gl asses</w>
Qu ant</w>
C- type</w>
en 's</w>
mor bid</w>
PI D</w>
Re c</w>
Twenty- four</w>
myel o
Jimene z</w>
20 46
acknowledg ed.</w>
direct ly.</w>
Hippocamp al</w>
Dise ase
10 77</w>
sup pl</w>
1. 98</w>
dos es,</w>
2 π
1 A),</w>
Wa als</w>
L ord</w>
H 37
thin ning</w>
rep ell
overl ay</w>
Pater son</w>
18 28
O SC
bottom -up</w>
11 ]</w>
oxido reductase</w>
nano composites</w>
Hardy- Weinberg</w>
re ch
NO VA</w>
Al kal
guid es</w>
arch iv
8 29
str up</w>
word s.</w>
AA AT
Hypothe tical</w>
sn ow
an aerob
pac emaker</w>
Fif teen</w>
medul lo
Hed gehog</w>
1, 5
Ro om</w>
6. 200
ec tion;</w>
Lymph oma</w>
Br as
IL- 4,</w>
22 27
L inn
s apon
Vancou ver,</w>
DAV ID</w>
ric s
prob e,</w>
o ).</w>
Epider mal</w>
z awa</w>
de struc
Miy azaki</w>
8 28
G is
re efs</w>
( .0
h inder</w>
sl ur
epitheli um.</w>
Su icide</w>
Ob ese</w>
Loc ation:</w>
Seman tic</w>
—H··· O</w>
what ever</w>
st ay,</w>
Mun oz</w>
moti f.</w>
larv ae.</w>
Stat es:</w>
Sou th-
Esp osito</w>
r ating
macroph age-
Colom bia</w>
set )</w>
titr e</w>
PD Z</w>
23. 1</w>
neo plasm</w>
um ).</w>
An dri
unc -
tocopher ol</w>
Gmb H</w>
9 97
ch et</w>
S on</w>
tax a,</w>
stri pe</w>
W D
Uni Prot</w>
1. 93</w>
thym ocytes</w>
V II
IN S</w>
analy tes</w>
17 90
on eg
bra sili
A 5
neoform ans</w>
r =
au -
agglutin ation</w>
advis ory</w>
18 ;</w>
hydrophob icity</w>
Fonsec a</w>
Br agg</w>
201 2.
k umar</w>
is ation,</w>
Stef an</w>
n im
ar ty</w>
ab at
C )
200 -
cont act,</w>
sus h
A bl
Ch ann
X L
/m g</w>
(19 77</w>
adv ancement</w>
J ean</w>
J X</w>
150 ,</w>
Rheumat oid</w>
mus carinic</w>
car ds</w>
2-s2.0-00 37
é c
past e</w>
cot yled
D an</w>
L V-
sub groups.</w>
ch or
10.1038/nr micro
mac k</w>
outcom es:</w>
object s.</w>
(A DP-
sh ock,</w>
gastro enter
an 's</w>
Le aves</w>
Gron ingen,</w>
ti ed</w>
ho v</w>
gram- negative</w>
cyclophosph amide</w>
Y ous
(1. 0</w>
pastor is</w>
no des
mis match
te in</w>
re alization</w>
distric t,</w>
arre st,</w>
≥ 2</w>
C —H</w>
: 17
11 19
/m L</w>
(F (1,
Add res
brain -derived</w>
U NE
11 50
read iness</w>
un preced
ion i</w>
CG G</w>
Adju vant</w>
ric a</w>
loop ,</w>
99 mT
CL )</w>
16 40
12 50</w>
ev al</w>
Psych os
Denmark ,</w>
kin son,</w>
Schu ster</w>
Carbohyd rate</w>
12 95
Re produc
J M,</w>
C app
em en
co expression</w>
MA N</w>
EGF R,</w>
juven iles</w>
no de-
ospor a</w>
(19 ).</w>
ex onic</w>
cardi ometabolic</w>
(2 )°</w>
vag al</w>
nov el,</w>
complex ed</w>
micro titer</w>
laev is</w>
[11 -
14 ;</w>
tion ?</w>
In sect
1- 7</w>
inter im</w>
Oper ating</w>
14 66
health y,</w>
able -
O HD
CA BG</w>
10.1136/bmj. 3
dar k-
120 1</w>
10 97</w>
merg e</w>
mat h</w>
anti- angiogenic</w>
f ent
electron ics</w>
(C C-
ST Z</w>
60 ].</w>
degener ation,</w>
assist ants</w>
GG C</w>
she et
ov ulation</w>
is ation.</w>
be ats</w>
GG G</w>
B land
( Qu
at rop
The or.</w>
En dom
Bro ck
chimpanze es</w>
categor ised</w>
C SP
C );</w>
sw im</w>
H3K4 me
10 49</w>
op p</w>
S ot
GT GA
z eta</w>
0.0 69</w>
(x )
D —C
Calcul ated</w>
metad ata</w>
harv ard
congru ence</w>
bed side</w>
Victori a,</w>
7 28
en feld</w>
AN S</w>
(3 %)</w>
U CP
Ch el
(D AP
Dem onstr
profession als,</w>
TG C</w>
(F ar
(S )-
–6 ].</w>
radi o-
EN CODE</w>
P. S.</w>
CV )</w>
chromatography -
l amin</w>
accid ental</w>
MC MC</w>
Per u</w>
ore -
[ F(
Statis tics,</w>
10.1038/n prot
research ers.</w>
Bar bara</w>
A/ G</w>
I di
Mac don
6 4-
clo pidog
Rus si
–15 ].</w>
a- related</w>
str on
sal ine,</w>
coinc ide</w>
ac o
W A
( mainly</w>
ob ses
leaf let</w>
germ plasm</w>
shi el
M und
6/j mir
ty re</w>
in hab
Inter leukin</w>
Bar nett</w>
12 87
ab normally</w>
GA S</w>
Un adjusted</w>
C itation</w>
de par
challeng ing.</w>
10.1093/brain/ aw
em et
dil ute</w>
U k
8 77
adop tive</w>
DO N</w>
otrop ical</w>
mix ture.</w>
instrum ent.</w>
valid ation,</w>
prefer able</w>
complex ity,</w>
di ,</w>
Dol an</w>
D 5</w>
Vienn a</w>
hypo thyroidism</w>
Pes qu
J Q</w>
C U</w>
ovi position</w>
( S.</w>
fer ric</w>
calcul ated,</w>
ampl ifications</w>
B S,</w>
10.216 5/
(1. 7)</w>
s RNA</w>
kine tics,</w>
tion s)</w>
ear th</w>
Weigh ted</w>
10 45</w>
so s</w>
edi al</w>
Reg ist
manufacture rs</w>
cap e</w>
Wel sh</w>
Cr it.</w>
13 ;</w>
0.0 35
G ates</w>
Tra umatic</w>
amin ergic</w>
spec ifying</w>
glut athion
Pear ce</w>
cm 3</w>
Or te
s RNAs</w>
Rou tine</w>
wavegu ide</w>
TN ,</w>
Hepat ocellular</w>
en thal
ME C</w>
long- chain</w>
E lim
Bhattachar ya</w>
P s.</w>
23 45
1 †
if ,</w>
evalu ates</w>
abrup t</w>
Tim ing</w>
oc aine</w>
keratin ocyte</w>
R 4</w>
ear um</w>
6 29
Frank fur
3- 2</w>
Wa ist</w>
11 30
10.1038/n m
epi phy
primor dial</w>
om el
antimicrobi als</w>
liqu ids</w>
R. G.</w>
10 75</w>
amb a</w>
elu ting</w>
bour ing</w>
Pool ed</w>
300 -
o ij
3, 0
α ,
ten ing</w>
cu ed</w>
tin gu
ad as</w>
R ie
symbi onts</w>
quench ed</w>
C as</w>
A -</w>
truncat ula</w>
coil ed-
U 6</w>
apo re,</w>
form at,</w>
dis agreement</w>
3 c).</w>
22 ),</w>
Emer gence</w>
( time</w>
accompl ish</w>
W are</w>
sep sis.</w>
p add
H 0
tr un
10 67</w>
v 2</w>
practic ed</w>
iden tic
f el</w>
is th
instrum ent
Mem .</w>
scenari o.</w>
11 12</w>
R. P.</w>
4 /0
ker ato
a ñ
S tig
v /v
label ,</w>
Registr ation</w>
Am p
10 93</w>
op a</w>
g or
tum e
stake holder</w>
en ;</w>
Brow n
3. 200
plas mac
dimen sions.</w>
Electro chemical</w>
11 13</w>
( miRNA
gro unds</w>
amp ut
T abl
RE ,</w>
100 ).</w>
heli x-
receptor s:</w>
al ity:</w>
plastic ity,</w>
ul s</w>
Sca ff
Jo b</w>
ol ol</w>
I SC
H Be
Committe e,</w>
ple uro
Sox 2</w>
16. 4</w>
a it
Mc Co
H ib
up dates</w>
rs fs
Analy zing</w>
tubercul osis,</w>
r inger</w>
HLA- DR
ro bi
pix el
Vari ant</w>
Ed gar</w>
F gf
Ac anth
150 1</w>
VEGF- A</w>
autophag y,</w>
op tions.</w>
n ylon</w>
eigen values</w>
e Life</w>
abund antly</w>
Phil os</w>
Bart lett</w>
stor age,</w>
oc alization</w>
matri x-
hist oly
Prit chard</w>
12 55
ol is</w>
modifi able</w>
dementi a,</w>
3- 6</w>
n esting</w>
convinc ing</w>
GF ,</w>
land .</w>
gl aci
2 E).</w>
( ≥</w>
c ec
Zie gler</w>
C27 —C
10.1542/ped s
spik e-
retro virus</w>
e sia</w>
1. 94</w>
stit utes</w>
i bu
a dis
120 7</w>
E wing</w>
18 34
CG ,</w>
genu ity</w>
re generated</w>
step s:</w>
oth re
Biom edic
( yellow</w>
S SA</w>
Observ ational</w>
17 67
10.1001/jama. 29
Pop ulations</w>
1. 97</w>
π -
en baum</w>
chond ral</w>
[6 2]</w>
A uck
5- 1</w>
16 25
estim ation.</w>
e GF
[3 H]
Article A</w>
sym biosis</w>
erg aard</w>
assembl age</w>
pun ishment</w>
non synonymous</w>
Sch ubert</w>
fl y
S atoh</w>
Cul tiv
10 30</w>
IS ME</w>
Bro d
punct ate</w>
lact ose</w>
green )</w>
glomer uli</w>
M 0
carbap enem
Less ons</w>
perovsk ite</w>
137 7</w>
) 3</w>
zz a</w>
C. D.</w>
son @
parasit es.</w>
10.1038/n n.
Scen ario</w>
S um</w>
L Z</w>
K DM
A >
peculi ar</w>
Trich oderma</w>
sp ans</w>
10.1128/JB. 18
hippocamp us.</w>
Incre ases</w>
G O-
p 16</w>
E-0 7</w>
A 1-
pum ping</w>
Le od</w>
50 ).</w>
hero in</w>
typ es:</w>
sc an
i el</w>
antigen s.</w>
Indu stri
AN CO
199 7,</w>
im pregn
dev ised</w>
4 19
E PA
D ashed</w>
Sol utions</w>
17. 6</w>
ro virus</w>
h us</w>
Vir ul
Intraven ous</w>
tau ght</w>
lung s,</w>
gri ds</w>
Mc Der
HS V</w>
DM N</w>
ox im
SE P</w>
steat ohep
nur ses
lact ating</w>
N ;</w>
ED s</w>
2-s2.0- 336
17 95
implic ate</w>
In put</w>
inflammat ory,</w>
chromosom e,</w>
Gest ational</w>
109. 4</w>
g/ kg</w>
Prac tition
Hatt ori</w>
ijerph -
comput ations</w>
119 3</w>
10 57</w>
(M or
un ya</w>
ing -based</w>
mi er</w>
cuc umber</w>
bol d.</w>
au str
Ima i</w>
CH 2</w>
whe el
speci es)</w>
iso form
jug ular</w>
im pose</w>
V PA</w>
contamin ation.</w>
Tianj in</w>
Indian apolis,</w>
Don ald
* .</w>
short com
I/ II</w>
C 36
plot s,</w>
N- methyl-
σ (F2)</w>
Haemat ol</w>
0.0 34
food s,</w>
c ip
8 5,</w>
fer romagnetic</w>
Electrophore sis</w>
sal es</w>
y gi
ten berg</w>
ul en</w>
ST IM
21 ],</w>
two- component</w>
10.1016/S0 378-
( 37)</w>
peroxidase- conjugated</w>
d v
Par ac
rhabdom y
Tibet an</w>
T l
Biology Cellular</w>
oz zi</w>
Depend ence</w>
D. P.</w>
(Promeg a)</w>
Rec all</w>
( Ex
valid ity,</w>
s ob
dis cour
Me m</w>
Loren z</w>
0.0 3,</w>
accord ingly.</w>
−0. 2</w>
gover n</w>
Nerv ous</w>
ch amb
thioredox in</w>
benthami ana</w>
am e,</w>
22. 2</w>
Vol t
Le gend
top ologies</w>
omy ces</w>
flu id.</w>
10.13039/ 50110000
Vog el
= [
lact one</w>
early- onset</w>
Yam ag
NS F</w>
stri k
NP s,</w>
140 1</w>
om ni
acin ar</w>
tun e</w>
fif teen</w>
Sing apore,</w>
Hild en,</w>
un successful</w>
g ob
Upt ake</w>
7 b</w>
res e</w>
Bifid obacterium</w>
responsi bilities</w>
fluorescent ly</w>
ch el</w>
maxim ally</w>
gener al.</w>
9 16
1 s</w>
noxi ous</w>
10.1002/ ana.
M 2,</w>
Chi en</w>
R s,</w>
7 12
pre motor</w>
Met formin</w>
[8 1].</w>
14 55
b x
Plas tic</w>
mag ent
Phar ma</w>
Br anch</w>
scre en,</w>
vi remia</w>
1 E</w>
inf ested</w>
gener ous</w>
Stein berg</w>
20 58
10.219 6/jmir
s ant
dev ast
G rac
130 5</w>
Ritch ie</w>
physi otherapy</w>
demograph ic,</w>
Akai ke</w>
valv ular</w>
scen es</w>
inc ar
ofron tal</w>
est ris</w>
p ush</w>
a uro
Perin atal</w>
Sp ain,</w>
N inet
IS I</w>
wri ting.</w>
kn ock</w>
difficul t,</w>
gel s.</w>
Hen ri
asi s:</w>
camer as</w>
S ide</w>
H anna</w>
GC- MS</w>
gastro cnemi
M anning</w>
Cal der
166 2-
se .
vari ant,</w>
monol ay
201 1.
zyn ski</w>
st am
t rough</w>
angiot ensin-
AC P</w>
post s</w>
in valuable</w>
T ;</w>
Q D
Kore a,</w>
scenari os,</w>
20 30</w>
Rad ical</w>
1— O2</w>
satisfac tion,</w>
C inc
10 66</w>
h s-
In spec
Pan els</w>
** p<0.0
unn an</w>
Lipp inc
multi faceted</w>
Ta x</w>
Sign als</w>
G6 PD</w>
gal ectin
imp act.</w>
(2. 1)</w>
int est</w>
aren a</w>
O ld
Blan c</w>
In activation</w>
Nan otechn
ud er</w>
subunit ,</w>
i PS</w>
ak ura</w>
PM 10</w>
Dam age</w>
ol ph</w>
P ast</w>
abnormal ities.</w>
199 9),</w>
in accurate</w>
o od</w>
dyne in</w>
transmit ting</w>
a ‐
1. 91</w>
transl ating</w>
miR- 14
lin es).</w>
Scienc es.</w>
Trans formation</w>
B 16
med itation</w>
bet a1</w>
k a,</w>
Us ers</w>
un characterized</w>
H. C.</w>
(P )
arg on</w>
CD I</w>
wt %</w>
N CC
MF I</w>
hair s</w>
under lined</w>
nanocryst als</w>
sar cop
My an
we i</w>
3 ,000</w>
2 g
U2 OS</w>
N K-
Mohamm ed</w>
23. 5</w>
( γ
poly (A)</w>
17 —H17
ch ial</w>
Kau r</w>
Wor d</w>
PI C</w>
EM A</w>
forc e.</w>
Syn dr</w>
RG Cs</w>
1. 25
Val le</w>
GL M</w>
ovol ta
dich ro
Impact J
A +</w>
e. org
16. 8</w>
C au
( 0.000
therm ally</w>
Cyto plasmic</w>
og h
methyl ation.</w>
K -1</w>
10 57
vor tex</w>
peric ardial</w>
infl ated</w>
K D
140 3</w>
od d</w>
1 %.</w>
Bo er
6 28
4 G
d ated</w>
oxid ation,</w>
Fro st</w>
P _
d as
Immun ization</w>
8 47
tax a.</w>
Se ed
" )</w>
V im
val pro
10.18632/oncotarg et.
− 6.
P ich
Mill an</w>
1. 15
G oth
C ay
glutar aldehyde</w>
bio activity</w>
RA CE</w>
Polym .</w>
N ie</w>
7 66
(Pro mega
α- tubulin</w>
Z al
10.1007/s 100
( vs.</w>
Utre cht,</w>
j m
- off</w>
bal ance.</w>
out standing</w>
program me.</w>
fold- change</w>
10 89</w>
(20 ).</w>
15 26
stem -like</w>
8 )
2-s2.0- 338
10 41</w>
post- mortem</w>
N a-
Jan u
HPV 16</w>
8 24
ext ent.</w>
en berg
n iger</w>
formul as</w>
v es,</w>
din oflagell
P )
12 56
D HE
time- course</w>
E PCs</w>
(N ik
ma ier</w>
jus tice</w>
Bio statistics,</w>
phot oc
Pe i</w>
Direc tor
14 98
10 56
otec an</w>
ang ial</w>
p g</w>
min −1</w>
ket one</w>
Bl om
10.1016/j.s oc
FK BP
B alb
26 ,
cap tive</w>
Gastro intest</w>
autum n</w>
Schr ö
Organ ization.</w>
I’ m</w>
17 68
clim bing</w>
nucleoti de-
distrib ute</w>
Fil e).</w>
Bow el</w>
simplic ity,</w>
L amin
Sy n</w>
arri ve</w>
Demograph ics</w>
11 78
z l
10 90</w>
DF T</w>
Fol ey</w>
CI I</w>
bl ank
Chan nel</w>
Z F</w>
electro de.</w>
haus en</w>
Mar row</w>
2- 6</w>
10.1186/1471- 2407-
medi an,</w>
azol e,</w>
Afric a
tr and</w>
pec ific</w>
metabolis m
bas e.</w>
2. 12</w>
Olig onucle
inter cep
f ight</w>
Le ad</w>
L ater</w>
De pres
1- deficient</w>
prokary otes</w>
meth acryl
Ed itor</w>
uni ver
hin dered</w>
ACT H</w>
(T LR
avail ability.</w>
HI V.</w>
res um
J A,</w>
deposi t</w>
10 91</w>
- K
+ β
Ku z
YF P-
( =
sampl es)</w>
occur red,</w>
] /
suppl i
al ar
z ur</w>
recurrenc e,</w>
12 62</w>
11 29</w>
10 22</w>
ste ep</w>
har bored</w>
atten tion-
5 G
Som mer</w>
opter a,</w>
º )</w>
paclit ax
(V ector</w>
percep tion.</w>
Cryptospor idium</w>
Ad di
M eng
> 2</w>
re form</w>
ber ries</w>
cav ity,</w>
ali phatic</w>
ent ri
cl ick</w>
[24, 25].</w>
Ren illa</w>
6 A,</w>
(E ),</w>
U ro
possi ble
T ann
7 )
Or d
G lia</w>
Embr yos</w>
19 53</w>
− 8
w ester
6 %),</w>
0. 5.</w>
se ated</w>
discharg es</w>
ran k-
Scre en</w>
Italy )</w>
quar ters</w>
16 ;</w>
ath in</w>
Ultim ately,</w>
35 /
9 3,</w>
dos ages</w>
dis assembly</w>
prot ection,</w>
ot .</w>
anc e).</w>
t mann</w>
gene )</w>
am ing</w>
DD T</w>
not ch</w>
H SA</w>
12 46
ver a</w>
ment /
Pro stagland
ul ation.</w>
aq a
Yi eld</w>
T IP
Satis faction</w>
provinc e,</w>
Cp Gs</w>
al so,</w>
AC R</w>
6 C</w>
CS P</w>
ga ther</w>
sk y,</w>
in sured</w>
far mer
P hi
si s.
jo y</w>
2- D</w>
correc tion,</w>
az im
Steph an</w>
mil ieu</w>
accoun t
H SD</w>
sup rac
G S)</w>
w edge</w>
transl ation.</w>
Con sorti
ID A</w>
ri vers</w>
cir c
Bj or
Sl c
B ST
1990 s</w>
( log
Pyth on</w>
F AS</w>
Associ ate</w>
Ad hesion</w>
lit ter
gl os
Radi c</w>
199 8)</w>
preven tion.</w>
decl ares</w>
11 58
w asp
recombin ase</w>
key words</w>
Sud an</w>
n in
CaMK II</w>
Bax ter</w>
arthro pod</w>
Ish ida</w>
17. 3</w>
120 2</w>
ma ker</w>
energ e
gem ein
7 17
I 3</w>
com bustion</w>
Wind ow
tic ism</w>
ev edo</w>
appro x.</w>
For mul
surve ys,</w>
like wise</w>
SO X2</w>
-to- treat</w>
Let t.
h CG</w>
AP A</w>
Mod ule</w>
Dens it
h as
Direc tor</w>
project .org/
(1. 8)</w>
Past eur</w>
ucle ated</w>
oid s.</w>
W GS</w>
S 7).</w>
Re ads</w>
vi i</w>
activ ity;</w>
Nag ai</w>
val ley</w>
F ort</w>
Ber th
un expect
fail ure:</w>
18 35
ph e
Cer tain</w>
CA L
119 7</w>
T1 D</w>
7 36
3 T3</w>
stor ies</w>
pul l
W S
6 38
á r
mean s.</w>
magn ification,</w>
community- acquired</w>
cont acting</w>
tex t,</w>
Le ban
∑ k
10 77
(T F
j ar</w>
horizont ally</w>
én é
sam e,</w>
ram s</w>
produc er</w>
Vari ants</w>
Relev ant</w>
IL I</w>
post- traumatic</w>
import ance,</w>
0.0 71</w>
amin e.</w>
Appropri ate</w>
en ing,</w>
Mo ff
IκB α</w>
10.1186/ 1743-
(H R)</w>
Pennsyl vania</w>
parent s’</w>
al p
Un less</w>
199 6)</w>
20 23
2. 2
(SNP s)</w>
tri but
aver age.</w>
Ill ness</w>
10.1098/rst b
n l</w>
cont our
infer tile</w>
Ser ot
Nor theast</w>
Bi anchi</w>
2 Research</w>
neuro transmission</w>
dat a/
firef ly</w>
Les lie</w>
7 ],</w>
48 8-
but anol</w>
(199 7)</w>
bi ophy
band .</w>
pseudomalle i</w>
larv ae,</w>
iz umi</w>
Dermat ology</w>
/ G
dos es.</w>
F Z
; 34</w>
nor theastern</w>
db /d
rapid ,</w>
Tre ated</w>
H2 B</w>
(19 75</w>
119. 1</w>
fac ets</w>
cle ave</w>
attitud es,</w>
ation ’</w>
M ak</w>
Ku w
restric ts</w>
pep per</w>
ha el</w>
120 9</w>
I 0
eng a</w>
absor p
Ott awa</w>
y d
ig ene</w>
experienc es,</w>
N el
—O 4</w>
Matsu i</w>
qu aternary</w>
her maph
di es</w>
at ani</w>
are z</w>
Ker n</w>
t ons</w>
object s,</w>
sensiti zes</w>
P ers</w>
Auth ority</w>
propag ate</w>
practic ing</w>
Pat ent</w>
IL ‐
H ;</w>
12 0.7</w>
electro -
15 49
tr in
bever age</w>
(9 1.
K ant
Hippocamp us</w>
negativ e)</w>
interview ,</w>
5 *</w>
1 L</w>
Na than</w>
(1. 9)</w>
plant s
con sorti
M av
A gen
SciencesImmunology Immune</w>
Aus tin,</w>
í fic
Co ast</w>
98 .</w>
intim al</w>
at re
W ich
Sho uld</w>
Se paration</w>
trial s.
ev oke</w>
epidermi dis</w>
con vol
ness :</w>
Micro -
nid ul
DC s,</w>
15 27
less -
lam ellar</w>
AR T,</w>
15 32-
10.1186/147 2-
syl v
W ise</w>
8 34
let t
t ure
[5 3],</w>
star tle</w>
A min</w>
17. 4</w>
si as</w>
prob es,</w>
k head</w>
k i,</w>
cult ure-
Cap ital</w>
dec ou
ri sts</w>
mach er</w>
33 29
h inge</w>
staphyloc occal</w>
method s:</w>
M L,</w>
an o-
A &
# 2</w>
factor- alpha</w>
es chi</w>
M Q</w>
two- hybrid</w>
37 /
Gynaec ol</w>
men arch
band s.</w>
10 36
flo od
Ly ons</w>
Mac K
sub types,</w>
cent ers,</w>
libr aries.</w>
u gh
room ,</w>
monit ors</w>
Scat ter</w>
Er as
12 13
ul ae</w>
document class
\ documentclass
pen sion</w>
O W
8 26
amph oter
LV EF</w>
GS K
Fernand o</w>
β /
sk ew</w>
rati o)</w>
L FP</w>
Check list</w>
(3 )°</w>
mut h</w>
dou ble
Nan og</w>
Estim ate</w>
C us
12 th</w>
10.1093/ eur
b acter</w>
16 68
. 198
pack aged</w>
6 26
tri angles</w>
fo il</w>
batter ies</w>
H R)</w>
Col ony</w>
er ved</w>
fig ure,</w>
cop per
( T</w>
a- specific</w>
McCor mick</w>
( RNA
sf onts
sb sy
\usepackage{ams symb
\usepackage{am sfonts
Scandin avian</w>
to il
Max well</w>
math rsfs
\usepackage{am sbsy
\usepackage{ mathrsfs
drop out</w>
Cros s
Th is,</w>
lipoph ilic</w>
Spragu e-
v /v)</w>
p 24</w>
lef t.</w>
11 46
Ca j
[3 2
Stim uli</w>
146 5-
119 5</w>
un structured</w>
10.1155/201 2/
am ox
PP 1</w>
epic ardial</w>
Hor mone</w>
0.0 72</w>
fol k</w>
R DT</w>
Pae diatric</w>
( 74
polyp eptides</w>
UK ;</w>
P CA
17 49
U 1</w>
hyph al</w>
Trem bl
9 )
Town send</w>
sis ting</w>
1/ 4</w>
method ology,</w>
–16 ].</w>
> 100</w>
exclud ed,</w>
CC I</w>
18 67
10.10 96
de hydro
au f</w>
2 c
10 38
relev ant.</w>
P SCs</w>
Sem in
ent re
f ran
pol is</w>
n ic</w>
adul t-
Rog er</w>
omet er,</w>
NA NO
dail y.</w>
ag li
8 14
lung .</w>
press or</w>
comm enc
S ard
NT A</w>
off line</w>
B. M.</w>
Chatter jee</w>
18 29
(B MI</w>
Institu te.</w>
Bloc king</w>
por ting</w>
pass aged</w>
Y ar
198 9).</w>
sc it
iti s:</w>
10.1096 /f
ri v
ANOV As</w>
T GG
dec oy</w>
2 i</w>
Y unnan</w>
T IG
id e)</w>
self- assembly</w>
fit .</w>
Mu sic</w>
s 2</w>
osse ous</w>
J H
G rig
asympto tic</w>
Weis sman</w>
water- soluble</w>
und ou
22 28
11 51</w>
contrac eption</w>
C E-
em ura</w>
c ure
record ed,</w>
interleukin -1</w>
11 24
rat s:</w>
af il
8 35
J emal</w>
Biom ass</w>
1 °</w>
(201 6)</w>
function ing.</w>
L ou</w>
V K
50 °C</w>
y et.</w>
J oy
11 25
sensitiv e,</w>
ribavir in</w>
p v.</w>
colon oscopy</w>
7 15
har bouring</w>
6 58
22 q
(2. 2)</w>
ü ller</w>
more over,</w>
fa ith
Otolaryng ol</w>
2 H),</w>
16 28
mesotheli oma</w>
m M
Fuk ushima</w>
t 2</w>
Ra ther</w>
D MD</w>
57 93
lig am
D 2,</w>
10.1016/j. ym
0 80
satis fying</w>
P 7</w>
i ov
12 11</w>
10– 20</w>
Cp G-
3/0 90
t k
11 57</w>
morph ologic</w>
18 68
conjunctiv al</w>
W ing</w>
HOMA- IR</w>
Dev ices</w>
aggres siveness</w>
Nk x
And ers</w>
−0.00 3</w>
overestim ation</w>
draw back</w>
diarrhe a,</w>
11 48
achiev able</w>
Surve ys</w>
Mil k</w>
Log an</w>
(green ).</w>
rate- limiting</w>
rich ,</w>
marri age</w>
201 1–
J. Y.</w>
( c.
is o</w>
if lu
u xim
el ess
tox in-
multi potent</w>
(Z e
rat t</w>
ak ova</w>
10.118 3/090
tox ication</w>
eti ological</w>
V 4</w>
Kaplan –
Electro physi
15 67
for age</w>
author s’</w>
ne u</w>
9 17
Oec ologia</w>
> 0.05).</w>
involv ement,</w>
16. 6</w>
CD 34</w>
C α</w>
M x
Diet rich</w>
RMS E</w>
Fac e</w>
AC E
10.1523/JNEUROSC I
LY 29400
sh in
ib ly</w>
Agra wal</w>
1. 99</w>
shut tle</w>
nano composite</w>
L ’
J ab
Clay ton</w>
mon d,</w>
L amp
receptor ;</w>
oc cult</w>
line age.</w>
Bre it
Be y
line ages,</w>
improv ed.</w>
target -
St ate,</w>
oph or
ê nci
ain er</w>
S 5.</w>
( 39)</w>
veter ans</w>
ax y</w>
possi bility,</w>
Hybridi zation</w>
Clin ics</w>
feedback ,</w>
lif e:</w>
[36 ,</w>
Ethn ic</w>
22 26
Z ika</w>
i ani</w>
acc ess,</w>
SNA RE</w>
tim ed</w>
p 300</w>
ile um</w>
Lin king</w>
11 10</w>
sel dom</w>
( Thermo
Epidemi ology
T AA</w>
GT C</w>
30 ),</w>
any one</w>
Pleist ocene</w>
28 ]</w>
C1 —H
16 80
pre- incubated</w>
co- localized</w>
í a,</w>
u g</w>
sev enth</w>
po x</w>
0.0 36
is sen</w>
habit uation</w>
band ing</w>
Le iden</w>
Er d
oc oc
nitrogen -
discharg e,</w>
14 69
oc ept
P HA</w>
(AT CC</w>
( J.
arrowhe ads</w>
V O2</w>
IV E</w>
glob al,</w>
MT S</w>
11 27</w>
attenu ating</w>
IP 1</w>
Classi cal</w>
10.1016/j.neuroimag e.200
ME D</w>
Alzheim ers</w>
end o-
down load</w>
a v</w>
[44 ,
[25 ,26].</w>
Santi ago</w>
simul ator</w>
s ays</w>
k un
coh esin</w>
Wiscon sin</w>
PI3 K-
ocycl ic</w>
financ ing</w>
Japan 2</w>
Le eu
az ,</w>
−0. 5</w>
B est
5 B,</w>
y oga</w>
thur ingi
NH 2</w>
Adolesc ents</w>
si RNA,</w>
NE ,</w>
Hist opathological</w>
11 13
wash ed,</w>
Pfei ffer</w>
urg ently</w>
miR- 15
fac et</w>
S re
sc an.</w>
[8 2].</w>
consecu tively</w>
Mathem atics</w>
it real</w>
S GA</w>
F 0</w>
amelior ated</w>
19 44
albopic tus</w>
7 25
cre ative</w>
Epigene tics</w>
Experim ent
md x</w>
BM I.</w>
T j
K oc
CO M</w>
– 49
usp id</w>
n ail</w>
N ath
GT AT
Sain t-
buff ering</w>
Miy amoto</w>
15 60
Abr am
(c ,
k et</w>
as yl
H h</w>
ris es</w>
c ig
anc a</w>
110 00
2. 13</w>
10 79</w>
j ack
amidino- 2-phenyl
Sustain able</w>
fo ve
Stat .</w>
ca dic</w>
block s,</w>
Mo tion</w>
Dav ey</w>
10.1006/j m
® )</w>
(c m
peptidogly can</w>
con centric</w>
Bas in</w>
( final</w>
Resist ant</w>
extr usion</w>
ud an</w>
sc ut
metabol omic</w>
D ahl</w>
Col -0</w>
Kaw ai</w>
pro of-
cm 2)</w>
gluc agon</w>
all y)</w>
Radi otherapy</w>
D A-
water )</w>
star s</w>
sc imed
bio degradable</w>
RI L</w>
op od</w>
K ent
11 60
10 87</w>
– 120</w>
t les</w>
Mil es</w>
Mal m
construct .</w>
Intellig ent</w>
HE K-
Carti lage</w>
5 -</w>
ather ogenic</w>
214 8-
histor ically</w>
extrem ities</w>
F uc
D ich
20 66
ith ub
:e 100
aph ids</w>
20 37
Lear n.</w>
F AD</w>
9 A</w>
post oper
* :</w>
stress- related</w>
hol otype</w>
18 47
bur den,</w>
t all</w>
inter course</w>
eth yl-
t ler</w>
sched ules</w>
hub s</w>
group s)</w>
ai res</w>
adv enti
Ster oid</w>
11 27
pa ste
Por phy
M are
root s.</w>
1 @
clon es,</w>
ang el
T EN
(19 76</w>
in activity</w>
TT T</w>
Medi ators</w>
Mach ado</w>
A ur
≥ 1</w>
Sm it</w>
12—C 11</w>
ul ar
F ab</w>
E SS</w>
il -
Phil os.</w>
Klu wer</w>
( https://
Sa f</w>
Fe asi
Cdc 42</w>
At titudes</w>
Now ak</w>
A trial</w>
TA T</w>
Cycl ic</w>
@126. com
stack ed</w>
Mc Ge
id azole</w>
his tid
10 51</w>
tri be</w>
tet ramer</w>
experiment ation</w>
Ac upunc
ron ,</w>
Gi ardia</w>
modifi ers</w>
low ski</w>
11 43</w>
ner i</w>
met atar
h it
tele ost</w>
Mu th
Chr ys
kow ska</w>
(1 %)</w>
( orang
sing er</w>
Entom ol.</w>
Barre tt
(J ack
ec o</w>
hypothe sised</w>
N. D.</w>
AG T</w>
19 28
(ER )</w>
popl ar</w>
CA L</w>
10.1016/00 22-
fac e,</w>
199 8
16 26
B alle
bott les</w>
K ho
un familiar</w>
PM ID:
130 9</w>
ro th</w>
[14 ,15
15 59
11 35</w>
109. 2</w>
y- like</w>
ul o</w>
phenyl )-
analysi s)</w>
Myc -
D AB</w>
proton ated</w>
R. B.</w>
L enn
A S.</w>
10.1371/journal.pbio .00
pro long</w>
nan otub
eal s</w>
control s)</w>
.2015. 00
ure a,</w>
prolac tin</w>
necro sis,</w>
g ab
C NP
N GO
Gl n</w>
Tor onto</w>
GT P-
G us
22. 0</w>
cri me</w>
BM P-2</w>
fram e,</w>
Bus h</w>
yeast .</w>
18 26
H Cl
hor st</w>
air flow</w>
CH F</w>
tal king</w>
rin a</w>
re w
[6 3]</w>
ar ini</w>
Compo und
Austri an</w>
spr uce</w>
sper sed</w>
employ ed,</w>
CK 2</w>
wat ching</w>
T CC
** **</w>
Y Q</w>
IL- 33</w>
percenti les</w>
ologi e,</w>
ij o
Out com
H ov
(00) 0
prot otyp
on ec
MA R</w>
6 24
2 f
Har ding</w>
gol den</w>
s acchar
Diast olic</w>
O K</w>
( score</w>
tremend ous</w>
Un its</w>
17. 8</w>
metazo an</w>
– 150</w>
S 11</w>
El is
S- transferase</w>
diamin obenz
Ref Seq</w>
PC L</w>
Dunn ett
2- 7</w>
I s.</w>
phenotyp ically</w>
consul ted</w>
M B,</w>
bod y
Mack ay</w>
C/ T</w>
/ R
ogrou ps</w>
galact os
0.0 27
( maximum</w>
flow ing</w>
[12 -
O :</w>
l abile</w>
haemorrh age</w>
ang le.</w>
G it
avi um</w>
A —N
sing leton</w>
ab ayashi</w>
Portu gal
i ana</w>
M app
17. 9</w>
I .,</w>
Col ombo</w>
Ara i</w>
2 %).</w>
Healthcare )</w>
Frequ ent</w>
hydro cephal
genom e-scale</w>
P yr
inter phase</w>
10 68</w>
10 64</w>
r g
(200 3).</w>
( 6-
11 31</w>
fin ely</w>
burn out</w>
Sch ell
18 58
Ther m
o ),</w>
el ong</w>
10 40</w>
clo th
Atmosph eric</w>
one- year</w>
dec eased</w>
un intended</w>
tic )</w>
part .</w>
cat .</w>
Kenn a</w>
C7—C 8—C
hour ,</w>
a emi
injur ies,</w>
c loc
aldo sterone</w>
Yam azaki</w>
Dev ice</w>
8 39
I s,</w>
pre- operative</w>
feb slet
IC U
CD 31</w>
10 92</w>
(97 )00
til a</w>
frame work
f eline</w>
absol utely</w>
dimorph ism</w>
3 0.0</w>
engraft ment</w>
aspar tic</w>
Dri ve,</w>
op ost
Mar c</w>
12 15</w>
N p
18 59
2 <
polymer ases</w>
acetyl transferase</w>
calend ar</w>
credi bility</w>
22. 1</w>
output ,</w>
calcul ates</w>
T emp
– 0.7
aa B
. it
E n</w>
0.00 12</w>
surve ys.</w>
olym ph</w>
disp osition</w>
1 a)</w>
com ments.</w>
K ai
A mic
204 1-
provid ers.</w>
( p.</w>
ne bul
0.0 70</w>
(T IF
P 450
3 ×
at ure.</w>
pa yments</w>
S end
G rat
gre en.</w>
7 20
gener ations.</w>
O H)</w>
myel inated</w>
et i</w>
ab domin
Wal king</w>
resid es</w>
id ge</w>
[pii ].</w>
34 /j.
ind etermin
f ac</w>
ati ds</w>
2.0.CO; 2</w>
rot ations</w>
mm ),</w>
Hôpit al</w>
put ting</w>
m at</w>
cent ric
appropriat eness</w>
Me in
Bas u</w>
phot ograph</w>
b end
14 60
11 75</w>
(bottom )</w>
hypometh ylation</w>
Stat 3</w>
Phyto chemistry</w>
repor ters</w>
crystall in</w>
IC E</w>
ag o.</w>
Wech sler</w>
Micro scopic</w>
7 16
(ref )</w>
n ings</w>
140 5</w>
10.10 34/j.
10.1093/ ij
cont act.</w>
minim ise</w>
Fried rich</w>
li st,</w>
ir on,</w>
Sh uk
N Q
in- binding</w>
10 98
α 1
cyt es,</w>
RA B
O ).</w>
Banglad esh
Mono clonal</w>
stitu to</w>
spectro metric</w>
retin a.</w>
chew ing</w>
2 d
sel ects</w>
Eis en</w>
te am,</w>
ACSEBHS16005 368
17 25
non- treated</w>
H emis
0000 000
I m</w>
B ech
10.11 28
transpor ting</w>
lub ric
8 1,</w>
Algorith ms</w>
198 5;</w>
ph ant
Res ult</w>
Rib osomal</w>
Green wood</w>
ucle oti
[ 0
Fl ynn</w>
r ps
angi ogenesis.</w>
pap er.
iso forms,</w>
Cha i</w>
b ed,</w>
Sprague- Dawley</w>
bo re
LO C
J I
−0.0 1</w>
s v
A 27
sw ollen</w>
hydroly zed</w>
F iv
Scienc e.</w>
S iz
For um</w>
ator -
affec ted,</w>
M P,</w>
48 ,
z a,</w>
uro log
Sim pl
10.1097/ Q
catast roph
N. J.</w>
B ind
as e),</w>
0.0 23
– R
bin ocular</w>
Angi ogenesis</w>
IP 3</w>
I ne
(F e
compl e
’ ),</w>
Flav on
sou theastern</w>
high ‐
Resid ues</w>
n .,</w>
con ting
Ko jima</w>
ver sion,</w>
neuro toxic</w>
child birth</w>
modul e.</w>
disper se</w>
St ar</w>
red oxin</w>
tor s,</w>
penicillin /
P ak</w>
10.1093/ aj
coordin ation,</w>
chondro genic</w>
over- represented</w>
distr actor</w>
Pol ar</w>
IN SER
sa id,</w>
R ü
8 27
um ps</w>
oste oblastic</w>
di phosphate</w>
B d
16 39
cha et
is o-
geomet rically</w>
arri ved</w>
2 A),</w>
trehal ose</w>
fo rensic</w>
aden yl
But ,</w>
it ating</w>
ce iling</w>
Kn ud
acetab ular</w>
Intr am
2010 This</w>
2-s2.0-00 35
0.000 1;</w>
box ,</w>
H2 A.
Fif ty</w>
f ts</w>
Jos eph
sc ro
d. )</w>
1 ***</w>
na p</w>
(Invitrogen ),</w>
flo od</w>
PA I-1</w>
constrain ts.</w>
18. 8</w>
(P V
lepro sy</w>
; 35</w>
self- care</w>
demonstr ated.</w>
M MT
ov o</w>
d UT
N ode</w>
enti tled</w>
Kaplan– Meier</w>
0.0 24
(ADP- ribos
sple ens</w>
E gr
57 -
peak ,</w>
Gi ord
17 7.
D 4
APEX II</w>
z aki</w>
intratum oral</w>
cobal t</w>
Uch ida</w>
Switzerland ).</w>
Mc Ke
independ ently.</w>
aer ts</w>
Z 1</w>
2 A-
18 —H18
f und</w>
adultho od.</w>
Os aka,</w>
Min eral</w>
+ 2</w>
Rob er
PS D</w>
(10 ,</w>
under weight</w>
resid ency</w>
persist ently</w>
- a</w>
pg/m L</w>
call osum</w>
omyc etes</w>
cor d,</w>
az ole-
S HI
008 -0
it ated</w>
Berg man</w>
120 8</w>
(4 2)</w>
Ne ub
row ing</w>
o edema</w>
def ault
♀ ,</w>
dat a.
de x</w>
ann is</w>
10.1016/j.soc scimed
unc tional</w>
anti oxidative</w>
é l
inocul ation.</w>
h pi
stem/ progenitor</w>
Zha i</w>
mer it</w>
amplitu de,</w>
F inder</w>
S unn
zh ang
load ing.</w>
Rock ford,</w>
camer a.</w>
Saú de</w>
Hub bard</w>
om b</w>
007 -0
st an</w>
host s,</w>
day -
Surge ons</w>
F FA</w>
Cigarett e</w>
phag ia</w>
B ench
ak ary
Mit su
o tis</w>
dens ity-
11 47
sig mo
11 19</w>
Tw itter</w>
K. H.</w>
Acqu ired</w>
system ;</w>
Frac tion</w>
d ab
Malay sia,</w>
n r</w>
ignor e</w>
MV s</w>
op od
Un clear</w>
pro mastig
architect ure,</w>
11 65</w>
li ,</w>
vomi ting,</w>
orh inal</w>
anc e-based</w>
Y ES</w>
Nish ida</w>
D rafting</w>
gre ek
Subj ective</w>
Fabric ation</w>
pseudo genes</w>
fundam entally</w>
cogni tion,</w>
Wel f
radi ograph
Respir .</w>
cyt ological</w>
W ade</w>
V P1</w>
Herre ra</w>
190 1</w>
0.0 28
multi focal</w>
America 3</w>
(H1N 1)</w>
k @
V y
n ing.</w>
dis similar</w>
crystalli zed</w>
tw o.</w>
osi s-
L L-
consul ting</w>
(00 )000
a ia</w>
10 60</w>
ze bra</w>
arter y.</w>
8 4,</w>
vacc ine.</w>
ur ine,</w>
199 9–
in patients</w>
PT X</w>
vibr ational</w>
ogen omics</w>
far nes
11 39
sum ming</w>
et )</w>
Sh ul
7 500</w>
si RNA.</w>
in ‐
Dict yost
log is
ar aj</w>
T CD
M ud
um oto</w>
rec ep
m h
Biot ec
17 66
12 66
1. 18
pneum ophila</w>
( due</w>
Diffrac tion</w>
sourc e-
inter- individual</w>
[15 ,16
mal ate</w>
Tan iguchi</w>
Offic ial</w>
Crypt ococcus</w>
-0 7</w>
ar ic</w>
Cas ey</w>
Bri ggs</w>
y on</w>
review ed.</w>
Ye ung</w>
Asi ans</w>
plant arum</w>
o rest</w>
gyn ec
T S-
histor ic</w>
[18F ]
W G
S 7
Infra red</w>
citrul lin
R ost
inten sively</w>
Inc ubation</w>
DA F-
ric e.</w>
proc es
pris tine</w>
aren sis</w>
tic ide</w>
schedul ing</w>
( 1%</w>
min/ 1.73</w>
Immunoblo tting</w>
1- 9</w>
O J</w>
12 41</w>
priv ileg
V alu
Cor yne
(0 /
vegetabl es,</w>
e– response</w>
G DN
S. G.</w>
L- type</w>
(R T)</w>
re traction</w>
sc an,</w>
B och
j es</w>
tumor- bearing</w>
TC P</w>
LD A</w>
ICD- 10</w>
(ELIS A)</w>
C. P.</w>
18. 3</w>
P ath</w>
Orte ga</w>
process or</w>
ter tile</w>
j n</w>
demograph ics,</w>
arrow s.</w>
N ou
(2. 5)</w>
( middle</w>
ter ic</w>
path ogenesis,</w>
MS I</w>
all ah</w>
M NH
20 100
is oc
caspase- 8</w>
Uni v</w>
G ren
Ch iba</w>
v end
unpreced ented</w>
Resourc es:</w>
ures )</w>
pip e</w>
Occurren ce:</w>
K ear
Green land</w>
F ull
(2 1).</w>
sec .</w>
conform ation.</w>
aptam ers</w>
t at
de k</w>
HF D-
11 59</w>
out do
lu c</w>
HR QOL</w>
zo obank
naph thal
7 30
ur u</w>
antec ed
review s,</w>
reversi bly</w>
cur ing</w>
dist antly</w>
cgi ?
D ot
16 37
0.0 73</w>
con cave</w>
s ending</w>
ero s</w>
servic e,</w>
hyper sensitive</w>
scin till
CT GA
ñ ez</w>
F US</w>
C. W.</w>
M ing
pyl ori
inevit ably</w>
quad rup
multi layer</w>
meth op
e.s. d.</w>
2. 14</w>
clear ing</w>
Neutroph il</w>
(98 )000
U RA
predisp ose</w>
of tw
us able</w>
concer t</w>
Mic ro</w>
( E</w>
al ising</w>
Editor ial</w>
abund ance.</w>
promo ters,</w>
oper ons</w>
long er-
gu il
F 3
≥ 3</w>
og luc
Me is
199 7)</w>
0.0 74</w>
( reference</w>
pul mon
group -
day s;</w>
Forsch ungs
op olym
ey es.</w>
CS T</w>
(P<0.0 5).</w>
vir gin</w>
t apping</w>
mal le
Al drich</w>
11 45</w>
um inal</w>
iso flav
e utroph
T 6
fron to-
Def ects</w>
cath eters</w>
Tukey 's</w>
20 49
or nam
confin ement</w>
Sper m</w>
( gray</w>
ent orhinal</w>
s c</w>
11 41</w>
Pu gh</w>
HSP 90</w>
0. 4,</w>
tryp an</w>
tot emporal</w>
cour t
unambigu ously</w>
(E B
w ill
Switzerland .</w>
20 68
ut es,</w>
fac e-
16 86
–17 ].</w>
spl ine</w>
ni an</w>
insul ator</w>
H C,</w>
—H 16</w>
Me OH</w>
Cre atin
magn ified</w>
imp acting</w>
benefit s.</w>
Por to</w>
(Le ica</w>
l ach</w>
CO R</w>
Bi osynthesis</w>
B ere
Al l-
11 89</w>
11 38
Hanc ock</w>
carr age
2.0 %</w>
10 96
f oci
10.1183/090 319
aden ylate</w>
D ang</w>
11 37</w>
( 4.0
ah aran</w>
ΔΔ Ct</w>
(33. 3)</w>
gg e</w>
F ad
China 4</w>
E specially</w>
flex or</w>
Lond .</w>
10.1038/ onc
d na
LT D</w>
lef t
exacerb ate</w>
1 C
Inj ur
32 ]</w>
. -
γ H2AX</w>
administ er</w>
Lind say</w>
μg/m l,</w>
14- 5793
metast ases,</w>
10.1104/pp .11
repl en
α- SMA</w>
P our
headach e,</w>
rang er</w>
dog s,</w>
CP P</w>
arter y,</w>
Jer se
Upreg ulation</w>
H2PO 4,</w>
( 2.0)</w>
kar ni</w>
journ al.</w>
21. 2</w>
11 61</w>
(1) °</w>
domestic ated</w>
ar aman</w>
est one</w>
10 28</w>
ros arcoma</w>
concer n.</w>
12 23</w>
innov ations</w>
Inter act</w>
0.00 11</w>
res ur
( age,</w>
9 2,</w>
Mad sen</w>
1- 8</w>
tric ho
Laparo scopic</w>
Re frac
11 25</w>
toxic ological</w>
cytokin esis</w>
Cl ade</w>
d ella</w>
ul e
k m2</w>
ocyto sis.</w>
anno unc
ink el</w>
T AK
H 23
small- scale</w>
miR- 125
integr ase</w>
R. K.</w>
8 36
10 32</w>
o yl
consum p
12 48
− 5
c ity,</w>
(Sup pl.</w>
controll able</w>
ateri al</w>
ad o-
15 69
dissi pation</w>
10.1371/journal.pgen .1000
qui et</w>
0.0 37
s weep</w>
cad aver
Mul tivariable</w>
associ ations,</w>
Ev ent</w>
B out
O’ Connor</w>
Ben ed
sim vastatin</w>
macro l
Pres entation</w>
a it</w>
Z one</w>
Col lo
bari atric</w>
Magn us
lat ex</w>
Veg a</w>
y ard</w>
Ltd.200 9
Ger ont
sequenc ed.</w>
1. 23
re ven
dis continuous</w>
dorm ant</w>
deri ving</w>
cell –
Al aska</w>
F Y
parsimon ious</w>
glucos amine</w>
P NAS</w>
E ver</w>
Bioscienc es).</w>
Laure n
De pressive</w>
(Abcam ,</w>
par s</w>
A 9</w>
st ayed</w>
pari et
10 000</w>
vaccin ation,</w>
revascul arization</w>
engine ering,</w>
2 K
10 99</w>
kern els</w>
genci es</w>
P ing</w>
/ .</w>
govern ments</w>
[6 4]</w>
SD s</w>
HT- 29</w>
e ol
calcineur in</w>
( low
bortezom ib</w>
C8—C 9—C
G> A</w>
6 46
18 49
10.1037/00 33-
p b
profession al
Hem oglobin</w>
He at
u ts</w>
fl ash
arra y,</w>
10.1001/arch inte
community- dwelling</w>
α ),</w>
u @
lymph ocytes.</w>
ahed ral</w>
240 0</w>
le bot
in- Aid</w>
L. C.</w>
broncho alveolar</w>
Lew y</w>
y no
em in
NO D</w>
Bi olog
( usually</w>
i qu
dis covering</w>
dec eler
countr y:</w>
sub cloned</w>
pair .</w>
19 25
amy cin,</w>
ain -
10.3389/fn hum
10 ],</w>
spectr a,</w>
Aldrich ,</w>
16. 9</w>
11 83</w>
non- overlapping</w>
pet roleum</w>
inc k</w>
Philip pe</w>
(P e
electr ically</w>
cep s</w>
A. -
6 39
stret ched</w>
E 2-
discus sion,</w>
Sch eff
50 ),</w>
( Stat
qu oti
gener ally,</w>
Phil ips</w>
Orth opa
Lang er
A 2-
Cor ne
where as,</w>
neuro biological</w>
Evol ution
27 ]</w>
harb ors</w>
Glut amate</w>
): 16
wor ry</w>
MyD 88</w>
Af gh
w amy</w>
prob es
200 3–
,14 ].</w>
un available</w>
g um</w>
[19 ,
T AA
Pro d</w>
15 80
11 79</w>
en rich</w>
conduc ted,</w>
com yc
up greek
sn ails</w>
4 2–
parasi tism</w>
jas mon
Techn ological</w>
MMP 9</w>
bou d</w>
12 37
11 55</w>
z el
ut ter</w>
meth adone</w>
S 2),</w>
rat .</w>
pup al</w>
mic e;</w>
m c.
MS D</w>
spirit ual</w>
12 68
p Y
ov ani</w>
od er</w>
material s
Gr uber</w>
s ell
co ok
anti serum</w>
ir ,</w>
carc ass</w>
autophag osome</w>
= 1</w>
pri se</w>
inte restingly,</w>
RA SS
R CA
AL I</w>
(p<0.0 5).</w>
tr it
S eng
Pow ers</w>
Labor atoire</w>
19 37</w>
per vasive</w>
(R E
y sym
pt ]{
end onucle
ase- 1</w>
[26, 27].</w>
D E,</w>
Ch ich
. 5
loc h</w>
Del hi,</w>
CO R
radi ograph</w>
long- distance</w>
decid ing</w>
G 1-
therap y;</w>
200 1.</w>
19 35
sym patric</w>
9 69
2 1.0</w>
10.1186/s12 88
pursu it</w>
ip el
awaren ess,</w>
23. 3</w>
ur tic
War ner</w>
Chin a),</w>
Wil l</w>
math }</w>
gir l</w>
db/d b</w>
\usepackage{amssymb }</w>
\usepackage{amsfonts }</w>
Phosph ate</w>
Hor ton</w>
17 96
ysym }</w>
was ysym}</w>
\usepackage{mathrsfs }</w>
\usepackage{amsbsy }</w>
\usepackage{ wasysym}</w>
70 °C</w>
clar ity.</w>
an hydr
Alvare z-
6 67
(2. 3)</w>
post translational</w>
aldehyde- 3-phosphate</w>
ur n</w>
app endix</w>
L AB
(B ecton</w>
herbivo res</w>
activ e-
110 ,</w>
1 ]
N ing</w>
CR Y
illustr ations</w>
\usepackage{ams math}</w>
( interquartile</w>
upgreek }</w>
2008 –
130 4</w>
c v
abs ent
1 B),</w>
Jak ob
1. 36
man ure</w>
lamb da</w>
estim ated.</w>
crimin al</w>
present ed,</w>
gu chi</w>
be y
2 ):</w>
10.1093/ij e/
0.0 38
in- vitro</w>
disp arate</w>
dis on</w>
del ay,</w>
Lear y</w>
Immun ological</w>
Go ul
X in
tumor s:</w>
ri ,</w>
Associ ation,</w>
1- 0</w>
(Bio- Rad</w>
J IA</w>
1. 5–
diffu sion-
Epidemi ologic</w>
6 D).</w>
possi bil
cz yn
ba it</w>
Charl son</w>
radi ofrequency</w>
fli es,</w>
F Y</w>
C M-
el iness</w>
cens ored</w>
Stoch astic</w>
PI N</w>
8—C 7</w>
22. 3</w>
I AP</w>
rp m.</w>
gras p</w>
RA D</w>
Har rington</w>
Adi pose</w>
24 h</w>
am i,</w>
Pas sive</w>
(6 %)</w>
di o
carb am
re ich</w>
Not es
CP T</w>
Pre treatment</w>
(8 %)</w>
insect s,</w>
15 28
r u</w>
qu ant
assess ments.</w>
O S.</w>
network s:</w>
Zo ology</w>
Rig aku</w>
siz e)</w>
season ality</w>
rem inder</w>
3 ):</w>
de activation</w>
Sevent h</w>
Inv asion</w>
-0 6</w>
M i</w>
(H ol
(2. 4)</w>
prote omes</w>
matur ation.</w>
N 2A</w>
2— figure</w>
2 BioMed</w>
W IL
H onda</w>
bot anical</w>
- 69
sens or,</w>
neutrop enia</w>
Copenh agen</w>
scienc e.</w>
remn ant</w>
k ovic</w>
is m:</w>
Nol an</w>
G PCRs</w>
pa ,</w>
Contr ast</w>
4 a,</w>
spra ying</w>
rib ose</w>
isother mal</w>
J ose</w>
20 67
10 46
o pl
ity .
8 59
7 38
J 2</w>
di m</w>
Nom ura</w>
Don ovan</w>
K X
C8 —H8
biomateri als
IL- 15</w>
presum ptive</w>
7 29
RPMI- 1640</w>
Hapl otype</w>
EC s.</w>
canti lever</w>
dimen sions,</w>
al en</w>
1 n
− 0.7
ori enting</w>
Tenn es
induc ers</w>
Cr ysAlis</w>
14-3- 3
} $
un corrected</w>
neg atives</w>
Ch ro
14 50
− 9
cost al</w>
coincid ed</w>
Gar g</w>
Hernán dez</w>
ar us</w>
nano fibers</w>
g d
R ace</w>
Men on</w>
MT A</w>
accep ting</w>
( 75</w>
Over -
oxygen ated</w>
e z,</w>
95 36
14 78
li ximab</w>
C 24</w>
− x
17 37
son t</w>
t ly.</w>
ex otic</w>
M erg
P ok
lo va</w>
i 1</w>
ax o
[10 -
H oy
B R-
Abcam ,</w>
lo fen
1—H 1</w>
psych otherapy</w>
Eis en
An tis
2– 5</w>
t- based</w>
(O R:</w>
inser ting</w>
Seg al</w>
Neuro imaging</w>
Ec topic</w>
19 29
perme ation</w>
Ser toli</w>
How e</w>
Fore stry</w>
30 ]</w>
1 x</w>
epo xy</w>
130 2</w>
Z ach
aure us,</w>
PONE-D- 13-
CI .</w>
CE )</w>
(A, B)</w>
Bio statistics</w>
/ K
Crystallo gr.</w>
Buck ley</w>
An ne
11 69</w>
ext ensor</w>
Z. -
Munic ipal</w>
IN s</w>
19. 2</w>
infu sions</w>
19. 1</w>
stere o
aglip tin</w>
Sp in</w>
dem arc
adjunc t</w>
op posit
18. 1</w>
Seph arose</w>
Extinc tion</w>
vers a</w>
bar s).</w>
Sh al
S is
110 )</w>
10.1037 /0
o fo
hydroxy apatite</w>
between- group</w>
15 23
oligonucle oti
c c.
Horv ath</w>
ou ght</w>
injur ies.</w>
es es</w>
Hi Seq</w>
2. 33</w>
0.00 13</w>
B 7-
2 0.5</w>
fibri l
se wage</w>
in del</w>
anticip ation</w>
Se if
Cyt ometry</w>
Ch ua</w>
k j
Visu alization:</w>
−0. 3</w>
Pow er
P Q</w>
un equivoc
s ay
linear ized</w>
ing er,</w>
11 47</w>
Cl p
Or land
1.00 1</w>
10.1016/j. clin
colour less</w>
South west</w>
200 1–
specific ations</w>
Mar uyama</w>
Hos se
under lin
B ill</w>
0.00 15</w>
cleav es</w>
Ly on,</w>
6 _
EB NA
Bio eng</w>
South am
Du al-
modul arity</w>
five- year</w>
H X
el o
Ne ar</w>
2 1),</w>
co iled</w>
24 66
Loren zo</w>
e '</w>
( human</w>
treat ed.</w>
dol lar
CD 19
# #</w>
model ;</w>
res ection.</w>
hem agglutinin</w>
U pd
Con text</w>
th inner</w>
11 85</w>
( days)</w>
lact am</w>
Quanti tation</w>
18. 4</w>
Deg ree</w>
A mo
1. 0000</w>
N IRS</w>
splic e
assi sting</w>
T CS</w>
construc t,</w>
interven ing</w>
hum id</w>
O j
11 16</w>
KSH V</w>
y et,</w>
(d otted</w>
ur in
longitudin ally</w>
band -
aneu ploidy</w>
virus ;</w>
(b ,
map s,</w>
ate- induced</w>
ME )</w>
Con ditional</w>
tro chan
tox o
ryst alli
in toxication</w>
201 6),</w>
sk ii</w>
op eptidase</w>
6 48
aflat oxin</w>
J Q
16 58
- E
Cho ice</w>
eLif e
Mag n.</w>
IL ).</w>
(O S)</w>
(F 1,
libit um.</w>
Down regulation</w>
16 49
10.105 3/
gr asses</w>
T ut
F MD
experienc es.</w>
S auer</w>
equ ation,</w>
ch ar</w>
Uppsal a,</w>
Bal ance</w>
100 /
Macdon ald</w>
IN R</w>
Bur ger</w>
(C y
t ens
Ser ver</w>
J ong
10 99
os :</w>
ç a</w>
let -7</w>
y al</w>
on ),</w>
Habit at</w>
3 1/
bodi es.</w>
BS A,</w>
100 ;</w>
coeffici ents.</w>
Gi em
eb el</w>
lys osome</w>
ind o</w>
decid uous</w>
de paraff
APEX 2</w>
Biot ech,</w>
trial s:</w>
Let t
stem ,</w>
L h
Con way</w>
19 49-
azol- 2-
F OR
Cur cumin</w>
12 10</w>
Prof ess
[5 4],</w>
Sigma )</w>
ex in-
registri es</w>
aa a
negl igi
Scal es</w>
P au
F ear</w>
Del gado</w>
Affec tive</w>
car p</w>
Endos copic</w>
Far rell</w>
10 26</w>
tion ”</w>
s ake</w>
nanoparticl es,</w>
mother ’s</w>
mobil ity,</w>
Ca ther
2- 29
sal ine.</w>
1/ 2;</w>
–18 ].</w>
concer ted</w>
Mont pell
adapt ation.</w>
. asp
Mar ques</w>
C annon</w>
1 q
(11 1)</w>
g yro
X C</w>
Ax ial</w>
trop ism</w>
Z S</w>
ud ing</w>
11 67</w>
Uni v.</w>
p<0.0 5.</w>
kin ase/
analog y</w>
S R,</w>
P re</w>
ic als,</w>
I stituto</w>
p H.</w>
[27, 28].</w>
Tax onomic</w>
AM Ps</w>
st eno
O2 —
w ak
qaaiab d
AA V-
ven om
it ani</w>
P ac</w>
CH Ws</w>
Ac id
sim ian</w>
sil ence</w>
F um
tempor arily</w>
4 33
8 3,</w>
17 44
(P r
run ,</w>
pull- down</w>
N 5
G ü
mal e.</w>
Salz berg</w>
Con version</w>
Availability The</w>
rig idity</w>
lear ners</w>
Palli ative</w>
2014 /0
gen ital
EN T</w>
/g ut
neuro l
(4 3)</w>
(0.0 1)</w>
TT G</w>
+ 2
(4 4)</w>
Ass oc.</w>
up p</w>
Wil le
10.1016/j. f
st ents</w>
leg ume</w>
S 1–
B ···
0.00 10</w>
streptomy cin,</w>
free ze</w>
(1. 00
chain s.</w>
res ection,</w>
j -
anc re
al y</w>
diab e
H ymen
-M SCs</w>
Prob es</w>
suc cession</w>
K u</w>
ta urine</w>
ori um</w>
ende av
profes sion</w>
anim al,</w>
Y es,</w>
K U</w>
( *p</w>
ile al</w>
epist atic</w>
3- 3</w>
Slo v
119 0</w>
10.1002/(SICI) 1097-0
non- alcoholic</w>
10.1155/201 3/
Per sson</w>
visc ous</w>
PT P
P al</w>
Hist ogram</w>
LI F</w>
Ju ven
Ar gon
10.1017/S 0
spro uting</w>
Nur ses</w>
CD 3+</w>
cry opreserv
(T R
( min)</w>
fil ter,</w>
anil ine</w>
24. 1</w>
15 25
PM N</w>
Categ orical</w>
27 —C
lesion ed</w>
N 1-
. 240
Mol in
par all
eli us</w>
– 137
Fi ber</w>
(K im</w>
publ ishing</w>
heat- inactivated</w>
ec centric</w>
answ ering</w>
D ar</w>
prioriti zation</w>
ex in
ad duct</w>
Here dity</w>
a ise</w>
J ank
mis -
literat ure
fish eries</w>
Associ ates</w>
(Qiagen ).</w>
incid ents</w>
conspic uous</w>
V ick
Brac hy
reconstruc tion.</w>
aro v</w>
LC- MS</w>
18 40
retin oblastoma</w>
n aked</w>
ever ything</w>
solid- state</w>
PR RSV</w>
G rin
famil y-
H umb
s. org
ha y</w>
me j
triple- negative</w>
mon oxide</w>
intra- abdominal</w>
infrequ ent</w>
arra ys.</w>
Osw aldo</w>
G al-
Fre e
18F- FDG</w>
( +/
c ic
Bri ef
199 6,</w>
pyri mid
Ta ich
2 ×</w>
10.1016/j. febslet
penetr ance</w>
expan sion,</w>
10 5,</w>
irrit able</w>
GA D
ogene sis
Good win</w>
6 23
tub es.</w>
annot ation,</w>
Bl um</w>
ologist s.</w>
offic ers</w>
9 %),</w>
ex cav
im perfect</w>
s é
com promising</w>
st ol
Stock holm</w>
Par ks</w>
Bal tic</w>
10.1136 /gut
uh an,</w>
Y. H.</w>
In cluding</w>
fix ation,</w>
eti er</w>
T d
PR I
atmosph ere.</w>
P2 Y
Cl ose</w>
PA L</w>
II ).</w>
E F,</w>
ha b</w>
[8 3].</w>
10 95
involv ement.</w>
K ran
in stitute</w>
GE NE
CB P</w>
A liqu
@126. com</w>
Mur ata</w>
Maryl and</w>
Examin ing</w>
A FLP</w>
10− 2</w>
scin ti
R n
i TRA
H 24
ano ic</w>
C F-
10 85</w>
ph ase
per mutations</w>
Percent ages</w>
ind ometh
carbo platin</w>
all y
Sch erer</w>
iter pene</w>
ci ,</w>
O liv
re pro
minim al
c aly
bt edly</w>
c n.
aug ments</w>
He par
[16 ,17
Nanj ing,</w>
27. 5</w>
s ock
antin ocic
variabl es:</w>
Gran ul
yr in</w>
Y ano</w>
P 6</w>
in activate</w>
hem angi
[37 ,</w>
Feed back</w>
Ex pan
Bi of
inclin ed</w>
Far mer</w>
2. 45</w>
ru p</w>
eh ler</w>
Hypo xi
29 ]</w>
12 36
inconsist encies</w>
le ast,</w>
Z /
ub o</w>
ob arbit
enceph alog
TG T</w>
predict ability</w>
ZIK V</w>
PE T-
J ack</w>
ME D
B ER</w>
at os</w>
shell s</w>
7 45
seg ment.</w>
c. ca
V AS
Mi Seq</w>
Mc Far
ent ífic
PA F</w>
McL aughlin</w>
G 0/
trac k
Lac Z</w>
I CD
temp ting</w>
spac e-
l h
Millipo re,</w>
F ung</w>
AU C
parasit es,</w>
30 99
on is</w>
compar ability</w>
a en
8 %),</w>
Gly cine</w>
dissec t</w>
2. 17</w>
1.00 2</w>
S PL
23 —H
isol euc
C28 —C
> 0.05</w>
war med</w>
para formaldehy
mas titis</w>
198 8).</w>
′ ),</w>
ure ly</w>
triglycer id
120 4</w>
br e</w>
G- quadru
p it</w>
ff in</w>
Yas uda</w>
PONE-D- 16-
U eno</w>
3 E).</w>
(C r
over weight/
Wat t</w>
polic y,</w>
Ses sion</w>
Roch ester,</w>
Deri ved</w>
10.1016/S0092-8674 (00)
Ste ele</w>
Dick son</w>
16—C 17</w>
13 17</w>
Johan sen</w>
Cu -
7 35
Polymorph ism</w>
AMP- activated</w>
10 87
exagger ated</w>
d. edu
a emic</w>
[45 ,
21. 4</w>
plasmo sis</w>
part s.</w>
nod ular</w>
ar tesun
/ L
F. J.</w>
11 79
stic kle
respon se:</w>
olith ic</w>
discover ies</w>
SD ).</w>
T MA</w>
7 46
11 20</w>
wal a</w>
M adden</w>
gend ers</w>
benz yl
Cult ure,</w>
3 X
antigen- presenting</w>
B 1-
10.1007/s00 40
anaph ase</w>
dar k
pupa e</w>
er d
w ski</w>
trich loro
omy osin</w>
et etra
Kem p</w>
pl e-
municip alities</w>
ID -
10 45
mer ozo
@ v
( de</w>
μg/ L</w>
RNA s:</w>
(P I)</w>
7. 200
elect romy
S. Y.</w>
up per-
evalu ated,</w>
ent ang
class room</w>
I ac
E- value</w>
x i,</w>
Publish er's</w>
(R os
Invitrogen ,</w>
repres sors</w>
der mis</w>
gene tic,</w>
bar coding</w>
L ass
Du arte</w>
bilater ally</w>
ac on</w>
D AT</w>
PE P</w>
Kin oshita</w>
Develop ment
2- 0</w>
(199 7).</w>
Jan s
119 8</w>
stat us
osit ol-
as ticity</w>
0.00 14</w>
in stead,</w>
Vog t</w>
O ECD</w>
put ation</w>
promo ters.</w>
S MI
f loc
elect rom
Vic tor</w>
Re ich</w>
Orth od</w>
109. 1</w>
(M T
Neurolog y
ph oto</w>
oxygen -
(P BM
Bloc k,</w>
Plat form</w>
lich en</w>
fri ed</w>
extrem es</w>
E S,</w>
CO PD,</w>
loop .</w>
endor sed</w>
FT O</w>
bystand er</w>
thi azol
kin ,</w>
biomark ers.</w>
at rac
= {
17. 7</w>
aut ophosphor
J ian</w>
10.1093/aj e/
ect oderm</w>
a- 1</w>
Nicol as</w>
E 1,</w>
-0 11-0
mg/m L)</w>
-0 8</w>
(Sp ear
ul ar,</w>
ati ,</w>
ass ure</w>
SI -
F unds</w>
Min as</w>
Mat te
11 24</w>
0.0 39
forc e-
endophy tic</w>
SH 3</w>
(22 ).</w>
10- 3</w>
am az
77 /
lat ter,</w>
3 C,</w>
AB )</w>
A, B).</w>
10.1080 /10
P 300</w>
De fic</w>
Ch un
2 d</w>
▸ )</w>
3 B)</w>
distr action</w>
broad- spectrum</w>
(Equ ation</w>
co- infected</w>
Pell egr
F it</w>
Donald son</w>
stres s:</w>
, p
pleg ia</w>
Tow n,</w>
CD11 b</w>
Neuro chem.</w>
24. 5</w>
Exp ect
199 5,</w>
(M on
Fri ston</w>
0. 200
Alber ta,</w>
(200 1).</w>
t +
250 ,</w>
O .,</w>
Casp ase</w>
50 ;</w>
ij s</w>
cl air</w>
USA 5</w>
Taiwan .</w>
SH S</w>
11 49</w>
crani ofacial</w>
reson ances</w>
n 1</w>
ligh tly</w>
T c</w>
Endom et
ä l
hol o
L aird</w>
interac tome</w>
140 7</w>
spon sor
rob enz
ucle otides</w>
20 69
v d
Ow ens</w>
C Q
prote oly
10 70</w>
acet aminoph
M G,</w>
0 90
burden .</w>
12 17</w>
on ic
6 35
small- molecule</w>
si i</w>
cy r
calcul ation.</w>
japon icum</w>
ig ,</w>
biomark ers,</w>
triplic ates</w>
reser ves</w>
annot ation.</w>
Penic illium</w>
v edi</w>
s ant</w>
ra e</w>
PS I-
10 46</w>
0.0 78</w>
1000 )</w>
Y R</w>
an oid</w>
VL Ps</w>
tex ts</w>
s den</w>
uve itis</w>
e a
configur ation.</w>
aro va</w>
